Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematological Diseases, Non-MalignantHematologic NeoplasmsPediatric Oncology and HematologySolid TumorsSupportive Therapy, ToxicityProtocol groupAcute LeukemiasAggressive LymphomasAnemias, CytopeniasBrain Tumors (ped.)Cellular TherapyComplicationsDermatologic OncologyEndocrine and Neuroendocrine OncologyGastroenterologic OncologyGynecological OncologyHead and Neck OncologyHematologic Diseases (ped.)Hemolytic DiseasesHistiocytic and Dendritic NeoplasmsHodgkin LymphomaImmunodeficienciesIndolent LymphomasLeukemias (ped.)Leukocyte diseasesLymphomas (ped.)Lymphoproliferative DisordersMyeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase FusionMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)Neuro-OncologyOther Solid Tumors (ped.)Plasma cell neoplasmsradiotherapyRare Diseases (ped.)SarcomasSarcomas (ped.)T-Cell and NK-Cell NeoplasmsThoracic TumorsTransplantationTumor, regardless of entityUrologic OncologyVisceral SurgeryDiseaseAcute Lymphoblastic LeukaemiaAcute Myeloid LeukemiaAcute Promyelocytic LeukemiaAdenoid Cystic CarcinomaAdrenocortical CarcinomaAmpullary CancerAmyloidosisAnal CarcinomaAnemiaAnemia, Autoimmune Hemolytic AnemiaAnemia, Vitamin B12 DeficiencyAntibody Deficiency, PrimaryAntibody Deficiency, Secondary to Hematological Neoplasms / after Stem Cell TransplantationBasal Cell CarcinomaBeta ThalassemiaBile Duct CarcinomaBladder CancerBlastic Plasmocytoid Dendritic Cell NeoplasiaBone MetastasesBreast CancerCAR T-Cell TherapyCervical CancerChondrosarcomaChorionic CarcinomaChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaChronic Myeloid LeukemiaChronic Myelomonocytic LeukemiaChronic Neutrophil LeukemiaColon CancerCytokine Release SyndromeEndometrial CancerEsophageal CancerEssential ThrombocythemiaEwing SarcomaExtravasation, Anthracycline (complication)Fallopian Tube CarcinomaGastric CancerGastrointestinal Stroma TumorGerm Cell TumorGestational Trophoblastic NeoplasiaGiant Cell Tumor of the BoneGlioblastomaGliomaGraft-versus-Host Disease, acuteGraft-versus-Host Disease, chronicHairy Cell LeukemiaHead and Neck Tumors (Squamous Cell)Hearing Loss, Cisplatin InducedHemophagocytic LymphohistiocytosisHepatoblastomaHepatocellular CarcinomaHodgkin LymphomaHypercalcemia of MalignancyHypereosinophilic SyndromeImmune ThrombocytopeniaIron DeficiencyIron OverloadJuvenile XanthogranulomaKaposi SarcomaLangerhans Cell HistiocytosisLiver Sarcoma UndifferentiatedLung Carcinoma, Non-Small CellLung Carcinoma, Small CellMalignant MeningitisMalignant PheochromocytomaMantle Cell LymphomaMastocytosis, SystemicMedulloblastomaMelanoma, MalignantMerkel Cell CarcinomaMulticentric Castleman DiseaseMultiple MyelomaMyelodysplastic neoplasia 5q-Myelodysplastic NeoplasmsMyelofibrosis, PrimaryMyelofibrosis, SecondaryMyeloid/Lymphoid Neoplasia with Eosinophilia and TC FusionNasopharyngeal CarcinomaNeuroendocrine CarcinomaNeuroendocrine TumorsNeurofibromatosisNeutropeniaNHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-PositiveNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, CutaneousNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, B-Cell Type, Lymphoblastic LymphomaNHL, B-Cell Type, Lymphoplasmocytic / Waldenström's diseaseNHL, B-Cell Type, Malt LymphomaNHL, B-Cell Type, Marginal Zone LymphomaNHL, B-Cell Type, Mediastinal (Thymic) Large B-Cell LymphomaNHL, B-Cell Type, Plasmoblastic LymphomaNHL, CNS-NHLNHL, T-cell typeNHL, T-Cell Type, Adult T-Cell Leukemia or LymphomaNHL, T-Cell Type, Anaplastic Large CellNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK-positiveNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK negativeNHL, T-Cell Type, AngioimmunoblasticNHL, T-Cell Type, Cutaneous, UnspecifiedNHL, T-Cell Type, Cutaneous Primary, CD30-PositiveNHL, T-Cell Type, Enteropathy TypeNHL, T-Cell Type, HepatosplenicNHL, T-Cell Type, Lymphoblastic LymphomaNHL, T-Cell Type, Mycosis FungoidesNHL, T-Cell Type, Other Specified Leukemias, Aggressive NK-Cell LeukemiaNHL, T-Cell Type, Peripheral, UnspecifiedNHL, T-Cell Type, Sézary SyndromeOccult Primary CarcinomaOsteolysisOsteomalacia, tumor-inducedOsteoporosisOsteosarcomaOvarian TumorPancreatic CancerParagangliomaParoxysmal Nocturnal HemoglobinuriaPenile CarcinomaPeritoneal Carcinoma, PrimaryPeritoneal Carcinomatosis, SecondaryPeritoneal MesotheliomaPleural MesotheliomaPolycythaemia VeraPrimary Lymphoma of the CNSProstate CancerPseudomyxoma PeritoneiRadionecrosisRectal CancerRenal Cell CarcinomaRenal Pelvic CarcinomaRhabdomyosarcomaRosai-Dorfman DiseaseSalivary Gland TumorSevere Aplastic AnemiaSickle Cell DiseaseSmall Bowel CarcinomaSoft Tissue SarcomaSquamous Cell Carcinoma of the SkinStem Cell mobilizationStem Cell Transplantation, AllogeneicStem Cell Transplantation, AutologousT-Cell Prolymphocyte LeukemiaTEMPI SyndromeTesticular TumorThrombocytopeniaThrombotic Thrombocytopenic PurpuraThymoma/Thymic CarcinomaThyroid CancerTumor, Various OrgansTumor Biomarker DefinedTumor Lysis SyndromeUveal MelanomaVon Hippel-Lindau DiseaseVulvar CarcinomaSubgroupAdenocarcinoma Esophagogastric Junction (AEG)AL AmyloidosisALK+also in pregnancyAlveolar Soft Tissue SarcomaanaplasticAndrogen receptor positiveAngiosarcomaATM-MutationB-ALLBCL2 expression highBCR-ABL negativeBRAF V600-MutationBRAF V600E mutationBRAF V600K mutationBrain MetastasesBRCA mutationCast nephropathycastration resistantCD20+CD22+CD30+CD33+cerebralChemotherapy inducedClear Cell CancerCold Agglutinin Diseasedel(17p), TP 53 mutationDermatofibrosarcoma protuberansDNA Repair DefectEGFR activating mutationEGFR exon 19 deletion mutationEGFR exon 20 insertionEGFR exon 21 Leu858Arg mutationEGFR T790M mutationepithelialER+ESR1-MutationFGFR1 RearrangementFGFR2 fusion/rearrangementFGFR2/3 FusionFGFR3 MutationFibromatosis, aggressiveFLT3 mutationFLT3-ITDFolate receptor alpha positivegBRCA mutationHemangiopericytomaHER2+HER2-lowHer2-mutatedHigh riskHIV-associatedHLA-A*02:01-positivehormone sensitiveHPV positiveHR+HR+ postmenopausalHR+ premenopausalIDH1-MutationintracranialIron Deficiency in CancerJAK2 rearrangementKRAS/NRAS WTKRAS G12C-MutationLeiomyosarcomaLeiomyosarcoma, uterineLeukemic MeningitisLiposarcomaLiposarcoma, dedifferentiatedLow riskLymphomatous MeningitisMalignant Germ Cell Tumor of the OvaryMET AmplificationMETex14 skipping mutationmethylated MGMT PromoterMismatch Repair - deficient / Microsatellite Instability - high (dMMR/MSI-H)mucosalMyofibroblast Tumor, inflammatoryNodular lymphocyte-predominant (NLPHL)non-squamousNTRK Gene FusionOctreotide Scintigraphy positivePALB2 mutationPD-L1 >50%PD-L1 from 1%PD-L1 with CPS from 1PD-L1 with CPS from 10PD-L1+PDGFRA D842V mutationPDGFRA rearrangementPDGFRB rearrangementPh/BCR-ABL+Ph/BCR-ABL-PIK3CA/AKT1/PTEN mutationsPIK3CA mutationPlasma Cell LeukemiaPlexiform NeurofibromaPOLE-alteredpostmenopausalRenal Cell CarcinomaRET fusion positiveRhabdomyosarcomaROS1+sarcomatoidSeminomaserousserous, borderlineserous, low-gradeSmoldering MyelomaSolitary Fibrous TumorSomatostatin receptor positiveSquamous Cell CarcinomaStage IIIA/BSynovial Sarcomat(11;14)T-ALLTMB - Tumor Mutational Burden highTP53 mutationtripel negativetype 1unfavorable prognosisunfitUrothelial Carcinoma of the Upper Urinary Tractwarm typeWHO grade 1 and 2WHO Grade 2WHO grade 2 and 3WHO Grade 3with Ring SideroblastsICD10C08.-C11.-C11.8C11.9C15.-C16.-C16.0C17.-C18.-C18.0C18.2C18.3C18.4C18.5C18.6C18.7C18.8C19C20C21.-C21.0C21.1C21.2C21.8C22.0C22.2C24.-C24.0C24.1C24.8C24.9C25.-C34.-C37C40.-C41.-C41.9C44.-C44.9C45.0C45.1C46.1C48.-C48.1C49.-C50.-C51.9C53.-C54.1C56C57.0C58C60.-C61C62.-C64C65C67.-C69.-C71.-C71.6C73C74.0C74.1C75.5C76.0C78.6C79.3C79.5C80.0C80.9C81.-C82.-C82.7C82.9C83.-C83.0C83.1C83.3C83.5C83.7C84.0C84.1C84.4C84.5C84.6C84.7C84.8C85.2C85.9C86.1C86.2C86.5C86.6C88.0-C88.4-C90.-C90.0-C91.0-C91.1-C91.4-C91.5-C91.6-C92.0-C92.1-C92.4-C92.5-C92.6-C92.7-C92.8-C92.9-C93.0-C93.1-C94.3-C94.7-C96.0C96.2C96.5C96.6D39.-D39.2D45D46.-D46.6D47.-D47.1D47.3D47.4D47.5D48.0D50.-D51.-D56.-D56.1D56.3D57.0D57.1D57.2D57.8D59.1D59.5D61.-D64.9D69.3D69.6-D70.-D75.1D76.1D76.3D80.9E34.0E61.1E83.59E85.-E88.3H91.0M31.1M80.-M80.0-M80.4-M81.-M81.0-M81.4-M83.8-M89.5-Q85.0Q85.8T66T80.-T86.01+T86.02+T86.05+T86.06+T86.07+Z94.80MeSHAcquired Immunodeficiency SyndromeAdrenocortical CarcinomaAgranulocytosisAmyloidosisAnemia, AplasticAnemia, Hemolytic, AutoimmuneAnemia, Iron-DeficiencyAnemia, PerniciousAnemia, Sickle CellAnthracyclinesAnus NeoplasmsAppendiceal NeoplasmsAstrocytomaBile Duct NeoplasmsBiliary TractBiliary Tract NeoplasmsBreast NeoplasmsBurkitt LymphomaCarcinoma, Adenoid CysticCarcinoma, Basal CellCarcinoma, HepatocellularCarcinoma, Merkel CellCarcinoma, NeuroendocrineCarcinoma, Non-Small-Cell LungCarcinoma, Ovarian EpithelialCarcinoma, Renal CellCarcinoma, Squamous CellCarcinoma, Transitional CellCarcinosarcomaCastleman DiseaseCentral Nervous System NeoplasmsChondrosarcomaChoriocarcinomaColonic NeoplasmsColorectal NeoplasmsCommon Bile Duct NeoplasmsDuodenal NeoplasmsEndometrial NeoplasmsEnteropathy-Associated T-Cell LymphomaErdheim-Chester DiseaseEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaFallopian Tube NeoplasmsFibromatosis, AggressiveGallbladder NeoplasmsGastrointestinal Stromal TumorsGestational Trophoblastic DiseaseGiant Cell Tumor of BoneGlioblastomaGliomaGraft vs Host DiseaseHearing LossHemangiosarcomaHematopoietic Stem Cell MobilizationHemoglobinuria, ParoxysmalHemosiderosisHepatoblastomaHistiocytosis, Langerhans-CellHistiocytosis, SinusHodgkin DiseaseHypercalcemiaHypereosinophilic SyndromeHypopharyngeal NeoplasmsIgG DeficiencyIleal NeoplasmsImmunoblastic LymphadenopathyIron DeficienciesJejunal NeoplasmsKidney NeoplasmsLaryngeal NeoplasmsLeiomyosarcomaLeukemia, Hairy CellLeukemia, Lymphocytic, Chronic, B-CellLeukemia, Monocytic, AcuteLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, MyeloidLeukemia, Myeloid, AcuteLeukemia, Myeloid, Chronic, Atypical, BCR-ABL NegativeLeukemia, Myeloid, Chronic-PhaseLeukemia, Myelomonocytic, ChronicLeukemia, Neutrophilic, ChronicLeukemia, Prolymphocytic, T-CellLeukemia, Promyelocytic, AcuteLiposarcomaLiver DiseasesLiver NeoplasmsLymphohistiocytosis, HemophagocyticLymphoma, B-Cell, Marginal ZoneLymphoma, Large-Cell, AnaplasticLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellLymphoma, Non-HodgkinLymphoma, Primary Cutaneous Anaplastic Large CellLymphoma, T-CellLymphoma, T-Cell, CutaneousLymphoma, T-Cell, PeripheralMacrophage Activation SyndromeMastocytosis, SystemicMediastinal NeoplasmsMedulloblastomaMelanomaMeningeal CarcinomatosisMesotheliomaMesothelioma, CysticMouth NeoplasmsMultiple MyelomaMycosis FungoidesMyelodysplastic SyndromesNasopharyngeal CarcinomaNeoplasmsNeoplasms, Connective and Soft TissueNeoplasms, Germ Cell and EmbryonalNeoplasms, Unknown PrimaryNeuroendocrine TumorsNeutropeniaOligodendrogliomaOropharyngeal NeoplasmsOsteolysisOsteoporosisOvarian NeoplasmsPancreatic NeoplasmsParagangliomaPenile NeoplasmsPeritoneal NeoplasmsPheochromocytomaPlasmablastic LymphomaPlasmacytomaPolycythemia VeraPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaPrimary Immunodeficiency DiseasesPrimary MyelofibrosisProstatic DiseasesProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantPseudomyxoma PeritoneiPurpuraPurpura, Thrombocytopenic, IdiopathicPurpura, Thrombotic ThrombocytopenicRadiation InjuriesRectal NeoplasmsRhabdomyosarcoma, EmbryonalSalivary Gland NeoplasmsSarcomaSarcoma, EwingSarcoma, KaposiSarcoma, SynovialSezary SyndromeSmall Cell Lung CarcinomaSquamous Cell Carcinoma of Head and NeckStomach NeoplasmsTesticular NeoplasmsThalassemiaThrombocythemia, EssentialThrombocytopeniaThymomaThymus NeoplasmsThyroid Carcinoma, AnaplasticThyroid NeoplasmsTumor Lysis SyndromeUreteral NeoplasmsUrethral NeoplasmsUrinary Bladder NeoplasmsUrogenital NeoplasmsUrologic NeoplasmsUterine Cervical NeoplasmsUterine NeoplasmsUveal Neoplasmsvon Hippel-Lindau DiseaseVulvaWaldenstrom MacroglobulinemiaSequenceAC (DOXO60/CYCL600) dose-dense x 4 followed by PACL175 x 4, Breast Ca, adj., A (PID402) -|- AC (DOXO60/CYCL600) dose-dense x 4 followed by PACL175 x 4, Breast Ca, adj., B (PID403)AC (DOXO60/CYCL600) x 4 followed by DOCE100 x 4, Breast Ca, adj., A (PID599) -|- AC (DOXO60/CYCL600) x 4 followed by DOCE100 x 4, Breast Ca, adj., B (PID395)AC (DOXO60/CYCL600) x 4 followed by PACL, Breast Ca, adj., A (PID394) -|- AC (DOXO60/CYCL600) x 4 followed by PACL80 x 12, Breast Ca, adj., B (PID397)AC (DOXO60/CYCL600) x 4 followed by PACL, Breast Ca, adj., A (PID394) -|- AC (DOXO60/CYCL600) x 4 followed by PACL175 x 4, Breast Ca, adj., B (PID396)AC (DOXO60/CYCL600) x 4 followed by PACL, Breast Ca, adj., A (PID394) -|- B C1 (PID491) -|- B C2+ (PID492) -|- TRAS6 (PID1474)ACAL/OBIN/VNTC: ACAL100, CLL, C1, var. 1 (PID2282) -|- C2 (PID2283) -|- C3 (PID2284) -|- C4 (PID2285) -|- C5-7 (PID2286) -|- C8+ (PID2287)AIO (CFOL500/FU1500)/IRIN80/CETU(400/250), colorect. Ca, C1 (PID485) -|- AIO (CFOL500/FU1500)/IRIN80/CETU250, C2+ (PID486)AIO KRK-0104: CETU(400/250)/CAPE800/IRIN200, colorect. Ca, C1 (PID1818) -|- CETU250/CAPE800/IRIN200, C2+ (PID1819)AIO KRK-0104: CETU(400/250)/CAPE1000/OXAL130, colorect. Ca, C1 (PID1820) -|- CETU250/CAPE1000/OXAL130, C2+ (PID1821)AIO KRK 0212: mFOLFOX-6 (OXAL85/CFOL400/FU2400)/PNTM6, colorect. Ca, ind. (PID1989) -|- PNTM6/CFOL400/FU2400, maint. (PID1988)ALCYONE: BORT1.3/DRTM(8/8/16)/MELP9/PRED60, MM, C1 (PID1433) -|- C2-9 (PID651) -|- C10+ (PID461)ALCYONE: BORT1.3/DRTM16/MELP9/PRED60, MM, C1 (PID588) -|- C2-9 (PID651) -|- C10+ (PID461)ALCYONE: BORT1.3/DRTM1800/MELP9/PRED60, MM, C1 (PID1617) -|- C2-9 (PID1618) -|- maint. (PID1619)ALEM(3/10/30), CLL (PID333) -|- ALEM30 (PID334)ALEM(3/10/30), T-PLL, C1 (PID1548) -|- ALEM30, C2+ (PID1549)ALFA-0701, AMLALL, Mini-hyperCVD/Inotuzumab Ozogamicin: Mini-hyperCVD (CYCL150/VNCR2/DEXA20)/INTZ(0.6/0.3)/RITU375, ALL/NHL, C1 (PID2098) -|- C2 (PID2097) -|- C3 (PID2099) -|- C4 (PID2097) -|- maint. (PID313)ALL,Ph/BCR-ABL+: Hyper-CVAD (CYCL300/VNCR2/DOXO50/DEXA40)/RITU375/IMAT800, ALL/NHL, Ph/BCR-ABL+, C1 (PID2084) -|- C2 (PID2085) -|- C3 (PID2086) -|-C4 (PID2085) -|- C5 (PID2087) -|- C6 (PID2088) -|- C7 (PID2089) -|- C8 (PID2090) -|- Month 1-5 (PID2073) -|- Month 6 (PID2110) -|- Month 7 (PID2113) -|- Month 8-17 (PID2073) -|- Month 18 (PID2110) -|- Month 19 (PID2113) -|- Month 20-24 (PID2073)ALTA-1L: BRGT(90/180), NSCLC, first line, C1 (PID48) -|- BRGT180, C2+ (PID49)ALTERNATIVE: TRAS8/LAPA1000/LETC2.5, Breast Ca, C1 (PID1768) -|- TRAS6/LAPA1000/LETC2.5, Breast Ca, C2+ (PID1769)ANCHOR CRC: ENCO300/BINI45/CETU(400/250), colorect. Ca, C1 (PID2464) -|- C2-7 (PID2465) -|- C8+ (PID2466)ANDROMEDA: DEXA(20/20)/CYCL300/DRTM1800/BORT1,3, AL amyloidosis, C1-2 (PID1631) -|- C3-6 (PID1632) -|-C7+ (PID1633)APHINITY: PERT840/TRAS8/DOCE75, Breast Ca adj., C1 (PID1165) -|- C2-4 (PID1166) -|- C5-18 (PID680)APHINITY: PERT840/TRAS8/PACL80, Breast Ca, adj., C1 (PID1167) -|- C2-4 (PID1168) -|- C5-18 (PID680)APL2016, arm A1: APL2006 V4.1 - A1, A2 and A3, Ind., APL, up to 70, leukoc. up to 10000/µl (PID1035) -|- 1st cons. (PID1042) -|- 2nd cons. (PID1043) -|- maint. (PID1053)APL2016, arm A2: APL2006 V4.1 - A1, A2 and A3, Ind., APL, up to 70, leukoc. up to 10000/µl (PID1035) -|- 1st cons. (PID1044) -|- 2nd cons. (PID1045) -|- maint. (PID1053)APL2016, arm A3: APL2006 V4.1 - A1, A2 and A3, Ind., APL, up to 70, leukoc. up to 10000/µl (PID1035) -|- 1st cons. (PID1046) -|- 2nd cons. (PID1047) -|- maint. (PID1053)APL2016, Arm B: APL2006 V4.1 - B - Ind., APL, older 70, leukoc. up to 10000/µl (PID1054) -|- 1st cons. (PID1055) -|- 2nd cons. (PID1056) -|- maint., C1 (PID1057) -|- maint., C2-5 (PID1058) -|- maint., C6-8 (PID1062)APL2016, arm C1: APL2006 V4.1 - C1 and C2, Ind., APL, up to 70, leukoc. above 10000/µl (PID1048) -|- 1st cons. (PID1049) -|- 2nd cons. (PID1050) -|- maint. (PID1053)APL2016, arm C2: APL2006 V4.1 - C1 and C2, Ind., APL, up to 70, leukoc. over 10000/µl (PID1048) -|- 1st cons. (PID1051) -|- 2nd cons. (PID1052) -|- maint. (PID1053)APL2016, Arm D: APL2006 V4.1 - D - Ind., APL, over 70, leukoc. over 10000/µl (PID1059) -|- 1st cons. (PID1060) -|- 2nd cons. (PID1061) -|- maint., C1 (PID1057) -|- maint., C2-5 (PID1058) -|- maint., C6-8 (PID1062)ARASENS: DOCE75/PRED5/DARO600/GOSE10.8, Prostate Ca (HS), A (PID2040) -|- B (PID2041) -|- C (PID2081)ARTIST, Gastric CaASPIRE: CARF(20/27)/LENA25/DEXA40, MM, C1 (PID522) -|- C2-12 (PID523) -|- C13-18 (PID524) -|- Maint., MM (PID525)ATEZ1200/BEVA15/PACL175/CRBP5, NSCLC (PID2525) -|- ATEZ1200/BEVA15, maint. (PID1209)Atezolizumab 840 / Nab-Paclitaxel 125, Breast Cancer, neoadjuvant, C1-3 (PID2423) -|- Atezolizumab 840 / Doxorubicin 60 / Cyclophosphamide 600, C4-5 (PID2424) -|- ATEC1200, adj. (PID2425)AVAPERL: PEME500/CISP75/BEVA7.5, NSCLC, A (PID185) -|- BEVA 7.5 maint., B (PID187).AVAPERL: PEME500/CISP75/BEVA7.5, NSCLC, A (PID185) -|- PEME500/BEVA7.5 maint., B (PID186).B-ALL/recurrent therapy: mini-hyperCVD (CYCL150/VNCR2/DEXA20)/INTZ(0.6/0.3)/RITU375, ALL/NHL, C1 (PID2098) -|- C2 (PID2097) -|- C3 (PID2099) -|- C4 (PID2097) -|- C1 (PID2117) -|- C2-4 (PID2118) -|- maint., Month 1-12 (PID2119) -|- maint., month 13-36 (PID2120)B-ALL: Hyper-CVAD (CYCL300/VNCR2/DOXO50/DEXA40)/RITU375, B-ALL/NHL, C1 (PID2061) -|- C2 (PID2064) -|- C3 (PID2061) -|- C4 (PID2064) -|- C5 (PID2063) -|- C6 (PID2065) -|- C7 (PID2063) -|- C8 (PID2065) -|- Month 1-5 (PID2072) -|- Month 6 (PID2074) -|- Month 7 (PID2061) -|- Month 8-17 (PID2072) -|- Month 18 (PID2074) -|- Month 19 (PID2061) -|- Month 20-30 (PID2072)BEACON: ENCO300/BINI45/CETU400, colorect. Ca, C1 (PID1406) -|- ENCO300/BINI45/CETU250, C2+ (PID1407)BEACON: ENCO300/CETU400, colorect. Ca, C1 (PID1605) -|- ENCO300/CETU250, C2+ (PID1606)BEATcc: ATEZ1200/BEVA15/PACL175/CISP50, Cervical Ca (PID2658) -|- ATEZ1200/BEVA15, Maint. (PID2659)BEATcc: ATEZ1200/BEVA15/PACL175/CRBP5, Cervical Ca (PID2657) -|- ATEZ1200/BEVA15, maint. (PID2659)BELLINI: VNTC800/BORT1,3/DEXA20, MM, C1-8 (PID1790) -|- VNTC800/BORT1,3/DEXA20, MM, C9+ (PID1791)BEND90/BORT1,3/PRED60, MM, C1 (PID1550) -|- BEND90/BORT1,3/PRED60, MM, C2-9 (PID1551)BEVA10/CRBP5/PGLDX30, ovarian Ca (PID2187) -|- BEVA15, maint. (PID1430)BEVA15/PACL175/CRBP5, Cervical Ca (PID2605) -|- BEVA15, maint. (PID2611)BEVA15/PACL175/CRBP5, ovarian Ca (PID1429) -|- BEVA15, maint.. (PID1430)BORT1,3, Waldenström, C1 (PID2343) -|- C2 (PID2342) -|- C3,4 (PID2344) -|- C5 (PID2342).BORT1,3/PANO20/DEXA20, MM, C1-8 (PID611) -|- BORT1,3/PANO20/DEXA20, MM, C9-16 (PID612)BORT1,6/RITU375, Waldenström, C1 (PID1235) -|- C2+3 (PID1266) -|- C4 (PID1235) -|- C5+6 (PID1266)BORT1.3/MELP9/PRED60, MM C1 (PID1003) -|- C2-5 (PID1004) -|- maint. (PID1005)BORT1.3/PGLDX30/DEXA40, MM, C1 (PID1963) -|- C2 (PID1964) -|- C3 (PID1963) -|- C4 (PID1964) -|- Cons. (PID1965)BORT1.5/CYCL300/DEXA40, MM, C1-2 (PID1852) -|- BORT1.5/CYCL300/DEXA40, MM, C3-4 (PID1853)BOVen: OBIN(100/900/1000)/ZANU160, CLL, C1 (PID2637) -|- C2 (PID2638) -|- C3 (PID2639) -|- C4-8 (PID2640) -|- C9+ (PID2641)BRGT(90/180), NSCLC, second line, C1 (PID54) -|- BRGT180, NSCLC, second line, C2+ (PID55)BRNT1.8/DCRB375, Hodgkin, C1-12 (PID2364) -|- BRNT1.8/DCRB375 - BRNT1.8, C1-16 (PID2365).BRNT1.8/NIVO3, Hodgkin, C1 (PID1903) -|- C2-4 (PID1904)BRNT1.8/NIVO240, NHL, C1 (PID1516) -|- C2+ (PID1515)CADENZA : SUTI6.5, Autoimmune Hemolytic Anemia, Cold Agglutinin Disease, C1 (PID2248) -|- SUTI6.5, C2+ (PID2249)CALGB 9431: VINO25/CISP80, NSCLC, A (PID261) -|- VINO15/CISP80/Radiation, B (PID262).CALGB 40302: LAPA1500/FLVS(500/250), Breast Ca, C1 (PID1770) -|- LAPA1500/FLVS250, Breast Ca, C2+ (PID1771)CANDOR: DRTM1800/CARF(20/56)/DEXA(20/20), MM, C1 (PID2152) -|- C2 (PID2330) -|- C3-6 (PID2153) -|- C7+ (PID2154)CAO/ARO/AIO-04CAO/ARO/AIO-12, Arm ACAO/ARO/AIO-12, Arm BCAPE1000/DOCE75, Breast Ca, adj., A (PID1643) -|- CAPE1000/EPIR75/CYCL500, B (PID1644)CAPItello-291: CAPI400/FLVS500/GOSE3.6, Breast Ca, C1 (PID2609) -|- C2+ (PID2610)CAPL10, TTP, C1 (PID2111) -|- C2+ (PID2112)CAPOX (CAPE1000/OXAL130), AEG/Gastric Ca, adj., A (PID689) -|- B (PID684) -|- C (PID689)CAPTIVATE (IBRU/VNTC): CLL, first-line, Z1-3 (PID1267) -|- Z4 (PID1236) -|- Z5-15 (PID1268)CARF(20/27)/POMA4/DEXA40, MM, C1 (PID1586) -|- C2-6 (PID1587) -|- C7+ (PID1588)CARF(20/36)/CYCL300/DEXA40, MM, C1 (PID1455) -|- C2-9 (PID1456) -|- Maint. (PID1457)CARF(20/36)/CYCL300/DEXA40, MM, C1, var. 1 (PID1458) -|- C2-9 (PID1459) -|- maint. (PID1457)CARF(20/70)/DRTM(8/8/16)/DEXA(20/20), MM, C1 (PID1438) -|- C2 (PID1439) -|- C3-6 (PID1440) -|- C7+ (PID1441)CARF20/RITU375/DEXA20, Waldenström, C1 (PID2586) -|- C2-6 (PID2587) -|- C7-14 (PID2588)CARF70/CYCL300/DEXA40, MM (PID1741) -|- CARF70/CYCL300/DEXA40 - CARF70 maint., MM (PID1742)CASPIAN: DURV1500/CISP80/ETOP100, SCLC (PID1734) -|- DURV1500 maint. (PID1594)CASPIAN: DURV1500/CRBP5/ETOP100, SCLC (PID1593) -|- DURV1500 maint.. (PID1594)CASSIOPEIA: BORT1.3/DRTM(8/8/16)/THAL100/DEXA40, MM, C1 (PID1482) -|- C2 (PID1483) -|- C3-4 (PID1484) -|- Cons. (PID1485) -|- maint. (PID1486)CASSIOPEIA: BORT1.3/DRTM1800/THAL100/DEXA40, MM, C1-2 (PID1628) -|- C3-4 (PID1629) -|- Cons. (PID1630) -|- maint. (PID1635)CASTOR: BORT1.3/DRTM(8/8/16)/DEXA(20/20), MM, C1 (PID1432) -|- C2-3 (PID818) -|- C4-8 (PID819) -|- C9+ (PID820)CASTOR: BORT1.3/DRTM16/DEXA(20/20), MM, C1 (PID817) -|- C2-3 (PID818) -|- C4-8 (PID819) -|- C9+ (PID820)CASTOR: BORT1.3/DRTM1800/DEXA(20/20), MM, C1-3 (PID1613) -|- C1-8 (PID1614) -|- maint. (PID1615)CECOG: FOLFOX-6 (OXAL100/CFOL400/FU2400)/CETU(400/250), colorect. Ca, C1 (PID1114) -|- FOLFOX-6 (OXAL100/CFOL400/FU2400)/CETU250, C2+ (PID1178)CELESTIMO: MOSU(1/2/30), foll. Lymphoma °I-IIIa, C1 (PID2075) -|- MOSU30/LENA20, foll. Lymphoma °I-IIIa, C2-12 (PID2076)CELESTIMO: RITU375/LENA20, foll. Lymphoma °I-IIIa, C1 (PID2077) -|- C2 (PID2079) -|- C3 (PID2078) -|- C4 (PID2079) -|- C5(PID2078) -|- C6 (PID2079) -|- C7 (PID2078) -|- C8 (PID2079) -|- C9(PID2078) -|- C10 (PID2079) -|- C11 (PID2078) -|- C12 (PID2079)CENTAURUS: DRTM(8/8/16), MM, smoldering, C1 (PID1556) -|- C2-3 (PID2123) -|- C4-7 (PID2124) -|- C8-20 (PID2125)CETU(400/250)/CISP80/VINO25, NSCLC, C1 (PID190) -|- C2-6 (PID191) -|- Erh (PID192)CETU(400/250)/CISP100, Head and Neck Tumors, C1 (PID1246) -|- CETU250/CISP100, C2+ (PID1271)CETU(400/250)/DOCE75/CISP100/FU700, Head and Neck Tumors, C1 (PID1348) -|- CETU250/CISP100/DOCE75/FU700, C2-3 (PID1349)CETU(400/250)/IRIN350, colorekt. Ca, C1 (PID425) -|- CETU250/IRIN350, C2+ (PID426)CETU(400/250)/PACL175/CISP75, Head and Neck Tumors, C1 (PID1273) -|- CETU250/PACL175/CISP75, C2+ (PID1274)CETU400, colorect. Ca, C1 (PID423) -|- CETU250, C2+ (PID424)CETU400, CSCC, C1 (PID2165) -|- CETU250, C2+ (PID2166)CETU400, Head and Neck Tumors, C1 (PID1220) -|- CETU250, C2+ (PID1221)CETU400/CRBP5/FU1000, Head and Neck Tumors, C1 (PID623) -|- CETU250/CRBP5/FU1000, C2+ (PID337)CETU400/PACL40/CRBP2/Radiation, Head and Neck Tumors, C1 (PID622) -|- CETU250/PACL40/CRBP2/Radiation, Head and Neck Tumors, C2+ (PID621)CETU400/PACL80, Head and Neck Tumors, C1 (PID707) -|- CETU250/PACL80, C2+ (PID708)CETU400/PACL90/CRBP2, Head and Neck Tumors, C1 (PID1242) -|- C2-6 (PID1243) -|- C7-11 (PID1244)CETU400/Radiation, CSCC, C1 (PID2163) -|- CETU250/Radiation, C2+ (PID2164)CETU400/Radiation, Head and Neck Tumors, C1 (PID1194) -|- CETU250/Radiation, C2+ (PID1195)CGOG1001 : TRAS8/OXAL130/CAPE1000, AEG/Gastric Ca, C1 (PID1258) -|- C2-6 (PID1301) -|- C7+ (PID1302)CheckMate-032: NIVO1/IPIL3, AEG/Gastric Ca (PID1492) -|- NIVO240 maint. (PID1493)CheckMate-142: NIVO3/IPIL1, colorect. Ca, second line (PID1386) -|- NIVO240 (PID1234)CheckMate 040: NIVO1/IPIL3, HCC (PID1788) -|- NIVO240, maint. (PID1789)CheckMate 067: NIVO1/IPIL3, Melanoma (PID711) -|- NIVO1/IPIL3 - NIVO240, Melanoma, Maint. (PID713)CheckMate 9LA: NIVO360/IPIL1/PACL200/CRBP6, NSCLC (PID1670) -|- NIVO360/IPIL1, maint. (PID1671)CheckMate 9LA: NIVO360/IPIL1/PEME500/CISP75, NSCLC (PID1676) -|- NIVO360/IPIL1, maint. (PID1671)CheckMate 9LA: NIVO360/IPIL1/PEME500/CRBP6, NSCLC (PID1669) -|- NIVO360/IPIL1, maint. (PID1671)CheckMate 204: NIVO1/IPIL3, Melanoma with Brain Metastases (PID1205) -|- NIVO1/IPIL3 - NIVO240, Maint. (PID1206)CheckMate 205: NIVO240, Hodgkin, A (PID1374) -|- N-AVD (NIVO240/DOXO25/VNBL6/DCRB375), B (PID1375)CheckMate 214: NIVO3/IPIL1, RCC (PID1138) -|- NIVO240, maint. (PID1139)CheckMate 214: NIVO3/IPIL1, RCC (PID1138) -|- NIVO480, maint. (PID2260)CheckMate 511: NIVO3/IPIL1, Melanoma (PID647) -|- NIVO3/IPIL1 - NIVO480, Melanoma, Maint. (PID648)CheckMate 577: NIVO240, Esophageal Ca/AEG, adj., C1-8 (PID1764) -|- NIVO480, C9-16 (PID1765)CheckMate 648: NIVO240/CISP80/FU800, Esophageal Ca (PID1985) -|- NIVO240, Maint. (PID1986)CheckMate 649: mFOLFOX-6 (OXAL85/LCVR400/FU2400)/NIVO240, Esophageal Ca/AEG/Gastric Ca (PID1905) -|- NIVO240 maint.,(PID1910)CheckMate 649: NIVO360/CAPE1000/OXAL130, Esophageal Ca/AEG/Gastric Ca (PID1906) -|- NIVO360 Maint. (PID1911)CheckMate 901: NIVO360/GEMC1000/CISP70, Urinary Bladder Ca (PID2490) -|- NIVO480 Maint. (PID2491)CHLO(0.4-0.7), CLL, C1-4 (PID320) -|- CHLO0.8, C5+ (PID868)CHOP 21 (CYCL750/DOXO50/VNCR2/PRED40), EATL, part A (PID1650) -|- IVE/MTX (EPIR50/ETOP200/IFOS3/MTRX1500), part B (PID1651)CHRYSALIS : AMIV(350/700/1050), NSCLC, C1 (PID1908) -|- AMIV1050, C2+ (PID1909)CHRYSALIS : AMIV(350/1050/1400), NSCLC, C1 (PID1912) -|- AMIV1400, C2+ (PID1913)CISP12/FU600/Radiation, Head and Neck Tumors, C1-2 (PID2059) -|- C3 (PID2060) -|- C4 (PID2062)CISP20/ETOP100, GTN, Ind. (PID1608) -|- EMA/CO (ETOP100/DCTN0.5/MTRX1000/VNCR1.0/CYCL600) (PID1610) or (PID1607) with (PID1616)CISP60/ETOP150, NSCLC, neoadj., C1-3 (PID620) -|- CISP50/ETOP100/Radiation, C1 (PID619).CISP75/TEGA25, AEG/Gastric Ca (PID202) -|- TEGA25 maint. (PID1106)CISP80/ETOP100/Radiation, SCLC, A (PID266) -|- IRIN60/CISP60, B (PID267)CISP100/Radiatio, Head and Neck Tumors (PID1334) -|- CISP100/CAPE1000, Nasopharyngeal Ca (PID1784).CISP100/Radiation, Nasopharyngeal Ca, A (PID1714) -|- CISP80/FU1000, Nasopharyngeal Ca, B (PID1707)CLAD5,6 followed by RITU375, HCL, A (PID865) -|- B (PID866)CLAG-Ida (CLAD5/CYTA2000/IDAR12/FILG300), AML, Ind. (PID2220) -|- CLAG-Ida (CLAD5/CYTA2000/IDAR12/FILG300), Cons. (PID2221)CLAG-M, r/r AML, Polish Adult Leukemia GroupCLEOPATRA: PERT840/TRAS8/DOCE75, Breast Ca, C1 (PID361) -|- PERT420/TRAS6/DOCE75, Breast Ca, C2+ (PID364)CM77T: NIVO360/CISP75/DOCE75, NSCLC, neoadj., C1-4 (PID2645) -|- NIVO480, adj., C5-18 (PID2646)CM77T: NIVO360/CRBP5/PACL175, NSCLC, neoadj., C1-4 (PID2642) -|- NIVO480, adj., C5-18 (PID2646)CM77T: NIVO360/CRBP5/PEME500, NSCLC, neoadj., C1-4 (PID2643) -|- NIVO480, adj., C5-18 (PID2646)CM77T: NIVO360/PEME500/CISP75, NSCLC, neoadj., C1-4 (PID2644) -|- NIVO480, adj., C5-18 (PID2646)COMPLEMENT 1: OFAT(300/1000)/CHLO10, CLL C1 (PID407) -|- OFAT1000/CHLO10, C2+ (PID408)COSMIC-313: NIVO3/IPIL1/CABO40, RCC, C1-4 (PID2352) -|- NIVO480/CABO40 maint., RCC, C5+ (PID2353)CRBP2/Radiation followed by CRBP 4.5/ETOP80, MCC, part A (PID109) -|- CRBP2/Radiation followed by CRBP 4.5/ETOP80, MCC, part B (PID1111)CRBP100/Radiation, Nasopharyngeal Ca, A (PID1781) -|- CRBP5/FU1000, Nasopharyngeal Ca, B (PID1782)CZLZ5, Sickle Cell Disease, C1 (PID1728) -|- CZLZ5, C2+ (PID1729)DA-EPOCH (ETOP50/PRED120/VNCR0.4/CYCL750/DOXO10)/RITU375, B-NHL, C1-2 (PID658) -|- C3-6 (PID2056)DA-EPOCH-R(R), Burkitt's lymphomaDANTE/IKF-s633: ATEZ840/FLOT (DOCE50/OXAL85/CFOL200/FU2600), AEG/Gastric Ca, perioperative, C1-4.5-8 (PID2563) -|- C1-4.5-8 (PID2563) -|- ATEZ1200, C9-17 (PID2564)DAUN60/CYTA200, AML ind. (PID1825) -|- HD CYTA 3000, AML cons., below 60, d1,3,5 (PID516)DAUN60/CYTA200/MDST50, AML Ind. (PID1079) -|- Cons. (PID1080) -|- maint. (PID1081)DECI15, AML, C1-4 (PID2321) -|- DECI20, C5+ (PID2322)DENO120, Giant Cell Tumor of the Bone, C1 (PID925) -|- C2+ (PID927)DEXA40/MELP0.22/BORT1.3, AL-Amyloidosis, C1-2 (PID1638) -|- C3-8 (PID1639)DGRL240, Prostate Ca, C1 (PID1524) -|- DGRL80, C2+ (PID1525)DOCE50/OXAL100/TEGA40, AEG/Gastric Ca, neoadj. (PID2038) -|- TEGA60, adj. (PID606)DOCE60/CISP60/FU600, Nasopharyngeal Ca (PID1373) -|- CISP100/Radiation, Head and Neck Tumors (PID1334)DOCE75/CISP75, Esophageal Ca/AEG, neoadj., A (PID1402) -|- DOCE20/CISP25/Radiation, B (PID1403)DOCE75/CISP75/FU750 - CISP40/Radiation, Nasopharyngeal Ca, A (PID1099) -|- B (PID1101)DOCE75/CISP75/FU750, Head and Neck Tumors (PID1102) -|- CRBP1.5/Radiation (PID1282)DOCE75/PRED5/GOSE10.8, Prostate Ca (HS), A (PID641) -|- B (PID664) -|- C (PID2082)DOXO40/ETOP100/CISP100/MTTN1,5, ACC, C1 (PID2021) -|- DOXO40/ETOP100/CISP100/MTTN1,5, ACC, C2+ (PID1257)DOXO40/LURB2, SCLC (PID2628) -|- LURB3.2, maint. (PID2629)DOXO60 x 4 / PACL175 x 4 / CYCL600 x 4, Breast Ca, adj., A (PID1141) -|- B (PID1142) -|- C (PID1143)DOXO60/CISP50, Endometrial Ca, C1-7 (PID894) -|- CISP50, C8 (PID895)DRTM(8/8/16), AL amyloidosis, C1 (PID1473) -|- C2 (PID1478) -|- C3-6 (PID1479) -|- C7+ (PID1480)DRTM(8/8/16)/CARF(20/36)LENA25/DEXA20, MM, C1 (PID2579) -|- C2 (PID2580) -|- C3-6 (PID2581) -|- C7 (PID2582) -|- C8-10 (PID2583) -|- Maint. (PID2584)DRTM(8/8/16)/LENA5/DEXA20, AL amyloidosis, C1 (PID2444) -|- C2 (PID2445) -|- C3-6 (PID2446) -|- C7+ (PID2447)DRTM(8/8/16)/POMA4/DEXA(20/20), MM, C1 (PID1435) -|- C2 (PID1223) -|- C3-6 (PID1224) -|- C7+ (PID1225)DRTM16/POMA4/DEXA(20/20), MM, C1 (PID1222) -|- C2 (PID1223) -|- C3-6 (PID1224) -|- C7+ (PID1225)DRTM1800, TEMPI syndrome, C1-2 (PID2167) -|- C3-6 (PID2168) -|- C7+ (PID2169)DRTM1800/LENA5/DEXA20, AL-Amyloidosis, C1-2 (PID2452) -|- C3-6 (PID2453) -|- C7+ (PID2454)DRTM1800/POMA4/DEXA(20/20), MM, C1-2 (PID1993) -|- C3-6 (PID1994) -|- C7+ (PID1995)DURV1500/GEMC1250/CISP75, NSCLC, neoadj., C1-4 (PID2493) -|- DURV1500, adj., C5-18 (PID2497)DURV1500/GEMC1250/CRBP5, NSCLC, neoadj., C1-4 (PID2495) -|- DURV1500, adj., C5-18 (PID2497)DURV1500/PACL200/CRBP6, NSCLC, neoadj., C1-4 (PID2496) -|- DURV1500, adj., C5-18 (PID2497)DURV1500/PEME500/CISP75, NSCLC, neoadj., C1-4 (PID2492) -|- DURV1500, adj., C5-18 (PID2497)DURV1500/PEME500/CRBP5, NSCLC, neoadj., C1-4 (PID2494) -|- DURV1500, adj., C5-18 (PID2497)EC (EPIR90/CYCL600), Breast Ca, adj. (PID579) -|- PACL80, Breast Ca, adj. (PID581)EC (EPIR90/CYCL600) x 4 followed by DOCE100, Breast Ca, neoadj., A (PID404) -|- EC (EPIR90/CYCL600) x 4 followed by DOCE100, Breast Ca, neoadj., B (PID405)eLEcTRA: TRAS8/LETR2.5, Breast Ca, C1 (PID764) -|- TRAS6/LETR2.5, Breast Ca, C2+ (PID765)ELEVATE TN: ACAL100, CLL, C1 (PID1654) -|- C2 (PID1655) -|- C3-7 (PID1656) -|- (PID1653)Elo-KRd TrialELOQUENT2: Elo-Rd (ELOT10/LENA25/DEXA28), MM, C1-2 (PID701) -|- Elo-Rd (ELOT10/LENA25/DEXA(28/40)), C3+ (PID702)ELOQUENT3: ELOT10/POMA4/DEXA28, MM, C1+2 (PID1227) -|- ELOT20/POMA4/DEXA28, MM, C3+ (PID1229)EMN09 trialEMPOWER-Lung 3: CEMI350/PACL200/CISP75, NSCLC, C1-4 (PID2274) -|- CEMI350, C5+ (PID2276).EMPOWER-Lung 3: CEMI350/PACL200/CRBP6, NSCLC, C1-4 (PID2275) -|- CEMI350, C5+ (PID2276).EMPOWER-Lung 3: CEMI350/PEME500/CISP75, NSCLC, C1-4 (PID2273) -|- CEMI350/PEME500, C5+ (PID2272).EMPOWER-Lung 3: CEMI350/PEME500/CRBP6, NSCLC, C1-4 (PID2271) -|- CEMI350/PEME500, C5+ (PID2272).ENDEAVOR: CARF(20/56)/DEXA20, MM, C1 (PID733) -|- CARF56/DEXA20, MM, C2+ (PID734)ENGOT-cx11/ GOG-3047/KEYNOTE-A18: PEMB200/CISP40/Radiation, Cervical Ca, C1-2 (PID2654) -|- PEMB200, C3-5 (PID2655) -|- PEMB400, C6-21 (PID2656)EORTC-GIMEMA AML-19: GEMOZO(6/3), AML, ind. (PID2590) -|- GEMOZO2, cons. (PID2591)EORTC 18071: IPIL10, Melanoma, adj., A (PID887) -|- IPIL10, Melanoma, adj., B (PID889)EPCO(0.16/0.8/48), DLBCL, C1 (PID2486) -|- EPCO48, C2-3 (PID2487) -|- EPCO48, C4-9 (PID2488) -|- EPCO48, C10+ (PID2489)EPIR90 x 4 / PACL175 x 4 / CYCL600 x 4, dose-dense, Breast Ca, adj., A (PID86) -|- B (PID87) -|- C (PID88)EPIR150 x 3 / PACL225 x 3 / CYCL2500 x 3, dose-dense, Breast Ca, adj., A (PID399) -|- B (PID400) -|- C (PID401)ESPATUE: PACL175/CISP50, NSCLC, ind., neoadj., A (PID 852) -|- VINO20/CISP50/Radiation B (PID 853) -|- possibly VINO15/CISP40/Radiation C (PID1169)Euro-B.O.S.S.: adjuvant (upfront tumor surgery), OsteosarcomaEuro-B.O.S.S.: neoadjuvant incl. postoperative therapy, OsteosarcomaEVER10/FLVS500, Breast Ca, C1 (PID1875) -|- C2+ (PID1876)EWING 2012 Arm A VIDEEWING 2012 Arm B VDC/IEFCR (RITU375/FLUD25/CYCL250), CLL, first-line C1 (PID317) -|- FCR (RITU500/FLUD25/CYCL250), C2-6 (PID318)FEC (FU500/EPIR100/CYCL500) x 3 followed by DOCE100 x 3, Breast Ca, adj., A (PID388) -|- FEC (FU500/EPIR100/CYCL500) x 3 followed by DOCE100 x 3, Breast Ca, adj., B (PID389)FeDeriCa: AC (DOXO60/CYCL600) dose-dense x 4 followed by PACL175 x 4, Breast Ca, adj., A (PID402) -|- B C1 (PID1753) -|- AB C2-4 (PID1754) -|- C5-18 (PID1755)FeDeriCa: AC (DOXO60/CYCL600) x 4 followed by DOCE100 x 4, Breast Ca, adj., A (PID599) -|-B C1 (PID1751) -|- B C2-4 (PID1752) -|- C5-18 (PID1755)FLAGIDA (FLUD30/CYTA1500/IDAR8)/VNTC400, AML, Ind. (PID2522) -|- Cons. (PID2524)FLAURA2: OSIM80/PEME500/CISP75, NSCLC, C1-4 (PID2540) -|- OSIM80/PEME500, C5+ (PID2541)FLAURA2: OSIM80/PEME500/CRBP5, NSCLC, C1-4 (PID2543) -|- OSIM80/PEME500, C5+ (PID2541)FOLFIRI (IRIN180/CFOL400/FU2400)/CETU(400/250), colorect. Ca, C1 (PID441) -|- FOLFIRI (IRIN180/CFOL400/FU2400)/CETU250, C2+ (PID442)FOLFIRINOX (OXAL85/CFOL400/IRIN180/FU2400), Rectal Ca, neoadj., A (PID2049) -|- B (PID2050) -|- C (PID2051)FOLFIRINOX (OXAL85/CFOL400/IRIN180/FU2400), Rectal Ca, neoadj., A (PID2049) -|- B (PID2050) -|- C (PID2052)FOLFOX-4 (OXAL85/CFOL200/FU600)/CETU(400/250), colorect. Ca, C1 (PID451) -|- FOLFOX-4 (OXAL85/CFOL200/FU600)/CETU250, C2+ (PID452)FOLFOXIRI (OXAL85/IRIN180/CFOL200/FU24000)/CETU(400/250), kolorekt. Ca, C1 (PID687) -|- C2+ (PID688)Freiburg CNS-NHL StudyFU425/CFOL/20/Radiation, AEG/Gastric Ca, adj., A (PID697) -|- B (PID698) -|- C (PID697).FU1000/Radiation, Rectal Ca, neoadj./adj. (PID464) -|- FU500, adj. (PID465)FUFOX (OXAL50/CFOL500/FU2000)/CETU(400/250), colorect. Ca, C1 (PID483) -|- FUFOX (OXAL50/CFOL500/FU2000)/CETU250, C2+ (PID484)GADOLIN: OBIN1000/BEND90, foll. Lymphoma °I-IIIa, C1 (PID710) -|- C2-6 (PID724) -|- maint. (PID725)GALEN: OBIN1000/LENA20, foll. Lymphoma °I-IIIa, C1 (PID2336) -|- C2-6 (PID2337) -|- C7-12 (PID2338) -|- C13-18 (PID2339)GARNET: DOST500, Endometrial Ca, C1-4 (PID1797) -|- DOST1000, C5+ (PID1798)GARNET: DOST500, Tumor Biomarker Defined, C1-4 (PID2632) -|- DOST1000, C5+ (PID2633)GBG 69-GeparSepto: PERT840/TRAS8/NPAC125, Breast Ca, neoadj., C1 (PID1355) -|- C2-4 (PID1356) -|- PERT420/TRAS6, adj. (PID1350).GEMC900/DOCE75, Soft Tissue Sarcoma, adj., A (PID1945) -|- DOXO60, B (PID1946)GEMC1000, Pancreatic Ca, A (PID285) -|- B (PID286)GEMC1000/CAPE830, Pancreatic Ca (PID1980) -|- CAPE830/Radiation (PID1968)GEMC1000/CISP80, Nasopharyngeal Ca (PID1325) -|- CISP100/Radiation (PID1334)GEMC1000/CRBP4/TRAS8, Breast Ca, C1 (PID413) -|- GEMC1000/CRBP4/TRAS6, Breast Ca, C2+ (PID414)GEMC1000/ERLO100, Pancreatic Ca, A (PID512) -|- B (PID513)GERCOR NEONIPIGA: NIVO240/IPIL1, AEG/Gastric Ca, perioperative, cycle 1-2 (PID2244) -|- NIVO480, cycle 3-11 (PID2245)GERCOR VELVET: mFOLFOX-7 (OXAL100/CFOL400/FU3000)/AFLI4, colorect. Ca (PID1916) -|- CFOL400/FU3000 /AFLI4, maint. (PID1917)GETUG 13GIVe (OBIN/IBRU/VNTC), CLLGMALL-ALL - FrailGMALL-ALL - Frail Ph/BCR-ABL+GMALL 08/2013-ALL/LBL, 56 - 75GMALL 08/2013-ALL/LBL, 56 - 75, Ph/BCR-ABL+GMALL 08/2013-ALL/LBL 18 - 55GMALL 08/2013-ALL/LBL 18 - 55, Ph/BCR-ABL+GMALL 08/2013-B-ALL/NHL 2002 Regimen, 18 - 55GMALL 08/2013-B-ALL/NHL 2002 regimen, older than 55, B-ALL onlyGMALL 08/2013-B-ALL/NHL 2002 regimen, older than 55, NHL onlyGMMG-HD7 (IB-IIA): BORT1,3/LENA25/DEXA20/ISAT10, MM, Ind., IB, C1 (PID41) -|- IB, C2-3 (PID42) -|- IIA, C1 (PID43) -|- IIA, C2-3 (PID44) -|- IIA, C4+ (PID37)GMMG-HD7 (IB-IIB): BORT1,3/LENA25/DEXA20/ISAT10, MM, Ind., IB, C1 (PID41) -|- IB, C2-3 (PID42) -|- IIB, C1 (PID45) -|- IIB, C2-3 (PID46) -|- IIB, 4+ (PID38)GORTEC: TPEx (CETU(400/250)/DOCE75/CISP75), Head and Neck Tumors, C1 (PID1275) -|- TPEx (CETU250/DOCE75/CISP75), C2+ (PID1276)GRIFFIN: BORT1.3/DRTM(8/8/16)/LENA25/DEXA20, Ind., MM, C1 (PID1718) -|- C2-4 (PID1719) -|- C5-6 (PID1720) -|- maint. (PID1721)GRIFFIN: BORT1.3/DRTM1800/LENA25/DEXA20, Ind., MM, C1-4 (PID1723) -|- C5-6 (PID1724) -|- maint. (PID1725)HELIOS: IBRU420/RITU375/BEND70, CLL, C1 (PID119) -|- C2+ (PID1179) -|- maint. (PID82)HER2CLIMB: TUCA300/CAPE1000/TRAS8, Breast Ca, C1 (PID1761) -|- TUCA300/CAPE1000/TRAS6, C2+ (PID1762)HERACLES: TRAS4/LAPA1000, colorect. Ca, C1 (PID72) -|- TRAS2/LAPA1000, C2+ (PID1155)HERNATA: TRAS8/DOCE100, Breast Ca, C1 (PID416) -|- TRAS6/DOCE100, Breast Ca, C2+ (PID417)HERNATA: TRAS8/VINO30, Breast Ca, C1 (PID418) -|- TRAS6/VINO30, Breast Ca, C2+ (PID419)HERO: RELU(360/120), Prostate Ca, C1 (PID2250) -|- RELU120, C2+ (PID2247).HIMALAYA: TREM300/DURV1500, HCC, C1 (PID2288) -|- DURV1500, C2+ (PID2289)HOVON 132 AML / SAKK 30/13, Arm AHOVON 132 AML / SAKK 30/13, Arm BIBRU420, CLL, C1 (PID1328) -|- C2 (PID1326) -|- C3-7 (PID1327) -|- maint. (PID1328)IBRU560, MCL, C1 (PID2184) -|- C2 (PID2185) -|- C3+ (PID2186)ICARIA-MM: ISAT10/POMA4/DEXA40, MM, C1 (PID1716) -|- ISAT10/POMA4/DEXA40, MM, C2+ (PID1717)IDEL150/RITU375, CLL C1 (PID276) -|- C2-5 (PID330) -|- C6-8 (PID331)IELSG-19 trial: CHLO6, MALT lymphoma, C1 (PID2568) -|- CHLO6, C2-5 (PID2569)iFCR (IBRU420/RITU375/FLUD25/CYCL250), CLL, first-line, C1 (PID1546) -|- iFCR (IBRU420/RITU500/FLUD25/CYCL250), C2-6 (PID1547)IFM 2009/DETERMINATION: BORT1.3/LENA25/DEXA20, Ind., MM (PID1036) -|- cons. after ASCT (PID1040) or cons. without ASCT (PID1037) -|- maint. after ASCT (PID891) or maint. (PID2181)IKEMA: ISAT10/CARF(20/56)/DEXA20, MM, C1 (PID1808) -|- ISAT10/CARF56/DEXA20, MM, C2+ (PID1809)iLLUMINATE: IBRU420/OBIN(100/900/1000), CLL, first-line, C1 (PID1339) -|- IBRU420/OBIN(1000), C2-6 (PID1340)IMAT400/BINI30, GIST, C1 (PID2009) -|- C2+ (PID2010)IMMUNED: NIVO1/IPIL3, Melanoma, adj., C1-4 (PID1894) -|- NIVO240, C5-24 (PID1895)IMpower130: ATEZ1200/CRBP6/NPAC100, NSCLC (PID1238) -|- ATEZ1200/CRBP6/NPAC100 - ATEZ1200 maint. (PID1272)IMpower133: ATEZ1200/CRBP5/ETOP100, SCLC (PID1341) -|- ATEZ1200, maint. (PID1342)IMpower150: ATEZ1200/BEVA15/PACL200/CRBP6, NSCLC (PID1208) -|- ATEZ1200/BEVA15, maint. (PID1209)IMROZ: BORT1.3/ISAT10/LENA25/DEXA20, MM, Ind., C1 (PID2660) -|- C2-4 (PID2661) -|- C5-17 (PID2662) -|- C18+ (PID2663)IMspire150: VEMU(960/720)/COBI60, Melanoma, C1 (PID2201) -|- ATEZ840/VEMU720/COBI60, C2+ (PID2202)iNNOVATE: IBRU420/RITU375, Waldenström (PID1255) -|- IBRU420/RITU375, Maint. (PID1265)IPIL3, Melanoma, adj., C1-4 (PID583) -|- IPIL3, Melanoma, adj., C5-8 (PID584)IXAC4/DEXA20, Waldenström, C1-2 (PID2025) -|- C3 (PID2026) -|- C4-8 (PID2027)IXAZ4/CYCL300/DEXA40, MM, C1-9 (PID2411) -|- IXAZ4, maint., C1+ (PID2410)IXAZ4/RITU1400/DEXA20, Waldenström (PID2025) -|- (PID2026) -|- (PID2027) -|- (PID310)JAVELIN Bladder 100: GEMC1000/CISP70, urinary bladder Ca (PID544) -|- AVEL800, maint. (PID679)JAVELIN Bladder 100: GEMC1000/CRBP5, urinary bladder Ca (PID1502) -|- AVEL800, maint. (PID679)KEYNOTE-021: PEMB200/PEME500/CRBP5, NSCLC (PID842) -|- PEMB200, maint. (PID1083)KEYNOTE-048: PEMB200/CISP100/FU1000, Head and Neck Tumors, First Line (PID1447) -|- PEMB200 (PID1445)KEYNOTE-048: PEMB200/CRBP5/FU1000, Head and Neck Tumors, first-line (PID1446) -|- PEMB200 (PID1445)KEYNOTE-059: PEMB200/CISP80/FU800, AEG/Gastric Ca (PID1451) -|- PEMB200/FU800 maint. (PID1507)KEYNOTE-189: PEMB200/PEME500/CISP75, NSCLC (PID1177) -|- PEMB200/PEME500, maint. (PID1170)KEYNOTE-189: PEMB200/PEME500/CRBP5, NSCLC (PID842) -|- PEMB200/PEME500, maint. (PID1170)KEYNOTE-355: PEMB200/CRBP2/GEMC1000, Breast Ca (PID1933) -|- PEMB200, maint. (PID1931)KEYNOTE-355: PEMB200/NPAC100, Breast Ca (PID1930) -|- PEMB200, Maint. (PID1931)KEYNOTE-355: PEMB200/PACL90, Breast Ca (PID1932) -|- PEMB200, maint. (PID1931)KEYNOTE-407: PEMB200/NPAC100/CRBP6, NSCLC (PID35) -|- PEMB200, maint. (PID1083)KEYNOTE-407: PEMB200/PACL200/CRBP6, NSCLC (PID36) -|- PEMB200, maint. (PID1083)KEYNOTE-522: PEMB200/PACL80/CRBP5, Breast Ca, neoadj., C1-4 (PID1464) -|- C5-8 (PID1465) or C5-8 (PID1466) -|- C9-17 (PID1868)KEYNOTE-585 (FLOT/PEMB)KEYNOTE-585: PEMB200/CISP80/CAPE1000, AEG/Gastric Ca, perioperative, C1-6 (PID2236) -|- PEMB200, C7-17 (PID2237).KEYNOTE-590: PEMB200/CISP80/FU800, Esophageal Ca/AEG (PID1822) -|- PEMB200/FU800 maint. (PID1823)KEYNOTE-604: PEMB200/CISP75/ETOP100, SCLC (PID610) -|- PEMB200, maint. (PID631)KEYNOTE-604: PEMB200/CRBP5/ETOP100, SCLC (PID630) -|- PEMB200, maint. (PID631)KEYNOTE-826: PEMB200/PACL175/CISP50, Cervical Ca, C1-6 (PID1900) -|- PEMB200, C7+ (PID1893)KEYNOTE-826: PEMB200/PACL175/CISP50/BEVA15, Cervical Ca, C1-6 (PID1891) -|- PEMB200/BEVA15, C7+ (PID2251) or PEMB200, C7+ (PID1893).KEYNOTE-826: PEMB200/PACL175/CRBP5, Cervical Ca, C1-6 (PID1892) -|- PEMB200, C7+ (PID1893)KEYNOTE-826: PEMB200/PACL175/CRBP5/BEVA15, Cervical Ca, C1-6 (PID1890) -|- PEMB200/BEVA15, C7+ (PID2251) or PEMB200, C7+ (PID1893).KRYSTAL-1: ADAG600/CETU400, colorect. Ca, C1 (PID2548) -|- ADAG600/CETU250, C2+ (PID2549)LDAUN-LCYTA144, AML Ind., C1 (PID1414) -|- C2 (PID1426) -|- cons. (PID1427)LDOX25/ETOP100/PRED20, HLH, A (PID947) -|- ETOP100/PRED0,4, HLH, B (PID1039)LMS-04: DOXO60/TRAB1.1, Soft Tissue Sarcoma (PID2210) -|- TRAB1.1, Maint. (PID2219)LOTIS-2: -|- LONTES150, DLBCL, C1-2 (PID2229) -|- LONTES75, DLBCL, C3+ (PID2230)LPA2005: TRET22.5/IDAR12, APL ind., high-risk (PID1118) -|- 1st cons. (PID1115) -|- 2nd cons. (PID1116) -|- 3rd cons. (PID1117) -|- maint. (PID1119)LYRA: DRTM1800/BORT1.5/CYCL300/DEXA(20/20), MM, C1-2 (PID1941) -|- C3-6 (PID1942) -|- C7-8 (PID1943) -|- Maint. (PID1944)MagnetisMM-3: ELRA(12/32/76), MM, C1 (PID2537) -|- C2-6 (PID2538) -|- C7+ (PID2539)MAIA: DRTM(8/8/16)/LENA25/DEXA(20/20), MM, C1, first line (PID1436) -|- C2 (PID1437) -|- C3-6 (PID1337) -|- C7+ (PID1338)MAIA: DRTM16/LENA25/DEXA(20/20), MM, C1, first line (PID1333) -|- C2 (PID1437) -|- C3-6 (PID1337) -|- C7+ (PID1338)MAIA: DRTM1800/LENA25/DEXA(20/20), MM, C1-2, first line (PID1625) -|- C3-6 (PID1626) -|- C7+ (PID1627)MajesTEC-1: TECL(0.06/0.3/1.5), MM, Z1 (PID2391) -|- TECL1.5, Z2+ (PID2392)MATRIXMAVORIC: MOGA1, CTCL, C1 (PID1397) -|- C2-12 (PID1398)MCL Younger Trial: R-CHOP (RITU375/CYCL750/DOXO50/VNCR2/PRED100), MCL C1,3,5 (PID291) -|- C2 (PID325) -|- C3 (PID291) -|- C4 (PID325) -|- C5 (PID291) -|- C6 (PID325)mFOLFOX-6 (OXAL85/CFOL350/FU2400), Colon Ca, perioperative (PID2257).mFOLFOX-6 (OXAL85/CFOL400/FU2400)/CETU(400/250), colorect. Ca, C1 (PID1112) -|- mFOLFOX-6 (OXAL85/CFOL400/FU2400)/CETU250, C2+ (PID1113)mFOLFOX-6 (OXAL85/CFOL400/FU2400)/NIVO240/TRAS6, Esophagus Ca/AEG/Gastric Ca, C1 (PID2421) -|- C2+ (PID2422).mFOLFOXIRI (OXAL85/IRIN130/CFOL200/FU2400)/CETU500, colorect. Ca, C1 (PID1553) -|- C2-8 (PID1541) -|- BEVA5 maint. (PID1543)mFOLFOXIRI (OXAL85/IRIN130/CFOL200/FU2400)/CETU500, colorect. Ca, C1 (PID1553) -|- C2-8 (PID1541) -|- CETU500 maint. (PID1542)MM-015: MPR-R (MELP0,18/PRED2/LENA10), Ind., MM, A (PID518) -|- MPR-R (MELP0,18/PRED2/LENA10) - LENA 10 maint., MM, B (PID520)MONARCH 2: ABEM150/FLVS500, Breast Ca, C1 (PID1408) -|- ABEM150/FLVS500, Breast Ca, C2+ (PID1409)monarcHER: TRAS8/ABEM150/FLVS500, Breast Ca, C1 (PID1601) -|- TRAS6/ABEM150/FLVS500, C2+ (PID1602)MonumenTAL-1: TALQ(0.01/0.06/0.4), MM, C1 (PID2469) -|- TALQ0.4, C2+ (PID2470)MonumenTAL-1: TALQ(0.01/0.06/0.4/0.8), MM, C1 (PID2467) -|- TALQ0.8, C2+ (PID2468)MOR208: TAFA12/LENA25, DLBCL, C1 (PID1848) -|- C2-3 (PID1849) -|- C4-12 (PID1850) -|- C13+ (PID1851)MOSU(1/2/60), B-NHL, C1 (PID2105) -|- C2 (PID2106) -|- C3+ (PID2107)MOUNTAINEER: TUCA300/TRAS8, colorect. Ca, C1 (PID2626) -|- TUCA300/TRAS6, C2+ (PID2627)MRC/NCRI LY10, Burkitt's LymphomaMTRX12, Malignant Meningitis, Ind. (PID608) -|- Cons. (PID871)MTRX8000/RITU375/TMZL150, CNS lymphoma, C1 (PID1859) -|- C2 (PID1860) -|- C3 (PID1861) -|- C4 (PID1864) -|- C5 (PID1865) -|- C6 (PID1866)MUK five protocol: CARF(20/36)/CYCL500/DEXA40, MM, second line, C1 (PID1460) -|- C2-6 (PID1461) -|- C7-12 (PID1462) -|- C13-24 (PID1463)Neoadjuvant WSG-TP-II (Letrozole)Neoadjuvant WSG-TP-II (Paclitaxel)Neoadjuvant WSG-TP-II (Tamoxifen) -|- PERT840/TRAS8/TMXF20, Breast Ca, adj., C1 (PID2450)NEOLAP - NPAC125/GEMC1000, Pancreatic Ca, neoadj. (PID782) -|- FOLFIRINOX (OXAL85/CFOL400/IRIN180/FU2400) (PID789) -|- (PID810)NeoSphere Arm B: PERT840/TRAS8/DOCE75, Breast Ca, neoadj., C1 (PID589) -|- C2-4 (PID750) -|- FEC adj. (PID759) -|- TRAS6 adj. (PID1474)NIVAHL Arm B: NIVO240, Hodgkin, A (PID1374) -|- N-AVD (PID1970) -|- AVD (PID257)NIVO240, Bile Duct Carcinoma, C1-8 (PID2482) -|- NIVO480, C9+ (PID2483).NIVO360/PACL200/CRBP6/BEVA15, NSCLC (PID1929) -|- NIVO360/BEVA15, maint. (PID2126)NLG MCL-2 regimen: C1, maxiCHOP, below 60 (PID289) -|- C2 (PID290) -|- C3 (PID268) -|- C4 (PID290) -|- C5 (PID268) -|- C6 (PID269)NPAC100/CYCL600/TRAS8, Breast Ca, adj. C1 (PID409) -|- NPAC100/CYCL600/TRAS6, Breast Ca, adj. C2+ (PID410)NPAC125/TRAS(4/2), Breast Ca C1 (PID427) -|- NPAC125/TRAS2, Breast Ca C2+ (PID428)NRG-GY018: PEMB200/PACL175/CRBP5, Endometrial Ca, C1-6 (PID2315) -|- PEMB400, C7-20 (PID2316).OBIN(100/900/1000)/CHLO0.5, CLL C1 (PID323) -|- OBIN1000/CHLO0.5, C2-6 (PID335)OBIN(100/900/1000)/VNTC20, CLL, C1, first-line (PID1259) -|- C2 (PID1316) -|- C3-6 (PID1317) -|- maint. (PID1318)OBIN-CHOP (OBIN1000/CYCL750/DOXO50/VNCR2/PRED100), foll. Lymphoma °I-IIIa, C1 (PID1171) -|- C2-6 (PID1172) -|- C7-8 (PID1174) -|- maint. (PID1173)OBIN-CVP (OBIN1000/CYCL750/VNCR2/PRED100), foll. Lymphoma °I-IIIa, C1 (PID2416) -|- C2-6 (PID2417) -|- C7-8 (PID2418) -|- maint. (PID2419)OBIN1000/BEND90, foll. Lymphoma °I-IIIa, C1, first line (PID1645) -|- C2-6 (PID1646) -|- maint. (PID1647)OBIN1000/GLOF(2.5/10), DLBCL, C1 (PID2393) -|- GLOF30, C2-12 (PID2394)OFAR (OXAL25/FLUD30/CYTA1000/RITU375), CLL (Richter Syndrome), C1 (PID828) -|- C2+ (PID829)OFAT(300/1000)/BEND90, CLL C1 (PID431) -|- OFAT1000/BEND90, C2+ (PID432)OFAT-CHOP (OFAT300/CYCL750/DOXO50/VNCR2/PRED100), foll. Lymphoma °I-IIIa C1 (PID133) -|- C2-6 (PID149)OLAR15/DOXO75, Soft Tissue Sarcoma, C1 (PID845) -|- C2-4 (PID846) -|- C5-8 (PID851) -|- Maint. (PID847)OPTIMISMM: BORT1,3/POMA4/DEXA20, MM, C1-8 (PID1591) -|- BORT1,3/POMA4/DEXA20, MM, C9+ (PID1592)PACL45/CRBP2/Radiation, NSCLC A (PID253) -|- PACL200/CRBP6 cons., B (PID254)PACL50/CRBP2/Radiation, NSCLC A (PID255) -|- PACL200/CRBP6 cons., B (PID256)PACL80/TRAS4, Breast Ca, adj., C1 (PID932) -|- PACL80/TRAS2, Breast Ca, adj., C2-12 (PID933)PACL90/BEVA15, Soft Tissue Sarcoma (PID1827) -|- BEVA15 (PID1826)PACL135/CISP30/Radiation, Cervical Ca (PID1990)PACL175/CRBP6/BEVA15, ovarian Ca C1 (PID498) -|- C2+ (PID499)PACL200/BEVA15,Soft Tissue Sarcoma (PID1828) -|- BEVA15 (PID1826)PACL200/CRBP6/BEVA15, NSCLC (Adeno) A (PID130) -|- BEVA15 maint., B (PID167)PAED B-NHL 2013 R1PAED B-NHL 2013 R2 stage I/IIPAED B-NHL 2013 R2 stage IIIPAED B-NHL 2013 R3PAED B-NHL 2013 R4PAED B-NHL 2013 R4 CNS+PAED CISP100/FU1000, Nasopharyngeal Ca, A (PID723) -|- B (PID682) -|- C (PID738)PAED CRBP500/FU1000, Nasopharyngeal Ca, A (PID681) -|- B (PID682) -|- C (PID738)PAED ETOP150/DEXA10, HLH, C1 (PID665) -|- C2 (PID666) -|- C3+ (PID667)PAED EuroNet-PHL-C2, Hodgkin, TL-1PAED EuroNet-PHL-C2, Hodgkin, TL-2PAED EuroNet-PHL-C2, Hodgkin, TL-3PAED SIOP CNS GCT II - ETOP100/CRBP600, Germ Cell Tumor, Intracranial, C1 (PID1555) -|- C2 (PID1382) -|- C3 (PID1555) -|- C4 (PID1382)PAED Soft Tissue Sarcoma, "Non-RMS-like"-tumors (NRSTS) in the High Risk GroupPAED Soft Tissue Sarcoma, CWS-PROPOSAL FOR ANGIOSARCOMAPAED Soft Tissue Sarcoma, Localised "RMS-like" tumours (SySa, STET (EES, pPNET), UDS)PAED Soft Tissue Sarcoma, Primary metastatic soft tissue tumoursPAED Soft Tissue Sarcoma, RMS Low Risk Group - Subgroup APAED Soft Tissue Sarcoma, RMS Standard Risk Group - Subgroup BPAED Soft Tissue Sarcoma, RMS Very High Risk Group- Subgroup HPAED Soft Tissue Sarcoma, second line therapy according to CWS-2002-P (TECC)PAED Soft Tissue Sarcoma, second line therapy ACCTTIVEPAED Soft Tissue Sarcoma, second line therapy CWS-91-REZPAED VNBL6/PRED40, LCH, Ind. (PID81) -|- maint. (PID78)PAED Weichteilsarkom, RMS Standard Risk Group – Subgroup CPAED Weichteilsarkom, RMS Standard Risk Group – Subgroup D, E, F, GPALOMA3: PALB125/FLVS500, Breast Ca, C1 (PID607) -|- PALB125/FLVS500, Breast Ca, C2+ (PID822)PARAMOUNT: PEME500/CISP75, NSCLC, A (PID179) -|- PEME500, B, maint. (PID180)PEACE-1: DOCE75/PRED5/ABIR1000/GOSE10.8, Prostate Ca (HS), A (PID2305) -|- B (PID2306) -|- C (PID2307).PEMB200, Hodgkin, A (PID1969) -|- AVD (DOXO25/VNBL6/DCRB375), B (PID1962)PEMB200/CISP75/GEMC1000, NSCLC, neoadj., cycle 1-4 (PID2376) -|- PEMB200, adj., cycle 5-18 (PID2378)PEMB200/LDOX15/GEMC1000/VINO20, Hodgkin (PID2024) -|- BRNT1.8, maint. (PID849)PEMB200/PEME500/CISP75, NSCLC, neoadj., cycle 1-4 (PID2377) -|- PEMB200, adj., cycle 5-18 (PID2378)PEMB200/PEME500/CISP75, Pleural Mesothelioma (PID2597) -|- PEMB200, Erh. (PID2613)PEMB200/PEME500/CRBP5, Pleural Mesothelioma (PID2598) -|- PEMB200, Erh. (PID2613)PEMB200/TRAS8/CISP80/FU800, AEG/Gastric Ca, C1 (PID2101) -|- PEMB200/TRAS6/CISP80/FU800, C2+ (PID2102)PEMB200/TRAS8/OXAL130/CAPE1000, AEG/Gastric Ca, C1 (PID2093) -|- PEMB200/TRAS6/OXAL130/CAPE1000, C2+ (PID2094)PEME50/DEXA5, Malignant Meningitis, C1 (PID2529) -|- C2 (PID2530) -|- C3+ (PID2531)PEME500/CISP75/Radiation, NSCLC, A (PID247) -|- PEME500 cons., B (PID249).PEME500/CRBP5/AMIV(350/1050/1400), NSCLC, C1 (PID2498) -|- C2 (PID2499) -|- C3-4 (PID2500) -|- C5+ (PID2501)PEME500/CRBP5/Radiation, NSCLC (Adeno) A (PID250) -|- PEME500 cons., B (PID251)PEME500/CRBP6, NSCLC (Adeno) A (PID181) -|- PEME500 maint., B (PID182)PEME500/CRBP6/BEVA15, NSCLC (Adeno) A (PID183) -|- PEME500/BEVA15 maint., B (PID184)PEME500/CRBP6/BEVA15, NSCLC (Adeno) A (Stevenson) (PID188) -|- BEVA15 maint., B (PID189)PERSEUS: DRTM1800/BORT1.3/LENA25/DEXA40, MM, Ind., C1-2 (PID2516) -|- C3-4 (PID2517) -|- DZ5-6 (PID2518) -|- C7+ (PID2519)PERT840, Breast Ca, C1 (PID2607) -|- PERT420, C2+ (PID2608)PERT840/TRAS8, colorect. Ca, C1 (PID1533) -|- PERT420/TRAS6, C2+ (PID1534)PERT840/TRAS8, Salivary Gland Tumor, C1 (PID1701) -|- PERT420/TRAS6, C2+ (PID1702)PERT840/TRAS8/DOCE75, NSCLC, C1 (PID1975) -|- PERT420/TRAS6/DOCE75, NSCLC, C2+ (PID1976)PERTAIN: PERT840/TRAS8/ANAS1, Breast Ca, C1 (PID1498) -|- PERT420/TRAS6/ANAS1, Breast Ca, C2+ (PID1500)PERTAIN: PERT840/TRAS8/LETR2.5, Breast Ca, C1 (PID1496) -|- PERT420/TRAS6/LETR2.5, Breast Ca, C2+ (PID1497)PNTS4, T-PLL, C1-4 (PID1562) -|- C5-8 (PID1563)PNTS4/ALEM(3/10/30), T-PLL, C1 (PID1566) -|- C2-4 (PID1567) -|- C5-8 (PID1568)POLARIX: Pola-R-CHP (POLVED1,8/RITU375/CYCL750/DOXO50/PRED100), DLBCL, C1-6 (PID1920) -|- RITU375, C7-8 (PID1921)POLLUX: DRTM(8/8/16)/LENA25/DEXA(20/20), MM, C1 (PID1434) -|- C2 (PID814) -|- C3-6 (PID815) -|- C7+ (PID816)POLLUX: DRTM16/LENA25/DEXA(20/20), MM, C1 (PID813) -|- C2 (PID814) -|- C3-6 (PID815) -|- C7+ (PID816)PORTEC-3: CISP50/Radiation, Endometrial Ca, adj. A (PID922) -|- PACL175/CRBP5, adj, B (PID923)POSEIDON: TREM75/DURV1500/GEMC1250/CISP75, NSCLC, C1-4 (PID2294) -|- C5 (PID2291) -|- C6 (PID2292) -|- C7+ (PID2291)POSEIDON: TREM75/DURV1500/GEMC1250/CRBP6, NSCLC, C1-4 (PID2293) -|- C5 (PID2291) -|- C6 (PID2292) -|- C7+ (PID2291)POSEIDON: TREM75/DURV1500/NPAC100/CRBP6, NSCLC, C1-4 (PID2290) -|- C5 (PID2291) -|- C6 (PID2292) -|- C7+ (PID2291)POSEIDON: TREM75/DURV1500/PEME500/CISP75, NSCLC, C1-4 (PID2296) -|- C5 (PID2297) -|- C6 (PID2298) -|- C7+ (PID2297)POSEIDON: TREM75/DURV1500/PEME500/CRBP6, NSCLC, C1-4 (PID2295) -|- C5 (PID2297) -|- C6 (PID2298) -|- C7+ (PID2297)PROSPECT: FOLFOX groupQuANTUM-First: DAUN60/CYTA100/QUIZ35.4, AML, Ind. (PID2551) -|- Cons. (PID2553) -|- maint., C1 (PID2554) -|- maint., C2+ (PID2555)QuANTUM-First: IDAR12/CYTA100/QUIZ35.4, AML, Ind. (PID2552) -|- Cons. (PID2553) -|- maint., C1 (PID2554) -|- maint., C2+ (PID2555)R-ACVBP (RITU375/DOXO75/CYCL1200/VIND2/BLEO10/PRED60) ind., DLBCL A (PID340) -|- cons., B (PID341) -|- cons., C (PID342) -|- cons., D (PID343)R-BAC (RITU375/BENDA70/CYTA800), MCL, C1 (PID690) -|- R-BAC (RITU375/BENDA70/CYTA800), MCL, C2+ (PID691)R-BENDA (RITU375/BEND70), CLL, second line, C1 (PID574) -|- R-BENDA (RITU500/BEND70), C2-6 (PID683)R-BENDA (RITU375/BEND90), CLL, first-line, C1 (PID315) -|- R-BENDA (RITU500/BEND90), C2-6 (PID316)R-CHOP (RITU375/CYCL750/DOXO50/VNCR2/PRED100), MCL (PID275) -|- RITU375 maint., MCL (PID288)R-CHOP 14 (RITU375/CYCL750/DOXO50/VNCR2/PRED100), DLBCL, C1-6 (PID112) -|- RITU375, C7-8 (PID1448)R-CHOP 14 smart (RITU375/CYCL750/DOXO50/VNCR2/PRED100), DLBCL, C1 (PID926) -|- C2 (PID929) -|- C3 (PID930) -|- C4 (PID929) -|- C5 (PID930) -|- C6 (PID929) -|- C7+ (PID75)R-CHOP 21 (RITU375/CYCL750/DOXO50/VNCR2/PRED100)/MTRX12, Testicular Lymphoma, C1 (PID901) -|- C2 (PID902) -|- C3-6 (PID903)R-FC (RITU375/FLUD30/CYCL250), MCL (PID326) -|- RITU375 maint., MCL (PID288)R-ICE (RITU375/ETOP100/CRBP5/IFOS5), DLBCL, C1 (PID348) -|- C2+3 (PID349)R-ICE (RITU375/ETOP100/CRBP635/IFOS3), Burkitt's Lymphoma, C1-2 (PID2223) -|- C3 (PID2224).R-MP (RITU375/MTRX3000/PRCR60), CNS Lymphoma, C1 (PID1191) -|- C2-3 (PID1030) -|- PRCR100, maint. (PID1031)RAMONA: NIVO240, Esophageal Ca, cycle 1-3 (PID2150) -|- NIVO240/IPIL1, cycle 4+ (PID2151)RATIONALE-306: TISL200/CISP80/CAPE1000, Esophagal Ca (PID2618) -|- TISL200, Erh. (PID2617)RATIONALE-306: TISL200/CISP80/CAPE1000, Esophagal Ca (PID2618) -|- TISL200/CAPE1000, maint. (PID2619) -|- TISL200, maint. (PID2617)RATIONALE-306: TISL200/CISP80/FU800, Esophagal Ca (PID2615) -|- TISL200, maint. (PID2617)RATIONALE-306: TISL200/CISP80/FU800, Esophagal Ca (PID2615) -|- TISL200/FU800, maint. (PID2616) -|- TISL200, maint. (PID2617)RATIONALE-306: TISL200/CISP80/PACL175, Esophagal Ca (PID2622) -|- TISL200, maint. (PID2617)RATIONALE-306: TISL200/CISP80/PACL175, Esophageal Ca (PID2622) -|- TISL200/PACL175, maint. (PID2623) -|- TISL200, maint. (PID2617)RATIONALE-306: TISL200/OXAL130/CAPE1000, Esophagal Ca (PID2621) -|- TISL200, maint. (PID2617)RATIONALE-306: TISL200/OXAL130/CAPE1000, Esophageal Ca (PID2621) -|- TISL200/CAPE1000, maint. (PID2619) -|- TISL200, maint. (PID2617)RATIONALE-306: TISL200/OXAL130/FU800, Esophagal Ca (PID2620) -|- TISL200, maint. (PID2617)RATIONALE-306: TISL200/OXAL130/FU800, Esophagal Ca (PID2620) -|- TISL200/FU800, maint. (PID2616) -|- TISL200, maint. (PID2617)RATIONALE 304: TISL200/PEME500/CISP75, NSCLC (PID2634) -|- TISL200/PEME500, maint. (PID2636)RATIONALE 304: TISL200/PEME500/CRBP5, NSCLC (PID2635) -|- TISL200/PEME500, maint. (PID2636)RATIONALE 307: TISL200/NPAC100/CRBP5, NSCLC (PID2648) -|- TISL200, maint. (PID2649)RATIONALE 307: TISL200/PACL175/CRBP5, NSCLC (PID2647) -|- TISL200, maint. (PID2649)RCC_HCRN GU16-260: Nivolumab and Salvage Nivolumab / IpilimumabRectal Ca adjuvant (Capecitabine/Radiation)Rectal Ca neoadjuvant/adjuvant (Capecitabine/Radiation)RHUH(800/1600/2400)/SCIgG(10/20/30), prim. Antibody deficiency, C1 (PID1726) -|- RHUH2400/SCIgG30, C2+ (PID1731)RHUH(800/1600/2400)/SCIgG(10/20/30), Sec. Antibody Deficiency, hemat. Neoplasia, C1 (PID1722) -|- RHUH2400/SCIgG30, C2+ (PID1727)RITU375 Ind., foll. Lymphoma °I-IIIa A (PID300) -|- maint. B (PID301)RITU375, Hodgkin, C1-4 (PID2360) -|- RITU375, maint., C5-8 (PID2361)RITU375/CHLO6, foll. Lymphoma °I-IIIa, C1 (PID1835) -|- C2-5 (PID1836)RITU375/CHLO6, MALT Marginal Zone B-NHL, C1 (PID1971) -|- C2-5 (PID1974)RITU375/CHLO10, CLL C1 (PID321) -|- RITU500/CHLO10, C2-6 (PID322)RITU375/LENA20, foll. Lymphoma °I-IIIa, C1 (PID1529) -|- C2-6 (PID1530) -|- C7-12 (PID1531) -|- maint. (PID295)RITU375/LENA20, ind. B-NHL ind. (PID309) -|- LENA20 maint. (PID329)RITU375/LENA20, MCL C1 (PID282) -|- RITU375/LENA20 - LENA20 maint., MCL C1+ (PID324)RITU375/MTRX3500/PRCR100/VNCR2, CNS lymphoma, C1-3 (PID1896) -|- RITU375/CYTA3000, C4-6 (PID1901)RITU375/PGLDX30/CYCL750/VNCR2/PRED40, DLBCL, C1 (PID2502) -|- C2-6 (PID2503)RITU375/POLVED1.8/BEND90, DLBCL, C1 (PID1422) -|- C2-6 (PID1423)RITU375/VEMU960 - RITU375, HCL, A (PID1802) -|- B (PID1803)RITU375/VNTC(20/50/100/200/400), CLL, C1 (PID1148) -|- C2 (PID1149) -|- C3-7 (PID1150) -|- maint. (PID1151)RITU750/TMZL150, CNS-NHL, ind. (PID2437) -|- TMZL150, cons. (PID2438) -|- MTPR1, maint. (PID2439)ROSEWOOD: OBIN1000/ZANU160, foll. Lymphoma °I-IIIa, C1 (PID2593) -|- C2-6 (PID2594) -|- C7+ (PID2595)RUBY: DOST500/PACL175/CRBP5, Endometrial Ca, C1-6 (PID2313) -|- DOST1000, C7+ (PID2314)SAL Study Group, AMLSAPPHIRE: PERT1200/TRAS600/NPAC125, Breast Ca, C1 (PID1756) -|- C2+ (PID1757) -|- maint. (PID1760)SAPPHIRE: PERT1200/TRAS600/PACL80, Breast Ca, C1 (PID1758) -|- C2+ (PID1759) -|- maint. (PID1760)SHINE: IBRU560/RITU375/BEND90, MCL (PID2103) -|- IBRU560/RITU375, maint. (PID2104)SIRIUS: DRTM(8/8/16), MM, C1 (PID1431) -|- C2 (PID746) -|- C3-6 (PID745) -|- C7+ (PID747)SIRIUS: DRTM16, MM, C1 (PID744) -|- C2 (PID746) -|- C3-6 (PID745) -|- C7+ (PID747)SIRIUS: DRTM1800, MM, C1-2 (PID1622) -|- C3-6 (PID1623) -|- C7+ (PID1624)SOLAR-1: ALPE300/FLVS500, Breast Ca, C1 (PID1620) -|- ALPE300/FLVS500, Breast Ca, C2+ (PID1621)SORMAIN: SORA400/600, AML, maint., C1 (PID1020) -|- SORA800, C2+ (PID1038)STRE1/MTTN1.5, ACC, C1 (PID2012) -|- STRE2/MTTN1.5, ACC, C2+ (PID2020)STUDY-AMLSG, Investigational armSTUDY - CLL2-BAG: OBIN1000/VNTC400 - OBIN(100/900/1000), CLL, Ind. C1 (PID609) -|- C2 (PID613) -|- C3-6 (PID624) -|- maint. (PID633)STUDY-CLL13-GVe: OBIN(100/900/1000)/VNTC20, CLL, C1 (PID1144) -|- C2 (PID1145) -|- C3-6 (PID1146) -|- C7-12 (PID1147)STUDY-CLL13-RVe: RITU375/VNTC20, CLL, C1 (PID1196) -|- C2 (PID1197) -|- C3-6 (PID1198) -|- C7-12 (PID1147)Study-CLL17-OBIN(100/900/1000)/VNTC20, CLL, C1 (PID1854) -|- C2 (PID1855) -|- C3-6 (PID1856) -|- C7-12 (PID1857)STUDY - Dauno DoubleSTUDY-GMMG-HD6 (arm A1): BORT1.3/LENA25/DEXA20, MM, Ind. A1 + A2, C1-2 (PID797) -|- C3-4 (PID800) -|- Cons. (PID801) -|- maint. C1-6 (PID1094) -|- maint. C7+ (PID1095)STUDY-GMMG-HD6 (arm A2): BORT1.3/LENA25/DEXA20, MM, Ind. A1 + A2, C1-2 (PID797) -|- C3-4 (PID800) -|- Cons. (PID802) -|- maint. C1-6 (PID1092) -|- maint. C7+ (PID1093)STUDY-GMMG-HD6 (arm B1): BORT1.3/LENA25/DEXA20/ELOT10, MM, Ind. B1 + B2, C1-2 (PID798) -|- C3-4 (PID799) -|- Cons. (PID801) -|- maint. C1-6 (PID1094) -|- maint. C7+ (PID1095)STUDY-GMMG-HD6 (arm B2): BORT1.3/LENA25/DEXA20/ELOT10, MM, Ind. B1 + B2, C1-2 (PID798) -|- C3-4 (PID799) -|- Cons. (PID802) -|- maint. C1-6 (PID1092) -|- maint. C7+ (PID1093)STUDY-GMMG-HD7 (IA-IIA): BORT1.3/LENA25/DEXA20, MM, Ind., IA (PID40) -|- IIA, C1 (PID43) -|- IIA, C2-3 (PID44) -|- IIA, C4+ (PID37)STUDY-GMMG-HD7 (IA-IIB): BORT1.3/LENA25/DEXA20, MM, Ind., IA (PID40) -|- IIB, C1 (PID45) -|- IIB, C2-3 (PID46) -|- IIB, 4+ (PID38)STUDY - levelSTUDY AMLSG, Standard armSTUDY OPTIMAL, Arm F-ASTUDY OPTIMAL, Arm F-BSTUDY OPTIMAL, Arm LF-ASTUDY OPTIMAL, Arm LF-BSTUDY OPTIMAL, Arm LF-CSTUDY OPTIMAL, Arm LF-DT-ALL: Hyper-CVAD (CYCL300/VNCR2/DOXO50/DEXA40)/RITU375, ALL/NHL, C1 (PID2061) -|- C2 (PID2064) -|- C3 (PID2061) -|- C4 (PID2064) -|- C4N (PID2083) -|- C5 (PID2063) -|- C5N (PID2083) -|- C6 (PID2065) -|- C7 (PID2063) -|- C8 (PID2065) -|- Month 1-5 (PID2072) -|- Month 6 (PID2083) -|- Month 7 (PID2083) -|- Month 8-17 (PID2072) -|- Month 18 (PID2074) -|- Month 19 (PID2061) -|- Month 20-30 (PID2072)T-VEC1, Melanoma, C1 (PID1182) -|- T-VEC100, Melanoma, C2+ (PID1184)TAD-HAM: TAD (TIOG100/CYTA60/DAUN100), AML ind. below 60 (PID519) -|- HAM (CYTA3000/MXNT10), AML ind. below 60 (PID596)TAnDEM: TRAS(4/2)/ANAS1, Breast Ca, C1 (PID755) -|- TRAS2/ANAS1, Breast Ca, C2+ (PID756)TCH (DOCE75/CRBP6/TRAS(4/2)), Breast Ca, adj., C1 (PID411) -|- C2+ (PID412) -|- TRAS6 adj. (PID1474)TCH (DOCE75/CRBP6/TRAS8), Breast Ca, neoadj., C1 (PID655) -|- C2+ (PID654) -|- TRAS8, adj., C1 (PID1687) -|- C2+ (PID1474)TEBE(20/30/68), Uveal Melanoma, C1 (PID883) -|- TEBE68, C2+ (PID2080)TEMS175/75, MCL C1 (PID273) -|- TEMS175/75, MCL C2+ (PID307)TI-CE (PACL200/IFOS2), Testicular Ca, Part A (PID780) -|- TI-CE (CRBP7/ETOP400), Part B (PID781)TMZL75/Radiation, Glioblastoma (PID546) -|- TMZL150 after Radio-Chemo, C1 (PID547) -|- TMZL200 C2-6 (PID548)TMZL75/Radiation, Glioblastoma, C1 (PID2472) -|- C2 (PID2473) -|- C3-12 (PID2474).TMZL75/Radiation, Glioma, C1 (PID1452) -|- C2 (PID1453) -|- C3-13 (PID1454)TOPAZ-1: DURV1500/CISP25/GEMC1000, Bile Duct Carcinoma (PID2145) -|- DURV1500, Maint. (PID2146)TRAIN-2: PERT840/TRAS8/PACL80/CRPB6, Breast Ca, neoadj., C1 (PID2121) -|- PERT420/TRAS6/PACL80/CRPB6, C2-9 (PID2122)TRAS6/FLOT (DOCE50/OXAL85/CFOL200/FU2600), AEG/Gastric Ca, perioperative, C1,5 (PID2034) -|- C2-4,6-8 (PID2035) -|- C9-17 (PID2036)TRAS8, Breast Ca, adj., C1 (PID1687) -|- TRAS6, Breast Ca, adj., C2+ (PID1688)TRAS8, Breast Ca, C1 (PID384) -|- TRAS6, Breast Ca, C2+ (PID385)TRAS8, met. Breast Ca, C1 (PID761) -|- TRAS6, met. Breast Ca, C2+ (PID760)TRAS8/CISP80/CAPE1000, AEG/Gastric Ca, C1 (PID221) -|- C2+ (PID220) -|- Maint. (PID222)TRAS8/CISP80/FU800, AEG/Gastric Ca, C1 (PID219) -|- C2+ (PID140) -|- maint. (PID222)TRAS8/DOCE70, Salivary Gland Tumor, C1 (PID1697) -|- C2+ (PID1698) -|- Maint. (PID1711)TRAS8/PACL175/CRPB5, Endometrial Ca, C1 (PID2215) -|- C2-6 (PID2216) -|- C7+ (PID2217)TRAS80, Malignant Meningitis, C1 (PID2526) -|- C2 (PID2527) -|- C3+ (PID2542)TRET45/ARSE0.15, Ind., APL (PID652) -|- Cons., C1-3 (PID653) -|- Cons., C4 (PID656)TRIBE: FOLFOXIRI (IRIN165/OXAL85/CFOL200/FU3200)/BEVA5, colorect. Ca (PID453) -|- BEVA5/CFOL200/FU3200 maint. (PID454)TRYPHAENA Arm A: FEC (FU500/EPIR90/CYCL600)/TRAS8/PERT840, Breast Ca, neoadj., C1 (PID1467) -|- C2-3 (PID1468) -|- PERT420/TRAS6/DOCE75, C4-6 (PID750) -|- TRAS6, adj. (PID1474)TRYPHAENA Arm B: FEC (FU500/EPIR90/CYCL600), Breast Ca, neoadj., C1-3 (PID1357) -|- PERT840/TRAS8/DOCE75, C4 (PID589) -|- C5-6 (PID750) -|- TRAS6, adj. (PID1474)TRYPHAENA Arm C: PERT840/TRAS8/DOCE75/CRBP6, Breast Ca, neoadj., C1 (PID1469) -|- C2-6 (PID1470) -|- TRAS6, adj. (PID1474)UNITO-EMN10 (IBd): IXAZ4/BEND75/DEXA40, MM, C1-9 (PID2409) -|- IXAZ4, maint., C1+ (PID2410)VAIA III, Soft Tissue SarcomaVINO25/CAPE1000, Breast Ca (PID1692) -|- VINO25/CAPE1000 - CAPE1000 maint., Breast Ca (PID1693)VINO60/CAPE1000, Breast Ca, C1 (PID942) -|- VINO80/CAPE1000, C2+ (PID943)VISTA: BORT1,3/MELP9/PRED60, MM C1-4 (PID533) -|- BORT1,3/MELP9/PRED60, MM C5-9 (PID534)VIT-0910: VIT (TMZL125/VNCR2/IRIN50), Soft Tissue Sarcoma, C1 (PID2255) -|- VIT (TMZL150/VNCR2/IRIN50), C2-12 (PID2256).VitB12(1000), Vitamin B12 Deficiency/Anemia (PID7) -|- maint.. (PID6)VNBL6/PRED(20/10), LCH, Ind. (PID963) -|- maint. (PID959)VNCR1/PRED60, DLBCL (PID1778) -|- C1 (PID2535) -|- C2-6 (PID2536)VNTC(20/50/100/200), CLL, C1 (PID854) -|- VNTC400, C2+ (PID855)VNTC(100/200/300/400/600)/CYTA20, AML, from 60 y., C1 (PID1260) -|- VNTC600/CYTA20, AML, from 60 y., C2+ (PID1319)VNTC(100/200/400)/AZCT75, AML, C1 (PID1595) -|- VNTC400/AZCT75, AML, C2+ (PID1596)VNTC(100/200/400)/DECI20, AML, C1 (PID1597) -|- VNTC400/DECI20, AML, C2+ (PID1598)VNTC(100/200/400)/GILT120, AML, C1 (PID2148) -|- VNTC400/GILT120, C2+ (PID2149)VNTC(400/800), Waldenström, C1 (PID2003) -|- VNTC800, C2+ (PID2004)ChemotherapyChemo-substanceAbemaciclibAbirateroneAcalabrutinibAdagrasibAfatinibAfliberceptAlectinibAlemtuzumabAlpelisibAmivantamabAmsacrineAnagrelideAnastrozoleApalutamideArsenic TrioxideAsciminibAsparaginaseAtezolizumabAvapritinibAvelumabAxitinibAzacitidineAzathioprineBelantamab MafodotinBelzutifanBendamustineBevacizumabBicalutamideBinimetinibBleomycinBlinatumomabBortezomibBosutinibBrentuximab vedotinBrigatinibBuserelinBusulfanCabazitaxelCabozantinibCapecitabineCapivasertibCapmatinibCarboplatinCarfilzomibCarmustineCemiplimabCeritinibCetuximabChlorambucilCiclosporin ACisplatinCladribineClofarabinCobimetinibCrizanlizumabCrizotinibCyclophosphamideCytarabineDabrafenibDacarbazineDacomitinibDactinomycinDaratumumabDarolutamideDasatinibDaunorubicinDaunorubicin-cytarabine liposomalDecitabineDecitabine-CedazuridineDegarelixDexamethasoneDocetaxelDostarlimabDoxorubicinDoxorubicin liposomalDoxorubicin pegylated liposomalDurvalumabEculizumabElacestrantElotuzumabElranatamabEmapalumabEncorafenibEnfortumab VedotinEntrectinibEnzalutamideEpcoritamabEpirubicinErdafitinibEribulinErlotinibEtoposideEverolimusExemestaneFedratinibFludarabineFluorouracilFolinic acidFruquintinibFulvestrantFutibatinibGefitinibGemcitabineGemtuzumab OzogamicinGilteritinibGlasdegibGlofitamabGoserelinHuman albumin 20%Human immunoglobulin (SCIg)HydrocortisoneHydroxyureaIbrutinibIdarubicinIdelalisibIfosfamideImatinibInotuzumab OzogamicinInterferon alpha-2aInterferon alpha-2a pegylatedInterferon beta-1aIpilimumabIrinotecanIrinotecan pegylated liposomalIsatuximabIvosidenibIxazomibLanreotideLapatinibLarotrectinibLenalidomideLenvatinibLetrozoleLeuprorelinLomustineLoncastuximab TesirinLorlatinibLurbinectedinMargetuximabMegestrolMelphalanMepolizumabMercaptopurineMesnaMethotrexateMethylprednisoloneMidostaurinMirvetuximab SoravtansinMitomycinMitotanMitoxantroneMogamulizumabMomelotinibMosunetuzumabMoxetumomab PasudotoxMycophenolate mofetilNab-paclitaxelNaCl 0.9%NelarabineNeratinibNilotinibNintedanibNiraparibNivolumabNivolumab-RelatlimabObinutuzumabOctreotideOfatumumabOlaparibOlaratumabOsimertinibOxaliplatinPaclitaxelPalbociclibPanitumumabPanobinostatPazopanibPeg asparaginasePegcetacoplanPembrolizumabPemetrexedPemigatinibPentostatinPertuzumabPirtobrutinibPixantronPolatuzumab vedotinPomalidomidePonatinibPralsetinibPrednisoloneProcarbazineQuizartinibRamucirumabRavulizumabRecombinant human hyaluronidaseRegorafenibRelugolixRibociclibRipretinibRituximabRopeginterferon alfa-2bRucaparibRuxolitinibSacituzumab GovitecanSelinexorSelpercatinibSelumetinibSiltuximabSodium FolinateSorafenibSotorasibStreptozocinSunitinibTafasitamabTagraxofuspTalazoparibTalimogen LaherparepvecTalquetamabTamoxifenTebentafuspTeclistamabTegafurTemozolomideTemsirolimusTepotinibThalidomideThiotepaTioguaninTislelizumabTisotumab vedotinTivozanibTocilizumabTopotecanTrabectedinTrametinibTrastuzumabTrastuzumab DeruxtecanTrastuzumab emtansineTremelimumabTreosulfanTretinoinTrifluridineTriptorelinTrofosfamideTucatinibVandetanibVemurafenibVenetoclaxVinblastineVincristineVincristine liposomalVindesineVinfluninVinorelbineVismodegibVoxelotorZanubrutinibChemo-substanceAbemaciclibAbirateroneAcalabrutinibAdagrasibAfatinibAfliberceptAlectinibAlemtuzumabAlpelisibAmivantamabAmsacrineAnagrelideAnastrozoleApalutamideArsenic TrioxideAsciminibAsparaginaseAtezolizumabAvapritinibAvelumabAxitinibAzacitidineAzathioprineBelantamab MafodotinBelzutifanBendamustineBevacizumabBicalutamideBinimetinibBleomycinBlinatumomabBortezomibBosutinibBrentuximab vedotinBrigatinibBuserelinBusulfanCabazitaxelCabozantinibCapecitabineCapivasertibCapmatinibCarboplatinCarfilzomibCarmustineCemiplimabCeritinibCetuximabChlorambucilCiclosporin ACisplatinCladribineClofarabinCobimetinibCrizanlizumabCrizotinibCyclophosphamideCytarabineDabrafenibDacarbazineDacomitinibDactinomycinDaratumumabDarolutamideDasatinibDaunorubicinDaunorubicin-cytarabine liposomalDecitabineDecitabine-CedazuridineDegarelixDexamethasoneDocetaxelDostarlimabDoxorubicinDoxorubicin liposomalDoxorubicin pegylated liposomalDurvalumabEculizumabElacestrantElotuzumabElranatamabEmapalumabEncorafenibEnfortumab VedotinEntrectinibEnzalutamideEpcoritamabEpirubicinErdafitinibEribulinErlotinibEtoposideEverolimusExemestaneFedratinibFludarabineFluorouracilFolinic acidFruquintinibFulvestrantFutibatinibGefitinibGemcitabineGemtuzumab OzogamicinGilteritinibGlasdegibGlofitamabGoserelinHuman albumin 20%Human immunoglobulin (SCIg)HydrocortisoneHydroxyureaIbrutinibIdarubicinIdelalisibIfosfamideImatinibInotuzumab OzogamicinInterferon alpha-2aInterferon alpha-2a pegylatedInterferon beta-1aIpilimumabIrinotecanIrinotecan pegylated liposomalIsatuximabIvosidenibIxazomibLanreotideLapatinibLarotrectinibLenalidomideLenvatinibLetrozoleLeuprorelinLomustineLoncastuximab TesirinLorlatinibLurbinectedinMargetuximabMegestrolMelphalanMepolizumabMercaptopurineMesnaMethotrexateMethylprednisoloneMidostaurinMirvetuximab SoravtansinMitomycinMitotanMitoxantroneMogamulizumabMomelotinibMosunetuzumabMoxetumomab PasudotoxMycophenolate mofetilNab-paclitaxelNaCl 0.9%NelarabineNeratinibNilotinibNintedanibNiraparibNivolumabNivolumab-RelatlimabObinutuzumabOctreotideOfatumumabOlaparibOlaratumabOsimertinibOxaliplatinPaclitaxelPalbociclibPanitumumabPanobinostatPazopanibPeg asparaginasePegcetacoplanPembrolizumabPemetrexedPemigatinibPentostatinPertuzumabPirtobrutinibPixantronPolatuzumab vedotinPomalidomidePonatinibPralsetinibPrednisoloneProcarbazineQuizartinibRamucirumabRavulizumabRecombinant human hyaluronidaseRegorafenibRelugolixRibociclibRipretinibRituximabRopeginterferon alfa-2bRucaparibRuxolitinibSacituzumab GovitecanSelinexorSelpercatinibSelumetinibSiltuximabSodium FolinateSorafenibSotorasibStreptozocinSunitinibTafasitamabTagraxofuspTalazoparibTalimogen LaherparepvecTalquetamabTamoxifenTebentafuspTeclistamabTegafurTemozolomideTemsirolimusTepotinibThalidomideThiotepaTioguaninTislelizumabTisotumab vedotinTivozanibTocilizumabTopotecanTrabectedinTrametinibTrastuzumabTrastuzumab DeruxtecanTrastuzumab emtansineTremelimumabTreosulfanTretinoinTrifluridineTriptorelinTrofosfamideTucatinibVandetanibVemurafenibVenetoclaxVinblastineVincristineVincristine liposomalVindesineVinfluninVinorelbineVismodegibVoxelotorZanubrutinibChemo-substanceAbemaciclibAbirateroneAcalabrutinibAdagrasibAfatinibAfliberceptAlectinibAlemtuzumabAlpelisibAmivantamabAmsacrineAnagrelideAnastrozoleApalutamideArsenic TrioxideAsciminibAsparaginaseAtezolizumabAvapritinibAvelumabAxitinibAzacitidineAzathioprineBelantamab MafodotinBelzutifanBendamustineBevacizumabBicalutamideBinimetinibBleomycinBlinatumomabBortezomibBosutinibBrentuximab vedotinBrigatinibBuserelinBusulfanCabazitaxelCabozantinibCapecitabineCapivasertibCapmatinibCarboplatinCarfilzomibCarmustineCemiplimabCeritinibCetuximabChlorambucilCiclosporin ACisplatinCladribineClofarabinCobimetinibCrizanlizumabCrizotinibCyclophosphamideCytarabineDabrafenibDacarbazineDacomitinibDactinomycinDaratumumabDarolutamideDasatinibDaunorubicinDaunorubicin-cytarabine liposomalDecitabineDecitabine-CedazuridineDegarelixDexamethasoneDocetaxelDostarlimabDoxorubicinDoxorubicin liposomalDoxorubicin pegylated liposomalDurvalumabEculizumabElacestrantElotuzumabElranatamabEmapalumabEncorafenibEnfortumab VedotinEntrectinibEnzalutamideEpcoritamabEpirubicinErdafitinibEribulinErlotinibEtoposideEverolimusExemestaneFedratinibFludarabineFluorouracilFolinic acidFruquintinibFulvestrantFutibatinibGefitinibGemcitabineGemtuzumab OzogamicinGilteritinibGlasdegibGlofitamabGoserelinHuman albumin 20%Human immunoglobulin (SCIg)HydrocortisoneHydroxyureaIbrutinibIdarubicinIdelalisibIfosfamideImatinibInotuzumab OzogamicinInterferon alpha-2aInterferon alpha-2a pegylatedInterferon beta-1aIpilimumabIrinotecanIrinotecan pegylated liposomalIsatuximabIvosidenibIxazomibLanreotideLapatinibLarotrectinibLenalidomideLenvatinibLetrozoleLeuprorelinLomustineLoncastuximab TesirinLorlatinibLurbinectedinMargetuximabMegestrolMelphalanMepolizumabMercaptopurineMesnaMethotrexateMethylprednisoloneMidostaurinMirvetuximab SoravtansinMitomycinMitotanMitoxantroneMogamulizumabMomelotinibMosunetuzumabMoxetumomab PasudotoxMycophenolate mofetilNab-paclitaxelNaCl 0.9%NelarabineNeratinibNilotinibNintedanibNiraparibNivolumabNivolumab-RelatlimabObinutuzumabOctreotideOfatumumabOlaparibOlaratumabOsimertinibOxaliplatinPaclitaxelPalbociclibPanitumumabPanobinostatPazopanibPeg asparaginasePegcetacoplanPembrolizumabPemetrexedPemigatinibPentostatinPertuzumabPirtobrutinibPixantronPolatuzumab vedotinPomalidomidePonatinibPralsetinibPrednisoloneProcarbazineQuizartinibRamucirumabRavulizumabRecombinant human hyaluronidaseRegorafenibRelugolixRibociclibRipretinibRituximabRopeginterferon alfa-2bRucaparibRuxolitinibSacituzumab GovitecanSelinexorSelpercatinibSelumetinibSiltuximabSodium FolinateSorafenibSotorasibStreptozocinSunitinibTafasitamabTagraxofuspTalazoparibTalimogen LaherparepvecTalquetamabTamoxifenTebentafuspTeclistamabTegafurTemozolomideTemsirolimusTepotinibThalidomideThiotepaTioguaninTislelizumabTisotumab vedotinTivozanibTocilizumabTopotecanTrabectedinTrametinibTrastuzumabTrastuzumab DeruxtecanTrastuzumab emtansineTremelimumabTreosulfanTretinoinTrifluridineTriptorelinTrofosfamideTucatinibVandetanibVemurafenibVenetoclaxVinblastineVincristineVincristine liposomalVindesineVinfluninVinorelbineVismodegibVoxelotorZanubrutinibChemo-substanceAbemaciclibAbirateroneAcalabrutinibAdagrasibAfatinibAfliberceptAlectinibAlemtuzumabAlpelisibAmivantamabAmsacrineAnagrelideAnastrozoleApalutamideArsenic TrioxideAsciminibAsparaginaseAtezolizumabAvapritinibAvelumabAxitinibAzacitidineAzathioprineBelantamab MafodotinBelzutifanBendamustineBevacizumabBicalutamideBinimetinibBleomycinBlinatumomabBortezomibBosutinibBrentuximab vedotinBrigatinibBuserelinBusulfanCabazitaxelCabozantinibCapecitabineCapivasertibCapmatinibCarboplatinCarfilzomibCarmustineCemiplimabCeritinibCetuximabChlorambucilCiclosporin ACisplatinCladribineClofarabinCobimetinibCrizanlizumabCrizotinibCyclophosphamideCytarabineDabrafenibDacarbazineDacomitinibDactinomycinDaratumumabDarolutamideDasatinibDaunorubicinDaunorubicin-cytarabine liposomalDecitabineDecitabine-CedazuridineDegarelixDexamethasoneDocetaxelDostarlimabDoxorubicinDoxorubicin liposomalDoxorubicin pegylated liposomalDurvalumabEculizumabElacestrantElotuzumabElranatamabEmapalumabEncorafenibEnfortumab VedotinEntrectinibEnzalutamideEpcoritamabEpirubicinErdafitinibEribulinErlotinibEtoposideEverolimusExemestaneFedratinibFludarabineFluorouracilFolinic acidFruquintinibFulvestrantFutibatinibGefitinibGemcitabineGemtuzumab OzogamicinGilteritinibGlasdegibGlofitamabGoserelinHuman albumin 20%Human immunoglobulin (SCIg)HydrocortisoneHydroxyureaIbrutinibIdarubicinIdelalisibIfosfamideImatinibInotuzumab OzogamicinInterferon alpha-2aInterferon alpha-2a pegylatedInterferon beta-1aIpilimumabIrinotecanIrinotecan pegylated liposomalIsatuximabIvosidenibIxazomibLanreotideLapatinibLarotrectinibLenalidomideLenvatinibLetrozoleLeuprorelinLomustineLoncastuximab TesirinLorlatinibLurbinectedinMargetuximabMegestrolMelphalanMepolizumabMercaptopurineMesnaMethotrexateMethylprednisoloneMidostaurinMirvetuximab SoravtansinMitomycinMitotanMitoxantroneMogamulizumabMomelotinibMosunetuzumabMoxetumomab PasudotoxMycophenolate mofetilNab-paclitaxelNaCl 0.9%NelarabineNeratinibNilotinibNintedanibNiraparibNivolumabNivolumab-RelatlimabObinutuzumabOctreotideOfatumumabOlaparibOlaratumabOsimertinibOxaliplatinPaclitaxelPalbociclibPanitumumabPanobinostatPazopanibPeg asparaginasePegcetacoplanPembrolizumabPemetrexedPemigatinibPentostatinPertuzumabPirtobrutinibPixantronPolatuzumab vedotinPomalidomidePonatinibPralsetinibPrednisoloneProcarbazineQuizartinibRamucirumabRavulizumabRecombinant human hyaluronidaseRegorafenibRelugolixRibociclibRipretinibRituximabRopeginterferon alfa-2bRucaparibRuxolitinibSacituzumab GovitecanSelinexorSelpercatinibSelumetinibSiltuximabSodium FolinateSorafenibSotorasibStreptozocinSunitinibTafasitamabTagraxofuspTalazoparibTalimogen LaherparepvecTalquetamabTamoxifenTebentafuspTeclistamabTegafurTemozolomideTemsirolimusTepotinibThalidomideThiotepaTioguaninTislelizumabTisotumab vedotinTivozanibTocilizumabTopotecanTrabectedinTrametinibTrastuzumabTrastuzumab DeruxtecanTrastuzumab emtansineTremelimumabTreosulfanTretinoinTrifluridineTriptorelinTrofosfamideTucatinibVandetanibVemurafenibVenetoclaxVinblastineVincristineVincristine liposomalVindesineVinfluninVinorelbineVismodegibVoxelotorZanubrutinibNo. Substances12345678910 RadiotherapySupportive therapySupportive substanceAcetylsalicylic acidAciclovirAllopurinolAmphotericin BAnakinraAnti-thymocyte Globulin (Equine)AprepitantAvatrombopagBalanced Crystalloid SolutionBevacizumabBurosumabCalcium carbonateCaplacizumabCiclosporin ACimetidineCiprofloxacinClodronic acidClonazepamColecalciferolCotrimoxazoleCyanocobalaminDalteparinDarbepoetinDeferasiroxDeferiproneDeferoxamineDenosumabDexamethasoneDexrazoxaneDextrose 5%DimetindenEltrombopagEnoxaparinEpoetin alfaEpoetin thetaFamotidineFerric carboxymaltoseFerric DerisomaltoseFilgrastimFluconazoleFluorometholoneFolic acidFolinic acidFosaprepitantFostamatinibFurosemideGranisetronHeparinHuman immunoglobulin (IVIg)Human immunoglobulin (SCIg)Hyaluronic acidHydrocortisoneIbandron AcidIptacopanItraconazoleLevetiracetamLevofloxacinLipegfilgrastimLoperamideLuspaterceptMagnesiumMagnesium sulfateMesnaMethylprednisoloneMinocyclineMontelukastNaCl 0.9%NaphazolinePantoprazoleParacetamolPegfilgrastimPlerixaforPosaconazolePotassium chloridePrednisolonePyridoxineRasburicaseRecombinant human hyaluronidaseRomiplostimSodium BicarbonateSodium ThiosulfateSutimlimabTocilizumabUrsodeoxycholic acidValaciclovirZoledronic AcidSupportive substanceAcetylsalicylic acidAciclovirAllopurinolAmphotericin BAnakinraAnti-thymocyte Globulin (Equine)AprepitantAvatrombopagBalanced Crystalloid SolutionBevacizumabBurosumabCalcium carbonateCaplacizumabCiclosporin ACimetidineCiprofloxacinClodronic acidClonazepamColecalciferolCotrimoxazoleCyanocobalaminDalteparinDarbepoetinDeferasiroxDeferiproneDeferoxamineDenosumabDexamethasoneDexrazoxaneDextrose 5%DimetindenEltrombopagEnoxaparinEpoetin alfaEpoetin thetaFamotidineFerric carboxymaltoseFerric DerisomaltoseFilgrastimFluconazoleFluorometholoneFolic acidFolinic acidFosaprepitantFostamatinibFurosemideGranisetronHeparinHuman immunoglobulin (IVIg)Human immunoglobulin (SCIg)Hyaluronic acidHydrocortisoneIbandron AcidIptacopanItraconazoleLevetiracetamLevofloxacinLipegfilgrastimLoperamideLuspaterceptMagnesiumMagnesium sulfateMesnaMethylprednisoloneMinocyclineMontelukastNaCl 0.9%NaphazolinePantoprazoleParacetamolPegfilgrastimPlerixaforPosaconazolePotassium chloridePrednisolonePyridoxineRasburicaseRecombinant human hyaluronidaseRomiplostimSodium BicarbonateSodium ThiosulfateSutimlimabTocilizumabUrsodeoxycholic acidValaciclovirZoledronic AcidSupportive substanceAcetylsalicylic acidAciclovirAllopurinolAmphotericin BAnakinraAnti-thymocyte Globulin (Equine)AprepitantAvatrombopagBalanced Crystalloid SolutionBevacizumabBurosumabCalcium carbonateCaplacizumabCiclosporin ACimetidineCiprofloxacinClodronic acidClonazepamColecalciferolCotrimoxazoleCyanocobalaminDalteparinDarbepoetinDeferasiroxDeferiproneDeferoxamineDenosumabDexamethasoneDexrazoxaneDextrose 5%DimetindenEltrombopagEnoxaparinEpoetin alfaEpoetin thetaFamotidineFerric carboxymaltoseFerric DerisomaltoseFilgrastimFluconazoleFluorometholoneFolic acidFolinic acidFosaprepitantFostamatinibFurosemideGranisetronHeparinHuman immunoglobulin (IVIg)Human immunoglobulin (SCIg)Hyaluronic acidHydrocortisoneIbandron AcidIptacopanItraconazoleLevetiracetamLevofloxacinLipegfilgrastimLoperamideLuspaterceptMagnesiumMagnesium sulfateMesnaMethylprednisoloneMinocyclineMontelukastNaCl 0.9%NaphazolinePantoprazoleParacetamolPegfilgrastimPlerixaforPosaconazolePotassium chloridePrednisolonePyridoxineRasburicaseRecombinant human hyaluronidaseRomiplostimSodium BicarbonateSodium ThiosulfateSutimlimabTocilizumabUrsodeoxycholic acidValaciclovirZoledronic AcidSupportive substanceAcetylsalicylic acidAciclovirAllopurinolAmphotericin BAnakinraAnti-thymocyte Globulin (Equine)AprepitantAvatrombopagBalanced Crystalloid SolutionBevacizumabBurosumabCalcium carbonateCaplacizumabCiclosporin ACimetidineCiprofloxacinClodronic acidClonazepamColecalciferolCotrimoxazoleCyanocobalaminDalteparinDarbepoetinDeferasiroxDeferiproneDeferoxamineDenosumabDexamethasoneDexrazoxaneDextrose 5%DimetindenEltrombopagEnoxaparinEpoetin alfaEpoetin thetaFamotidineFerric carboxymaltoseFerric DerisomaltoseFilgrastimFluconazoleFluorometholoneFolic acidFolinic acidFosaprepitantFostamatinibFurosemideGranisetronHeparinHuman immunoglobulin (IVIg)Human immunoglobulin (SCIg)Hyaluronic acidHydrocortisoneIbandron AcidIptacopanItraconazoleLevetiracetamLevofloxacinLipegfilgrastimLoperamideLuspaterceptMagnesiumMagnesium sulfateMesnaMethylprednisoloneMinocyclineMontelukastNaCl 0.9%NaphazolinePantoprazoleParacetamolPegfilgrastimPlerixaforPosaconazolePotassium chloridePrednisolonePyridoxineRasburicaseRecombinant human hyaluronidaseRomiplostimSodium BicarbonateSodium ThiosulfateSutimlimabTocilizumabUrsodeoxycholic acidValaciclovirZoledronic AcidNo. Substances1234567891011121314151617Protocol classificationTherapy classificationalternativecurrent standardempirical, modifiedformer alternativeindividual (author)older age and/or reduced general conditionother protocolspecial situationstudy analogStudy protocol, currentIntensityDose denseDose intensifiedhigh doseHigh dose myeloablativeLow doseStandard doseTherapy indicationFirst lineRefractory diseaseRelapse therapySecond lineseveral possibleThird line Therapy phaseautologous stem cell transplantationconditioningConsolidationInductionMaintenanceneoadjuvantneoadjuvant / adjuvantpost-neoadjuvantPre-phaseReinductionSalvageseveral possibleTherapy intentionconsolidationcurativecurative or palliativedisease controlpalliativesupportiveRisksAbdominal PainAcute Kidney InjuryAdrenal InsufficiencyAllergic ReactionAlopeciaAnemia Hb below 8g/dlAnemia Hb below 10g/dlAnorexiaArachnoiditisArthalgiaAstheniaAtrial FibrillationBleedingBone PainCapillary Leak SyndromeCardiotoxicityCataractCholangitisCholelithiasisCholinergic SyndromeCMV Infection (asympt. + sympt.)CNS ToxicityColitisConjunctivitisConstipationCystitisCytokine Release SyndromeDehydrationDepigmentationDepressionDiabetic KetoacidosisDiarrheaDifferentiation syndromeDrowsinessDysphagiaDysphoniaDyspneaEdemaElectrolyte DisturbanceEmbolismEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Endocrine Side EffectsEsophagitisExanthema, AcneiformFatigueFebrile NeutropeniaFistulasFlu-like SymptomsFractureGastrointestinal ToxicityGynecomastiaHand-Foot SyndromeHeadacheHeart FailureHematotoxicityHematuriaHemolytic Uremic SyndromeHemorrhageHepatotoxicityHerpes ZosterHyperbilirubinemiaHypercalcemiaHypercholesterolemiaHyperglycemiaHyperhidrosisHyperkalemiaHyperkeratosisHyperphosphatemiaHypertensionHyperthyroidismHypertriglyceridemiaHypoalbuminemiaHypocalcemiaHypogammaglobulinemiaHypoglycemiaHypokalemiaHypomagnesemiaHyponatremiaHypophosphatemiaHypophysitisHypotensionHypothyroidismIncrease Alkaline PhosphataseIncrease AminotransferasesIncrease Creatinine PhosphokinaseIncrease in lipaseInfectionsInfusion ReactionKeratopathyLeukopeniaLibido ReductionLymphopeniaMucositisMuscle WeaknessMyalgiasMyocarditisMyositisNail ChangesNasopharyngitisNauseaNephritisNephrotoxicityNeuropathyNeurotoxicityNeutropeniaOral MucositisOsteonecrosis of the JawOsteopeniaOtotoxicityPainPalpitationsPancreatitisParesthesiaPhotosensitivityPleural EffusionPneumoniaPneumonitisProteinuriaPruritusPyrexiaQTc Time ExtensionRadiation DermatitisRashRenal FailureRenal failure!RetinopathySeizuresSepsisSerum SicknessShockSpinal Cord CompressionTachycardiaTear DropThrombocytopenia below 50 000/µlThromboembolic EventTumor Lysis SyndromeUpper Respiratory Tract InfectionVenous ThrombosisVisual DisturbancesVOD/SOSVomiting only studiesPublicationAuthorAapro MAbali H Abou-Alfa GKAbramson JAdams SAddeo RAdelstein DAdkinson NAgarwal NAghajanian CAgulnik MAhmed AAiroldi MAisner JAix SAjani JAAkaike TAl-Batran SAl-Batran SEAl-Sawaf OAlbain KSAlbers PAlifrangis CAllegra CJAllen PAlley EWAlvarez-Twose IAmadori SAndersen JAndersson MAnderton JAndre FAndre TAndré TAndré T Andtbacka RAngelotti FAngelucci EAntonia SApostolidis LArance AArdeshna KMArmand PArnold DArriagada RArriagada R Asai S Assenat EAtaga KIAter JLAtkins MB Attal MAuerbach MAvvisati GAydin SB. LöwenbergBaas PBaba HBahadoer RRBaiocchi RABajorin DFBalar ABang YBang YJBardia ABarete SBaselga JBastholt LBatchelor TTBatist GBaudin EBauml JBauml J / Cohen EBayraktar SBaz RBeer TBehringer KBekaii-Saab TS Belani CPBell JBellmunt JBenboubker LBerentsen SBerghmans TBerry WBhattasali OBias PBidard FCBirgegård GBirgens HBirtle ABlack DBlay JYBleehen, NBleiberg HBluthgen MV Boccia RBody JBokemeyer CBolton EM Bonner JBonner JBorchmann PBosl GBossi EBossi PBraess JBrahmer JBrandenburg ABriasoulis ABriasoulis EBringhen ABringhen SBrizel DMBrock PBrose MBrown JRBrown SBruix JBröckelmann PBuckner JCBudach V Budde LEBudd GTBuehrlen MBui NBurchert ABurger JBurger RABurkhardt BBurnett ABurnett AKBurotto MBurris HABurstein HJBurtness BBusakhala NWBusea JBuske CBussel JByrd JCBöll BBüchner TCaballero MDCalais GCalaminus GCamidge DCampbell MTCancer Care OntarioCanon JCantu MACao XCapdevila JCaplin MECappellini MDCappuzzo FCasassus PCascone TCasey ACassidy JCastillo JCastillo JJCats ACencini ECenter for Esophageal and Gastric Cancer, Dana-Farber/Brigham and Women’s Cancer Center, Boston, ZAMEGA trialCercek A Chalabi MChalandon YChan AChandra P. BelaniChan SChao NJChao YChapel HChapman PChari AChawla SCheeseman SChen APChen RCheson BDChi KChi KNChi PChitapanarux ICho BCCho JChoudhury AChoueiri TChoueiri TKChow W Choy HChugh RChung HCChu QCianfrocca MCinieri SCitron MLClarke NWC ManegoldCohenCohen ACohen OC Coiffier 2002Coleman JAColeman RColleoni MColombo NColwill RConconi AConnors JConroy, ThierryConroy TConteduca VCoombes RCCooper JCooper MACoppin CMCorn PG Corso ACortes JCortes JECortés JCraddock CCramer PCrawford JCremolini CCrump MC SederholmCullen MCunningham DCurran WCzuczman MSDamaj GDao KTDasari ADash ADaver NDavids MSDavies ADavis EDavis IDDavis LEDeAngelo DJDearden CDebaere DDe Boer Sde Bono JDe Bono Jde Bono JSDecker TDefachelles ASde Gramont Ade Haar-Holleman ADelyon Jde Man FM Demetri GDemetri GDDenise YardleyDenschlag DDepartment of Medical Oncology, Franco-British Institute, GERCOR VELVET trialDerman BADe Santis MDevalia VDiamond EDickinson MJDickson MDiel IDierks CDietrich SDi Lauro LDi Leo ADi Lorenzo GDilz LMDimopolous MDimopoulos MDimopoulos MADiNardo CDDirix LDirksen UDispenzieri A Doebele RDoki YDombret HDonadieu JDouillard, JYDouillard JYDreyling MDreyling M et al.Drilon ADu Bois ADucreux MDuell JDummer RDunleavy KDuvic MEarly Breast Cancer Trialists Collaborative Group (EBCTCG)Eberhardt WEbert MPEckardt JRE F SmitEggermont AEggermont A /Luke JEhl SEichenauer DAEichhorst BEichhorst BFEisenberger MEl Gnaoui TElias DElisei RElse MEmilia GEngert AE QuoixErba HPEscudier BEskander RNFacon TFader ANFaivre-Finn CFalcone 2007Fan CF A ShepherdFassnacht MF BarlesiFeldman DFelip EFenaux PFerrandina GFerrari SFerreri AJFerris RF FossellaFields PAFinn RFinn RSFischer KFizazi KFolprecht GFong CFoote MCForde PMFornasiero AForstpointnerFoà RFraser GFridle CFriedberg JW Friedlander MFriedman HSFrikha MFritsch KFuchs, CSFuchs CFuchs CSFukano RFukuoka SFurmanFurqan FFury MFushimi CGabrilove JGadner HGaidzik VGainor JFGandhi LGarcia-Manero GGarcıá-del-Muro XGaron EGasparini G Gatzemeier UGavriatopoulou MGay FGbolahan OBGeisler CHGeorgoulias VGershenson DMGeyer CEG FrasciGhia PGhielmini MGhi MGhobrial IMGhorani EGiaccone GGiannatempo PGianni LGianni L / Schneeweiss AGiesen N Gilbert JGisselbrecht CGisslinger HGlantz MGleeson MGluz OGnant MGodeau BGoede VGoetz MGogishvili MGolan TGoldschmidt HGong JGonzález Martín A Gopal AGopal AKGordon ANGoss GGotlib JGoto KGounder MMGoy AGoyal LGradishar WJGrau JGreenberg PGrever MGridelli CGriffin TCGrivas PGrob JGrobmyer SRGrobost VGronchi AGrosicki SGross-Goupil MGross AMGrossman HBGrossman SGross NDGrothey AGroves MGrünwald VGuardiola EGuigay JGulhati PGuo CGustave Roussy, Villejuif, FranceGutierrez AGutzmer RG V ScagliottiGökbuget DGökbuget NGökbuget N, Hartog CHaarst JMWHaas NHaddad RHainsworth JHainsworth JDHallek MHaller DGHall PSHamilton EHandolias DHanna, NHanna GJHanna NHarbeck NHarousseau JHarrison CHarstrick AHarvey VHedenus MHegenbart UHeidemann EHeidemann WHeigener DFHeinemannHeinrich MCHelbekkmo NHeld GHellmann MDHellström-Lindberg EHensley MLHerbaux CHerbrecht RHerbst RHerold MHerold M Herrera AFHerrlinger UHerskovic AHertzberg MSHe SHess GHeymach JV HiddemannHillmenHillmen PHironaka SHirose THitt RHochster HHochster HSHodi FHoelzer DHofheinz RDHolowieki JHomesley HHong DSHong WKHopfinger GHorn LHorowitz NS Horstmann MHortobagyi GHorwitz SHosseinipour MCHouillier CHoward JHuang HHuber HHudes GHuebner GHulshof MCCMHunold AHunter AMHuober JHurt CHussein AHu XCIacovelli RRIhde, DIllerhaus GIlson DHIm SAInternational Collaboration of TrialistsItaliano AItzykson RJ-L PujolJabbour EJackisch CJames NJan de Beur SMJanjigian YJanjigian YYJaramillo SJassem JJawhar MJ CarmichaelJD HainsworthJD PatelJhaveri KLJimenez CJoan H. SchillerJoensuu HJohnson DHJohnson MLJohnston SRDJoly FJonasch EJones EJones GLJoseph KJosting AJP StevensonJudson IJurczak WJäger UJänne PAJürgens CKaira KKalakonda NKang EJKang JHKang YKantarjian HKantarjian HMKantarjian JKastritis EKatanyoo KKato KKatsumata NKaufman BKaufman JLKaufmann HKawaguchi TKelley RKKellokumpu-Lehtinen PKelly RJKersten MKhansur T Kim DKim HDKimmich CRKim RDKim SKim STKim YHKirschey SKitagawa RKlotz LKluin-NelemansKnauf WKnauf WUKollmannsberger CKonstantinopoulos PAKoopman MKopetz SKopmar NKorblum NKortmann RKoscielniak E, Klingebiel TKosmidis PKotake MKo YJKraybill WGKreitman RKreitman RJKrishnan AKrop IEKuboki YKudo MKuhfahl JKuijpers AKumar AKumar SKKumthekar PKunitoh HKunitoh H Kunzmann VKuriakose ETKurzrock RKuter DKwok MKöhne CKöhne C, Metzger RKöhne CHKönig LKörholz DLakshman ALamarca ALambert JLancet JELandgren COLanger CLang ILangley RELarkin JLebbé CLeDeley MLe DTLee ALee AWMLee CKLee JLee J / Kulasekararaj ALee JLLemma GLemma GLLentzsch SLenz GLenz HLeone FLe RQLesokhin AM Levine ALevin VALevis MJLeypoldt LBL G Paz-AresLi BTLi JLim KHLin JLipton ALissoni ALittle RLitton JLiu E Liu YLi XLlovet JLo-Coco FLocatelli FLocati LDLoehrer, PJLoehrer PLoehrer PJLoesch DLong GLong HLonial SLorch ALorenzen SLorenzen S Loriot YLorusso DLoupakis FLudwig HLuminari SLu SLuskin MRLv JLynch RCLöwenberg BLübbert MLück HJM. DankMacDonald JSMacManus MMaio M Maisch BMaki RMakker VMalinovszky K Mamdani H Mannone LMao YMarabelle AMarcus RMarina NMaring SMarkman MMartin AMartinelli GMartin MMartinoni A Massard CMasuda NMatei DMateos MMattson K Matulonis UAMaude SLMavroudis DMayer R / Van Cutsem EMayer RJMazieres JMcCarthy PMcNeish IAMead GMMedina JAMeerpohl JJMehanna HMehta RSMercieca JMeric-Bernstam FMesa RMichel MMigden MRMileshkin LMiller DSMiller KMina RMinashi KMinckwitz GMinKe HeMirtsching BMirza MMirza MRMittendorf EM KarayamaMoccia AAModest DModest D.Modi SMoebus VMoehler MMoertel CGMok TMok T SMondaca SMonk BJMontagna EMontesinos PMoore DHMoore K / Pujade-Lauraine EMoore MJMoosmann NMoreau PMoreno CMorgan GJMorgan RDMorizane CMorris VKMorschhauser FMorschhauser F Morton DMoskowitz AJMoskowitz AJ Moskowitz CMotzer RMotzer RJMouridsen HMoyo VMMross KMubarak AMuers MFMulherin BPMunemoto YMunir TMurthy RKMusch EMuss HBMutch DGM ZukinNabholtz JMNakagawa KNapolitano S Nasti GNathan PNayak LNecchi ANeoptelemos JNeubauer MNghiem PN HannaNiederle NNishimoto NNoda, KNoda KNoronha VNottage MKNowak AKO'Brien MO'Connor OAO'Shaughnessy JOaknin AOaknin A Oberic L Oberkampf FOcvirk JOettle HOffner FOh DYOkamoto HOliva EN Oliver ROnoda NOosterom ATOpat SOrlowski RZOsborne RJOtt POtt PAOudard SOverman MOverman MJO´Brien SO´Malley DO´Reilly EPagliaro LPaik PKPalassini EPalladini GPalmeriniPalmieri G Pal SKPalumbo APandya KJPapadimitriou CAParker JPark KPark MSPark SPark YPark YHPaseo de San Vicente, Salamanca, Spain, ALCYONE trialPassweg JRPatel SPaterson APatil VMPautier PPawel JPaz-Ares LPaz-Ares LGPectasides DPedersen KSPeeters MPeffault de Latour R Pemmaraju NPenel NPentheroudakis GPerez EA Perl APerren TJPerrone FPeters SPettengell RPeyrade FP FidiasPfister CPfisterer JPfreundschuhPfreundschuh MPhillips AAPiccart MPignata SPinto CPirker RPizzocarro GP KosmidisPlanchard D Platzbecker UPolizzotto MNPorschen RPosch DPosner MPouessel DPoulsen MPourcher VPowles TPreneau SPreudhomme CPria APrice SPrimrose JN Prince HMPro BProvencio MPrusila REIPujade-Lauraine EPujol JLPujol JL et al.Purev EPönisch WQi FQuereux GQuinta´s-Cardama, A.Quoix, EQureshi ARaghav KRaghav KPRaje NRaj NRamaswamy ARamchandren RRandall MRao SRaspagliesi FRausch CRausch CRRavandiRavandi FRavaud ARay-Coquard I Raymond EReck MReece DReeder CBReid EGRha SYRibas ARichardson PRichardson PGRimawi MRini BRini B / Hutson ERini BIRinke ARittmeyerRivera ERizzieri DAR M RuddRobak TRobert CRoberts DJ Robinson KSRobson MRoché HRodriguez MARomero-Laorden NRomond EHRoschewski MRosenberg JRosenberg JERosen LRossel RRossi GRothenberg MLRoufosse FRoyer BRubenstein JRubenstein JLRudin CRugo HSRuhstaller TRummel MJRutkowski PRyan CRéa DRécherRödel CRöllig CRöth ASaglio GSaito HSakuramoto SSalama AKSSalles GSaltz LBSamlowski ESan-Miquel JFSanchorawala VSandler, A.Sanfilippo RSan Miguel JFSantoro ASanz ASartore-Bianchi ASasaki KSauer RSaura CSawaki MScagliotti et alSchaich MScheinberg PScheinberg T Scher HScherpereel ASchiller JSchiller JH et al.Schlumberger MSchmid PSchmiegel WSchmittel, ASchmittel ASchmitz NSchneeweiss AScholz CWSchrag DSchroeder TSchuetze SMSchuler M Schuster SJSchwaab JSchwartzberg LSchöffski PScully MSehn LSehn LHSehouli CSehouli JSeidman ADSeifart USeiter KSekiguchi NSekulic ASemrau SSenkus ESequist LVSerra-Aracil XSeto TSeymour JSeymour MTSezer AShah CShah JShah MShakoory BShanafelt TDSharama PSharman J PSharma PShaw AShaw ATShen LShimaoka KShitara KShore NDSiena SSieniawski MSikov WMSimko SSimon ASkarlos DVSkoulidis FSlamon DSledge GWSlomovitz BSmith, IESmith ISmith M / Cummings S / Saag KSmith MRSocincki MSocinski MSocinski MASoff GSolomon BSolomon BJSonneveld PSorbe, BSoria JSoria JCSosa JASoumerai JDSparano JASperone PSperr WRSpigel DSpigel DRStacchiotti SStasi RStebbing JSteensma DStein AStemmer HJSternberg CNStewart AKStilgenbauer SStockler MRStone RStone RMStorti SStratigos AJStrati PStratmann JStrauss GMStrickler JStrickler JHStrosberg JRStupp RSubbiah VSugawara SSugiyama T Sundstrøm SSuntharalingam MSun YSweeney CJSweeney JCSykes DBTabernero JTagawa STTakada MTakahashi HTakatoku M Talpaz MTam CSTan ARTanizaki JTannock ITannock IFTanyi JTao Y Tap WTap WDTarhini ATawbi HTawbi HATaylor MHTazi ATaïeb J Tchekmedyian, VTedeschi ATepper JTerzolo MTessoulin BTewari KSThatcher NThe Netherlands Cancer InstituteThieblemont CThiel AThind GThomas AThomas DAThomson DJ Thuss-Patience PTiacci ETillmanns TTilly HTjulandin STolaney STolaney SMTopalian SL Toumishey ETournigandTouzeau C Townsley DMToyokawa GTreon SPTreon SP Treuner J. Koscielniak ETrigo JTsimberidou ATurner NCTurrisi ATTuscano JMTutt ATutt ANJTwelves CUldrick TUntch MValle Jvan Cutsem EVan Cutsem Evan den Bent MJ van der Graaf WTvan der Heijden MS Van de Wyngaert Zvan Driel Wvan HagenVannucchi Avan Oers MHJvan Ramshorst MSVan Rhee FVasey PVasey PAVelasquez WSVellenga EVenner CPVerma SVermorken JVermorken JBVerstovsek SVichinsky EVillegas AVisani GVisco CVitolo UVogelzang NJVokes EEvon der Maase HVon Hoff DDvon Minckwitz Gvon Rohr AVoorhees PMWadler SWainberg ZAWakelee HWalter TWanebo HWang-Gillam AWang ESWang JWang MWang MLWang YWasserman RLWeber JWeber JSWeh HJWei AWei AHWeidmann EWein AWeisel KWelch JWells SWest HWhelan JWick WWierzbowska AWilke HWilky BAWilliamsWilliamson SWilliams SDWiner EWinton T Witzig TEWJ TesterWolf JWolfson AHWon YWWoodward NW SchuetteW SchütteWu YLXu JYaeger R Yamada YYamaguchi MYamamoto NYang HYan XYao JCYardley DYardley DAYates JWYau TYchou MYimer HYokoi KYoshida KYoshida MYou BYounes AYou RZaja FZalcman GZalupski MZeidan AMZeiser RZer AZhang LZheng YZhong WZZhou CZhou DZhu AZimmer LZinn DZinzani PZinzani PLZsiros RZucali PAZucca EZulu SDiseaseAdeno-, gering diff. oder gerin diff. Plattenepithel-CUP, ECOG 0-2Adeno-, gut oder gering diff. , ECOG 0-2, ErstlinieAdeno-Ca des Magens oder des ösophagogastr. Überganges, cT2 und höher oder cN+, M0Adeno-Ca des Magens oder des ösophagogastr. Überganges, HER2-positiv, cT2 und höher und/oder cN+, M0, ECOG 0-2Adeno-Ca des Magens oder des ösophagogastr. Überganges, mind. cT2 und/oder cN+, ECOG 0-1Adeno-Ca des Magens oder des ösophagogastr. Überganges, Stadium II, III, oder IVA, ECOG 0-1Adeno-Ca des Magens oder des ösophagogastr. Überganges, Stadium II, III, oder IV A, ECOG 0-1Adeno- oder Plattenepithelkarzinom des Ösophagus, lokal fortgeschritten, nicht resektabelAdeno- und undiff. metastasiertes CUP, ECOG 0-2, ErstlinieAdenoid-zystisches Karzinom, rezidiviert, inoperabel oder metastasiert, ECOG 0-1Adenokarzinom des Dünndarms oder der Papilla Vateri, ECOG 0-2Adenokarzinom des gastroösophagealen Übergangs oder des Magens, dMMR/MSI-H, cT2-4cN0/+cM0Adenokarzinom des Magens nach R0 Resektion und D2 Lymphknoten Dissektion, ECOG 0-1Adenokarzinom des Magens oder gastroösophagealen Übergangs nach R0 Resektion, Stadium Ib-IV, ECOG 0-1Adenokarzinom des Pankreas, frühes Stadium, adjuvant, ECOG 0-2Adenokarzinom nichtkleinzelliges Lungenkarzinom, Stadium IIIb/IV oder rezidiviert, ECOG 0-1Adenokarzinom ösophagogastraler Übergang und Magen, HER2+, ECOG 0-2Adenokarzinom ösophagogastraler Übergang und Magen, lokal fortgeschritten, inoperabel, oder metastasiert, ECOG 0-1Adenokarzinom ösophagogastraler Übergang und Magen, metastasiert, Erstlinie, ECOG 0-1adjuvante Behandlung des Kolon-Karzinoms, Stadium 2/3, ECOG 0-1Adultes T-Zell Lymphom, rezidiviert oder therapierefraktär, ECOG 0-2AEG- oder Magenkarzinom, Adenokarzinom, Stadium II/III, ECOG 0-1AEG-Tumor und Magen-Ca (Adenokarzinom), metastasiert, Erstlinie, ECOG 0-2AEG/Magenkarzinom lokal fortschritten, inoperabel, mindestens 1 platinhaltige VortherapieAggr. B-NHL, Rezidiv oder therapierefraktäraggr. B-NHL incl. DLBCL, nach Rezidiv oder bei fehlendem CR unter Erstlinie mit CHOP, ECOG 0-1Aggr. B-NHL über 80 Jahre oder unter 80 mit KI gegen R-CHOP, ErstlinieAggr. oder de novo transf. B-NHL, Rezidiv - Drittlinie und höher, ECOG 0-2aggr. syst. Mastozytose, Mastozytose mit hämatolog. Neoplasie, Mastzellenleukämie, ECOG 0-3aggressive, CD 20+ B-NHL, 18-60 Jahre, Erstlinie, ECOG 0-3Aggressive B-NHL, Patienten zwischen 65 und 85 Jahren, ECOG 0-2aggressive CD20+ B-NHL, 61-80 Jahre, ECOG 0-1aggressive CD20+ B-NHL, 61-80 Jahre, ECOG 0-4aggressive CD20+ B-NHL, 61-80 Jahre, Hochrisiko-Patienten, ECOG 0-1Aggressive Fibromatose (Desmoid), neu diagnostiziert oder rezidiviert, nicht operabel, ECOG 0-1Aggressive Fibromatose, lokal fortgeschrittenaggressives B-/T-NHL, Erstlinie, ECOG 0-3Aggressives B-NHL, 61-80 Jahre, Erstlinie, ECOG 0-2Aggressive systemische Mastozytose, systemische Mastozytose mit assoziierter hämatologischer Neoplasie, Mastzellleukämie aktive, unbehandelte CLL, mit Behandlungsindikation, ungeeignet für Chemoimmuntherapie oder ≤60 Jahre, ECOG 0-2aktive, unbehandelte CLL, mit Behandlungsindikation, ungeeignet für Chemoimmuntherapie oder ≥ 65 Jahre, ECOG 0-2Aktue Promyelozyten Leukämie, Hochrisiko (Leukozyten >10 000/µl), ECOG 1-3Akute Graft-versus-Host-Erkrankung Grad II-IV, steroidrefraktärAkute lymphatische Leukämie, 18-55 JahreAkute lymphatische Leukämie, 56-75 JahreAkute lymphatische Leukämie, 56-75 Jahre, Ph/BCR-ABL+Akute lymphatische Leukämie, B/T lymphoblastisches LymphomAkute lymphatische Leukämie, lymphoblastische Lymphome, 18-55 JahreAkute lymphatische Leukämie, lymphoblastische Lymphome, 56-75 JahreAkute lymphatische Leukämie, lymphoblastische Lymphome, Therapieversagen oder MRD-Persistenz nach Konsolidation I,18-55 JahreAkute lymphatische Leukämie, Ph/BCR-ABL+, 18-55 JahreAkute lymphatische Leukämie, Rezidiv nach der ErstlinientherapieAkute myeloische Leukämie, RezidivtherapieAL-AmyloidoseAL-Amyloidose, mindestens 1 Vortherapie, ECOG 0-2AL-Amyloidose, neu diagnostiziertAL-Amyloidose, neu diagnostiziert, ECOG 0-2AL-Amyloidose, neu diagnostiziert, nicht geeignet für ASCTAL-Amyloidose, neu diagnostiziert oder rezidiviertAL-Amyloidose, nicht für ASCT geeignet, mindestens 1 Vortherapie, ECOG 0-2AL-Amyloidose, nicht vorbehandelt, nicht geeignet für ASCTAL-Amyloidose, rezidiviert oder therapierefraktär, 1-2 VortherapienAL-Amyloidose, therapierefraktär oder rezidiviertAL-Amyloidose, vorbehandeltAL-Amyloidose, vorbehandelt, ECOG 0-1, Kreatinin-Clearance über 40 ml/min, EF über 40%AL-Amyloidose ohne fortgeschrittene kardiale Beteiligung (Stadium IIIb nach Mayo 2004/European cardiac staging system), nicht geeignet für eine ASCTALL, rezidiviert oder therapierefraktärALL bei Frail Patienten, ErstlinieALL bei Frail Patienten, Ph/BCR-ABL+, ErstlinieAlveoläres Weichteilsarkom, nicht resezierbar oder metastasiert, ab 2 JahreAML (Doppel-)InduktionAML, Alter ab 55 J., CR/CRi nach Induktion, nicht für eine HSZT geeignet, ECOG 0-3AML, CD33 positiv, rezidiviertAML, Erstlinie Induktion, ECOG 0-4AML, Erstlinientherapie, für eine Standardtherapie nicht geeignet, ECOG 0-2AML, FLT3-ITD positiv, komplette hämatologische Remission nach allogener SCTAML, FLT3-Mutation (ITD oder TKD), mind. 1 Vortherapie, ECOG 0-2AML, neu diagnostiziertAML, neu diagnostiziert, FLT3-ITD+AML, nicht geeignet für intensive Chemotherapie, nicht vorbehandelt, Alter >65 J.AML, rezidiviert oder therapierefraktärAML, rezidiviert oder therapierefraktär, IDH-1-mutiert, ECOG 0-2AML- oder CMML-Rezidiv nach allogener StammzelltranplantationAML- oder MDS-Rezidiv nach allogener StammzelltranplantationAML > 60 Jahre, rezidivierende AML oder transfusionspflichtiges MDS, ECOG 0-2AML KonsolidierungAML oder Hochrisiko MDS, nicht für eine Standard-Induktionschemotherapie geeignet, ECOG 0-2AML therapierefraktär oder FrührezidivAnalkarzinom, Plattenepithel-, metastasiert oder nichtresezierbares Rezidiv, ECOG 0-1 anaplastisches diffus großzelliges B-Zell-Lymphom, ALK+, Zweitlinieanaplastisches großzelliges T-Zell Lymphom, rezidiviert oder therapierefraktär, ECOG 0-1Anaplastisches Schilddrüsenkarzinom, lokal fortgeschritten oder metastasiert, ECOG 0-2Anaplastisches Schilddrüsenkarzinom, RET-fusionspositivAngiosarkom, bis zu 2 Vortherapien, ECOG 0-1Angiosarkom oder epitheloides Hämangioendotheliom, bis zu 3 Vortherapien, ECOG 0-1APL mit t(15;17) und/oder PML-RARA Rearrangement, ErstlinieAtypische chronische myeloische Leukämie, BCR-ABL-negativautoimmune Thrombozytopenieautoimmunhämolytische Anämie, kälteagglutinin-induzierte Durchblutungsstörungenautoimmunhämolytische Anämie, Kälteagglutininerkrankungautoimmunhämolytische Anämie, KälteagglutininkrankheitAutoimmunhämolytische Anämie, Kälteagglutininkrankheit, symptomatisch, Hämoglobinwert unter 10.0 g/dL, autoimmunhämolytische Anämie, vom Wärmetyp, Drittlinieautoimmunhämolytische Anämie, vom Wärmetyp, refraktäre ErkrankungB-/T-ALL, Ph/BCR-ABL-, 18-59 Jahre, ECOG < 4B-ALL, CD19+ rezidivierte oder refraktäre B-ALL, Lymphodepletion vor CAR T-Zell TherapieB-ALL, Ph/BCR-ABL+, 18-59 Jahre, ECOG < 4B-NHL, refraktär oder rezidivierend, ohne Eignung zur HochdosistherapieB-NHL, rezidiviert oder therapierefraktär, CD19- positiv, Lymphodepletion vor CAR T-Zell TherapieB-Non-Hodgkin-Lymphom/Hodgkin LymphomB-Vorläufer ALL, mit MRD > 0,1%, nach Chemotherapie B/T-ALL, Ph/BCR-ABL-, 18-59 Jahre, ECOG < 4Blastische plasmazytoide dendritische Zellneoplasie, ECOG 0-2Brustkrebs bedingte KnochenmetastasenBurkitt-Lymphom, ZNS-Befall vor Beginn der TherapieBurkitt-Lymphom bei ErwachsenenBurkitt-Lymphom bei Erwachsenen, ErstlinieCAR-T-Zell-induziertes Zytokin-Freisetzungs-SyndromCD20-positives follikuläres Lymphom Grad I-IIIa, rezidiviert oder therapierefraktär, nach mindestens 1 rituximabhaltiger Therapie, ECOG 0-2CD20-positives indolentes B-Non-Hodgkin-Lymphom, rezidiviert oder therapierefraktär, nach mindestens 1 rituximabhaltiger Therapie, ECOG 0-2Chemonaive Patienten mit metastasiertem MagenkarzinomChemotherapieinduzierte Anämie, Hb < 10,5 g/L, Ferritin < 450 pmol/L oder < 675 pmol/L mit einer TSAT < 19%, ECOG 0-2Chemotherapierefraktäres MerkelzellkarzinomChondrosarkom, Grad 1-2, Chordom, ab 13 J., ECOG 0-2Chondrosarkom, lokal fortgeschritten oder metastasiert, IDH1 Mutation, ECOG 0-1Chrondrosarkom, lokal fortgeschritten, oder metastasiert, ECOG 0-2Chronische Graft-versus-Host-Erkrankung moderat oder schwer, steroidrefraktär oder steroidabhängigChronische Immunthrombozytopenie, vortherapiertChronische ITP, therapierefraktär, Karnofsky über 70Chronische lymphatische Leukämie, CD20+, ErstlinieChronische lymphatische Leukämie, ErstlinieChronische lymphatische Leukämie, Erstlinie, > 64 Jahre, ECOG: 0-2Chronische lymphatische Leukämie, Erstlinie, del(17p) und/oder TP53 MutationChronische Myelomonozytäre Leukämie, Erstline, ECOG 0-2chronische Neutrophilenleukämiechronisch myeloische Leukämie, Ph+/BCR-ABL+, Drittlinie und höherCLL, Erstline bei Patienten ohne Eignung für Fludarabin, Zweitlinie bei RezidivCLL, Erstlinie, ECOG 0-2CLL, Erstlinie, ECOG 0-2 CLL, Erstlinie, ECOG 0-2, älter als 65 J (oder älter als 18 und Kreatinin-Clearance von 30–69 ml/min oder CIRS größer 6)CLL, Rezidiv, Progress innerhalb von 24 Monaten nach letzter Therapie, nicht Chemotherapie geeignet CIRS mindestens 6, CD20 Antikörper-Therapie oder 2 frühere ChemotherapienCLL, rezidiviert oder therapierefraktär, ECOG 0-2CLL, Rezidiv oder refraktär, ECOG 0-2CLL, therapiebedürftig nach iwCLL 2008-Kriterien, Patientenalter 18-65 Jahre, ECOG 0-1CLL mit Behandlungsindikation, ECOG 0-2, ErstlinieCLL mit Behandlungsindikation, Erstlinie, aufgrund Alter oder AZ Kontraindikation gegen Fludarabin-basierte TherapieCLL mit Behandlungsindikation, Erstlinie, ECOG 0-1, geringe Komorbiditäten CLL mit Behandlungsindikation, Erstlinie, ECOG 0-2CLL mit Behandlungsindikation, Erstlinie, ECOG 0-2, Patienten zwischen 65 und 80 Jahre altCLL mit Behandlungsindikation, Erstlinie, relevante Komorbidität (CIRS-Score >6 oder KreaClearance zwischen 30 und 69 ml/min)CLL oder SLL, Erstlinie, > 65 Jahre, ECOG 0-2CLL oder SLL, mindestens eine VortherapieCLL Stadium B und C mit Behandlungsindikation, Erstlinie, ECOG 0-2CLL Std. B und C mit Behandlungsindikation, Erstlinie, ECOG 0-2CML, chronische Phase, Erstlinie, ECOG 0-2CML in der SchwangeschaftCML oder Ph+/BCR+ ALL, resistent auf Dasatinib oder Nilotinib, ECOG 0-2CMML (WHO 2016)Coiffier 2002: DLBCL, 60-80 Jahre, ECOG 0-2, Erstlinie , Cunningham 2013: DLBCL, ab 18 Jahren, ECOG 0-3, Erstlinie.CUP, nach platinhaltiger Chemotherapie, ECOG 0-1CUP Syndrom, ECOG 0-2, ErstlinieCUP Syndrom mit guter Prognose, ECOG 0-1, Erstliniede-novo oder sekundäre AML, mindestens 1 nicht-kurative Vortherapie, über 65 JahreDecitabin für Patienten ab 61 Jahren mit de novo oder sekundärer AML, für intensive Therapie nicht geeignet, ECOG 0-2Decitabin für Patienten ab 65 Jahren mit neudiagnostizierter de novo oder sekundärer AML, ECOG 0-2De novo oder sekundäre AML, Hochrisiko MDS, PS 0-4De novo oder sekundäres myelodyplastisches Syndrom, alle Risikogruppen, ECOG 0-2Dermatofibrosarcoma protuberans, lokal fortgeschritten oder metastasiert, teilweise mit fibrosarcomatöser Transformationdiffus großzelliges B-Non-Hodgkin-Lymphom, 2-5 Vortherapien, nicht geeignet für autologe SCT, ECOG 0-2diffus großzelliges Non-Hodgkin-Lymphom, HochrisikoDLBCL, 60-75 J., ErstlinieDLBCL, Ann-Arbor II-IV, CR oder PR nach 6-8 Zyklen R-CHOP, 60-80 J., ECOG 0-2DLBCL, Ann Arbor Stadium I-IV, über 80 J., ECOG 0-2DLBCL, Erstlinie, bis 59 JahreDLBCL, Erstlinie, IPI 2-5, ECOG 0-2DLBCL, Erstlinie, Kontraindikation für AnthrazyklineDLBCL, kardiale Komorbiditäten mit Kontraindikation für die Anthrazyklingabe, ErstlinieDLBCL, Kontraindikation für AnthrazyklineDLBCL, rezidiviert oder therapierefraktär, mind. 2 VortherapienDLBCL, Rezidiv nach mind. 2 Vortherapien, ASCT ungeeignet oder bereits unterzogen, Lymphodepletion vor CAR-T-Zell TherapieDLBCL, Rezidiv nach mind. 2 Vortherapien, ASCT ungeeignet oder bereits unterzogen, Lymphodepletion vor CAR T-Zell TherapieDLBCL, Rezidiv oder refraktär, mit mindestens einer anthrazyklinhaltigen VortherapieDLBCL, Stadium II - IV, CD20+, Erstlinie, ECOG 0-2DLBCL, über 80 Jahre, ECOG 0-2, ErstlinieDLBCL Stadium I-IV, älter als 60 Jahre, Erstlinie, ECOG 0-2Drohendes AML- oder MDS-Rezidiv nach allogener Stammzelltranplantation (Spenderchimärismus <80%)Dysgerminom, Stadium IB-III, nach kompletter Resektion, bei Patientinnen, die keine hohe Toxizität tolerieren könnenEisenmangel- / Anämie, Hb ≤11 g/dL, Transferrinsättigung (TSAT) <20%, and S-Ferritin <100 ng/mLEisenmangelanämie Hämoglobin <12,0 g/dL (Frauen) und <14,0 g/dL (Männer) und Transferrinsättigung 20% oder Ferritin 100 ng/mL innerhalb von 60 Tagen nach der Verabreichung)Eisenüberadung beim MDS (IPSS low/intermediate risk I)Eisenüberladung bei IPSS low- or intermediate-1–Risiko MDSEisenüberladung bei ThalassämieEndometrium-Ca, Stadium III-IV, adjuvant und nach Strahlentherapie, ECOG 0-2Endometriumkarzinom, adeno- oder plattenepithel-adeno, Zweitlinie, ECOG >1Endometriumkarzinom, FIGO III-IVA, ECOG 0-2, ErstlinientherapieEndometriumkarzinom, lokal fortgeschritten, nicht operabel oder metastasiert, FIGO III oder IV, ECOG 0-1Endometriumkarzinom, lokal fortgeschritten, nicht operabel oder metastasiert, FIGO III oder IV, ECOG 0-2Endometriumkarzinom, nach Versagen einer vorangegangenen hormonellen oder BestrahlungstherapieEndometriumkarzinom, Stadium I-III, postoperativ, ECOG 0-2Endometriumkarzinom, Stadium III-IV, nicht operabel, ECOG 0-2, ErstlinieEndometriumkarzinom Stadium III-IV, ECOG 0-3Entdifferenziertes Liposarkom, nach 2-5 Vortherapien, ECOG 0-1Enteropathie assoziiertes T-Zell-Lymphom, ErstlinieEntzündlicher Myofibroblastentumor (inflammatorischer Myofibroblastentumor), lokal fortgeschritten, inoperabel, ALK+Erdheim-Chester-Krankheit / Langerhanszell-Histiozytose, Erst- und Zweitlinie, älter 16 Jahre, ECOG 0-3Erdheim-Chester-Krankheit und Langerhanszell-Histiozytose, BRAF V600–Mutation, Erstlinie, ECOG 0-2Erstdiagnose eines primären NHL des ZNS, 18-65 JahreErstlinie bei unresektablem, metastasiertem kolorektalen Karzinom, ECOG 0-1Erstlinie bei unresektablem, metastasiertem kolorektalen Karzinom, RAS and BRAF wt, ECOG 0-2Erstlinientherapie beim Burkitt-LymphomErstlinientherapie beim inoperablen, malignen Pleuramesotheliom, Karnofsky Status > 70Erstlinientherapie beim malignen Pleuramesotheliom, Alter <75 Jahre, ECOG 0-2Erstlinientherapie beim malignen Pleuramesotheliom, ECOG 0-2Erstlinientherapie beim primär mediastinalen B-Zell LymphomErstlinientherapie fortgeschrittenes kolorektales KarzinomErstlinientherapie met. kolorektales Karzinom, ECOG 0-2essentielle Thrombozythämie, nach WHO KlassifikationEssentielle Thrombozythämie, neu diagnostiziert oder vorbehandeltEwing Sarkom, ErstlinieExtensive-Stage SCLC, Erstlinie, ECOG 0-1Extensive-Stage Small-Cell Lung CancerExtensive disease small cell lung cancerExtranodales Marginalzonen-B-NHL MALT Typ, Erst- und ZweitlinieExtranodales NK/T-Zell Lymphom, Stadium III-IV, ErstlinieExtravasation nach Anthrazyklin, ECOG 0-2FIP1L1-PDGFRA–negative HES oder unkontrolliertes HES, ZweitlinieFLT3-ITD+ AML nach allogener SCTFludarabin-refraktäre CLL oder Transormation zum Richter Syndrom, ECOG 0-2Foll. L. °I-II, Marginalzonen-L., kleines lymphozyt. L., ECOG 0-2, mind. eine Vortherapiefoll. L. °I-II, Marginalzonen-L., kleines lymphozyt. Lymphom, mind. eine Vortherapie, ECOG 0-2Foll. L. °I-IIIa, kleines lymphozyt. L., Marginalzonenl., lymphoplasmoyt. L., Drittlinie bei Rituximab- u Alkylanz-RefraktäritätFoll. Lymphom, Grad 1-2, Stadium III oder IV mit Therapieindikation, ErstbehandlungFoll. Lymphom, Grad I-III, ECOG 0-2, Erst- und ZweitlinieFoll. Lymphom, Grad I-III, Stadium III oder IV mit Therapieindikation, ECOG 0-2, ErstlinieFoll. Lymphom, Grad I-III, Stadium III und IV, Zweit- bis Drittlinie, ECOG 0-2Foll. Lymphom, Grad I-IIIa, ECOG 0-2, nach Ansprechen auf R-CHOP, R-CVP oder R-FCMFoll. Lymphom, Grad I-IIIa, Stadium I-II, ErstlinientherapieFoll. Lymphom, Grad I-IIIa, Stadium II bis IV mit Therapieindikation, Patienten älter als 50, ErstlinieFoll. Lymphom, Stadium I-IIFoll. Lymphom Grad 1-2, MCL, lymphoplasmozytisches Lymphom, Therapieindikation, Erstlinie ECOG 0-2Foll. Lymphom Grad 1-2, Stadium III und IV, ECOG 0-2, nach Ansprechen auf ErstlinieFoll. Lymphom Grad 1-3a, CD20 pos.,behandlungsbedürftig nach GELF Kriterien, ErstlinientherapieFoll. Lymphom Grad 1-3a, CD20 pos., behandlungsbedürftig nach GELF Kriterien, mind. 1 VortherapieFoll. Lymphom Grad I-III, Progress innerhalb von 6 Monaten oder nach Nichtansprechen auf Rituximab-InduktionFoll. Lymphom °I-III, Std. III u IV oder bulky Std. II, ECOG 0-2, ErstlinieFollikuläres Lymphom, ErstlinieFollikuläres Lymphom, Grad I-III, ECOG 0-2, Erst- und ZweitlinieFollikuläres Lymphom, kleines lymphozytische Lymphom, Erst- bis Fünftlinie, Karnofsky-Index größer 60%Follikuläres Lymphom °I-II, Rituximab-refraktär, ECOG 0-2Follikuläres Lymphom °I-IIIa, nicht vortherapiert, Ann-Arbor Stadium III-IV , oder II mit Bulk über 7 cm, ECOG 0-2Follikuläres Lymphom °I-IIIa, Rezidiviert oder therapierefraktär nach mindestens 2 Vortherapien, inkl. Therapie mit einem Anti-CD20-Antikörperforgeschrittenes oder metastasiertes Pankreaskarzinom, Erstlinie, Karnofsky > 70fortgeschr. rezidiv. Endometriumkarzinomfortgeschrittene Langerhanszell-Histiozytose, WHO Lungen- Funktionsklasse Stadium II-IVfortgeschrittener, gut-diff., nicht funktionaler neuroendokriner Tumor der Lunge oder gastrointestinaler Herkunft, Grad 1 und 2, WHO Status 0-1fortgeschrittener, nicht operabler gastrointestinaler Stromatumor, Zweitlinie nach Imatinib, ECOG 0-1fortgeschrittener gastrointestinaler Stromatumor, Erstlinie oder Imatinib adjuvant, ECOG 0-1fortgeschrittener Kopf-Hals-Tumor, Erstlinie, Stadium III-IV, ECOG 0-1fortgeschrittener oder metastasierter pankreatisch neuroendokriner Tumorfortgeschrittener oder rezidivierter Morbus Waldenström, ECOG 0-2fortgeschrittener pankreatisch neuroendokriner Tumorfortgeschrittener pNET oder geNET, Zweitlinie nach TA oder SSA, ECOG 0-1Fortgeschrittener solitärer fibröser Tumor, ECOG 0-3fortgeschrittenes (Stadium IIIb) oder metastasiertes NSCLC (Patienten älter als 70 Jahre)fortgeschrittenes, klarzelliges Nierenzellkarzinom, Erstlinie, Karnofsky > 70fortgeschrittenes, kutanes T-Zell-Lymphomfortgeschrittenes, metastasiertes oder wiederkehrendes nichtkleinzelliges Adenokarzinom der Lunge, ECOG 0-1fortgeschrittenes, nicht-resezierbares metastasiertes kolorektales Karzinom, Adeno-, ECOG 0-2Fortgeschrittenes, nichtkleinzelliges Lungenkarzinom, Stadium IIIA und IIIB, Erstlinie, ECOG 0-1fortgeschrittenes, nicht reserzierbares oder metastasiertes Melanom, Stadium IIIC oder IV, 2. und weitere Linien, ECOG 0-1Fortgeschrittenes, nicht resezierbares oder metastasiertes Nebennierenrindenkarzinom, ECOG 0-2fortgeschrittenes, plattenepitheliales, nichtkleinzelliges Lungenkarzinom nach Platinhaltiger Therapie, ECOG 0-1fortgeschrittenes, unbehandeltes Nierenzellkarzinom, klarzellig, ECOG 0-1fortgeschrittenes, unbehandeltes Nierenzellkarzinom, klarzellig, sarcomatoid, PD-L1 Expression gleich/über 1%, ECOG 0-1fortgeschrittenes, wiedergekehrtes oder metastasiertes Nierenzellkarzinom mit schlechter Prognose, Erstlinie, Karnofsky Status > 60fortgeschrittenes, wiederkehrendes oder metastasiertes kolorektales Karzinom, ECOG 0-2fortgeschrittenes Adenokarzinom des Magens/ösophagealen Übergangs, resezierbar, ECOG 0-1fortgeschrittenes Endometriumkarzinom, metastasiertes, nichtresezierbares -, MSI-H/dMMR, ECOG 0-1fortgeschrittenese oder metastasiertes Nierenzellkarzinom, klarzellig, Zweitlinie nach VEGFR-Therapie, ECOG 0-1fortgeschrittenes follikuläres Lymphom, Mantelzelllymphom und Morbus Waldenström, Stadium III-IV, Erstlinie, ECOG 0-2fortgeschrittenes follikuläres Lymphom °I-IIIa, Stadium III oder IV, Erstlinie, ECOG 0-2fortgeschrittenes Hodgkin Lymphom, Stadium III-IV, Erstlinie, ECOG 0-2Fortgeschrittenes hormonsensitives Prostatakarzinomfortgeschrittenes klassisches Hodgkin Lymphom, Erstlinie, ECOG 0-1Fortgeschrittenes kleinzelliges Lungenkarzinom (M1), Karnofsky-Index von 70% oder mehrfortgeschrittenes kolorektales Karzinom, Erstlinie, ECOG 0-2fortgeschrittenes Leberzellkarzinom, Erstlinie, ECOG 0-2fortgeschrittenes Mamma-Ca, Erstliniefortgeschrittenes Mamma-Ca, HR+, HER-2-, ECOG 0-1fortgeschrittenes Mamma-Ca, ungeeignet für intensivere Chemotherapiefortgeschrittenes Mamma-Ca, Zweitlinie, ECOG 0-2fortgeschrittenes Mammakarzinom, HR+, HER2-, Erstlinie, ECOG 0-1fortgeschrittenes Melanom, mukosal, Stadium III/IV, nichtresezierbar, Erstlinie, ECOG 0-1fortgeschrittenes Merkelzellkarzinomfortgeschrittenes metastasiertes Mammakarzinomfortgeschrittenes Nasopharynxkarzinom, T1-4N2-3M0, ECOG 0-2Fortgeschrittenes Nebennierenrindenkarzinom, ECOG 0-2Fortgeschrittenes Nebennierenrindenkarzinom, Erstlinie, ECOG 0-2Fortgeschrittenes Nebennierenrindenkarzinom, palliativ oder additiv nach Resektionfortgeschrittenes Nierenzellkarzinom, sarkomatoid, Erstlinie, ECOG 0-1fortgeschrittenes NSCLC, BRAF V600-Mutation, ECOG 0-2fortgeschrittenes NSCLC, nichtresezierbares, Stadium III, ECOG 0-1fortgeschrittenes oder early unfavorable Hodgkin Lymphom, Erstlinie, ECOG 0-1fortgeschrittenes oder metastasiertes, klarzelliges Nierenzellkarzinom, Zweitlinie, ECOG 0-2fortgeschrittenes oder metastasiertes, klarzelliges Nierenzellkarzinom, Zweitlinie, intermediäres oder niedriges Risiko, ECOG 0-2Fortgeschrittenes oder metastasiertes Adeno-Ca des Magens, des gastroösophagealen Übergangs oder des Ösophagus, HER2-negativ, ECOG 0-1fortgeschrittenes oder metastasiertes Adenokarzinom des Pankreas, gBRCA/PALB2+, Erstlinie, ECOG 0-1Fortgeschrittenes oder metastasiertes adrenokortikales Karzinom, nicht resezierbar, ECOG 0-2fortgeschrittenes oder metastasiertes AEG, Magen- oder kolorektales Karzinom, refraktär oder intolerant, ECOG 0-1fortgeschrittenes oder metastasiertes Basalzellkarzinom nach Hedgehog Inhibitor-Therapie, ECOG 0-1fortgeschrittenes oder metastasiertes Gallengangkarzinom, ECOG 0-3Fortgeschrittenes oder metastasiertes Karzinom des Ösophagus, gastroösophagealen Übergangs oder des Magens, Erstlinie, unfit fortgeschrittenes oder metastasiertes kleinzelliges Lungenkarzinom, Erstlinie, ECOG 0-2fortgeschrittenes oder metastasiertes kolorektales Karzinom, ECOG 0-2fortgeschrittenes oder metastasiertes kutanes Plattenpithelkarzinom, ECOG 0-1fortgeschrittenes oder metastasiertes kutanes Plattenpithelkarzinom, ECOG 0-2Fortgeschrittenes oder metastasiertes Mammakarzinom, HR+, Her2-, nach endokriner Vortherapie, ECOG 0-1fortgeschrittenes oder metastasiertes Nierenzellkarzinom, 2.-3. Linie, Karnofsky Status > 70fortgeschrittenes oder metastasiertes Nierenzellkarzinom, ECOG 0-1fortgeschrittenes oder metastasiertes Nierenzellkarzinom, Erstliniefortgeschrittenes oder metastasiertes Nierenzellkarzinom, Erstlinie, Karnofsky Status >70fortgeschrittenes oder metastasiertes Nierenzellkarzinom, klarzellig, Erstliniefortgeschrittenes oder metastasiertes NSCLC, ALK Translokation, Erstliniefortgeschrittenes oder metastasiertes NSCLC, ALK Translokation, Zweitlinie nach CrizotinibFortgeschrittenes oder metastasiertes Ovarialkarzinom, Rezidivtherapie, ECOG 0-2Fortgeschrittenes oder metastasiertes Ovarialkarzinom, Rezidivtherapie, platinresistent, ECOG 0-1Fortgeschrittenes oder metastasiertes Pankreaskarzinom, KRAS p.G12C–mutiert, Zweitlinie, ECOG 0-2Fortgeschrittenes oder metastasiertes Phäochromozytom oder Paragangliom, ECOG 0-2Fortgeschrittenes oder metastasiertes Plattenepithelkarzinom des Ösophagus, Progress nach Erstlinientherapie, ECOG 0-1Fortgeschrittenes oder metastasiertes Plattenepithelkarzinom des Ösophagus, unabhängig von PD-L1 StatusFortgeschrittenes oder metastasiertes Plattenepithelkarzinom des Ösophagus, unabhängig von PD-L1 Status, ECOG 0-1Fortgeschrittenes oder metastasiertes Plattenepithelkarzinom des Ösophagus, unabhängig von PD-L1 Status, Progress nach Erstlinientherapie, über 65 Jahrefortgeschrittenes oder metastasiertes Prostata-Ca, kastrationsresistent, ECOG 0-2fortgeschrittenes oder metastasiertes Schilddrüsenkarzinom, refraktär auf radioaktive Iodtherapie, ECOG 0-3fortgeschrittenes oder metastasiertes Thymuskarzinom, Erstlinie, ECOG 0-1Fortgeschrittenes oder metastasiertes Thymuskarzinom, Progress nach platinhaltiger Chemotherapie, ECOG 0-2fortgeschrittenes oder metastasiertes Thymuskarzinom oder Thymom, ECOG 0-2fortgeschrittenes oder metastasiertes Weichteilsarkom, Zweitlinie nach Anthrazyklin oder Ifosfamid oder Kontrainidikation, ECOG 0-2fortgeschrittenes oder refraktäres Ewing Sarkom, Rezidivtherapiefortgeschrittenes oder rezidiviertes Endometriumkarzinom, 0-2 Vortherapien, ECOG 0-2Fortgeschrittenes oder rezidiviertes Magenkarzinomfortgeschrittenes oder rezidiviertes Mammakarzinom, HR+, Her2neu+, ECOG 0-1, mind. 2 anti-Her2-Vortherapien im palliativen Settingfortgeschrittenes oder rezidiviertes Zervixkarzinom, Stadium IVb, ECOG 0-2fortgeschrittenes Oropharynxkarzinom, nicht metastasiert, Stadium III-IV, Karnofsky <60fortgeschrittenes Pleuramesotheliom, Erstlinie, ECOG 0-1Fortgeschrittenes Prostatakarzinomfortgeschrittenes Thymom bzw. Thymuskarzinom, ECOG 0-1fortgeschrittenes Weichteilsarkom, ECOG 0-1fortgeschrittenes wiederkehrendes NHLfortgeschrittenes Zervix-Ca, nach Vorbehandlung, ECOG 0-1fortgeschrittenes Zervixkarzinom, Stadium IIb-IVafortschreitende Keimzelltumoren nach cisplatinbasiertem Regime bei schlechter Prognosefortschreitendes, nicht heilbares adenoid-zystisches Karzinom, Erst (nach Bestrahlung)- und Zweitlinie, ECOG 0-1fortschreitendes oder wiederkehrendes MM, Stadium I - IIIFrauen postmenopausal mit Frakturen / Männer unter Androgendeprivationstherpaie / Glucokorticoidinduzierte Osteoporose, ECOG 0-2frühes Ovarial-Ca, Stadium I und II, ErstlinieGallengangs-, Ampulla vateri- oder Gallenblasenkarzinom, nicht resezierbar oder rezidiviert, ECOG 0-1, ErstlinientherapieGallengangskarzinom, adjuvant, ECOG 0-3Gallengangskarzinom, metastasiert oder lokal fortgeschritten, IDH1-mutiert, chemotherapierefraktär, ECOG 0-1Gallengangskarzinom, metastasiert oder lokal fortgeschritten, vortherapiert, mit FGFR2-Fusion/-Rearrangement, ECOG 0-2Gallengangskarzinom, vortherapiert, ECOG 0-2Gallengangskarzinom fortgeschritten oder metastasiert, vortherapiert, ECOG 0-1gastrointestinaler Stromatumor, adjuvantGastrointestinaler Stromatumor, inoperabel, PDGFRA D842V-mutiert, ECOG 0-2gemcitabinbasierte Chemotherapie, solide Tumoren, ECOG <2Gestationale trophoblastäre Neoplasie, rezidiviert oder refraktär nach Therapie mit EMA/COGlioblastom, ECOG 0-2Glioblastom, Erst- oder Zweitredzidiv, nach Standard Radiatio und TemozolomidGlioblastom, Progress nach Chemoradiatio, ECOG 0-2Glioblastom Rezidiv nach vorangegangener Temozolomid-Therapie und Bestrahlung, ECOG 0-2Gliome WHO-Grad 2, Erstlinie, ECOG 0-2Haarzelleukämie, Drittlinie, ECOG 0-2Haarzellleukämie (Varianten), Erst- und ZweitlinieHaarzellleukämie, aktive Erkrankung, ECOG 0-3Haarzellleukämie, BRAF-V600E Mut +, vorbehandelt (z.T. mehrfach)Haarzellleukämie, BRAF-V600E Mutation, refraktär gegen Purinanaloga, oder ein früheres Rezidiv nach PurinanalogaHaarzellleukämie, Erstlinie, ECOG 0-2Haarzellleukämie, therapieresistent oder rezidiviert.Haarzellleukämie, Zweitlinie nach Nukleosidanalogon, ECOG 0-2Haarzellleukämie Erstdiagnose oder Rezidiv nach nicht Cladribin-haltiger Vortherapie, ECOG 0-2Haarzellleukämie Erstlinie, ECOG 0-3Harnblasen-Ca, operabel bis T4aHarnblasenkarzinom, muskelinvasiv, nicht metastasiert, ECOG 0-2HCC, nach Therapie mit Sorafenib, Child–Pugh A, ECOG 0-1HCC lokal fortgeschritten oder metastasiert, nicht operabel, BCLC B oder C, ChildPugh A, ECOG 0-1HCC mit Fernmetastasen oder einer Tumorlokalisation, die lokoregionär nicht kontrolliert oder reseziert werden kann, ChildPugh A, ECOG 0-1HCC mit Fernmetastasen oder nicht resektabelHCC nicht operabel, Child-Pugh A, ECOG 0-1, ErstlinientherapieHepatoblastom, Erstlinientherapie mit Cisplatin, < 18 Jahrehepatozelluläres Karzinom, portal vein invasion, Child Pugh Class A, Erstlinie, ECOG 0-2hepatozelluläres Karzinom, Zweitlinie nach Sorafenib, Child-Pugh-Class A, ECOG 0-1HER2+ Brustkrebs, adjuvant oder neoadjuvant, ECOG 0-2HER2+ Brustkrebs, neoadjuvant, ECOG 0-2HER2+ Mamma-Ca, adjuvante Erhaltung nach neoadjuvanter ChemotherapieHER2+ Mamma-Ca, adjuvante Therapie, 70-80 J.HER2+ Mamma-Ca, ErhaltungHER2+ und Hormonrezeptor +, metastasiertes Mamma-Ca, postmenopausalm, ECOG 0-1HER2+ und HR+, lokal fortgeschrittenes oder metastasiertes Mamma-Ca, postmenopausal, ECOG 0-1HER2+ und HR+, lokal fortgeschrittenes oder metastasiertes Mamma-Ca, postmenopausal, ECOG 0-1HER2+ und HR+, metastasiertes Mamma-Ca, postmenopausal, ECOG 0-1High-grade Osteosarkom, Alter 41-65High-grade Osteosarkom, Alter 41-65, postoperativhigh-grade uterines Leiomyosarkom, FIGO I-IIIA, ECOG 0-1, adjuvanthigh-risk primäre Myelofibrose, Post-Polycythaemia Vera-Myelofibrose oder Post-Essentielle Thrombozythämie-MyelofibroseHochmaligne B-ALL/T-ALL und Burkitt-Lymphom bei Erwachsenen, ErstlinieHochmaligne B-ALL bei Erwachsenen, RezidivtherapieHochmaligne B-ALL und B-NHL bei Erwachsenen, ErstlinieHochmalignes Weichteilsarkom (Grad 2-3), fortgeschritten oder metastasiert, ECOG 0-1, 18-60 JahreHochrisiko ET oder PV, intolerant oder resistent gegen HydroxyureaHochrisiko MDS und AML, Rezidiv oder de novo MDSHochrisiko myelodysplastisches Syndrom, ECOG 0-2Hoden-Ca, mind. 2 cisplatinhaltige Vortherapien (inkl. ASCT), ECOG 0-1Hoden-Ca, Progress nach 2 cisplatinhaltigen Therapien oder nach ASCT, ECOG 0-2Hoden-Ca, Rezidiv nach Erstlinientherapie und Salavagetherapie mit ASCTHoden-Ca., mind. 2 Vortherapien, ECOG 0-2Hodenkarzinom, rezidiviert, Erhaltungstherapie bei CR oder PR nach HochdosistherapieHodenkarzinom, rezidiviert oder therapierefraktär, ECOG 0-2, Kreatinin-Clearance mind. 70 ml/minHodenkarzinom cisplatinrefraktär oder rezidiviert nach HochdosistherapieHodenlymphom, Stadium I-II, ECOG 0-1Hodgkin Lymphom, Erhaltung nach ASZT bei Patienten mit erhöhtem Rezidiv- oder Progressionsrisiko, ECOG 0-2Hodgkin Lymphom, Erstlinientherapie, >60 Jahre, ECOG 0-1Hodgkin Lymphom, NLPHL Stadium IA ohne RisikofaktorenHodgkin Lymphom, nodulär-lymphozytenprädominant (NLPHL)Hodgkin Lymphom, rezidiviert nach autologer Stammzelltransplantation, Ann Arbor II-IVHodgkin Lymphom, rezidiviert oder therapierefraktärHodgkin Lymphom, rezidiviert oder therapierefraktär, ECOG 0-3Hodgkin Lymphom, rezidiviert oder therapierefraktär, nach autologer SCT oder SCT ungeeignetHodgkin Lymphom, Stadium I-II, ErstlinieHodgkin Lymphom, Stadium IIb - IV, Erstlinie, 18-60 JahreHodgkin Lymphom, therapierefraktär oder rezidiviert, ECOG 0-1Hodgkin Lymphom, über 60 J., unfit, ECOG 0-3, ErstlinieHodgkin Lymphom Stadium IIb mit Risikofaktoren, Stadium III und IV, Erstlinie, 18-60 JahreHodgkin Lymphom Stadium I und II ohne RisikofaktorenHodgkin Lymphom Std. IIb mit Risikofaktoren, Std. III u IV, Erstlinie, 18-60 JahreHormon Rezeptor +, HER2 -, fortgeschrittenes oder wiederkerhrendes Mammakarzinom während vorangegangengener endokriner Therapie, ECOG 0-1Hormon Rezeptor +, HER2 -, fortgeschrittenes oder wiederkerhrendes Mammakarzinom während vorangegangengener endokriner Therapie.Hormon Rezeptor +, HER2 -, lokal fortgeschrittenes Mammakarzinom, Erstlinie, ECOG 0-2Hämophagozytische LymphohistiozytoseHämophagozytische Lymphohistiozytose des ErwachsenenHämophagozytische Lymphohistiozytose des KindesInduktion AMLinoperables, malignes Pleuramesotheliom, Erst- oder Zweitlinie, Karnofsky Status >70inoperables oder metastasiertes Harnblasenkarzinom, ECOG 0-1Intermediär-1 und -2-Risiko oder Hochrisiko MDS, Alter > 60 Jahre, ECOG 0-2Invasives Thymom Stadium III oder IVIpilimumab refraktäres Melanom, BRAF V600 positiv, ECOG 0-1ITP, splenektomiert und nicht-splenektomiert, Thrombozytenzahlen < 30 000/µlITP, splenektomiert und nicht-splenektomiert, Thrombozytenzahlen im Durchschnitt 30 000/µlITP, Zweitlinie, Thrombozytenzahlen < 30000/µl, Kandidaten für eine SplenektomieKaposi-Sarkom, therapiepflichtigKaposi Sarkom, Erstlinie, ECOG 0-2Kaposi Sarkom, HIV-assoziiert, Erstlinie, ECOG 0-2Kaposi Sarkom, HIV-assoziiert, rezidiviert oder therapierefraktär, ECOG 0-3Kaposi Sarkom, HIV-assoziiert, rezidiviert oder therapierefraktär, unter antiretroviraler TherapieKaposi Sarkom, mild-moderat, HIV-assoziiert, ErstlinieKaposi Sarkom, mindestens 1 VortherapieKaposi Sarkom, rezidiviert oder therapierefraktärKarzinom bei unbekanntem Primärkarzinom, Erstlinie, ECOG 0-1Karzinom bei unbekanntem Primärkarzinom, Patienten mit ungünstiger Prognose, niedrige Tox., ErstlinieKarzinom bei unbekanntem Primärtumor, Erstlinie, ECOG 0-2Karzinom bei unbekanntem Primärtumor, metastasiert, nicht lokal therapierbar, poor risk, Erstlinie, ECOG 0-2Karzinom bei unbekanntem Primärtumor, mindestens 1 Vortherapie, ECOG 0-1Karzinom bei unbekanntem Primärtumor, Zweitlinie, ECOG 0-2Karzinom des Oro- und, Hypopharynx, Larynx, Stadium III und IV, nicht metastasiert, Erstlinie, Karnofsky > 60Karzinosarkom des Endometriums, FIGO I-IVB Karzinosarkom des Uterus, FIGO-Stadium I-IVkastrationsresistentes Prostatakarzinom, Progress nach Docetaxel, Testosteron < 50 ng/dl, ECOG 0-2Keimzelltumor, ZweitlinieKlarzelliges Nierenzellkarzinom, metastasiert oder lokal fortgeschritten, Erstlinie, ECOG 0-2Klarzelliges Ovarialkarzinom, max. 6 Wochen nach der Operation, ECOG 0-1klassisches Hodgkin lymphom, early stage und unfavorable, ECOG 0-1klassisches Hodgkin Lymphom, Rezidiv nach ASZT und Brentuximab Vedotin, ECOG 0-1Kleinzelliges Lungenkarzinomkleinzelliges Lungenkarzinom, limited disease, ECOG 0-2Kleinzelliges Lungenkarzinom, limited und extensive disease, Erstlinie, ECOG 0-2kleinzelliges Lungenkarzinom, Stadium IV, Erstlinie, ECOG 0-1kleinzelliges Lungenkarzinom Stadium I-IIIB, Erstlinie, ECOG 0-2kleinzelliges Lungenkarzinom Stadium IV, Erstlinie, ECOG 0-2Kolon-Ca (T1-4/N1-2/M0), adjuvantKolon-Ca, T3-4, N0-2, M0Kolon-Ca Std. III, adjuvant, ECOG 0-1Kolonkarzinom, Stadium, II und III, adjuvantKolorekt. Adeno-Ca, metastasiert, Progress unter oder innerhalb von 3 Monaten nach Irinotecan-TherapieKolorektales Adenokarzinom, metastasiert, Erstlinie, ECOG 0-2kolorektales Karzinomkolorektales Karzinom, dMMR, Stadium I-III, ECOG 0Kolorektales Karzinom, metastasiert, nach Versagen von mindestens 2 Standardtherapien, ECOG 0-1kolorektales Karzinom, RAS wild-Typ, Erstlinie, ECOG 0-1kolorektales Karzinom, Stadium III, adjuvantKolorektales Karzinom, Stadium IV, dMMR/MSI, nach Erstlinientherapiekolorektales Karzinom, Stadium IV, MSI-H/dMMR, ECOG 0-1kolorektales Karzinom mit nichtresektablen Metastasen in der Leber (ausschließlich), ECOG 0-1Kopf-Hals-Tumor,nicht-metastasiert, cisplatinungeeignet, ECOG 0-1Kopf-Hals-Tumoren (Plattenepithel-), adjuvant, ECOG 0-1Kopf-Hals-Tumoren (Plattenepithel-), resektabel, Stadium III-IV, ECOG 0-1Kopf-Hals-Tumoren, cTx cNx cM0, nicht cisplatingeeignet, ECOG 0-2Kopf-Hals-Tumoren, nicht resektabel, UICC Stadium III/IV, ECOG 0-1Kopf-Hals-Tumoren, Plattenepithel-, Erstlinie, ECOG 0-1Kopf-Hals-Tumoren, Plattenepithel-Ca, cT3/cT4, cN0-3, cM0 (bei Zungengrund-Ca max. cT2cN0), 18-75J., ECOG 0-2Kopf-Hals-Tumoren, Stadium III -IV, nicht metastasiert, Erstlinie, ECOG 0-1Kopf-Hals-Tumoren, Stadium III oder IV, ohne Fernmetastasen, Erstlinientherapie, ECOG 0-2Kopf-Hals-Tumoren, Stadium IV, platinresistent, Rezidivtherapie, ECOG: 0-2Kortikoid-refraktäre ITP, splenektomiertkutanes Plattenpithelkarzinom, II, III, oder IV (M0), operabel, ECOG 0-1Kutanes Plattenpithelkarzinom, nicht resektabel, oder metastasiert, nach Nierentransplantation, ECOG 0-2kutanes T-Zell-Lymphom, CD30+, mindestens eine Vortherapie, ECOG 0-2Kutanes T-Zell-Lymphom, vortherapiert, ECOG 0-1Langerhanszell-Histiozytose, unter 18 Jahre, ErstlinieLangerhanszell-Histiozytose des Erwachsenen, ErstlinientherapieLCH, JXG, RDD, Rezidivtherapie, im Median 22 Monate altLCH des Kindes, BRAFV600E positiv, therapierefraktärLCH mit CD1a+ mit Knochenläsionen des ErwachsenenLCH mit einem Risiko-Organ, Rezidiv nach Vinblastin /Prednisolon, Leberzellkarzinom, Zweitlinie nach Sorafenib, Child-Pugh A, ECOG 0-1Leiomyosarkom, metastasiert oder lokal fortgeschritten, inoperabel, ErstlinieLeptomeningeale Metastasen beim Mamma-Ca, HER2+, ECOG 0-3Leptomeningeale Metastasen beim Mamma-Ca, HER2+, Karnofsky >50Liposarkom, entdifferenziert, metastasiert oder lokal fortgeschritten, ECOG 0-1, 18-75 J., max. 1 VortherapieLiposarkom oder Leiomyosarkom, nicht resektabel oder metastasiert, Rezidiv nach Anthrazyklin und Ifosfamid (in Kombi oder sequentiell), ECOG 0-1local rezidivierte oder metastasierte Kopf-Hals-Tumoren, Erstlinie, ECOG 0-2locoregionales Nierenzellkarzinom nach Nephrektomie, Hochrisiko: Tumorstadium > 3 und/oder regionale Lymphknotenmetastasen, Erstlinie, ECOG 0-2Lokal fortgeschrittene Kopf-Hals-Tumoren, cT2 oder höher und N2–N3b nach AJCC 1997, ECOG 0-2Lokal fortgeschrittene Kopf-Hals-Tumoren, Stadium III und IV, adjuvant oder definitive Chemo-Radiotherapie ECOG 0-2Lokal fortgeschrittene oder metastasierte Karzinome, BRAF V600E mutiert, Progress nach der Erstlinientherapie, ECOG 0-2Lokal fortgeschrittener, nicht resezierbarer oder metastasierter solider Tumor, TMB-hoch, mindestens 1 Vortherapielinie, ECOG 0-1lokal fortgeschrittener oder metastasierter Tumor, unabhängig von der Entität, NTRK-Genfusion, ECOG 0-3lokal fortgeschrittener oder metastasierter Tumor, unabhängig von der Entität, progredient nach 2 oder weniger Therapielinien, ECOG 0-1lokal fortgeschrittenes, nicht-resezierbares Pankreas-Ca, ECOG 0-1lokal fortgeschrittenes, nicht operables oder metastasiertes Analkarzinom, PD-L1+, Zweitlinientherapie, ECOG 0-1lokal fortgeschrittenes, nicht operables oder metastasiertes Analkarzinom, Zweitlinientherapie, ECOG 0-1lokal fortgeschrittenes, nichtresektables, nichtkleinzelliges Lungenkarzinom, Stadium III, nach Platin und Radiotherapie, ECOG 0-1lokal fortgeschrittenes, nicht reserzierbares Plattenepithel-Karzinom des Kopf/Halses, Stadium III-IV,M0 Erstlinie, Karnofsky >70lokal fortgeschrittenes, nicht resezierbares oder metastasierendes Mamma-Ca, triple neg., Erstlinie, ECOG 0-1Lokal fortgeschrittenes, nicht resezierbares oder metastasiertes kolorektales Karzinom, MSI-H/dMMR, mindestens 1 Vortherapielinie, ECOG 0-1Lokal fortgeschrittenes, nicht resezierbares Plattenepithelzellkarzinom des Kopf-Hals-BereichsLokal fortgeschrittenes, oder metastasiertes Mamma-Ca, Triple-negativ, metastasiert, mindestens 2 VortherapienLokal fortgeschrittenes Nasopharynx-Ca, Tx und N2/N3 oder T3/T4 und Nx, ECOG 0-2Lokal fortgeschrittenes NasopharynxkarzinomLokal fortgeschrittenes Nasopharynxkarzinom lokal fortgeschrittenes oder metastasierendes Harnblasenkarzinom, nach 1-2 Vortherapien, ECOG 0-1lokal fortgeschrittenes oder metastasierendes Harnblasenkarzinom, Progress nach Platin, ECOG 0-2Lokal fortgeschrittenes oder metastasierten Pleuramesotheliom, vortherapiert oder chemotherapieungeeignet, PD-L1 positiv, ECOG 0-1Lokal fortgeschrittenes oder metastasierten Zervixkarzinom, ohne Möglichkeit einer kurativen Therapie, Erstlinie, ECOG 0-1lokal fortgeschrittenes oder metastasiertes, differenziertes Schilddrüsenkarzinom, refraktär auf radioaktive Iodtherapie, ECOG 0-2Lokal fortgeschrittenes oder metastasiertes adenoid-zystisches Karzinom im Kopf-/Halsbereich, ECOG 0-1lokal fortgeschrittenes oder metastasiertes anaplastisches Schilddrüsenkarzinom, BRAF V600E mutiert, ECOG 0-2lokal fortgeschrittenes oder metastasiertes BasalzellkarzinomLokal fortgeschrittenes oder metastasiertes Dünndarm-Ca, mindestens 1 Vortherapie, ECOG 0-1lokal fortgeschrittenes oder metastasiertes Gallengangskarzinom, nach Therapie mit Gemcitabin/Cisplatin, ECOG 0-1lokal fortgeschrittenes oder metastasiertes Gallengangskarzinom, nach Therapie mit Gemcitabin/Cisplatin, ECOG 0-2Lokal fortgeschrittenes oder metastasiertes Harnblasen-Ca, Erstlinie, ECOG 0-1Lokal fortgeschrittenes oder metastasiertes Harnblasen-Ca, Progress nach platinbasierter Chemotherapie, ECOG 0-1Lokal fortgeschrittenes oder metastasiertes Harnblasenkarzinom, mind. 1 Vortherapie, FGFR3 Mutation oder FGFR2/3 Fusion, ECOG 0-2Lokal fortgeschrittenes oder metastasiertes Harnblasenkarzinom, mindestens 1 Vortherapie (neoadjuvant, adjuvant, oder palliativ), ECOG 0-2Lokal fortgeschrittenes oder metastasiertes Harnblasenkarzinom, Zweitlinientherapie, ECOG 0-1lokal fortgeschrittenes oder metastasiertes Harnblasenkarzinom nach Platintherapie, ECOG 0-1Lokal fortgeschrittenes oder metastasiertes Karzinom des Ösophagus, PD-L1 CPS ≥10lokal fortgeschrittenes oder metastasiertes kolorekt. Ca, Progress nach 1 oder 2 Vorbehandlungen, BRAF V600E, ECOG 0-1Lokal fortgeschrittenes oder metastasiertes kolorektales Karzinom, ECOG 0-2Lokal fortgeschrittenes oder metastasiertes kolorektales Karzinom, Her2+, RAS Wild-typ, ECOG 0-2lokal fortgeschrittenes oder metastasiertes Lungenkarzinom, ALK+, Erstlinie, ECOG 0-2lokal fortgeschrittenes oder metastasiertes Lungenkarzinom, ALK+, Progress unter Crizotinib, ECOG 0-2Lokal fortgeschrittenes oder metastasiertes Lungenkarzinom, Erstlinie, EGFR Exon 20 Insertionen, ECOG 0-1Lokal fortgeschrittenes oder metastasiertes Mamma-Ca, Her2+, mindestens 2 gegen HER2 gerichtete Behandlungsschemata, ECOG 0-1lokal fortgeschrittenes oder metastasiertes Mamma-Ca, Zweitlinie, ECOG 0-1lokal fortgeschrittenes oder metastasiertes Mammakarzinom, BRCA-Mutation, Her2-, ECOG 0-2, bis 3 vorausgegangene ChemotherapielinienLokal fortgeschrittenes oder metastasiertes Mammakarzinom, HR+, HER2+, nach vorangegangener endokriner Therapie.Lokal fortgeschrittenes oder metastasiertes Mammakarzinom, HR+, HER2+, postmenopausal, ECOG 0-1Lokal fortgeschrittenes oder metastasiertes Nierenzellkarzinom, assoziiert mit von Hippel-Lindau-Erkrankung ECOG 0-2Lokal fortgeschrittenes oder metastasiertes Nierenzellkarzinom mit einer klarzelligen Komponente, Intermediate-/poor-risk nach IMDCLokal fortgeschrittenes oder metastasiertes Osteosarkom, mind. 1 Vortherapie, ECOG 0-2Lokal fortgeschrittenes oder metastasiertes Plattenepithelkarzinom der Haut, ECOG 0-3Lokal fortgeschrittenes oder metastasiertes Plattenepithelkarzinom des Ösophaguslokal fortgeschrittenes oder metastasiertes Thymom, ECOG 0-2Lokal fortgeschrittenes oder metastasiertes Thymom, ECOG 0-2Lokal fortgeschrittenes oder metastasiertes Thymom, nach platinhaltiger TherapieLokal fortgeschrittenes oder metastasiertes Thymom/Thymuskarzinom, Progress nach platinbasierter Chemotherapie, ECOG 0-2lokal fortgeschrittenes oder metastasiertes Urothelkarzinom, ohne Vorbehandlung, ECOG 0-1Lokal fortgeschrittenes oder metastasiertes Urothelkarzinom nach platinhaltiger Therapie und Therapie mit Anti-PD-1/L1-Inhibitoren, ECOG 0-1lokal fortgeschrittenes und nicht resezierbares oder metastasiertes Harnblasenkarzinom, ungeeignet für eine Cisplatin-Therapie, ECOG 0-2lokalisiertes Ewing-Sarkom, unter 50 Jahrelokalisiertes Weichteilsarkom, Grad 3 oder 2 mit 50% Nekrosen, ECOG < 1Lymphatische Neoplasien und Anämie, Hb 8,5-10,5 g/dl, TSAT < 20%, Serum-Ferritin > 30 ng/ml, ECOG 0-2Lymphom, rezidiviert oder therapierefraktärLymphom, Rezidiv oder refraktär, mit mindestens einer anthrazyklinhaltigen VortherapieLymphom mit positiver CSF Zytologie, Karnofsky > 50%Magenkarzinom, Stadium IB– IVA, perioperativ, ECOG 0-1Magenkarzinom, Stadium II-III, R0 nach D2-GastrektomieMagenkarzinom Stadium IIIA-IIIC nach R0-Resektion, ECOG 0-1Maligner Perikarderguss, hämodynamisch relevantMaligner Perikarderguss beim Mamma-Ca, hämodynamisch relevantMaligner Perikarderguss beim NSCLC, hämodynamisch relevantMalignes Melanom, Stadium III-IV, Progress nach PD-1/PD-L1-Inhibitor Therapiemalignes Melanom, Stadium IIIa, IIIB oder IV, R0-Resektion, ECOG 0-1Malignes Melanom, Stadium IIIA-IIIC, R0-Resektion, ECOG 0-1Malignes Melanom, Stadium IV, nach OP oder Radiatio, ohne nachweisbare Resterkrankung, 18-80 Jahre, ECOG 0-1malignes Melanom mit Hirnmetastasen, ECOG 0-1malignes Melanom mit Hirnmetastasen ohne Strahlentherapie, ECOG 0-1Malignes PleuramesotheliomMALT-Lymphom, auch gastrisches, neu diagnostiziert oder nach lokaler TherapieMamma-Ca, adjuvantMamma-Ca, adjuvant, ECOG 0-1, Beginn innerhalb von 42 Tagen nach der OPMamma-Ca, adjuvant, ECOG 0-1, Beginn innerhalb von 42 Tagen nach der OPMamma-Ca, HER2+, adjuvantMamma-Ca, HER2+, ECOG 0-2Mamma-Ca, HER2+, nach neoadjuvanter ChemotherapieMamma-Ca, high risk, Stadium I-III, adjuvantMamma-Ca, high risk, Stadium I-III oder 0-3 befallene Lymphknoten, adjuvantMamma-Ca, LK-positiv, adjuvantMamma-Ca, met. oder fortgeschr., ER+, postmenopausalMamma-Ca, metastasiert oder hohes Rezidivrisiko, 65-79 Jahre, adjuvant, ECOG 0-1Mamma-Ca, metastasiert oder rezidiviert, prämenopausal, HR+, HER2-, ECOG 0-2Mamma-Ca, nach neoadjuvanter Chemotherapie, HER2-negativ, ECOG 0-1Mamma-Ca, neoadjuvantMamma-Ca, operabel, Stadium II–IIIC, Her2+, ECOG 0-1Mamma-Ca, Stadium I-IV, adjuvantMamma-Ca, Stadium II oder III, HR+, HER2-, ECOG 0-1Mamma-Ca, tripel-negativ, ECOG 0-1Mamma-Ca, tripel-negativ, Stadium II/III, neoadjuvante TherapieMamma-Ca, tripel neg., operabel, Erstlinie, ECOG 0-1Mamma-Ca mit KnochenmetastasenMamma-Ca mit Knochenmetastasen, ECOG 0-2Mamma-Ca mit Knochenmetastasen, ECOG 0-3Mamma-Ca Stadium I und II, HR+, adjuvant, prämenopausalMammaCa, adjuvant, Paclitaxel wöchentlichMammakarzinom, adjuvant, 65 Jahre oder älter, ECOG 0-2Mammakarzinom, BRCA-Mutation, HER2-, ECOG 0-1Mammakarzinom, BRCA-Mutation, HER2-, nach neoadjuvanter oder adjuvanter taxan- und/oder anthrazyklinhaltiger Chemotherapie, ECOG 0-1Mammakarzinom, cT1c-T4a-c, cN0/N+, cM0, HER2+ (IHC/FISH), ECOG 0-1Mammakarzinom, Her2 negativ, metastasiert, nach mind. 2 Vortherapien, ECOG 0-1Mammakarzinom, Her2 pos., Drittlinie oder höher, ECOG 0-1Mammakarzinom, HER2+ ECOG 0-2Mammakarzinom, HER2+ und HR+, postmenopausal, ECOG 0-1Mammakarzinom, HR+, HER2-, Hochrisiko, adjuvantMammakarzinom, HR+, nodalpositiv (Stadium IIA-IIIC), ECOG 0-1Mammakarzinom, HR+, Stadium I-IIICMammakarzinom, lokal fortgeschritten oder metastasiert, ECOG 0-2Mammakarzinom, lokal fortgeschritten oder metastasiert, Her2+, nach vorheriger Therapie mit Trastuzumab Emtansin, ECOG 0-1Mammakarzinom, lokal fortgeschritten oder metastasiert, HR+, Her2-, PIK3CA, AKT1 oder PTEN mutiert, nach vorheriger endokriner TherapieMammakarzinom, lokal fortgeschritten oder metastasiert, HR+, Her2-, PIK3CA mutiert, nach vorheriger endokriner TherapieMammakarzinom, lokal fortgeschritten oder metastasiert, mindestens 1 Vortherapie, inkl. adjuvante Behandlung, ECOG 0-2Mammakarzinom, metastasiert, Karnofsky-Score über 50, ZweitlinientherapieMammakarzinom, metastasiert, nach anthrazyklinhaltiger Chemotherapie, ECOG 0-1Mammakarzinom, postmenopausal, HR+ oder unbekannt, nach adjuvanter 2-3-jähriger Therapie mit TamoxifenMammakarzinom, Stadium I-III, HER2+, Trastuzumabtherapie bis zu 2 Jahren, ECOG 0-1Mammakarzinom, tripel-negativ, neoadjuvant, Erstlinie, ECOG 0-1Mammakarzinom, tripel negativ, ECOG 0-1Mammakarzinom, tripel negativ, Stadium I-IIIMammakarzinom, tripel negativ, ZweitlinieMammakarzinom, Östrogenrezeptor+, HER2-, ESR1-Mutation , Drittlinie nach CDK4/6-Inhibitor und Chemotherapie, ECOG 0-1Mammakarzinom adjuvant, HER2+, Tumor < 3 cmMammakarzinom Stadium IIA-IIIB, R0-Resektion, Karnofsky > 80Mantellzelllymphom, Alter > 65, ECOG 0-2Mantelzelllymphom, refraktär oder rezidiviert, ECOG 0-3Mantelzelllymphom Stadium II-IV, Erstlinie, ECOG 0-1Marginalzonen-B-NHL MALT TypMarginalzonenlymphom, therapierefraktär oder rezidiviert, mindestens eine Vortherapie, ECOG 0-2MAS-like SepsisMCLMCL, 66 Jahre und älter oder 60-65 und nicht geeignet zur Hochdosistherapie, nach Erstlinie R-FC oder R-CHOP, ECOG 0-2MCL, Dritt- bis AchtlinieMCL, follikuläres (Grad 1und 2), lymphoplasmozytisches, Marginalzonen-, kleines lymphozytisches Lymphom, Std. III u IV, ErstlinieMCL, follikuläres, lymphoplasmozytisches, kleines lymphozytisches u Marginalzonen-Lymphom, 2.-4.-LinieMCL, follikuläres Lymphom, Grad 1 und 2, Zweitlinie oder höherMCL, follikuläres Lymphom, lymphoplasmozytisches Lymphom, ZweitlinieMCL, höhergradiges Rezidiv, Bortezomib VortherapieMCL, rezidiviert oder therapierefraktär, ECOG 0-2MCL, Stadium II-IV, Erstlinie, ECOG 0-2, jünger als 65 JahreMCL, Stadium III und IV, chemo-naivMCL, Std. II-IV, ErstlinieMCL, Zweit- bis FünftlinieMCL, Zweit- bis SechstlinieMCL, Zweit- und DrittlinieMCL rezidiviert/therapierefraktär oder MCL in der Erstlinie nicht chemotherapiefähig, ECOG 0-2MCL Stadium II-IV ohne Eignung zur StammzelltransplantationMedulloblastom im Kindesalter, Alter 3-18Melanom, R0-Resektion, Stadium IIIA-C, BRAF-V600+, ECOG 0-1Melanom, Stadium IIB/IIC und IIIA-C, Metastasen in regionalen Lymphknoten, adjuvant, ECOG 0-1Melanom, Stadium IIIA-C, Metastasen in regionalen Lymphknoten, adjuvant, ECOG 0-1Melanom, Stadium IIIB-IIID oder oligometastatisch resektabel Stadium IV, ECOG 0-2Mengingeosis neoplastica durch solide Tumoren, Karnofsky > 50%Meningeosis neoplastica bei NSCLC, EGFR+, nach Vortherapie mit TKI, ECOG 1-3Meningeosis neoplastica bei soliden Tumoren 80% und hämatologischen Neoplasien 20%, ECOG 1-3Merkellzellkarzinom, nicht operabelMerkelzellkarzinomMerkelzellkarzinom, ECOG 0-2Merkelzellkarzinom, resektabel, ECOG 0-1Merkelzellkarzinom, Stadium IV, nicht resektabel, rezidiviert, auch nach Therapie mit PD-1- oder PD-L1-InhibitorenMet. Gallengangkarzinome, ECOG 0-2met. kolorektales Karzinom, Drittlinie im met. Std., ECOG 0-2; Fuchs 2007: met. kolorektales Karzinom, Erstlinie im met. Std., ECOG 0-1met. kolorektales Karzinom, EGFR+, Erstlinie im met. Std., ECOG 0-2met. kolorektales Karzinom, EGFR+, Erstlinie im met. Std., ECOG 0-2 met. kolorektales Karzinom, Erstlinie, ECOG 0-1met. kolorektales Karzinom, Erstlinie, ECOG 0-2met. kolorektales Karzinom, Erstlinie, ECOG 0-2, über 70 Jahre nur bei ECOG 0met. kolorektales Karzinom, Erstlinie im met. Stadiummet. kolorektales Karzinom, Erstlinie im met. Std., ECOG 0-1met. kolorektales Karzinom, Erstlinie im met. Std., ECOG 0-2met. kolorektales Karzinom, Erstlinie im met. Std., über 70 Jahre, nicht für oxaliplatin- oder irinotecanbasierte Regime geeignetmet. kolorektales Karzinom, höhere Linie nach Versagen der Standardtherapien im met. Std., ECOG 0-1met. kolorektales Karzinom, Progress nach/unter 5-FU, max. 2 Vortherapien im met. Std., ECOG 0-2met. kolorektales Karzinom, Progress nach/unter 5-FU-basierter Therapie in Erstlinie, ECOG 0-2met. kolorektales Karzinom, Progress nach/unter 5-FU-haltiger Therapiemet. kolorektales Karzinom, Progress nach/unter Oxaliplatin-basiertem Regime, ECOG 0-2met. kolorektales Karzinom, Progress unter/innerhalb 6 Monaten nach 5-FU, Irinotecan und Oxaliplatin, ECOG 0-2, ab Drittliniemet. Mamma-Ca, 2-5 Vortherapien (Taxan oder Anthracyclin enthaltend) oder 2 oder mehr Vortherapien bzgl. des met. Stadiums, ECOG 0-2met. Mamma-Ca, ECOG 0-2, Erstlinie im met. Stadium, im Falle anthrazyklinhaltiger Vortherapien (neo-/adj.) mehr 12 Monate Intervallmet. Mamma-Ca, Erst- bis Viertlinie im met. Stadium, kein Taxan in den pall. Vortherapienmet. Mamma-Ca, Erstlinie im met. Stadium nach vorangeg. neo-/adjuvanter anthrazyklinhaltiger Chemotherapiemet. Mamma-Ca , Erstlinie in met. Stadiummet. Mamma-Ca, Erstlinie in met. Stadiummet. Mamma-Ca, Erstlinie in met. Stadium, Patientinnen älter als 70 Jahremet. Mamma-Ca, Progress nach mehreren Therapienmet. Mamma-Ca, triple-negativ, Erstlinie im met. Stadium, ECOG 0-1met. Mamma-Ca HER2+, Drittlinie mit Trastuzumab, Lapatinib und Taxan in der Vortherapiemet. Mamma-Ca HER2+, Erstliniemet. Mamma-Ca HER2+, Progress nach Behandlung mit Regimen die Anthrazykline, Taxane und Trastuzumab beinhaltetenmet. Mamma-Ca HER2+, Zweitlinie nach Vorbehandlung mit Trastuzumab + Taxanmet. Mamma-Ca HER2negativ, ECOG 0-1, max. eine Vortherapie bzgl. der met. Erkrankungmet. Mamma-Ca HER2negativ, ECOG 0-2, Erstliniemet. Mamma-Ca HR+/HER2+, postmenopausal, Progress nach Behandlung mit endokriner Therapie oder Trastuzumab/Chemotherapie, ECOG 0-1Met. oder fortgeschr. Magen-Ca und Adeno-Ca des ösophagogastr. Überganges, Progress nach platinbasierter Erstlinientherapie, ECOG 0-1Met. oder fortgeschr. Magen-Ca und Adeno-Ca des ösophagogastr. Überganges, Zweitlinie, Progress innerhalb 4 Monaten nach Erstlinie, ECOG 0-1Met. oder fortgeschr. Magen-Ca und Adeno-Ca des ösophagogastr. Überganges, Zweitlinie, Progress innerhalb 4/6 Monaten nach Erstchemo (adj. oder palliativ), ECOG 0-1met. Pankreaskarzinom, BRCA1 oder BRCA2- Mutation, nach mind. 16 Wochen platinbas. Therapie, ECOG 0-1Metastasierendes, wiederkehrendes oder persistierendes Zervix Ca, ECOG/GOG 0-1Metastasierte, refraktäre, progrediente Mismatch-Repair Deficiency Karzinome, ECOG 0-1metastasierter, fortgeschrittener Hodentumor, nicht-seminom, IGCCCG-Prognosegruppe schlechtmetastasierter, fortgeschrittener Keimzelltumormetastasierter, fortgeschrittener Keimzelltumor, ZweitlinieMetastasierter, fortgeschrittener Keimzelltumor, Zweitlinie nach Platinkombination metastasierter, inoperabler gastrointestinaler Stromatumor nach Imatinib und Sunitinib, ECOG 0-1metastasierter oder rezidivierter Kopf-Hals-Tumor, Stadium III-IV, nach Cisplatin, Karnofsky > 60Metastasierter therapieresistenter Speicheldrüsentumor, Her2+, ECOG 0-2metastasiertes, HER2+ Mamma-Ca, ECOG 0-2metastasiertes, hormonresistentes Prostata-Ca, Serumtestosteron < 50 ng/dl, Karnofsky > 60metastasiertes, hormonsensitives Prostata-Ca, Serumtestosteron < 50 ng/dl, ECOG 0-2Metastasiertes, hormonsensitives ProstatakarzinomMetastasiertes, hormonsensitives Prostata Karzinommetastasiertes, hormonsensitives Prostata KarzinomMetastasiertes, kastrationsresistentes Prostata-Ca, Progress unter Abirateron/Prednisolon, Serumtestosteron < 50 ng/dl, ECOG 0-1metastasiertes, kastrationsresistentes Prostata-Ca, Serumtestosteron < 50 ng/dl, ECOG 0-1metastasiertes, kastrationsresistentes Prostata-Ca, symptomatisch, ECOG 0-3metastasiertes, kastrationsresistentes Prostata-Ca mit BRCA1, BRCA2, oder ATM Mutation, Progress nach Androgenrezeptor-Antagonisten der 2. GenerationMetastasiertes, kastrationsresistentes Prostatakarzinom, asymptomatisch oder wenig Symptome, ECOG 0-1metastasiertes, kastrationsresistentes Prostatakarzinom, Progress nach Docetaxel, Testosteron < 50 ng/dl, ECOG 0-2metastasiertes, kastrationsresistentes Proststa Karzinom nach Docetaxel Therapie, ECOG 0-2metastasiertes, klarzelliges Nierenzellkarzinom, ECOG 0-1metastasiertes, klarzelliges Nierenzellkarzinom, Erstlinie, ECOG 0-1metastasiertes, nicht kurativ-resezierbares Kolon- oder Rektum-Ca, ECOG 0-2Metastasiertes, nicht resektierbares Karzinom des gastroösophagealen Übergangs oder des Magens, ECOG 0-2Metastasiertes, oder nicht resektables Karzinom des gastroösophagealen Übergangs oder des Magens, Her2+, mind. 2 Vortherapien inkl. Trastuzumab-Vortherapie, ECOG 0-1Metastasiertes, oder nicht resektables kolorektales Karzinom, BRAF und KRAS Wildtyp, mind. 2 Vortherapien, ECOG 0-1metastasiertes, tripel-negatives Mamma-Ca, PD-L1+, ECOG 0-1metastasiertes, triple-negatives Mamma-Ca, Erstlinie, ECOG 0-1metastasiertes, wiederkehrendes oder persistierendes Zervix Ca, ECOG/GOG 0-1metastasiertes Adeno-Ca des Magens und AEGmetastasiertes Adeno-Ca des Ösophagus, des gastralen Übergangs oder des Magens, ECOG 0-2Metastasiertes Adenokarzinom des Magens oder des gastroösophagealen Übergangs, ECOG 0-2, ErstlinientherapieMetastasiertes Adenokarzinom des Magens oder des ösophagogastralen ÜbergangsMetastasiertes Adenokarzinom Karzinom des Ösophagus, ösophago-gastralen Übergangs oder Magens; Zweitlinie nach Kombination von Fluoropyrimidin mit Cisplatinmetastasiertes Aderhautmelanom, HLA-A*02:01–positiv, Erstlinie, ECOG 0-1metastasiertes Adernhautmelanom, Karnofsky >60Metastasiertes AEG und Magenkarzinom, mindestens 2 Vorberhandlungen, PD-L1+metastasiertes Endometriumkarzinom, Zweit- oder Drittlinie, ECOG 0-1Metastasiertes gastroösophageales Adeno-Ca.metastasiertes gastroösophageales Adeno-Ca.Metastasiertes gastroösophageales AdenokarzinomMetastasiertes Harnblasenkarzinom, Progress nach platinhaltiger oder Checkpoint-Inhibitor-TherapieMetastasiertes hormonsensitives Prostatakarzinom, ECOG 0-1Metastasiertes hormonsensitives Prostatakarzinom, ECOG 0-2, mindestens 2 von 3 Kriterien positiv: Gleason Score gleich oder höher 8; 3 oder mehr Knochenmetastasen; viszerale Metastasen.metastasiertes Karzinom bei unbekanntem Primärtumor, Erstlinie, ECOG 0-2Metastasiertes kastrationsresistentes Prostata-Ca, ErstlinieMetastasiertes kastrationsresistentes Prostata-Ca, Erstlinie, HRR+Metastasiertes kastrationsresistentes Prostata-Ca, progredient nach Therapie mit z.B. Enzalutamid oder AbirateronMetastasiertes kastrationsresistentes Prostatakarzinom, ECOG 0-2metastasiertes kastrationsresistentes Prostatakarzinom, Erstlinie, ECOG 0-2metastasiertes kolorekt. Ca, Progress nach 1 oder 2 Vorbehandlungen, BRAF V600E, ECOG 0-1Metastasiertes kolorektales Adeno-Ca, Erstliniemetastasiertes kolorektales Adenokarzinom, Drittlinie, ECOG 0-2metastasiertes kolorektales Adenokarzinom, ECOG 0-2metastasiertes kolorektales Adenokarzinom, Erstlinie, ECOG 0-1metastasiertes kolorektales Adenokarzinom, KRAS/NRAS Wildtyp, Erstlinie, ECOG 0-1metastasiertes kolorektales Karzinom, dMMR/MSI-H, Erstlinie, ECOG 0-1metastasiertes kolorektales Karzinom, dMMR/MSI-H, Rezidiv, ECOG: 0-1metastasiertes kolorektales Karzinom, dMMR/MSI-H, Rezidivtherapie, ECOG 0-1Metastasiertes kolorektales Karzinom, Erstlinie, BRAF V600E, ECOG 0-1metastasiertes kolorektales Karzinom, Erstlinie, BRAF V600E, ECOG 0-1metastasiertes kolorektales Karzinom, Erstlinie, ECOG 0-1metastasiertes kolorektales Karzinom, Erstlinie, ECOG 0-2metastasiertes kolorektales Karzinom, Erstlinie im metastasierten Stadium, ECOG 0-2metastasiertes kolorektales Karzinom, HER2+, Rezidivtherapie, ECOG 0-1Metastasiertes kolorektales Karzinom, Progress nach 5-FU, Irinotecan, Oxaliplatin und AngiogeneseinhibitorMetastasiertes kolorektales Karzinom, vortherapiertmetastasiertes kolorektales Karzinom in Zweitlinie nach Folfox/Bevacizumab, ECOG 0-1Metastasiertes kolorektales Karzinom mit EGFR Expression, Erstlinie, Karnofsky Status >60%metastasiertes Lungenkarzinom, Erstlinie, PD-L1 ab 1%, ECOG 0-1Metastasiertes Magenkarzinom, Erstlinie, ECOG 0-2metastasiertes Mamma-Ca, ECOG 0-1, vorbehandeltmetastasiertes Mamma-Ca, Erst- und Zweitlinientherapiemetastasiertes Mamma-Ca, Erstlinie, ECOG 0-2metastasiertes Mamma-Ca, Erstlinie, ohne anthrazyklinhaltige Vortherapie, ECOG 0-2metastasiertes Mamma-Ca, Erstlinie in metastasiertem Stadiummetastasiertes Mamma-Ca, Erstlinie in metastasiertem Stadium, ECOG 0-1metastasiertes Mamma-Ca, Erstlinientherapie, ECOG 0-3metastasiertes Mamma-Ca, HER2-, Erstlinie, Karnofsky > 70metastasiertes Mamma-Ca, HR+ postmenopausal, ECOG: 0-2metastasiertes Mamma-Ca, Progress nach mehreren Therapienmetastasiertes Mamma-Ca, tripel-negativ, Erstlinie, ECOG 0-1metastasiertes Mamma-Ca, triple-negativmetastasiertes Mamma-Ca, triple-negativ, ErstlinieMetastasiertes Mamma-Ca der Frau, ECOG 0-2, Erstlinientherapie, keine Herzinsuffizienz NYHA II-IV, kein Myokardinfarkt in den letzten 6 Mo.metastasiertes Mamma-Ca HER2 negativ, ECOG 0-2, ErstlinieMetastasiertes Mammakarzinom, ECOG 0-2Metastasiertes Mammakarzinom, ECOG 0-2, bis zu 2 VortherapienMetastasiertes Mammakarzinom, Karnofsky-Index über 60%, Drittlinie oder höhermetastasiertes Mammkarzinom, Rezidivtherapie, Karnofsky Status > 70%metastasiertes Melanom, komplette Lymphadenektomie oder Resektion, Stadium IIIb, IIIc oder IV, Alter > 15 Jahre, ECOG 0-1Metastasiertes Nasopharynxkarzinom, CR oder PR nach 3 Zyklen Chemotherapie mit Cisplatin/5-FU, ECOG 0-2metastasiertes Nierennzellkarzinom, klarzellig, Zweitlinie, Karnofsky Status > 70%metastasiertes Nierenzellkarzinom, Resektion oder partielle Resektion, Erstlinie, Karnofsky Status >70%Metastasiertes oder fortgeschrittenes Anal-Ca, nichtresezierbar, ECOG 0-1metastasiertes oder fortgeschrittenes Angiosarkom, Rezidivtherapie, ECOG 0-2Metastasiertes oder fortgeschrittenes nichtkleinzelliges Lungenkarzinom, ECOG 0-1metastasiertes oder fortgeschrittenes nichtkleinzelliges Lungenkarzinom, ECOG 0-1Metastasiertes oder lokal fortgeschrittenes, nicht operables NSCLC, ALK+, Erstlinie, ECOG 0-2Metastasiertes oder lokal fortgeschrittenes Gallengangskarzinom, Progress nach gemcitabinhaltiger Chemotherapie, ECOG 0-1Metastasiertes oder lokal fortgeschrittenes Mamma-Ca, ERBB2-pos., mind. 2 VortherapienMetastasiertes oder lokal fortgeschrittenes Mamma-Ca, Her2-pos., mind. 2 VortherapienMetastasiertes oder lokal fortgeschrittenes nicht operables Harnblasenkarzinom, cisplatin-ungeeignet, PD-L1 positivMetastasiertes oder lokal fortgeschrittenes nicht operables Harnblasenkarzinom, ECOG 0-1Metastasiertes oder lokal fortgeschrittenes Osteosarkom / Ewing Sarkom, > 12 Jahre, ECOG 0-1Metastasiertes oder lokal fortgeschrittenes rezidiviertes Endometriumkarzinom, ohne vorherige antihormonelle Behandlung, ER und /oder PR positiv, EGOG 0-2Metastasiertes oder lokal fortgeschrittenes rezidiviertes Endometriumkarzinom, ohne vorherige antihormonelle Behandlung, GOG 0-2metastasiertes oder nicht-resektables lokal fortgeschrittenes Urothelkarzinom, Zweitlinie nach Platin, ECOG 0-1Metastasiertes oder rezidiviertes Adenokarzinom des Magens ohne signifikante Peritonealkarzinose nach der Erstlinientherapie mit Fluoropyrimidin plus Platin, ECOG 0-2Metastasiertes oder rezidiviertes Thymom, ECOG 0-2metastasiertes oder wiederkehrendes Zervixkarzinom, Platin-Vortherapie, keine Taxan-Vortherapie, ECOG 0-2Metastasiertes Pankreaskarzinom, ECOG 0-1metastasiertes Pankreaskarzinom, Zweitlinie nach Gemcitabin, Karnofsky Status > 50Metastasiertes Plattenepithelkarzinom des ÖsophagusMetastasiertes therapieresistentes Kolonkarzinom, Her2 amplifiziert, ECOG 0-2metastasiertes Weichteilsarkom, 2.- 5.-Linie, ECOG 0-1metastasiertes Weichteilsarkom, Anthrazyklinnaiv, ECOG 0-2metastasiertes Weichteilsarkom, Erstliniemetastasiertes Weichteilsarkom, Erstlinie, über 60 Jahre, ECOG 0-2Metastatsiertes Gallengangkarzinome, ECOG 0-2mind. 1 Knochenmetastase beim Mamma-Ca mit ECOG 0-2 oder 1 osteolytsche Läsion beim MM Stadium IIImind. 4 vorangegeangene Transfusionen in den letzten 12 Monaten, mind. 10% PNH Zellen und 100.000 Thrombozyten/µlmind. 4 vorangegegangene Transfusionen in den letzten 12 Monaten, mind. 10% PNH Zellen und 100.000 Thrombozyten/µlMM, Erstlinie, > 65 JahreMM, refraktär, mindestens 2 Vortherapien (u.a. Bortezomib, Lenalidomid, Alkylanz)MM, rezidiviert oder therapierefraktär, ECOG 0-2MM, symptomatisch, nicht zur SZT geeignet aufgrund Komorbiditäten oder älter als 65 JahreMM, symptomatisch, nicht zur Transplantation geeignet, älter als 65 JahreMM, symptomatisch, nicht zur Transplantation geeignet oder über 65 Jahre, ErstlinieMM mit Therapieindikation, neudiagnostiziert, ECOG 0-2MM Rezidiv, 1-3 VortherapienMM Stadium II und III, 18 - 65 Jahre, ECOG 0-3 (3 nur wenn durch Myelom bedingt), ErstlinieMorbus WaldenströmMorbus Waldenström, Alter über 65Morbus Waldenström, CD20+, ErstlinieMorbus Waldenström, Erstlinie oder Rezidivtherapie, ECOG: 0-2Morbus Waldenström, symptomatisch, Erst-oder ZweitlinieMorbus Waldenström, symptomatisch, ErstlinieMorbus Waldenström, Zweitlinie, rezidiv oder refraktär, ECOG 0-1Morbus Waldenström symptomatisch, ErstlinieMultiples Myelom, 1-3 Vortherapielinien, ECOG 0-2multiples Myelom, 1-3 Vortherapien, inkl. IMIDs und Proteasom-Inhibitor, ECOG 0-2Multiples Myelom, 1-3 Vortherapien, inkl. Proteosominhibitor, ECOG 0-2Multiples Myelom, 65 J. oder älter und/oder nicht-transplantationsfähig, ECOG 0-2Multiples Myelom, 65 J. oder älter und/oder nicht-transplantationsfähig, rezidiviert oder therapierefraktär, ECOG 0-2Multiples Myelom, ASCT-geeignet, 18 - 70 Jahre, ECOG 0-2Multiples Myelom, ASCT-geeignet, 18-70 Jahre, ECOG 0-2Multiples Myelom, BCL2-Expression hoch oder t(11;14), rezidiviert oder refraktär, 1-3 Vortherapien, PI sensitiv oder naiv, ECOG 0-2Multiples Myelom, dreifach refraktär, ECOG 0-2Multiples Myelom, Drittlinie oder Spätere, ECOG 0-2Multiples Myelom, Drittlinie oder spätere, ECOG 0-2Multiples Myelom, ECOG 0-1Multiples Myelom, ErstdiagnoseMultiples Myelom, Erstdiagnose, Hoch-Risiko Zytogenetik, ECOG 0-2, transplantationsfähigMultiples Myelom, Erstdiagnose, Hoch-Risiko Zytogenetik, ECOG 0-2, transplantfähigmultiples Myelom, Erstdiagnose nach Induktionstherapie und autologer Transplantation, ECOG 0-1multiples Myelom, Erstlinie, < 70 Jahre, ECOG 0-3Multiples Myelom, Erstlinie, > 65 JahreMultiples Myelom, Erstlinie, ECOG 0-2multiples Myelom, Erstlinie, transplantationsfähig, ECOG 0-2multiples Myelom, Hochdosis-Therapie möglich, Erstlinie, ECOG 0-2Multiples Myelom, Hochrisiko (del17p, t(4;14) oder t(14;16) oder >3 Kopien von 1q21) und ISS Stadium II oder IIIMultiples Myelom, Hochrisiko (del17p, t(4;14) oder t(14;16) or >3 Kopien von 1q21) und ISS Stadium II oder IIIMultiples Myelom, Induktionstherapie vor ASCT nach mindestens 2 Zyklen Standardtherapiemultiples Myelom, mindestens 2 Vortherapien, und Resistenz gegen Lenalidomid und Proteasom-InhibitorMultiples Myelom, mindestens eine Vortherapie, ECOG 0-1Multiples Myelom, mindestens eine Vortherapie, ECOG 0-2Multiples Myelom, neu diagnostiziert oder rezidiviert, ECOG 0-2multiples Myelom, Rezidiv, 1-3 VortherapienMultiples Myelom, rezidivierend oder refrakrär nach Lanalidomid, 1-5 Vortherapien, ECOG 0-2Multiples Myelom, rezidiviert oder therapierefraktär, mind. 2 vorherige Therapielinien, BRAF V600E MutationMultiples Myelom, Rezidiv nach 1-3 VortherapienMultiples Myelom, Rezidivtherapiemultiples Myelom, Rezidivtherapie nach Proteasomeninhibitor und Immunmodulator, ECOG 0-2Multiples Myelom, t(11;14), rezidiviert oder refraktär, nach Vortherapie mit PI, IMiD und anti-CD38-Antikörper, ECOG 0-1Multiples Myelom mit Cast-Nephropathiemultizentrische Castleman-Krankheit, HIV-negative und HHV-8-negative Patienten, ECOG 0-2multizentrische Castleman-Krankheit, HIV-positive Patienten, ECOG 0-2multizentrische Castleman-Krankheit, HIV-positive und HHV-8-positive Patientenmuskelinvasives Harnblasen-Ca, cT2 G3, cT3, oder cT4a und cN0/X, cM0muskelinvasives Harnblasen-Ca, cT2, cT3, oder cT4a N0, ECOG 0-1Muskelinvasives Harnblasenkarzinom, cT2-cT4b, cN0-N3, cM0 Muskelinvasives Urothelkarzinom, adjuvantMuskelinvasives Urothelkarzinom des oberen Harntraktes, entweder pT2–T4 pN0–N3 M0 oder pT1-4 pN1–3 M0Muskelinvasives Urothelkarzinom des oberen Harntraktes, high-grade, cT2-T4a cN0/X cM0Myelodysplastisches Syndrom, Niedrig-/Intermediär-1-Risiko, Thrombozytenwert unter 30.000/μl, ECOG 0-3Myelodysplastisches Syndrom, niedriges - intermediäres Risiko, Epo < 500 mU/mlMyelodysplastisches Syndrom, niedriges - intermediäres Risiko, Epo < 500 mU/ml, Hgb <10 g/dL, niedrige TransfusionsrateMyelodysplastisches Syndrom, niedriges - intermediäres Risiko, Epo < 500 mU/ml, niedrige Transfusionsrate, ECOG 0-1Myelodysplastisches Syndrom, Niedrigrisiko, ECOG 0-2Myelodysplastisches Syndrom mit refraktärer Anämie mit/ohne Sideroblasten, RAEB-I, oder hypoplastisch, ECOG 0-2Myelodysplastisches Syndrom und chronische myelomonozytäre Leukämie, ECOG 0-2Myeloische Neoplasien mit EosinophilieMyeloische Neoplasien mit Eosinophilie mit JAK2-Rearrangement (PCM1-JAK2, BCR-JAK2 und ETV6-ABL1 Fusion)Myeloische Neoplasien mit Eosinophilie und FGFR1 RearrangementMyxoides Liposarkom (HG-MLPS) G3, ab 5cm Größe, cM0Nasopharynx-Ca, Stadium III-IVb, ECOG0-2Nasopharynxkarzinom, Stadium I- IV, unter 25 JahreNasopharynxkarzinom, Stadium I - IV, unter 25 JahreNasopharynxkarzinom, Stadium III - IV, unter 25 JahreNasopharynxkarzinom, Stadium III- IV, unter 25 JahreNasopharynxkarzinom, Stadium III-IVB, ErstlinieNebennierenrindenkarzinom, ENSAT Stadium I–III, nach R0 Resektion, ECOG 0-2Nebennierenrindenkarzinom, nicht reseziert oder metastasiert, ECOG 0-1Neo/adjuvante Therapie des Weichteilsarkoms mit niederiger Hospitalisierungsrate, ECOG 0-1, T 2b, G2-3Neo/adjuvante Therapie des Weichteilsarkoms mit niedriger Hospitalisierungsrate, ECOG 0-1, T 2b, G2-3Neoadjuvante Chemotherapie bei resektablem Adenokarzinom des unteren Ösophagus, gastroösophagealen Übergangs oder MagensNeoplasien mit hohem Tumorlysesyndrom-RisikoNeoplasien mit mittlerem Tumorlysesyndrom-RisikoNET, inoperabel oder met., Mitteldarm-Tumor oder unbek. PrimariusNET des Pankreas, met. oder nicht resezierbar, low- oder intermediate-grade, Progress innerhalb der letzten 12 MonateNET des Pankreas, met. oder nicht resezierbar, Progress innerhalb der letzten 12 Monate, ECOG 0-1neu-diagnostizierte AMLneu-diagnostizierte AML, intermediäres/ungünstiges genetischen Risiko (ELN 2017), ECOG 0-2neudiagnostizierte, Ph+/BCR-ABL+, chronische myeloische Leukämie, chronische Phase < 15% Blasten, < 20% basophile Granulozyten, ECOG 0-2neudiagnostizierte, Ph+/BCR-ABL+, chronisch myeloische Leukämie, ECOG 0-1neudiagnostizierte, Ph+ chronische myeloische Leukämie, ECOG 0-2neudiagnostizierte, rezidivierte oder refraktäre T-PLL, PTCL, HSTCL, extranodales killer/T-Zell Lymphom, ECOG 0-2neudiagnostizierte, rezidivierte oder refraktäre T-PLL, PTCL, HSTCL, extranodales NK/T-Zell Lymphom, ECOG 0-2neudiagnostizierte akute lymphatische Leukämie, Ph+/BCR-ABL+, ECOG 0-1Neu diagnostizierte AL-Amyloidose, nicht geeignet für ASCTneudiagnostizierte AML, CD33 positiv, Induktion, Erstlinieneudiagnostizierte AML, CD33 positiv, Induktion, Erstlinie, Leukozytenzahl < 30.000/µlneudiagnostizierte AML, CD33 positiv, Induktion, Erstlinie, Leukozytenzahl ab 30.000/µlneudiagnostizierte AML, CD33 positiv, Induktion, Erstlinie, Leukozytenzahl bis 30.000/µlneudiagnostizierte AML, ECOG 0-2neudiagnostizierte AML, Erhaltung bei Patienten in kompletter Remission, FLT3-Mutation, ErstlinieNeu diagnostizierte AML, FLT3+, nicht für eine intensive Therapie geeignet, ECOG 0-2Neu diagnostizierte AML, IDH-1-mutiert, nicht für eine intensive Therapie geeignet, ECOG 0-2neudiagnostizierte AML, Induktion, FLT3-Mutation, Erstlinieneudiagnostizierte AML, Konsolidierung, FLT3-Mutation, Erstlinieneudiagnostizierte AML, primär oder sekundär, Erstlinie, ECOG 0-2neudiagnostizierte de-novo oder sekundäre AML, ECOG 0-4Neu diagnostizierte de-novo oder sekundäre AML mit Knochenmarkblasten > 30%, Alter > 65 Jahre, ECOG 0-2neudiagnostizierte de novo oder sekundäre AML, 18-60 Jahre, ECOG < 3Neu diagnostizierte MS LCH oder ss-M LCH, Alter über 18Neudiagnostizierte oder sekundäre, unbehandelte AMLneu diagnostizierte oder sekundäre AML, Alter ≥60 JahreNeudiagnostizierter, lokal fortgeschrittener Kopf-Hals-Tumor, Stadium III-IV, Plattenepithel-, ECOG 0-1neudiagnostizierter, lokal fortgeschrittener Kopf-Hals-Tumor, Stadium III-IV, Plattenepithel-, ECOG 0-1neudiagnostizierter nichtmetastasierter, intrakranieller Keimzelltumorneudiagnostiziertes, HIV assoziiertes T-Zell Lymphom, Erstlinie, Karnofsky >50%Neudiagnostiziertes, multiples Myelom, Erstlinie in Kombination mit der Induktion und als Erhaltung für alle PatientenNeu diagnostiziertes, nicht 1p/19q kodeletiertes anaplastisches Gliom WHO Grad 2 oder 3, ECOG 0-2Neu diagnostiziertes, resezierbares high-grade Osteosarkom, Alter bis 40, ECOG 0-2Neudiagnostiziertes, unbehandeltes multiples Myelom, ECOG 1-4Neu diagnostiziertes anaplastisches Gliom, Grad 3, Erstlinieneu diagnostiziertes Glioblastom, Karnofsky > 70%Neudiagnostiziertes high grade Gliom, Erstlinie, Karnofsky größer 60%neudiagnostiziertes Hodgkin Lymphom, Ann Arbor stage IA-IIB, ECOG 0-2neu diagnostiziertes Hodgkin Lymphom, fortgeschritten, Alter 60-75, ECOG 0-2Neudiagnostiziertes Hodgkin Lymphom im Kindes- und Jugendalterneudiagnostiziertes MM, nicht zur Transplantation geeignet oder über 65 Jahre, ECOG 0-2neudiagnostiziertes multiples Myelom, < 65 JahreNeu diagnostiziertes multiples Myelom, nach autologer Stammzelltransplantation, < 65 JahreNeu diagnostiziertes multiples Myelom, nicht-transplantationsfähig, ECOG 0-2neudiagnostiziertes multiples Myelom, nicht geeignet für Hochdosis + ASZT, ECOG 0-2Neu diagnostiziertes multiples Myelom, Stadium II oder III oder progredientes Stadium I nach Durie and Salmon, transplantationsfähigNeu diagnostiziertes multiples Myelom, transplantationsfähig, ECOG 0-2neu diagnostiziertes multiples Myelom mit mind. einer lytischen Knochenläsionneu diagnostiziertes oder rezidiviertes Nierenzellkarzinom, Stadium IV, Erstlinie, Karnofsky > 70Neudiagnostiziertes Ovarial-Ca, Eileiter-Ca oder Peritoneal-Ca, Stadium III mit neoadjuvanter Therapie, ECOG 0-2neudiagnostiziertes Ovarial-Ca, Stadium III/IV, Erstlinienbehandlung mit Platin-/Taxan-/Bevacizumabtherapie, ECOG 0-1neudiagnostiziertes primäres ZNS-Lymphom, > 60 Jahreneudiagnostiziertes primäres ZNS-Lymphom, > 66 Jahre, Karnofsky > 70Neu diagnostiziertes primäres ZNS-Lymphom, > 66 Jahre, Karnofsky > 70neudiagnostiziertes primäres ZNS-Lymphom, ECOG 0-2Neudiagnostiziertes primäres ZNS-Lymphom, ECOG 0-2neudiagnostiziertes Prostatakarzinom, metastasiert, hormonsensitiv, ECOG 0-2Neuroendokrines Karzinom, gastroententeropankreatisch, nach Erstlinie mit Cisplatin, ECOG 0-2Neuroendokrines Karzinom des Verdauungstraktes, nicht resezierbar, Erstlinie, ECOG 0-1Neuroendokrines Prostatakarzinom, Erst- und Zweitlinieneuroendokrine Tumore, gastroenteropankreatisch, unbekannter Primarius, nicht reserzierbar oder met., Ki-67 Index bis 10%, G1 u G2, ECOG 0-2Neurofibromatose Typ 1, Plexiforme Neurofibrome nicht operabel, <18 JahreNHL, HL, Rezidiv, fehlende Remission nach kurativer ChemotherapieNicht-resektables Adeno- oder Plattenepithelkarzinom des Ösophagus, cT1-4 cN0-3 M0 oder M1 (supraklavikuläre Lymphknoten)nicht-resezierbares, metastasiertes Magen-/AEG-Ca (Adeno-), Zweitlinie, ECOG 0-1Nicht-Seminom, adjuvant, ErstlinieNichtkleinzelliges Lungen-Ca Stadium IIIb, IV oder RezidivNichtkleinzelliges Lungen-Ca Std. IIIb, IV oder Rezidivnichtkleinzelliges Lungenkarzinom (Adenokarzinom), Stadium IB-IIIA, neoadjuvant, ECOG 0-1, ALK und EGFR neg.nichtkleinzelliges Lungenkarzinom (Plattenepithelkarzinom), Stadium IB-IIIA, neoadjuvant, ECOG 0-1, ALK und EGFR neg.nichtkleinzelliges Lungenkarzinom, Adeno-, Stadium IV, Erstlinie, ECOG 0-1nichtkleinzelliges Lungenkarzinom, Plattenepithel-, Stadium IV, Erstlinie, ECOG 0-1nichtkleinzelliges Lungenkarzinom, Stadium I, II und III, adjuvant, ECOG 0-1Nichtkleinzelliges Lungenkarzinom, Stadium IB, II, IIIA (UICC 8), ECOG 0-1nichtkleinzelliges Lungenkarzinom, Stadium IB-IIIA, neoadjuvant, ECOG 0-1, ALK und EGFR neg.nichtkleinzelliges Lungenkarzinom, Stadium IB-IIIA, R0-Resektion, adjuvant, ECOG 0-1Nichtkleinzelliges Lungenkarzinom, Stadium II, IIIA, or IIIB (N2), ECOG 0-1nichtkleinzelliges Lungenkarzinom, Stadium II, IIIA, or IIIB (N2), ECOG 0-1Nichtkleinzelliges Lungenkarzinom, Stadium II-IIIA, adjuvant, nach platinbasierter ChemotherapieNichtkleinzelliges Lungenkarzinom, Stadium IIA/IIIB, ECOG 0-1, ALK und EGFR neg.Nichtkleinzelliges Lungenkarzinom, Stadium IIIA/IIIB, ECOG 0-1, ALK und EGFR neg.Nichtkleinzelliges Lungenkarzinom lokal fortgeschritten oder metastasiert, ROS1+, ECOG 0-2nicht kurativ resezierbares Melanom, Stadium III-IV, Karnofsky Status >50nicht metastasiertes, HR+ Mamma-Ca, postmenopausal, adjuvant kombiniert mit Aromatase-Inhibitor Therapienicht metastasiertes, kastrationsresistentes Hochrisiko Prostata-Canicht metastasiertes, kastrationsresistentes Prostata-Ca, ECOG 0-1nicht metastasiertes, kastrationsresistentes Prostata-Ca, PSA-Verdopplungszeit weniger als 10 Monate, ECOG 0-1nicht metastasiertes, lokal fortgeschrittenes Adenokarzinom des Pankreas, Erstlinie, ECOG 0-1nichtmyeloische Tumorerkrankung, Hb < 10 g/dl, ECOG 0-2nichtmyeloische Tumorerkrankung, Hb < 11 g/dl, ECOG 0-4Nichtmyeloische Tumore und Anämie, Hb < 12 g/dl, TSAT < 50%, Serum-Ferritin < 800 ng/L, ECOG 0-2nicht operabeles, lokal fortgeschrittenes oder metastasiertes Urothelkarzinom, Cisplatin- ungeeignet, Erstlinie, ECOG 0-2nicht operables, lokal fortgeschrittenes oder metastasiertes Ösophaguskarzinom, ERBB+, Erstlinie, ECOG 0-2nicht operables, lokal fortgeschrittenes oder metastasiertes Ösophaguskarzinom, HER2+, Erstlinie, ECOG 0-2nichtresektables, fortgeschrittenes oder metastasiertes Ösophaguskarzinom, Zweitlinie, ECOG 0-2nichtresektables kolorektales Karzinom, Zweitlinie nach AIO/Oxaliplatin, 18-75 Jahre, ECOG 0-2nichtresektables Ösophaguskarzinom, Stadium I-IVA, ECOG 0-2nicht reserzierbares, fortgeschrittenes oder metastasiertes Melanom in der Erstlinie, ECOG 0-1Nicht resezierbare Kopf-Hals-Tumoren (Plattenepithel-), Stadium III - IV, ECOG 0-1nichtresezierbarer oder metastasierter gastrointestinaler Stromatumor, CD117 expressionierend, ECOG < 3nichtresezierbarer oder metastasierter GIST, nach Therapie mit 3 oder mehr Kinase-Hemmern, einschließlich Imatinib, Sunitinib und Regorafenibnichtresezierbares, lokal fortgeschrittenes oder metastasiertes medulläres Schilddrüsenkarzinom, ECOG 0-2nicht resezierbares, lokal fortgeschrittenes oder metstasiertes medulläres Schilddrüsenkarzinom, ECOG 0-2nicht resezierbares, malignes Melanom, Stadium III-IV, ECOG 0-1nicht resezierbares, metastasiertes kolorektales Karzinom, Adeno-, Erstlinie, ECOG 0-1nicht resezierbares, rezidivertes oder metastasiertes Gallengangskarzinom, ECOG 0-2Nicht resezierbares, rezidiviertes oder metastasiertes Gallengangskarzinom, Erstlinie, ECOG 0-2nicht resezierbares / borderline Adenokarzinom des Pankreas, neoadjuvant, Erstlinie, ECOG 0-2nichtresezierbares fortgeschrittenes, refraktäres oder rezidiviertes Ösophaguskarzinom, ECOG 0-1nichtresezierbares fortgeschrittenes oder rezidiviertes Karzinom des gastroösophagealen Übergangs oder des Magens, Drittlinie, ECOG 0-1nichtresezierbares fortgeschrittenes oder rezidiviertes Karzinom des gastroösophagealen Übergangs oder des Magens, ECOG 0-1nichtresezierbares hepatozelluläres Karzinom, Erstlinie, ECOG 0-1Nicht resezierbares kolorektales Karzinom, Drittlinie, RAS Wildtypnichtresezierbares kolorektales Karzinom, Erstlinie, ECOG 0-2Nicht resezierbares kolorektales Karzinom, Rezidivtherapie, ECOG 0-1nicht resezierbares Melanom, Stadium III-IV, Erstlinie, ECOG 0-1nichtresezierbares Melanom, Stadium IIIB oder IV, ECOG 0-1nicht resezierbares Melanom, Stadium IIIC oder IV, Erstlinientherapie, BRAF V600 Mutation, ECOG 0-1Nicht resezierbares Melanom, Stadium III oder IV, Erstlinientherapie, BRAF V600 Mutation, ECOG 0-1nicht resezierbares Melanom, Stadium III oder IV, Erstlinientherapie, BRAF V600 Mutation, ECOG 0-1nicht resezierbares NSCLC, Stadium I-IIIB, ECOG 0-3Nicht resezierbares NSCLC, Stadium IIIA und IIIB, Erstlinie, ECOG 0-2Nicht resezierbares oder metastasiertes malignes Melanom, Stadium III/IV, ECOG 0-1nicht resezierbares Pleuramesotheliom ohne vaskuläre Komorbidität, Erstlinie, ECOG 0-2nichtresezierbraes Melanom, Stadium III und IV, Zweitlinie nach Chemotherapie, ECOG 0-2Nicht transplantationsfähige Patienten mit neu diagnostiziertem multiplen Myelom, über 65 Jahre, ECOG 0-2Nicht transplantationsfähige Patienten mit rezidiviertem oder therapierefraktärem multiplen Myelom, über 65 Jahre, ECOG 0-2Niedrig- oder Intermediär-1-Risiko, singuläre Deletion am Chromosom 5, transfusionspflichtige Anämieniedriges bis mittleres Risiko der akuten Promyelozyten Leukämie, ECOG 0-2Nodulär-lymphozytenprädominantes Hodgkin-Lymphom (NLPHL)Nodulär-lymphozytenprädominantes Hodgkin-Lymphom (NLPHL), therapierefraktär oder rezidiviert, ECOG 0-1Non-Hodgkin-Lymphom / Hodgkin LymphomNon-Hodgkin Lymphom, low-grade, nicht-aggressiv, Stadium III-IVNSCLC (Adeno-), Stadium IIIb oder IV, EGFR- und ALK-, Erstlinie, ECOG 0-1NSCLC (Adeno-) Stadium III (maligner Pleuraerguss) und Stadium IV, ECOG PS 2NSCLC (Adeno-) Stadium IIIA und IIIB (ohne Pleuraerguss), ECOG 0-1NSCLC (Adeno-) Stadium IIIb (maligner Pleuraerguss) und Stadium IV, ECOG PS 2NSCLC (Adeno-) Stadium IIIb oder IVNSCLC(Adeno-) Std. IIIb und Std. IV, Wenig- oder NichtraucherNSCLC (Adeno-, EGFR-Mutation+) fortgeschrittenNSCLC (Adenokarzinom), Stadium IB-IIIA, EGFR mutiert (Ex19del oder L858R), adjuvant, ECOG 0-1NSCLC (Nicht-Plattenepithel) inoperabel Std. IIIb u Std. IVNSCLC (Nicht-Plattenepithel) Stadium IIIb (maligner Pleuraerguß) und Stadium IVNSCLC (Nicht-Plattenepithel) Stadium IIIb (mit Pleuraerguß) und Stadium IVNSCLC (Nicht-Plattenepithel) Stadium IIIb(spraclavic. Lymphknoten, malig. Pleura- oder Perikardergüsse) und Stadium IVNSCLC (Nicht-Plattenepithel) Std. IIIb (supraclavic. Lymphknoten, malig. Pleura- oder Perikardergüsse) und Std. IVNSCLC, ECOG 0-2, perioperativNSCLC, limited und extensive disease, Zweitlinie, Progress nach Erstlinie mind. 60 Tage nach ErstlinienkomplettierungNSCLC, lokal fortgeschritten oder metastasiert, Her2+, nach vorheriger Therapie, ECOG 0-1NSCLC, metastasiert, ECOG 0-2, ErstlinieNSCLC, potenziell resezierbar, Stadium IIIA oder IIIB, ECOG 0-1NSCLC, Stadium IIIa und IIIb, ECOG 0-1, therapie-naivNSCLC, Stadium IIIa und Stadium IIIb, ECOG 0-1, therapie-naivNSCLC, Stadium IIIB oder IV, ALK+, Erstlinie, ECOG 0-2NSCLC, Stadium IIIB oder IV, ALK+, Zweitlinie nach Crizotinib, ECOG 0-2NSCLC, Stadium IIIB oder IV, ECOG 0-1NSCLC, Stadium IIIB oder IV, ELK/EGFR neg., ECOG 0-1NSCLC, Stadium IIIb und IV, Patienten über 70 JahreNSCLC, Stadium II und III, nicht resezierbar, Karnofsky > 70NSCLC, Stadium IV, BRAF V600 mutiert, Erstlinie, ECOG 0-2NSCLC, Stadium IV, Progress nach ciplatin- oder anti–PD-(L)1-haltiger TherapieNSCLC, STD. IIIb (mit Pleuraerguss) und Std. IV, älter als 70 Jahre, chemo-naiv, ECOG 0-1NSCLC, Zweitlinie nach Platinkombination oder TKI, PD-L1 Expression > 1%, ECOG 0-1NSCLC fortgeschritten oder metastasiert, ALK+, Erstlinie, ECOG 0-2NSCLC fortgeschritten oder metastasiert, ALK+, ZweitlinieNSCLC fortgeschritten oder metastasiert, Erstlinie, WHO 0-2NSCLC fortgeschritten oder metastasiert, METex14+, ECOG 0-2NSCLC fortgeschritten oder metastasiert, nach VortherapieNSCLC fortgeschritten oder metastasiert, Progress nach platinbasierter Therapie, ECOG 0-1NSCLC fortgeschritten oder metastasiert, ROS1+, ECOG 0-2NSCLC fortgeschritten oder metastasiert, Zweitlinie nach Progress unter TKI, WHO 0-2NSCLC fortgeschritten und metastasiert, Progress unter mind. einer platinbasierten VortherapieNSCLC fortgeschritten und metastasiert, Progress unter mind. einer platinbasierten Vortherapie, ECOG 0-2NSCLC im Stadium IIIB/IV, EGFR Mutation, keine Vortherapie für die fortgeschrittene Erkrankung, keine Hirnmetastasen, ECOG 0-1NSCLC im Stadium IIIB oder IV, MET Exon 14 Mutation oder MET Amplifikation, ECOG 0-1NSCLC im Stadium IIIB oder IV, MET Exon 14 Skipping Mutation, nach vorherigen Therapie, ECOG 0-1NSCLC im Stadium IV, EGFR mutiert (Exon 19 Deletion oder Exon 21 Substitution), ECOG 0-1, keine zerebralen MetastasenNSCLC inoperabel (Stadium IIIa und b), Rezidiv oder Metastasen, Stadium IVNSCLC inoperabel (Std. IIIa u b), Rezidiv oder Metastasen, Std. IVNSCLC lokal fortgeschritten, inoperabel, oder metastasiert, Her2-Mutation, Progress nach platinhaltiger TherapieNSCLC lokal fortgeschritten, nicht operabel oder metastasiert, PD-L1 Expression über 50%, ECOG 0-1NSCLC lokal fortgeschritten, oder metastasiert, EGFR Exon-19-Deletion oder L858R-Mutation, ECOG 0-1NSCLC lokal fortgeschritten oder metastasiert, taxanhaltige Vortherapie, Karnofsky Index 50-100NSCLC metastasiert, nach Rezidiv oder Nichtansprechen einer Vortherapie, ECOG 0-1, ZweitlinieNSCLC metastasiert oder lokal fortgeschritten, RET-Fusion, ECOG 0-2NSCLC metastasiert oder lokal fortgeschritten mit KRAS p.G12C Mutation, Progress nach Immuntherapie und/oder platinbasierter Chemotherapie, ECOG 0-1NSCLC nicht resezierbar oder metastasiert, nach 4 Zyklen platinbasierter Kombinationstherapie ohne ProgressNSCLC nicht resezierbar Stadium IIIb (mit oder ohne Pleuraerguss) und Stadium IVNSCLC Stad. IIIb od IV ohne Eignung für OP oder kurative Radiatio (außer bronchoalveoläres Ca)NSCLC Stadium III (nicht für Radiatio geeignet) und Stadium IV , Patienten älter als 70 JahreNSCLC Stadium IIIa und Stadium IIIbNSCLC Stadium IIIbNSCLC Stadium IIIb (Pleuraerguss oder met. supraclavic. Lymphknoten) und Stadium IV, Patienten älter als 70 JahreNSCLC Stadium IIIb, IV oder RezidivNSCLC Stadium IIIb mit malig. Pleuraergüssen oder supraclavic.Lymphknoten und Stadium IVNSCLC Stadium IIIb mit malig. Pleuraergüssen oder supraclavic. Lymphknoten und Stadium IV, < 70 JahreNSCLC Stadium IIIb mit malig. Pleuraergüssen oder supraclavic.Lymphknoten und Stadium IV, jünger als 70 JahreNSCLC Stadium IIIb mit malig. Pleuraergüssen oder supraclavic. Lymphknoten und Stadium IV, jünger als 70 JahreNSCLC Stadium IIIb mit malignen Pleuraergüssen oder supraclavic. Lymphknoten und Stadium IVNSCLC Stadium IIIb oder IV, (Plattenepithel-), Zweitlinie nach platinbasierter Therapie, ECOG 0-1NSCLC Stadium IIIb oder IV, Erstlinie für fortgeschrittene Erkrankung, ECOG 0-1NSCLC Stadium IIIB oder IV, Zweit- oder Drittlinie nach Platin, ECOG 0-1NSCLC Stadium IIIb oder IV ohne Eignung für OP oder kurative Radiatio (außer bronchoalveoläres Ca)NSCLC Stadium IIIb und IVNSCLC Stadium IIIb und IV, exclusive vorrangiger histolog. PlattenepithelkomponenteNSCLC Stadium IIIb und IV, palliativNSCLC Stadium IIIb und IV ohne Eignung zur kurativen TherapieNSCLC Stadium IIIb und Stadium IVNSCLC Stadium IIIb und Stadium IV, EGFR-ExpressionNSCLC Stadium III nicht resezierbarNSCLC Stadium III und IV, palliativ, ZweitlinieNSCLC Stadium IV, PD-L1 Expression > 50%, keine EGFR Mutationen / ALK Translokationen, Erstlinie, ECOG 0-1NSCLC Stadium IV mit Progress unter oder nach Platinum-basierter ErstlinieNSCLC Stadium T2N0, T1N1, T2N1 in adjuvantem Setting nach KomplettresektionNSCLC Stadium V oder IIIb ohne Eignung für multimod. Therapie, Patienten älter als 65 und nicht für Kombinationschemotherapie geeignet)NSCLC Std. I (nur T2N0), Std. II u Std. IIIa nach Komplettresektion, ECOG 0-2, exclusive histolog. brochoalveoläres Ca.NSCLC Std. I, II u III nach KomplettresektionNSCLC Std. IIIa (falls inoperabel), IIIb oder IVNSCLC Std. IIIb (mit Pleuraerguss) u Std. IV, EGFR Mut+(Deletion Exon 19 oder L858R Mut in Exon 21)NSCLC Std. IIIB oder IV, ECOG 0-2, jünger als 75 Jahre, ErstlinieNSCLC Std. IIIb u IV, palliativNSCLC Std. IIIb und IV NSCLC Std. IIIb und IV, Zweit- und Drittlinie bei Patienten ohne Eignung zur weiteren ChemotherapieNSCLC Std. IIIb und Std. IV, EGFR-ExpressionNSCLC Std. IVoperables, lokal fortgeschrittenes Mamma-Ca, Tumor > 2cm, HER2+, ECOG 0-1operables, lokal fortgeschrittenes oder entzündliches Mamma-Ca, HER-2+, Erstlinie, ECOG 0-1Oropharynxkarzinom (Plattenepithel), HPV-positiv und low-risk (nie Raucher oder weniger als 10 PY), T3N0–T4N0, and T1N1–T4N3, ECOG 0-1Osteoporose bei Frauen postmenopausal, Alter 65-89, T-score -2,5Ovarial-Ca, FIGO Ic–IV, postoperativ, ECOG 0-2, keine vorausgegangene Chemotherapie oder RadiatioOvarial-Ca, fortgeschritten, nach Debulking-OP, ECOG 0-2Ovarial-Ca, inkompl. resekt. Stadium III oder jedes Stadium IV, ErstlinieOvarial-Ca, nach OP, high-risk early stage oder fortgeschritten, ECOG 0-2Ovarial-Ca, Rezidiv, platinsensitiv, Zweitlinie, BRCA Mutation, ECOG 0-1Ovarial-Ca, Rezidiv innerhalb von 6 Monaten nach platinbasierter ErstlinieOvarial-Ca, Rezidiv innerhalb von 6 Monaten nach platinbasierter Erstlinie/ZweitlinieOvarial-Ca, Rezidiv nach oder refraktär nach/unter platinbasierter Erstlinie.Ovarial-Ca, Rezidiv nach oder refraktär nach/unter platinbasierter Erstlinie innerhalb von 12 Monaten, ECOG 0-2Ovarial-Ca fortgeschritten, Stadium II-IVOvarial-Ca Rezidiv, mehr als 6 Monate nach Komplettierung der Platinum-basierten Erst- oder Zweitlinie (Platinum-sensitives Rez.), Taxan-Vorhterapie, ECOG 0-2Ovarial-Ca Rezidiv, mehr als 6 Monate nach Komplettierung der Platinum-basierten Erstlinie (Platinum-sensitives Rez.), ECOG 0-1Ovarial-Ca Rezidiv, mehr als 6 Monate nach Komplettierung der Platinum-basierten Erstlinie (Platinum-sensitives Rez.), ECOG 0-2Ovarial-Ca Rezidiv, nach Platinum-basierter Erstlinie, Progress innerhalb und nach mehr als 6 Monaten (Platinumresistent und -sensibel; Platinumrefraktäre Patienten waren ausgeschlossen), ECOG 0-2Ovarialkarzinom, Erstlinie, ECOG 0-2Ovarialkarzinom, Peritonealkarzinom, Karzinom der Eileiter, Rezidivtherapie, >6 Monate Erstlinie mit Platin, ECOG 0-2Ovarialkarzinom, Rezidiv nach oder refraktär nach/unter platinbasierter ErstlinieOvarialkarzinom, Rezidiv nach oder refraktär nach/unter platinbasierter Erstlinie, ECOG 0-2Ovarialkarzinom, serös, low-grade oder Borderline-Tumor, Progress nach platinhaltiger ChemotherapieOvarialkarzinom, Stadium IC-IV, ECOG 0-2Paclitaxel wöchentlich, Mamma-Ca, adjuvantPaclitaxel wöchentlich, MammaCa, adjuvantPaclitaxel wöchentlich, Mammakarzinom, adjuvantPankreas-Ca, fortgeschritten oder metastasiert, ECOG 0-2, ErstliniePankreas-Ca, lokal fortgeschritten oder metastasiert, chemo-naivPankreas-Ca, metastasiert, chemo-naiv, Karnofski-Index von 70 und höherPankreas-Ca, nach R0 oder R1-Resektion, Karnofsky Index über 50%, keine vorangegangene Chemo- oder RadiotherapiePankreaskarzinom (Adeno-), metastasiert, ECOG 0-1Pankreaskarzinom, MSI-H/dMMR, Zweitlinie, ECOG 0-1Pankreaskarzinom, Progress unter Erstlinie Gemcitabin, Karnofsky Status >70Pankreaskarzinom adjuvant, Adeno-, R0- oder R1-Resektion, Erstlinie, ECOG 0-1pankreatisches neuroendokrines Karzinom, ErstliniePatienten mit Cisplatin refraktärem Keimzelltumor oder Rezidiv nach Hochdosistherapie mit PBSCTPatienten mit Nierenzellkarzinom in der Zweitlinie / Erstlinie, klarzellig, ECOG 0-1Patienten mit operiertem Karzinom des gastroösophagealen Übergangs oder des MagensPatienten mit primär nicht resektablen Lymphnotenmetastasen oder Rezidiv der LymphknotenmetastasenPenis-Ca, vortherapiert mit CisplatinPeniskarzinom im Stadium cTx, cN2/N3, cM0, ECOG 0-2, neoadjuvante TherapiePeripheres T- oder NK-Zell Lymphom, kutanes T-Zell Lymphom (Stadium IB oder höher), T-PLLperipheres T-Zell Lymphom, CD30+, Erstlinie, ECOG 0-2Peripheres T-Zell Lymphom, Erstlinie, ECOG 0-2peripheres T-Zell Lymphom, Zweitlinie nach CHOP, ECOG 0-2Peripheres T-Zell Lymphom oder Mykosis fungoides, mindestens 2 VortherapienPeritonealkarzinom durch kolorektales Ca oder Pseudomyxoma peritonii, operabel, T1-T4, Stadium I-IVPeritonealkarzinose ausgehend vom kolorektalen Karzinom, ECOG 0-2Peritonealmesotheliom, Zweitlinie oder höher, ECOG 0-1Ph+/BCR-ABL+ chronische myeloische Leukämie, chronische Phase < 15% Blasten, < 20% basophile GranulozytenPhäochromozytom, Paragangliom, fortgeschritten oder metastasiertPlasmazell-Leukämie, Erstlinie, ECOG 0-3plasmoblastisches Lymphom, mit und ohne HIV-Infektion, ECOG 0platinsensitives Ovarial-Ca oder primäre Peritonealkarzinose, Drittlinie, ECOG 0-1Plattenepithel- , Basalzell- oder kloakogenes Anal-Ca, T2-T4, jedes N, M0Plattenepithel- oder kloakogenes Anal-Ca, Stadium I-III, ECOG 0-2Plattenepithelkarzinom der Haut, lokal fortgeschritten, nicht operabel, ECOG 0-2Plattenepithelkarzinom der Haut, lokal fortgeschritten oder Lymphknotenmetastasen, nicht operabel, ECOG 0-2Plattenepithelkarzinom der Haut, lokal fortgeschritten und nicht operabel, oder metastasiert, ECOG 0-2Pleuramesotheliom, Erstlinie, ECOG 0-1Pleuramesotheliom, metastasiert, nach platinhaltiger Chemotherapie, ECOG 0-1Pleuramesotheliom, Progress nach Platin/Pemetrexed, ECOG 0-2Pleuramesotheliom, unter 75 J, ECOG 0-2Pleuramesotheliom, Zweitlinie nach Platin-Pemetrexed, ECOG 0-1PNH, Erst-oder Zweitlinie nach EculizumabPNH, Klongröße mind 10%, Hämoglobinwert unter 10 g/dlPNH mit Hämoglobin < 10,5g/dl während 3 Monaten EculizumabPolycythaemia vera, HU, IFNa resistent oder intolerant, Patienten in fortgeschrittenem LebensalterPolycythaemia vera, Phlebotomie-abhängig, ECOG 0-2Polycythaemia vera, Phlebotomie-abhängig oder symptomatischPolycythemia vera, Erstline, ECOG 0-2postmenopausale Frauen, fortgeschr. Mamma-Ca, HR+, HER2-, Progress nach Anastrozol oder LetrozolPotentiell resektables Adeno- oder Plattenepithelkarzinom des Ösophagus.potenziell resezierbares Plattenepithelkarzinom des Ösophagus, Karnofsky > 90Potenziell resezierbares Plattenepithelkarzinom des Ösophagus, Karnofsky >90prim. Brustkrebs, 18-65 Jahre, R0-Resektion, HER2+, Karnofsky Status > 80%prim. Brustkrebs, 18-65 Jahre, R0-Resektion, Karnofsky Status > 80%primär disseminiertes Ewing Sarkom, Alter unter 50primäre autoimmunhämolytische Anämie, vom Wärmetypprimäre autoimmunhämolytische Anämie, vom Wärmetyp, ErstliniePrimäre HypogammaglobulinämiePrimäre hämophagozytische Lymphohistiozytose, neu diagnostiziert oder nach Versagen oder Unverträglichkeit der Primärtherapie, unter 18 JahrenPrimäre Myelofibrose, post-PV oder Post-Essentielle-Thrombozythämie-Myelofibrose, intermediäres oder hohes Risiko, ECOG 0-3primäre oder sekundäre AML, Erstdiagnose, 18-65, ECOG 0-2primäres, kutanes B-Zell-Lymphomprimäres Mamma-Caprimäres Mamma-Ca, adjuvant, HER2+primäres Mamma-Ca, HR+, HER2+, Karnofsky > 80primäres myelodysplastisches Syndrom länger als 6 Monate, nicht-transfundierter Hämoglobinwert < 10 g/dl, ECOG 0-2primäres ZNS-Lymphom, Rezidivtherapie, Karnofsky Status größer 60%primäres ZNS-NHL, Erstdiagnoseprimär mediastinales Non-Hodgkin-Lymphom, R/R, CD30+, ECOG 0-1primär refraktäre oder rezidivierende AMLprimär refraktäres oder rezidiviertes Hodgkin Lymphom, ECOG 0-2Primär therapierefraktäres oder rezidiviertes B-NHL oder B-ALL, <21 Jahre, ECOG 0-2progredientes NSCLC, ALK+, ECOG 0-2Progressives oder residuelles Low-Grade Gliom bei Kindern, WHO Grad 1+ 2, Alter unter 10, ErstlinieProstatakarzinom, alle Stadien, ECOG 0-2Prämedikation der autologen StammzellinfusionPTCL oder CTCL, Stadium IIB oder höher, max. 3 Vortherapien, ECOG 0-2R/R DLBCL, mindestens 1 Vortherapie, ECOG 0-2, nicht geeignet für eine ASCT, periphere Neuropathie bis Grad 1R0 reseziertes klarzelliges Nierenzellkarzinom, hohes Rezidivrisiko, adjuvant, +/- MetastasektomieR0-reseziertes Karzinom des Ösophagus oder des gastroösophagealen Übergangs, Stadium cT1-4N1-3M0 (AJCC 7), nach neoadjuvanter Radiochemotherapie ohne pCR, adjuvantR0-reseziertes Karzinom des Ösophagus oder des gastroösophagealen Übergangs, Stadium II-III, nach neoadjuvanter Radiochemotherapie mit residuellem Tumor, adjuvantrefraktäre/rezidivierende CLL/SLL ohne Deletion p17, ECOG 0-1refraktäre Anämie, mit Sideroblasten oder exzessiven Blasten, nichtproliferative CMLrefraktäre Anämie beim myelodysplastischen Syndrom, niedrig-intermediäres Risiko, Epo < 500 mU/ml, niedrige TransfusionsrateRefraktäre Meningeosis neoplastica, Erstlinie für Meningeosis neoplastica, Karnofsky > 60refraktäre oder rezidivierende ALL, BCR-ABL/Ph negativ, Blasten > 5%, ECOG 0-2refraktäre oder rezidivierende HCL nach Pentostatin oder Cladribintherapierefraktäres oder rezidivierendes Hodgkin Lymphom, ECOG 0-1refraktäres oder rezidivierendes kutanes T-Zell-Lymphom, 2 oder mehr Vorbehandlungen, ECOG 0-2refraktäres oder rezidivierendes kutanes T-Zell-Lymphom, eine oder mehr Vorbehandlungen, ECOG 0-1refraktäres oder rezidivierendes NHL oder HL, Rituximab VortherapieRefraktäres oder rezidivierendes Non-Hodgkin-Lymphomrefraktäres oder rezidiviertes Hodgkin Lymphom, für eine Transplantation geeignet, ECOG 0-1Refraktäres oder rezidiviertes Marginalzonenlymphom, Zweitlinie, ECOG 0-2Refraktäres oder rezidiviertes multiples Myelom, ECOG 0-2, 1-3 Vortherapienrefraktäres oder rezidiviertes multiples Myelom, ECOG 0-2, 1-3 Vortherapienrefraktäres oder wiederkehrendes Karzinosarkom des Uterus, Stadium III - IV, ECOG 0-2refraktäres oder wiederkehrendes multiples Myelom, 1-3 Vortherapien, ECOG 0-2Refraktäres oder wiederkehrendes Multiples Myelom, 2.-4. Linie, ECOG 0-2refraktäres oder wiederkehrendes multiples Myelom, ECOG 0-2, 1-3 Vortherapienreife, aggressive B-Zell-Lymphome und -Leukämien, CD20+, Erstlinie, Alter bis 18 Jahrereife, aggressive B-Zell-Lymphome und -Leukämien, CD20+, R2 Stadium I, II und III mit Rituximab, R3/R4 ZNS negativ, Erstlinie, Alter bis 18 Jahrereife, aggressive B-Zell-Lymphome und -Leukämien, CD20+, R2 Stadium III und R4 ZNS+, Erstlinie, Alter bis 18 Jahrereife, aggressive B-Zell-Lymphome und -Leukämien, CD20+, ZNS negativ, Erstlinie, Alter bis 18 Jahrereife, aggressive B-Zell-Lymphome und -Leukämien, CD20+, ZNS positiv, Erstlinie, Alter bis 18 Jahrereife, aggressive B-Zell-Lymphome und -Leukämien, Erstlinie, Alter bis 18 Jahrereife, aggressive B-Zell-Lymphome und -Leukämien, Erstlinie, R2 Stadium I/II, Alter bis 18 Jahrereife, aggressive B-Zell-Lymphome und -Leukämien, Erstlinie, R2 Stadium III, Alter bis 18 Jahrereife, aggressive B-Zell-Lymphome und -Leukämien, ZNS+, Erstlinie, Alter bis 18 JahreRektum-Ca, cT2N+, cT3N+/-, cM0, ECOG 0-2Rektum-Ca, cT3 oder cT4, M0, ECOG 0-1Rektum-Ca, cT4a oder cT4b, cN2, ECOG 0-1Rektum-Ca, resektabel (exklusive Std. I ), Patienten unter 75Rektum-Ca, Stadium cT2-T3a/b, cN0, cM0Rektum-Ca adj.: nach TME oder PME mit R0 Resektion, neoadjuvant prä-OP; ECOG 0-1Rektumkarzinom, nicht weiter als 12 cm, neoadj./adj., ECOG 0-2Rektumkarzinom, Stadium II/III, dMMR/MSI-Hresezierbares Adenokarzinom des ösophagogastralen Übergangs Typ I und II/Ösophaguskarzinom, Erstlinie, ECOG 0-1Resezierbares Adenokarzinom des ösophagogastralen Übergangs Typ I und II/Ösophaguskarzinom, Erstlinie, ECOG 0-1residuelles invasives, nicht met. Mamma-Ca HER2+, nach neoadjuvanter Vorbehandlung mit Trastuzumab und TaxanRET-bedingte Tumoren, Zweitlinie oder höher, ECOG 0-2Rezidiv. Ovarial-Ca, mind. 6 Mo krankheitsfreies Intervall nach letzter Cisplatingabe und Ansprechen auf mind. 3 Zyklen Cisplatin in der Erstlinie, ECOG 0-2rezidivierende oder metastasierte Kopf-Hals-Tumoren, Zweitlinie, ECOG 0-2rezidivierende oder refraktäre ALL, CD-22+, ECOG 0-2rezidivierende oder refraktäre chronisch lymphatische Leukämie, 1-3 Vortherapien, ECOG 0-1rezidivierende oder refraktäre CLL, del17p, ECOG 0-2 rezidivierendes (erstlinie mit Anthrazyklin) oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2, ECOG 0-2rezidivierendes, platinsensitives Ovarialkarzinom, Rezidivtherapie, ECOG 0-1rezidivierendes Endometriumkarzinom, 1-2 vorangegangene Therapien, GOG 0-2rezidivierendes oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2rezidivierendes oder metastasiertes Mamma-Ca, postmenopausal, HR+, HER2-, Erstlinie, ECOG 0-1rezidivierendes oder metastasiertes Mamma-Ca, prä- und perimenopausal, HR+, HER2-, ECOG 0-1Rezidivierendes oder progressives Weichteilsarkom, ECOG 0-2, ab 10 Jahrenrezidivierendes oder refraktäres Ewing Sarkom, Zweitlinierezidivierendes oder refraktäres Hodgkin Lymphom, 18-65 Jahre, ECOG 0-2rezidivierendes oder refraktäres multiples Myelom, 1-3 Vortherapien, ECOG 0-2rezidivierendes oder refraktäres multiples Myelom, Drittlinie oder Spätere, ECOG 0-2rezidivierendes oder refraktäres Myelom, Drittlinie refraktär auf Lenalidomid, ECOG 0-2 rezidivierendes oder refraktäres Non-Hodgkin-Lymphom, ECOG 0-2Rezidivierendes oder therapierefraktäres Osteosarkom, ECOG 0-2rezidivierendes Ovarialkarzinom, Drittlinie, Karnofsky > 70%rezidivierendes Ovarialkarzinom, fallopian tube or primary peritoneal cancer, ECOG 0-1rezidivierendes Ovarialkarzinom, nach platinbasierter Erstlinie, ECOG 0-2rezidivierte aggressive B-NHL, 18-65 Jahre, ECOG 0-2Rezidivierte oder metastasierte Kopf-Hals-Tumoren (Plattenepithel-), ECOG 0-1rezidivierte oder metastasierte Kopf-Hals-Tumoren (Plattenepithel-), Erstlinie, ECOG 0-1Rezidivierte oder metastasierte Kopf-Hals-Tumoren (Plattenepithel-), Erstlinie, ECOG 0-1Rezidivierte oder metastasierte Kopf-Hals-Tumoren (Plattenepithel-), Erstlinie, ECOG 0-1Rrezidivierte oder metastasierte Kopf-Hals-Tumoren, Erstlinie, ECOG 0-2Rezidivierte oder refraktäre, aggressive Lymphome, 2. Linie vor ASCT, ECOG 0-3Rezidivierte oder refraktäre CLLrezidivierte oder refraktäre Langerhanszell-Histiozytose, Alter 0-72 JahreRezidivierte oder therapierefraktäre AML, ECOG 0-2Rezidivierte oder therapierefraktäre AML, FLT3 ITD oder TKD D835 oder I836 Mutationrezidivierter oder metastasierter Kopf-Hals-Tumor, Erstlinie, ECOG 0-1rezidiviertes/metastasiertes, platin- und cetuximabrefraktäres Plattenepithelzellkarzinom des Kopf-Hals-Bereichs, ECOG 0-2 Rezidiviertes DLBCL, 1-3 Vortherapien, ungeeignet für eine ASCTRezidiviertes Endometriumkarzinom, mismatch repair proficient (MMRP)Rezidiviertes fortgeschrittenes oder metastasiertes OvarialkarzinomRezidiviertes fortgeschrittenes oder metastasiertes Ovarialkarzinom, nach platinhaltiger Therapie, ECOG 0-1Rezidiviertes fortgeschrittenes oder metastasiertes Ovarialkarzinom, platinresistent, FR-alpha positiv, ECOG 0-1Rezidiviertes fortgeschrittenes oder metastasiertes Ovarialkarzinom, Zweitlinierezidiviertes oder fortgeschritten Endometriumkarzinom, dMMR/MSI-H, nach platinbasierter Therapierezidiviertes oder metastasiertes Adenokarzinom des Magens / gastroösophagealen Übergangs, Erstlinie, ECOG 0-1rezidiviertes oder metastasiertes kutanes Plattenepithelkarzinom, ECOG 0-1rezidiviertes oder metastasiertes Mammakarzinom, ECOG 0-2rezidiviertes oder metastasiertes Mammakarzinom, Zweitlinie, ECOG 0-2rezidiviertes oder metastasiertes Plattenepithelkarzinom des Larynx oder Pharynx, Karnofsky > 70Rezidiviertes oder nicht-resezierbares Penis-/Urethrakarzinomrezidiviertes oder refraktäres B-NHL, mindestens zwei vorherige systemische BehandlungenRezidiviertes oder refraktäres diffus großzelliges anaplastisches Lymphom, Zweitlinie, ECOG 0-2Rezidiviertes oder refraktäres Hodgkin Lymphom, ECOG 0-1Rezidiviertes oder refraktäres Hodgkin Lymphom nach Hochdosis Chemotherapie und ASZT, ECOG 0-1Rezidiviertes oder refraktäres multiples Myelomrezidiviertes oder refraktäres peripheres T-Zell Lymphom, CD30+, ECOG 0-3Rezidiviertes oder therapierefraktäres multiples Myelom, mindestens 3 Vortherapien (inkl. mind. einen Proteasom-Inhibitor, einen Immunmodulator und einen monoklonalen Anti-CD38-Antikörper), ECOG 0-2Rezidiviertes oder therapierefraktäres primär mediastinales B-Zell-Lymphom, ECOG 0-1rezidiviertes Ovarialkarzinom, Eileiterkarzinom oder primäres Peritonealkarzinom, Cisplatin-sensitiv, Drittlinie, ECOG 0-1rezidiviertes Ovarialkarzinom, nach platinbasierter Erstlinie, ECOG 0-2Rezidiviertes und therapierefraktäres DLBCL, 1-3 Vortherapien, ECOG 0-1Rezidiviertes und therapierefraktäres DLBCL, FL Grad 3b, mind. 2 Vortherapien, ECOG 0-2Rezidivtherapie des multiplen Myeloms, 1-3 VortherapienRezidivtherapie des multiplen Myeloms, mindestens 2 VortherapienRiesenzelltumor des Knochens, Alter > 12 Jahre, Karnofsky > 50Rituximab refraktäre indolente B-NHL, ECOG 0-2Sarkome der Extremitäten und des Körperstammes, Tumordurchmesser >8 cm, high-grade, high-riskSchilddrüsenkarzinom, lokal fortgeschritten oder metastasiertSchwelendes Myelom, intermediär- oder hoch-Risiko, asymptomatischSchwelendes Myelom, intermediär- oder hoch-Risiko, ECOG 0-1schwere aplastische Anämie, Alter > 2 Jahre schwere aplastische Anämie, Alter > 12 Jahre SCLC, cT3/4 ohne Möglichkeit zur Radiatio oder extensive disease, ECOG 0-1SCLC, Erstlinientherapie bei Extensive-DiseaseSCLC, Erstlinientherapie bei Extensive-Disease SCLC, Erstlinientherapie bei extensive diseaseSCLC, Erstlinientherapie bei extensive disease SCLC, extensive disease, >70 Jahre und ECOG 0-2 oder < 70 Jahre und ECOG 3SCLC, extensive disease, Erstlinie, Patienten > 70 Jahre und ECOG 0-2 oder < 70 Jahre und ECOG 2SCLC, inoperabel, limited u extensive disease, männlichSCLC, LD und ED, komplette oder Teilremission nach Erstlinie, Therapiepause > 90 Tage, ECOG 0-2SCLC, limited diseaseSCLC, limited disease, ECOG 0-2SCLC, limited disease, ECOG: 0-2, CONVERT TrialSCLC, limited disease, kein Progress nach Radiochemotherapie, ECOG 0-1SCLC, limited disease, Stadium II-IVSCLC, limited disease exclusive Stadium ISCLC, limited disease ohne Möglichkeit zur Radiatio, extensive disease, Patienten älter als 70 Jahre, ECOG 0-2SCLC, limited und extended diseaseSCLC, limited und extended disease, ECOG 0-2, chemo-naivSCLC, limited und extensive diseaseSCLC, Progress > 90 Tage nach Ansprechen und Komplettierung der Erstlinie, ECOG 0-2SCLC, therapierefraktär oder rezidivierend, ECOG 0-2SCLC, therapierefraktär oder rezidivierend, mind. eine VortherapieSCLC, Zweitlinie, ECOG 0-2SCLC, Zweitlinie nach platinbasierter Therapie, ECOG 0-2SCLC, Zweitlinie nach platinbasierter Therapie ECOG 0-2SCLC, Zweitlinie nach Platinkombination oder TKI, PD-L1 Expression > 1%, ECOG 0-1SCLC extensive disease, chemo-naiv, ECOG 0-2SCLC limited u extensive diseaseSCLC limited u extensive disease, unbehandeltSCLC limited und extensive diseasesekundäre Anämie nach oder während Chemotherapie, nichtmyeloische Grunderkrankung, Hb < 11 g/dl , ECOG 0-2Sekundäre Anämie nach platinhaltiger Chemotherapie bei soliden Tumoren, Hb < 11 g/dL, ECOG 0-3Sekundäre Hypogammaglobulinämie bedingt durch eine lymphoproliferative ErkrankungSekundäre Neutropenie-ProphylaxeSekundärer Immunglobulinmangel bei hämatologischen oder soliden NeoplasienSeminom, Zweitlinie nach CisplatinSeminom im Stadium I, nach einer OrchidektomieSeröses Endometrium-Ca, lokal fortgeschritten oder rezidiviert, FIGO III-IV, Her2/neu-Überexpression, ECOG 0-2 SichelzellerkrankungSichelzellerkrankung, 2 bis 10 Schmerzkrisen in den letzten 12 Monaten, mit oder ohne Therapie mit HydroxyureaSichelzellerkrankung, 2 bis10 Schmerzkrisen in den letzten 12 Monaten, mit oder ohne Therapie mit HydroxyureaSichelzellerkrankung, 12-65 Jahre, Hb-Wert 5,5-10,5 g/dl, 1-10 vasooklusive Krisen in den letzten 12 MonatenSolider Tumor, dMMR/MSI-HSolider Tumor, lokal fortgeschritten oder metastasiert, aktivierende Her2-Mutation, nach vorheriger Therapie, ECOG 0-1Solider Tumor metastasiert oder lokal fortgeschritten mit KRAS p.G12C Mutation, ECOG 0-1Solide Tumoren, CIT > 4 Wochen, Grund für Verschiebung/Dosisreduktion, ECOG 0-2Solide Tumoren HER2 amplifiziert, außer Mamma-Ca oder AEG-Tumoren und Magen-Ca, ECOG 0-1Solide Tumoren mit NTRK-Fusion, TKI-naiv, ECOG 0-2Solitärer fibröser Tumor oder metastasiertes HämangioperizytomSpeicheldrüsenkarzinom, lokal fortgeschritten oder metastasiertSpeicheldrüsentumor, Androgen-Rezeptor positiv, lokal fortgeschritten oder metastasiert, ECOG 0-2Speicheldrüsentumor, Her2+, metastasiert oder lokal fortgeschritten und nicht resektabel (T4b, N2c oder N3), ECOG 0-2Speicheldrüsentumor, lokal fortgeschritten, nach oder ohne Debulking-OPSpeicheldrüsentumor, lokal fortgeschritten oder metastasiert, Androgen-Rezeptor positiv, kastrationsresistent, ECOG 0-2Speicheldrüsentumor, lokal fortgeschritten oder metastasiert, vortherapiert, ECOG 0-2Speicheldrüsentumor: mucoepidermoides Karzinom oder Adenokarzinom, metastasiert oder rezidiviertSporadische desmoide Fibromatose (aggressive Fibromatose)Stadium IIA-IIC, gute Prognose, HodentumorStadium III oder IV Melanom ohne BRAF Mutation, ECOG 0-1Stadium IV oder rezidivierend metastasierendes NSCLC, Adeno-, ECOG 0-1 Stadium IV oder rezidivierend metastasierendes NSCLC, EGFR-Mutation oder ALK-Translokation, Progress unter TKIStd. Ib (T2 N0 M0) nach Resektion (Lobektomie oder Pneumektomie); ECOG 0-1Symptomatisches multiples Myelom, für ASCT nicht geeignet, mind. partielle Remission 6-12 Monate nach Standardtherapie, ECOG 0-2Symptomatisches multiples Myelom, nicht ASCT geeignetsymptomatische Thrombozytopenie, teilweise trotz PrednisolonSystemische MastozytoseSystemische Mastozytose, KIT D816 negativSystemische Mastozytose, ohne Ansprechen auf die symptomatische Behandlung, oder zytoreduktive TherapieSystemische Mastozytose mit assoziierter hämatologischer NeoplasieT-ALL, 18-59 Jahre, ECOG < 3T-ALL, 18-59 Jahre, ECOG < 4T-ALL, erstes Rezidiv, 15-55 J.T-ALL, Ph/BCR-ABL-, 18-59 Jahre, ECOG < 4T-ALL/LBL, therapierefraktär oder rezidiviertT-ALL/T-LBL, therapierefraktär oder rezidiviertT-PLL, Erst- und ZweitlinieT-PLL, T-NHL, ATLL, Sézary Syndrom, Erstlinie und RezidivtherapieT-Zell-Lymphom, mind. 1 Vortherapie, ECOG 0-2T-Zell-Lymphom, Stadium I-IV, ECOG 0-3T-Zell Lymphom, Erstlinie, ECOG 0-2T-Zell Prolymphozytenleukämie, Erst-, Zweit-, oder Drittlinie, ECOG 0-3T-Zell Prolymphozytenleukämie, Erst- und ZweitlinieT-Zell Prolymphozytenleukämie, mehrere Linien möglich, ECOG 0-3Tansfusionsabhängige Anämie bei MDS mit Ringsideroblasten, sehr niedriges, niedriges oder intermediäres Risiko nach IPSS-R, kein Ansprechen auf Erythropoetinbasierte Therapie oder nicht dafür geeignet TCC, muskelinvasives, fortgeschrittenes Harnblasen-Ca, neoadjuvant, ECOG 0-1TCC des Urothels, fortgeschr. oder metastasiert, ErstlinieTCC des Urothels, fortgeschr. oder metastasiert, Progress nach platin-haltiger Erstlinie, ECOG 0-1TCC des Urothels, fortgeschritten oder metastasiert, Erstlinie, ECOG 0-2TEMPI-SyndromTherapierefraktäre Hämophagozytische Lymphohistiozytose des Erwachsenentherapieresistente gestationale trophoblastäre NeoplasieThorakales Plattenepithelkarzinom des Ösophagus, Stadium II-IIIThorakales Ösophagus-Ca, unter 5 cm, T1b N0 M0 mit makroskopisch negativen Resektionsränder oder T1a N0 M0 mit lymphovaskulärer Invasion, nach endoskopischer Resektion, ECOG 0-1Thymom, Masaoka Stadium IVB, mindestens 2 Vortherapien, ECOG 0-1Thymom/Thymuskarzinom, lokal fortgeschritten oder metastasiert, vortherapiertThymom/Thymuskarzinom lokal fortgeschritten oder metastasiert, Octreotid-Szintigraphie positiv, ECOG 0-1Thymom in Masaoka Stadium IVa oder IVb, 15-70 Jahre, ECOG 0-2transfusionsabhängige Anämie bei beta-Thalassämietransfusionsbedingte Eisenüberadung bei beta-Thalassämietransfusionsbedingte Eisenüberladung bei beta-Thalassämietriple-negatives Mamma-Ca neoadjuvant, Erstlinie, Karnofsky Status > 80Trophoblastäre gestationale Neoplasie, chemotherapieresistent, ECOG 0-2Trophoblastäre gestationale Neoplasie, high-risk (FIGO score 7 oder höher)Trophoblastäre gestationale Neoplasie, high-risk (FIGO score über 12)Trophoblastäre gestationale Neoplasie, low riskTrophoblastäre gestationale Neoplasie, rezidiviert oder therapierefraktärTrophoblastäre gestationale Neoplasie und nichtmetastasiertes ChorionkarzinomTTP, älter 18 JahreTumorinduzierte Osteomalazie durch erhöhten FGF23-Spiegel, gekennzeichnet durch renalen Phosphatverlust und Knochendemineralisation i.d.R aufgrund eines gemischt bindegewebigen phosphaturischen mesenchymalen Tumorsunbehandelte chronische lymphatische Leukämie, ≤70 Jahre, ECOG 0-2unbehandeltes diffus großzelliges B-Non-Hodgkin Lymphom bei älteren, gebrechlichen Patienten (>70 Jahre)unbehandeltes fortgeschrittenes Adenokarzinom des Magens/Ösophagusunbehandeltes fortgeschrittenes Adenokarzinom des Magens/Ösophagus, ECOG 0-1Urothel-Ca, Progress oder Rezidiv nach/unter Cisplatin Erstlinientherapie, Karnofsky Status > 60%Urothelkarzinom, cT2-4a cN0-2/x cM0/xUrothelkarzinom, fortgeschritten oder metastasiert, Erstlinie, ECOG 0-1Urothelkarzinom inoperabel oder metastasiert, ECOG 2 und/oder GFR zwischen 30 und 60 ml/min, ErstlinientherapieUrothelkarzinom T2-3, N0, M0 nach transurethraler ResektionVHL Syndrom mit assoziiertem Nierenzellkarzinom, ECOG 0-1Vitamin B12 Mangelvollständig reseziertes, EGFR+ nichtkleinzelliges Lungenkarzinom, Stadium II-IIIA, ECOG 0-1Vorbehandeltes metastasiertes kolorektales KarzinomVorläufer-B- und T-Zell Leukämie, Hochrisiko ALLVulvakarzinom, T2/T3, N0-3, M0, für eine radikale Vulvektomie nicht geeignet, keine VortherapieVulvakarzinom, T3/T4, N0-3, M0, für eine radikale Vulvektomie nicht geeignet, keine VortherapieWaldenström´s Macroglobulinämie, MYD88 L265P pos., mindestens 1 Vortherapie, ECOG 0-2Waldenström´s Macroglobulinämie, MYD88 L265P pos., rezidiviert, therapierefraktär, oder ungeeignet für eine ChemotherapieWaldenström´s Macroglobulinämie, Zweitlinie, ECOG 0-2Weichteilsarkom, alveoläres WeichteilsarkomWeichteilsarkom, alveoläres Weichteilsarkom, ab 16 J., ECOG 0-1, ab ZweitlinieWeichteilsarkom, HRWeichteilsarkom, Kinder, Jugendliche und junge ErwachseneWeichteilsarkom, neoadjuvantWeichteilsarkom, rezidiviertWeichteilsarkom, Rezidiv oder metastasiertWeichteilsarkom, Rhabdomyosarkom, Leiomyosarkom, Erstlinie, ECOG 0-2Weichteilsarkom, SynovialsarkomWeichteilsarkom schnell fortschreitend, ECOG 0-2wiederkeherendes oder refraktäres Myelom, mindestens Zweitlinie nach Lenalidomid, ECOG 0-2Wiederkehrende, refraktäre CLL, 2.-4. Linie, ECOG 0-1Wiederkehrende, refraktäre CLL, 2.-4. Linie, ECOG 0-2wiederkehrender oder metastasierter Kopf-Hals-Tumor nach Platintherapiewiederkehrendes, lokal fortgeschrittenes oder metastasiertes Lipo-/ Leiomyosarkom, ECOG 0-2wiederkehrendes oder fortschreitendes Ovarial-Ca/Peritoneal-Ca, Stadium I-IV, nach Platintherapie, ECOG 0-1wiederkehrendes oder metastasiertes, nicht resezierbares Analkarzinom, ECOG 0-1wiederkehrendes oder metastasiertes Nasopharynxkarzinom, nach Radiatio, ECOG 0-1Wiederkehrendes oder metastasiertes Plattenepithel-Karzinom des Kopf und Halses, Karnofsky >70, ErstlinieWiederkehrendes oder metastasiertes Plattenepithelkarzinom des Larynx oder Pharynx, Karnofsky > 70wiederkehrendes oder refraktäres multiples Myelomwiederkehrendes oder refraktäres multiples Myelom, Stadium I,II,III, ECOG 0-2wiederkehrendes oder refraktäres multiples Myelom, Stadium I-IIIwiederkehrendes oder refraktäres Myelom, mindestens Zweitlinie nach Lenalidomid, ECOG 0-2Wiederkehrendes oder refraktäres ZNS Lymphom primär oder NHL, CD20+, PS über 50Zentrales B-NHL, Erstlinie, ECOG 0-3Zerebrale Radionekrose, nach Therapie mit DexamethasonZervix-Ca, metastasiert oder rezidiviert, Progress nach platinhaltiger Therapie, ECOG 0-1Zervix-Ca lokal fortgeschritten, nicht operabel oder metastasiert, nach platinhaltiger Therapie, ECOG 0-1Zervix Ca, FIGO IB1, IB2, IIA1, IIA2, nach Hysterektomie und pelviner LymphadenektomieZervixkarzinom, FIGO Stadium IB2-IIB oder IBI + Risikofaktoren, nach radikaler HysterektomieZervixkarzinom, lokal fortgeschritten, Hochrisiko (FIGO 2014 IB2–IIB, N+, oder III–IVA), ECOG 0-1Zervixkarzinom, metastasiert oder rezidiviert, inoperabel, ECOG 0-1Zervixkarzinom, rezidiviert oder metastasiert, ECOG 0-1Zweitlinientherapie beim fortgeschrittenen, malignen Pleuramesotheliom, Karnofsky Status >70Zweitlinientherapie des malignen Pleuramesothelioms, ECOG 0-2Zweitlinientherapie des sensitiven kleinzelligen Lungenkarzinom, <75 Jahre, ECOG 0-2Ösophaguskarzinom (Plattenepithel- und Adeno-Ca), Karnofsky Status > 60Ösophaguskarzinom sowie AEG-Tumor Siewert-Typ I/II (Plattenepithel- und Adeno-Ca), cT1-3, cNX, cM0, neu diagnostiziert, Kreatinin-Clearance mind. 50 ml/minOrigin301/302 studyAbramson Cancer Center, Philadelphia, ECOG 8802Abramson Cancer Center, University of Pennsylvania, Philadelphia, JULIET trialAbramson Cancer Center, University of Pennsylvania, USA, ADMIRAL StudieAbramson Cancer Center and the Division of Hematology and Oncology, Perelman School of Medicine at the University of PennsylvaniaAbramson Cancer Center of the University of Pennsylvania, KEYNOTE-021Abteilung für Hämatologie, Onkologie und Tumor Immunologie, Charité Berlin, DeutschlandAbteilung für Hämatologie, Universität Duisburg-Essen, DeutschlandAbteilung für Hämatologie/Onkologie, Onkologische Praxis Frankfurt, DeutschlandAbteilung für Innere Medizin III, Ludwig-Maximilians-Universität, München, DeutschlandAbteilung für Onkologie/Hämatologie, Kliniken Essen-Mitte, Deutschland, RAINBOW Study Group, RAINBOW StudieAbteilung für Onkologie und Hämatologie, Charité Berlin, DeutschlandAbteilung für thorakale Onkologie, Krankenhaus Grosshansdorf, Universität Hamburg, DeutschlandAcademic Department of Haematology and Cytogenetics, The Royal Marsden Hospital, London, UKAcademic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK, AZURE InvestigatorsAdamson Cancer Center, Philadelphia, USAAddenbrooke's Hospital, Cambridge, EnglandAdjuvant Navelbine International Trialist Association (ANITA)AGO-OVAR, NCIC CTG, EORTC GCGAGO Breast Cancer GroupAIOAix-Marseille University, Marseille, France, KEYNOTE-629Albert-Ludwigs University, Freiburg, Germany, Freiburger ZNS-NHL ProtokollAlbert Einstein College of Medicine, Bronx, New York, USA, PrE0102 TrialAlbert Ludwigs Universität, Freiburg, deutsche MDS- StudiengruppeAllegheny General Hospital, Pittsburgh, USAAllergy/Immunology Research Center of North Texas, Dallas, USAAllgemeine Innere Medizin, Marienhospital Bottrop, GermanyA Medical Research Council ReportAmerican Society of Clinical OncologyAmyloidosis Research and Treatment Center, Pavia, Italy, ANDROMEDA trialAnderson Cancer Center, Houston, TX, USAAnderson Cancer Center, The University of Texas MD, HoustonAndreas Syggros Hospital - National and Kapodistrian University of Athens, Athens, GreeceAntwerp University Hospital, Department of Medical Oncology, Edegem, BelgiumArbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group and Gynaecologic Oncology Center, Kiel, Germany, AGO-OVAR 2.21/ENGOT-ov 18 InvestigatorsArbeitsgemeinschaft Gynäkologische OnkologieArbeitsgemeinschaft Internistische OnkologieArbeitsgemeinschaft Internistische Onkologie (AIO)ARCADE trialArhus University Hospital, DänemarkAsan Medical Center, University of Ulsan College of Medicine, Seoul, Prodigy trialassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, ARASENS trialAssistance Publique-Hopitaux de Paris, Hopital Europeen Georges Pompidou, Paris, France, SAMCO-PRODIGE 54 trialAssistance Publique-Hopitaux de Paris, Hopital Saint-Louis, Centre National de Reference de l'Histiocytose Langerhansienne, Paris, FranceAssistance Publique-Hopitaux de Paris, Paris, France, ANRS 154 Lenakap TrialAthens Medical Center, Greeceausgedehnte MARGIT / AIO StudieAVOID Neutropenia, Merckle GmbHAzienda Ospedaliera-Universitaria Pisana, University of Pisa, Pisa, ItalyAzienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy, EQoL-MDS trialAzienda Ospedaliera–Universitaria Careggi, University of Florence, RESPONSE trialAzienda Ospedaliero-Universitaria Citt `a della Salute e della Scienza di Torino, ItalyBadgers, Tonbridge, United KingdomBadgers, Tonbridge,United KingdomBarbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, United StatesBarcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, IDIBAPS-Hospital Clinic de Barcelona, CIBERehd, Universitat de Barcelona, Catalonia, SpainBarnard Cancer Center, Washington University School of MedicineBarts Cancer Institute, Queen Mary University of London, IMpassion130 TrialBarts Cancer Institute Biomedical Research Centre, Queen Mary University of London, LondonBattista Hospital and University, Turin, IELSG-10Baylor-Sammons Cancer Center, Dallas, and US Oncology, Houston, USABaylor College of Medicine, Houston, TexasBaylor College of Medicine, Houston, Texas, United States of AmericaBC Cancer and The University of British Columbia, Vancouver, BC, CanadaBeatson Oncology Centre, Western Infirmary, Glasgow, UKBelani CP, University of Pittsburgh Cancer Institute, USABenjamin Franklin Campus Berlin, St. Marien Hospital Amberg, Universitätsmedizin Mainz, Westpfalzklinikum KaiserslauternBexley Wing, St. James’s University Hospital, Leeds, United Kingdom, Pegasus trialBing Center for Waldenström´s Macrglobulinemia, Dana Faber-Institute, Boston, MA, USABloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Kimmel Cancer Center, Baltimore, CheckMate 816 trialBMT Program, Roswell Park Cancer Institute, Buffalo, NY, CALGB 100104Boston University School of Medicine, United StatesBrain Tumour Centre at Erasmus, Rotterdam, Netherlands, CATNON trial (EORTC study 26053-22054)Breast and Gynecologic Cancer Medicine Service, Sloan-Kettering Institute for Cancer Research, New York, USABreast Cancer International Research Group, BCIRG 001 StudieBreast Cancer International Research Group, BCIRG 006 StudieBreast Cancer Now Research Centre, The Institute of Cancer Research, London, the TNT trialBreast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College LondonBreast Cancer Research Centre-Western Australia and Curtin University, Perth, WA, Australia, ExteNETBreast Cancer Unit, Kyoto University Hospital, JapanBreast Center, University of Munich, GermanyBreast Center Kantonsspital St. Gallen, Schweiz, eLEcTRA trialBreast Oncology, Department of Medicine und Robert H. Lurie Comprehensive Cancer Center, Chicago, USABrigham and Women's Hospital, Dana-Farber Cancer Institute, GOG Study 279Bristol Lung Cancer Study GroupBritish Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada, GADOLIN trialBritish Medical Research Council LU21 StudieBritish National Lymphoma Investigation, CRC and UCL Cancer Trials Centre, London, UKBrody School of Medicine, Division of Gynecologic Oncology, Leo Jenkins Cancer Center, Greenville, GOGBrussels, Belgium, HES Mepolizumab study groupCAC Val dÁurelle, Montpellier, France, ERBIRINOXCancer and Leukemia Group BCancer and Leukemia Group B, Intergroup Trial C9741Cancer and Leukemia Group B, Radiation Therapie Group and North Central Cancer Treatment Study GroupsCancer and Leukemia Group B Studie 9431Cancer Care Ontario, Drug Formulary, RegimenCancer Care Services, Royal Brisbane and Women's Hospital, Herston, Queensland, AustraliaCancer Center, Clinique de Genolier, Vaud, SwitzerlandCancer Center, Indiana University, IndianapolisCancer Center, Massachusetts General Hospital, BostonCancer Center and Research Institute, Magnolia, Tampa, PACIFIC StudieCancer Center at Hackensack University Cancer Center, Hackensack, USACancer Center of Sun Yat-Sen University, Guangzhou, People's Republic of ChinaCancer Chemotherapy Center, Osaka Medical College Hospital, Osaka, ACTS-CC trialCancer Research UK, Imperial College London, Hammersmith Hospitals Trust, London, UKCancer Research UK Centre, University of Southampton, UK, SABRINA StudieCancer Research UK Clinical Centre in Leeds, Cookridge Hospital, UKCancer Research UK Clinical Trials Unit, University of Birmingham, BILCAP trialCardiology Unit, Milan, ItalyCarl Gustav Carus Technical University of Dresden, Dresden, Germany, RELAZA trialCarolina Urologic Research Center, Myrtle Beach, SC, HERO trialC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, British Columbia, CanadaCELESTIMO trialCenter for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USACenter for Cancer and Blood Disorders, Bethesda, MDCenter for Cancer Research, Divison of Cancer Treatment and Diagnosis, National Cancer Institute, BethesdaCenter for Chronic Immunodeficiency, Faculty of Medicine, University of Freiburg, Freiburg, GermanyCenter for Chronic Immunodeficiency, Faculty of Medicine, University of Freiburg, Freiburg, Germany, HLH-94Center for Chronic Immunodeficiency, Faculty of Medicine, University of Freiburg, Freiburg, Germany, modifiziertes HLH-94 ProtokollCenter for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, MACenter for Immuno-Oncology, Dana-Farber Cancer Institute, BostonCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, KEYNOTE-028Center for Lymphoid Malignancies, Columbia University Medical Center-College of Physicians and Surgeons, New York, NY, USACenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, USACenter for Oncology Research and Treatment, Dallas, Texas, USACenter of Oncology and Hematology, Wilhelminenspital, Vienna, AustriaCentre Antoine Lacassagne, Nice, France, LYSA groupCentre de Reference des Maladies Trophoblastiques, Lyon, France, TROPHIMMUNCentre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, GAUSS StudyCentre Francois Baclesse, Caen, FranceCentre Henri-Becquerel, Rouen Cedex, France, POLARIX trialCentre Hospitalier Unciversitaire, Lille, FrankreichCentre Hospitalier Universitaire, Amiens, France, BENTLY TrialCentre Hospitalier Universitaire de Lille, Rue Michel Polonovski, Lille, France, IMROZ trialCentre Hospitalier Universitaire Tours, France, 94-01 French Head and Neck Oncology and Radiotherapy GroupCentre Hospitalo-Universitaire (CHU) Grenoble, GOELAMS-LTP95 trialCentre Leon Berard, Lyon, France, INVICTUS trialCentre Léon Bérard, France, PAOLA-1 TrialsCentre René Gauducheau,Nantes/St. Herblain, IFM2005-01Centre René Gauducheau, St-Herblain, Frankreich; PRIME StudieCentro di Riferimento Oncologico, Aviano, ItalyCentrum Haematologie and Onkologie Bethanien, Frankfurt, Germany, GMMG trialCentrum Hämatologie and Onkologie Bethanien, Frankfurt, Germany, GMMG trialCharing Cross Hospital, Imperial College London, UKCharite-University Medicine Berlin, Berlin, Germany, AIO-STO-0218 trialCharité University Medical Center and Center for Clinical Research, Berlin, NOGGOCharles A. Sammons Cancer Center at Baylor University Medical Center, Dallas, USA, CheckMate 577Charles Nicolle University Hospital, Rouen, France, GETUG/AFU V05 VESPER TrialCheckmate 025 StudieCheckMate 067 Study, Dana-Faber Cancer Institute, Boston and Memorial Sloan Kettering Cancer Center, New YorkChiang Mai University, Chiang Mai, ThailandChiba Cancer Center, Chiba, Japan, WJOG 4007 TrialChibaudel BChildrens Cancer Research Institute and St. Anna Childrens Hospital, Vienna, AustriaChinese Academy of Medical Sciences, Peking Union Medical College, Beijing, ChinaChinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, RATIONALE 307 trialChoy H, University of Texas Southwestern, Dallas, TexasChoy H, Vanderbilt University Medical School, Nashville, USACHU Jean Minjoz, Service Oncologie medicale, Cedex, FranceCHU Toulouse-Hopital Larrey, Universite Paul Sabatier, Toulouse, France, IFCT-1703 R2D2 TrialCity of Hope Comprehensive Cancer Center, Duarte, USA, COSMIC-021 StudyCity of Hope National Medical Center, Duarte, CACity of Hope National Medical Center, Duarte, CanadaCleary JCleopatra Study Group, CLEOPATRA StudieCleveland Clinic Foundation, ClevelandCleveland Clinic Taussig Cancer, KEYNOTE-426 InvestigatorsCleveland Clinig Taussig Cancer Institute, Main Campus, Cleveland, Ohio, AXIS trial / Baylor Sammons Cancer Center, Dallas TexasClinical Center - all at the National Institutes of Health, BethesdaClinical Development, Ablynx, Zwijnaarde, Belgium, HERCULES investigatorsClinical Research Development Program of the Samsung Medical Center, Seoul, Korea.Clinical Trial Centre, University of Sydney, AustraliaClinical Trial Promotion Department, Chiba Cancer Center, Chiba, JapanClinical Trial Service Unit, Oxford, UK Clinical Trials Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione G. Pascale–IRCCS, NapolClinica Universidad de Navarra-CIMA, Pamplona, Spain, PANORAMA1 CLL14 trial, Department I of Internal Medicine, Center of Integrated Oncology, University Hospital of CologneC Manegold, Thoraxklinik Heidelberg, DeutschlandCollaborative Innovation Center for Cancer Medicine, Guangzhou, China, STARS trialCologne University Hospital, Cologne, GermanyColumbia University Medical Center, New York, USAComplutense University and Ciberonc, Madrid, Spain, EVOKE-01 trialComprehensive Cancer Center, Mayo Clinic, Rochester, MNCONKO 003, Universitätsmedizin Berlin Charité, Zentrum für TumormedizinCopenhagen University Hospital, and the Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen, RUBY trialCROSS-Studiengruppe, Erasmus University Medical Center, Rotterdam, NLCross Cancer Institute, Edmonton, AB, Canada, IND227 TrialCWS 2002 Protokoll der Gesellschaft für pädiatrische Onkologie und Hämatologie (GPOH)Dalhousie University, Saint John, New Brunswick, CanadaDana-Faber Cancer Institute, BostonDana-Faber Cancer Institute, Boston, USA; BICC-C; FIRE-3Dana-Farber/Brigham and Women’s Cancer Center, Boston, MA, USA, IMpassion031 TrialDana-Farber/Brigham and Women’s Cancer Center, Boston, MA, USA IMpassion031 TrialDana-Farber Cancer Institute, BostonDana-Farber Cancer Institute, Boston, ALPINE trialDana-Farber Cancer Institute, Boston, CALGB 40302Dana-Farber Cancer Institute, Boston, KEYNOTE-564Dana-Farber Cancer Institute, Boston, MADana-Farber Cancer Institute, Boston, MA, SORAYA StudyDana-Farber Cancer Institute, Boston, MA, USADana-Farber Cancer Institute, Boston, MA, USA, monarcHER trialDana-Farber Cancer Institute, Boston, MassachusettsDana-Farber Cancer Institute, Boston, METEOR investigatorsDana-Farber Cancer Institute, Boston, RECOURSE Study GroupDana-Farber Cancer Institute, Boston, USADana-Farber Cancer Institute, Boston, USA, KEYNOTE170Dana-Farber Cancer Institute, Boston MADana-Farber Cancer Institute, Boston MA, RATIFY trialDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA, OPTIMISMM trialDana-Farber Cancer Institute, Harvard Medical School, Boston, USA, REGARD StudieDana-Farber Cancer Institute, The Lank Center for Genitourinary Oncology, Boston, USA, CheckMate 9ER trialDana-Farber Cancer Institute and Harvard Medical School, Boston, USADana–Farber Cancer Institute, Boston, TAX 324 Study GroupDan L. Duncan Comprehensive Cancer Center, Baylor College ofMedicine, Houston, PERTAIN StudieDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, PERTAIN StudieDavid Geffen School of Medicine at the University of California, Los Angeles, NATALEE trialDCLLSG, HOVON, SAKK, GAIA trialDenosumab HALT Prostate Cancer Study Group / FREEDOM Trial / University of Alabama, Birmingham, USADepart. of Gastroint. Med. Oncology, Anderson Cancer Center, Texas, USA. Intergroup RTOG 98-11 StudieDepartement de Cancerologie Generale, Unite de Biostatistiques, and Departement d’Imagerie Medicale, Centre Oscar Lambret, ANGIOTAX studyDepartmentGastroenterological Surgery, Kumamoto University, Japan, SOFT studyDepartment of Bone Marrow Transplantation, Comprehensive Cancer Center M. Curie- Sklodowska Memorial Institute, Branch Gliwice, PolandDepartment of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TexasDepartment of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, JapanDepartment of Cancer Medicine, Gustave Roussy, Villejuif, FranceDepartment of Cancer Medicine, Institut Gustave Roussy, Villejuif, GETUG trialDepartment of Clinical Hematology, Henri Mondor Hospital, Créteil, FrankreichDepartment of Clinical Hematology, The Alfred Hospital, Melbourne, AustraliaDepartment of Clinical Oncology, The University of Hong Kong, NPC‐0501 trialDepartment of Clinical Pharmacology and Chemotherapy, Russian Cancer Research Center, Moscow und Department of Clinical Research, Merckle GmbH, Ulm, GermanyDepartment of Clinical Sciences and Community, University of Milan, Milan, Italy, BELIEVEDepartment of Clinical Therapeutics, Alexandra Hospital, Athens University School of Medicine, AthensDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, iNNOVATE StudyDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, iNNOVATE trialDepartment of Clinical Therapeutics, University of Athens School of Medicine, Athens, GreeceDepartment of Dermatology, The University of Texas M. D. Anderson Cancer Center, HoustonDepartment of Dermatology and Allergy, Skin cancer centre Charité, Charité-Universitätsmedizin BerlinDepartment of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, JapanDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan, ATTRACTION-3 trialDepartment of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, HoustonDepartment of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center, Tampa, FloridaDepartment of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, FloridaDepartment of Gastrointestinal Oncology, University Cancer Hospital and Institute, BeijingDepartment of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, BelgiumDepartment of Genitourinary Medical Oncology, The University of Texas, Houston, TexasDepartment of Gynecological Oncology, University Hospital, Orebro, SchwedenDepartment of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New YorkDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas, Houston, USA, GOG-0213Department of Gynecology, Hochtaunuskliniken Bad Homburg, Bad Homburg, GermanyDepartment of Gynecology, Netherlands Cancer Institute, AmsterdamDepartment of Haematological Medicine, King's College School of Medicine and Dentistry, LondonDepartment of Haematology, Cardiff University School of Medicine, UK, AML15 trialDepartment of Haematology, Copenhagen University Hospital, HerlevDepartment of Haematology, Jagiellonian University, Krakow, PolandDepartment of Haematology, Nice University Hospital, Groupe Francais des Myelodysplasies (GFM)Department of Haematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University MainzDepartment of Haematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Primain StudyDepartment of Haematology, Peter MacCallum Cancer Centre, Melbourne, VictoriaDepartment of Haematology, St George's Hospital, University of London, EnglandDepartment of Haematology, St Jame's University Hospital, Leeds, United KingdomDepartment of Haematology, St Jame's University Hospital, Leeds, United Kingdom, COMPLEMENT 1Department of Haematology, The Alfred Hospital, MelbourneDepartment of Haematology, Wales School of Medicine, Cardiff University, UK, Leukaemia Research Fund AML14Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo Department of Hematology, ASST Spedali Civili, Brescia, Italy, GIMEMA studyDepartment of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, ChinaDepartment of Hematology, Clinical Oncology and Hemostasiology, University of Leipzig, GermanyDepartment of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, iLLUMINATEDepartment of Hematology, Hospital Universitario Salamanca, SpanienDepartment of Hematology, Huddinge University Hospital, Huddinge, SwedenDepartment of Hematology, Internal Medicine, Pathology, Ohio State University, Columbus, RESONATE trialDepartment of Hematology, Medical University of Lodz, PALGDepartment of Hematology, Oncology, Immunology, Rheumatology and Pulmonology, University Hospital of Tuebingen, Germany, PERSPECTIVE trial, German-speaking Myeloma Multicenter Group (GMMG)Department of Hematology, Oncology and Tumorimmunology, Charite-Universitätsmedizin Berlin, Panama trial/AIO KRK 0212Department of Hematology, Peking, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Union Medical College, Beijing, ChinaDepartment of Hematology, Section of Lymphoma , M.D. Anderson Hospital, Houston, TexasDepartment of Hematology, University Medical Center Groningen, NiederlandeDepartment of Hematology, University of Amsterdam, HOVON124/ ECWM-R2 StudyDepartment of Hematology, University of Groningen and University Medical Center Groningen, HOVON/SAKK AML-29/42Department of Hematology, University of Turin, Italy, CASTORDepartment of Hematology, Universitätsklinikum Giessen und Marburg GmbH, Marburg, GermanyDepartment of Hematology/Oncology at University of Tuebingen Medical Center, TuebingenDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CADepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USADepartment of Hematology and Medical Oncology, Deaconess Hospital, Oncological Center of Stuttgart, GermanyDepartment of Hematology and Medical Oncology, WInship Cancer Institute, Atlanta, ELOQUENT-2Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, SIRIUSDepartment of Hematology and Oncology, University Halle-Wittenberg, Halle, GermanyDepartment of Hematology and Oncology, University of Hannover Medical SchoolDepartment of Hematology‑Oncology, Inha University College of Medicine and Hospital, Shinheung‑dong Jung‑gu, Incheon, Republic of KoreaDepartment of Immunology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USADepartment of Immunology, Oxford Radcliffe Hospital, The John Radcliffe CampusDepartment of Internal Medicine, Seoul National University Hospital, KoreaDepartment of Internal Medicine, Sundsvall Hospital, Sundsvall, SwedenDepartment of Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium, The Xeloda Colorectal Cancer Study GroupDepartment of Internal Medicine, Washington University School of MedicineDepartment of Internal Medicine, Yale University School of Medicine, Eastern Cooperative Oncology Group Study Department of Internal Medicine-Cardiology, Philipps University, Marburg, GermanyDepartment of Internal Medicine 1, Friedrich-Alexander-University, Erlangen NurembergDepartment of Internal Medicine and Department of Surgery, Seoul, CLASSIC trialDepartment of Internal Medicine and Radiotherapy, West German Cancer Center University, EssenDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany, AMLSGDepartment of Internal Medicine III, University ofMunich, German Low-Grade Lymphoma Study GroupDepartment of Internal Medicine III with Hematology, Medical Oncology, Paracelsus Medical University Salzburg, AustriaDepartment of Leukemia, Division of Cancer Medicine, University of Texas, Houston, USDepartment of Leukemia, MD Anderson Cancer Center, Houston, RESONATE-2Department of Leukemia, The University of Texas MD Anderson Cancer Center, HoustonDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TXDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USADepartment of Leukemia, University of Texas M.D. Anderson Cancer CenterDepartment of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, PACE trialDepartment of Leukemia and Hematopathology, University of Texas, MD Anderson Cancer Center, USADepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TXDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FLDepartment of Medical Oncology, Baskent University, Adana, Turkey, EMPOWER-Lung 1Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, ECHELON-1Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), BeijingDepartment of Medical Oncology, Centre Antoine Lacassagne, Nice, TPEx, GORTEC studyDepartment of Medical Oncology, Centre Regional de Lutte contre le Cancer Val d´Aurelle, Montpellier, FranceDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Cancer and Leukemia Group B study 19801Department of Medical Oncology, Dana Farber Cancer Institute, BostonDepartment of Medical Oncology, Dana–Farber Cancer Institute, BostonDepartment of Medical Oncology, Glasgow, U.K.Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, KEYNOTE-407Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, KEYNOTE-407 InvestigatorsDepartment of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain, ATLANTISDepartment of Medical Oncology, Hôpital Edouard Herriot, Hospices Civils de Lyon, France, RODIGE 41-BEVANECDepartment of Medical Oncology, Hôpital Saint André, Bordeaux, S-TRAC trialDepartment of Medical Oncology, London, MRC/EORTC seminoma trial collaboratorsDepartment of Medical Oncology, Piemonte Oncology Foundation, Candiolo, ItalyDepartment of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, AustraliaDepartment of Medical Oncology, St. Bartholomew's Hospital, LondonDepartment of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, IndiaDepartment of Medical Oncology, Toulouse, Frankreich. FNCLCC PACS 01 StudieDepartment of Medical Oncology, Touluse, Frankreich. FNCLCC PACS 01 StudieDepartment of Medical Oncology, University Hospital Antwerp, Edegem, BelgiumDepartment of Medical Oncology, University Hospital de Mar, SpanienDepartment of Medical Oncology, University Hospital HeidelbergDepartment of Medical Oncology, University of Crete, GriechenlandDepartment of Medical Oncology, West German Cancer Centre, Ruhrlandklinik, ESPATUEDepartment of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, ItalyDepartment of Medical Oncology and Hematology, Mayo Clinic, Scottsdale, KRYSTAL-1 trialDepartment of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, TAX 327 InvestigatorsDepartment of Medical Oncology and Therapeutics Research, City of Hope Medical Center, Duarte, CaliforniaDepartment of Medical Sciences, Regina Apostolorum Hospital, Albano LazialeDepartment of Medicine, Brown University School of Medicine, Providence, Rhode IslandDepartment of Medicine, Division of Medical Oncology, University of Washington School of Medicine, USADepartment of Medicine, Georgetown University School of Medicine, Washington, DC, FERWON-IDA trialDepartment of Medicine, Haugesund Hospital, Haugesund, NorwayDepartment of Medicine, Indiana University, IndianapolisDepartment of Medicine, Indiana University and the Walther Cancer Institute, IndianapolisDepartment of Medicine, Indiana University Medical Center, Indianapolis, USADepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New YorkDepartment of Medicine,Memorial Sloan Kettering Cancer Center, New York, USADepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA, ClarIDHy trialDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA, FIGHT-202 trialDepartment of Medicine, Memorial Sloan–Kettering Cancer Center, New York, NY, USADepartment of Medicine, Stanford University School of Medicine, CADepartment of Medicine, SUNY Upstate Medical University, Syracuse, USADepartment of Medicine, Tom Baker Cancer Centre, University of Calgary and Alberta Cancer Board, Edmonton, CanadaDepartment of Medicine, University of Alabama, BirminghamDepartment of Medicine, University of MainzDepartment of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CADepartment of Medicine, University of Washington, Seattle, WA, USADepartment of Medicine, Wilhelminenspital, Vienna, AustriaDepartment of Medicine and the Department of Biostatics and Computational Biology, Dana Farber Cancer Institute, BostonDepartment of Medicine II, Goethe University Hospital, Frankfurt, GermanyDepartment of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TexasDepartment of Neurology, Memorial Sloan-Kettering Cancer Center, New York, USA, North American Brain Tumor ConsortiumDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NYDepartment of Neurology at The Feinberg School of Medicine at Northwestern University, USDepartment of Neurology Clinic, University of Heidelberg, NOA-04Department of Neurosurgery andNeurooncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology, South ChinaDepartment of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy and University Paris-Sud, FranceDepartment of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas, USADepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, NC, A Gynecologic Oncology Group StudyDepartment of Obstetrics and Gynecology, S. Gerardo Hospital, University of Milan, Monza, ItalyDepartment of Obstetrics and Gynecology, Sana Klinikum Offenbach, HannaHDepartment of Obstetrics and Gynecology, University of Heidelberg, HeidelbergDepartment of Oncology, Antwerp University Hospital, Edegem, BelgienDepartment of Oncology, Auckland Hospital, AucklandDepartment of Oncology, Catholic University, Campobasso, ItalienDepartment of Oncology, Copenagen, DänemarkDepartment of Oncology, Copenagen, Dänemark, HERNATA StudieDepartment of Oncology, Copenhagen University Hospital, DenmarkDepartment of Oncology, Helsinki University Central Hospital, FinnlandDepartment of Oncology, Institut Curie-St Cloud, FranceDepartment of Oncology, Odense University Hospital, Odense, DenmarkDepartment of Oncology, Shanghai Medical College, Fudan University, ChinaDepartment of Oncology, Tampere University Hospital, Tampere, Finland, PROSTY study groupDepartment of Oncology, The Chelsea and Westminster Hospital, London, United KingdomDepartment of Oncology, The First Affiliated Hospital of Zhengzhou UniversityDepartment of Oncology, University Hospital of Besancon, Besançon, FranceDepartment of Oncology, University Hospital of TrondheimDepartment of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany, AML-CGDepartment of Oncology and Hematology, Hôpital de Hautepierre, Strasbourg, France, PIX203 trialDepartment of Oncology and Hematology, Martin-Luther-University Halle-Wittenberg, Halle, AIO study groupDepartment of Oncology, Rigshospitalet–Copenhagen University Hospital, ENGOT-OV16/NOVA InvestigatorsDepartment of Otorhinolaryngology: Head and Neck Surgery, and Abramson Cancer Center of the University of Pennsylvania, Philadelphia, DECISION trialDepartment of Pediatric and Adolescent Medicine, University Hospital Aachen, Germany, NPC-2003-GPOH/DCOGDepartment of Pediatric Hematology and Oncology, University Children's Hospital, Muenster, GermanyDepartment of Pediatrics, National Hospital Organization Kyushu Cancer Center, Fukuoka, JapanDepartment of Pediatrics, Sapienza, University of Rome, ItalyDepartment of Pharmacy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USADepartment of Pulmonary and Thoracic Oncology, University of Lille, University Hospital of Lille, France, MAPS-2Department of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi, JapanDepartment of Pulmonology and Thoracic Oncology, University of Caen, France, MAPSDepartment of Radiation Oncology, Kaiser Permanente Medical Center, Los Angeles, CaliforniaDepartment of Radiation Oncology, Leiden University Medical Center, Netherlands PORTEC-3Department of Radiation Oncology, Sun Yatsen University Cancer Centre, ChinaDepartment of Radiation Oncology, University Hospital of Muenster, Muenster, GermanyDepartment of Radiation Oncology, University of Heidelberg, Heidelberg, GermanyDepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore BDDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, RTOG 9410Department of Radiology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, ThailandDepartment of Radiotherapy, Amsterdam UMC, Amsterdam, the Netherlands, ARTDECO studyDepartment of Radiotherapy, University of Rostock, Germany, PET-PlanDepartment of Radiotherapy University of Tübingen, HIT 91 / HIT 2000 trial / HIT-MED study centerDepartment of Research and Innovation, Haugesund Hospital, Hausgesund, NorwayDepartment of Respiratory Medicine, Louis Pradel Hospital, Lyon, FranceDepartment of Solid Tumor Oncology, Taussig Cancer Center, Cleveland, USA SWOG S0221Department of Surgery, Cancer Medicine and Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, ISG-STS 1001Department of Surgery, Duke University School of Medicine , Durham, North CarolinaDepartment of Surgery, Landmark Medical Center, Woonsocket, ECOG-ACRIN trial (E2303)Department of Surgery, Leiden University Medical Center, Leiden, Netherlands, RAPIDO trialDepartment of Surgery and Comprehensive Cancer Center, Medical University of Vienna, ABCSG-18Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA, Oncology Group Trial 9514Department of Surgical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, AmsterdamDepartment of Thoracic Oncology, German Center for Lung Research, Germany, IMpower150 Study GroupDepartment of Thoracic Oncology, Grosshnasdorf, Germany, AVAiL trialDepartment of Thoracic Oncology, National Cancer Center Hospital East, Chiba, JapanDepartment of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, JapanDepartment of Thoracic Surgery, Sun Yatsen University Cancer Center, AME Thoracic Surgery Collaborative GroupDepartment of Translational and Precision Medicine, Sapienza University of RomeDepartment of Urology, Düsseldorf UniversityDepartment of Urology, St James's Hospital, Dublin, IrelandDepartment of Urology, St James Hospital, Dublin, IrelandDepartments of Clinical Therapeutics, Internal Medicine, and the Second Department of Propedeutic Medicine, University of Athens School of MedicineDepartments of Dermatology, Centre Hospitalier Universitaire, Nantes, FranceDepartments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer CenterDepartments of Internal Medicine III, Hematology, Oncology and Transfusion Medicine, Charité, GermanyDepartments of Leukemia and Experimental Therapeutics, The University of Texas, Anderson Cancer Center Departments of Leukemia and Experimental Therapeutics, The University of Texas, Anderson Cancer Center HoustonDepartments of Leukemia and Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX.Departments of Medical Oncology, Ioannina University Hospital, Hellenic Cooperative Oncology Group StudyDepartments of Medicine and Immunology, Roswell Park Cancer Institute, Buffallo, USADept. of Hepatology and Gastroenterology, Campus Virchow Klinikum, Charite, BerlinDeptartment of Internal Medicine I und CCC, Medical University of ViennaDermatology CIC Departments, Saint-Louis Hospital, Paris, CheckMate 511 TrialDermatology Service, Gustave Roussy, Villejuif-Paris Sud, FranceDevelopmental Therapeutics, Cancer Institute Medical Group, Santa Monica, CaliforniaDigestive Oncology Unit, University Hospital Gasthuisberg, Leuven, BelgienDigestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgien, VELOURDigestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgien; FIRE-3 (Zweitliteratur)Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgien; FIRE-3 (Zweitliteratur)Dipartimento di Oncologia, Napoli, ItalienDipartimento di Scienze Mediche, Oncologiche e Radiologiche, Università di Modena, ItalyDivisione di Oncologia Medica, PadovaDivision Hematology and Oncology, University of Freiburg Medical Center, Freiburg, GermanyDivision of Cancer Medicine, Peter MacCallum Cancer Centre, The University of Melbourne, ALCANZADivision of Cancer Medicine, The University of Texas, M.D. Anderson Cancer Center, HoustonDivision of Cancer Medicine, The University of Texas, M.D. Anderson Cancer Center, Houston, SWOG 8710Division of Cancer Medicine, The University of Texas MD Anderson Cancer, USADivision of Cancer Medicine, University of Texas, RELATIVITY-047 trialDivision of Cancer Medicine, University of Texas M.D. Anderson Cancer CenterDivision of Cancer Services, Princess Alexandra Hospital,University of QueenslandDivision of Cancer Services, Princess Alexandra Hospital, University of QueenslandDivision of Clinical Hemato-oncology, European Institute of Oncology, Milan, ItalyDivision of Clinical Hemato-Oncology, European Institute of Oncology, Milan, ItalyDivision of Clinical Oncology, University of Kansas Medical Center, Kansas.Division of Hemato-oncology, Sungkyunkwan University School of Medicine, SeoulDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MADivision of Hematology, Department of Medicine, Stanford University School of MedicineDivision of Hematology, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, USADivision of Hematology, Mayo Clinic, Rochester, NY, USA, TOURMALINE-AL1Division of Hematology, Ospedale Niguarda Ca´Granda, Milano, ItalyDivision of Hematology, Stanford Cancer Institute / Stanford University School of Medicine, Stanford, FIGHT-203 trialDivision of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, ChicagoDivision of Hematology/Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, USADivision of Hematology/Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA, KEYNOTE-966 trialDivision of Hematology/Oncology, University of Michigan, Ann Arbor, MI, United StatesDivision of Hematology/Onkology, University of Michigan, Ann Arbor, MI, United StatesDivision of Hematology and Oncology, Department of Internal Medicine, Wayne State University School of Medicine and Harper Hospital, DetroitDivision of Hematology and Oncology, University of Pittsburgh School of Medicine and Cancer Institute, Pittsburgh, USADivision of Hematology Oncology, University of California; Memorial Sloan-Kettering Cancer Center, New YorkDivision of Medical Oncology, Instituto Europeo di Oncologia, Milan, ItalyDivision of Medical Oncology, Massachusetts General Hospital Cancer Center, ASCENT trialDivision of Medical Oncology, University of Colorado, Aurora, CO, USADivision of Medical Oncology, Vanderbilt University Medical CenterDivision of Medical Senology, European Institute of Oncology, Milan, ItalyDivision of Molecular and Clinical Cancer Sciences, University of Manchester, UKDivision of Molecular and Clinical Cancer Sciences, University of Manchester, UK, CONVERT studyDivision of Oncology, Rambam Health Care Campus, HaifaDivision of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TexasDivision of Rheumatology, Department of Medicine, George Washington University, Washington, USADivision of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, USADivisions of Hematology, Mayo Clinic, Rochester, MinnesotaDivisions of Hematology/Oncology and Biostatistics, Indiana University Medical Center, IndianapolisDMU Hématologie, Hôpital Saint-Louis, Paris, France, ASCEMBL trialDr. Roland Bugat, Institut Claudius Regaud, ToulouseDSHNHL 2002-1DSHNHL 2009-1, OPTIMAL > 60Duke Cancer Institute, Durham, USADuke Cancer Institute, Durham, USA, QuANTUM-First trialDuke Comprehensive Cancer Center, Duke University Medical Center, Durham, USADuke University, Durham, NC, NCI-MATCH Trial Subprotocol HDuke University Medical Center, Durham, NC, USA, MOUNTAINEER trialDuke University Medical Center, Durham, North Carolina, CALGB 9251 trialDuke University Medical Center and Durham Veterans Affairs Medical Center, Durham, USADutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK)Département d´Oncology Médicale, Vandoeuvre-lés-Nancy, France, PRODIGE5/ACCORD17Eastern Cooperative Oncology GroupEastern Cooperative Oncology Group, Philadelphia, USEastern Cooperative Oncology Group, Studie E3E93Eastern Cooperative Onkology GroupEastern Cooperative Onkology Group, Southwest Oncology Group, Southeastern Cancer Study GroupEast German Study GroupEast German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL)Eberhard Karls University, Hematology/Oncology, TübingenEBMT, Cancer Services, Royal Free Hospital, London, UKEMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigatorsEMILIA Study Group, EMILIA StudieEmory University, Atlanta, USAEmory University, Winship Cancer Institute, Atlanta, GA, USA, DREAMM-2 StudieEmory University Winship Cancer Institute, Atlanta, GAEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, USA, PROSPER trialEORTCEORTC, HOVON, NCIC, CTG, BNLI, ALLG, NLGEORTC, NCICEORTC Soft Tissue and Bone Sarcoma GroupEORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group; PALETTE StudieErasmus MC Cancer Institute, Rotterdam, The NetherlandsErasmus MC Cancer Institute, Rotterdam, the Netherlands, PERSEUS TrialESMO Guidelines 2015Euro-E.W.I.N.G.99 and Ewing-2008EURO-EWING 99 clinical trialEuro18-trial Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena Cancer Center, ItalyEuro Ewing 2012 protocolEuropean APL GroupEuropean Institute of Oncology, Milan, ItalyEuropean Network-Paediatric Hodgkin’s LymphomaStudy Group (EuroNet-PHL)European Network-Paediatric Hodgkin’s Lymphoma Study Group (EuroNet-PHL)European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupEuropean Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative GroupEuropean Organisation für Research and Treatment of Cancer (EORTC), Lung Cancer Cooperative GroupEuropean Study Group for Pancreatic Cancer, ESPAC-4 trial F A Shepherd, Department of Medical Oncology and Hematology and Radiation Ocology, Toronto, KanadaF Barlesi, Sce Oncologie Multidisciplinaire et Innovations Therapeutiques, Marseille, Frankreich. AVAPERL (MO22089)Fifth Medical Center, Chinese PLA General Hospital, Beijing, China, RATIONALE-306 trialFLEX Studien TeamFondazione IRCCS Istituto Nazionale dei Tumori, Milan, ItalyFondazione IRCCS Istituto Nazionale dei Tumori, Milan, PEANUT studyFondazione IRCCS Istituto Nazionale Tumori, Milan, ItalyFondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Nazionale dei Tumori, Milan, ItalyFondazione Policlinico Universitario A Gemelli IRCCS and Catholic University of Sacred Heart, Rome, Italy, ENGOT-cx11/ GOG-3047/KEYNOTE-A18 trialFor the Aranesp 20030231 Study GroupFox Chase Cancer Center, PhiladelphiaFox Chase Cancer Center, Philadelphia, SGN-35 trialFred Hutchinson Cancer Center, University of Washington, Seattle, WA, TROPHY-U-01 trialFrench Federation of Cancer InstitutesFrom the Dana–Farber Cancer Institute and Harvard Cancer Center, BostonFront the British Columbia Cancer Agency Vancouver Cancer Centre, CanadaFudan University, Shanghai Cancer Center, Minhang Branch, ChinaFudan University Shanghai Cancer Center, Shanghai, People's Republic of China, CBCSG010 StudyFudan University Shanghai Cancer Center, Shanghai, People’s Republic of China, CBCSG010 StudyFukui-ken Saiseikai Hospital, Japan, SAPPHIRE StudieFunctional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment (EWING 2008)Fédération Nationale des Centres de Lutte Contre le Cancer, Fédération Francophone de Cancérologie DigestiveGastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, TRICOLORE trialGBG Forschung, Neu-Isenburg, APHINITY Steering Committee and InvestigatorsGCIG, GINECO, AGO, NSGO, ANZGOG, NCIC-CTG, EORTC, MITO, MaNGO; CALYPSO StudieGEFCAPI 02 Trial, Institut Gustave Roussy, University of Paris Sud, Villejuif, FranceGeffen School of Medicine at UCLA, Santa Monica, USA, IMbrave150GEL/TAMO cooperative groupe, SpanienGenitourinary Cancers Program, Perlmutter Cancer Center. New York University Langone Medical Center, IMvigor210 Study GroupGenitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, COU-AA-302 InvestigatorsGenitourinary Oncology and Rare Cancer Center, Federico II University, Naples, ItalyGenitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer CenterGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, IMvigor210Genitourinary Section, Department of Medicine and the Urology Service, Memorial Sloan-Kettering Cancer Center, New York;George Pompidou European Hosptial, Paris, FIRSTANAGeorgetown Lombardi Comprehensive Cancer Center, Washington, HCRN GU16-260 trialGeparSixto StudieGerman-Speaking Myeloma Multicenter Group, GMMG-HD6German-Speaking Myeloma Multicenter Group, GMMG-HD6, GHSG-HD21 German-Speaking Myeloma Multicenter Group, GMMG-HD7German AML Cooperative GroupGerman Breast Group, Frankfurt, GermanyGerman Breast Group, GBG Forschungs, Martin-Behaim- Str. 12, Neu-Isenburg, KATHERINEGerman Center for Lung Research, LungClinic, Grosshansdorf, Germany, CheckMate 9LAGerman Chronic Lymphocytic Leukemia Study Group (GCLLSG)German Cochrane Centre, Medical Center - University of Freiburg, Freiburg, GermanyGerman Esophageal Cancer Study Group, AGMT, FFCD/FRENCH, SAKK 75/08 trialGerman High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL), RICOVER-60German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL)German Hodgkin Study Group (GHSG) German Hodgkin Study Group (GHSG), University Hospital of Cologne, HD 13German Hodgkin Study Group NIVAHL TrialGerman Low-Grade Lymphoma Study GroupGerman Low Grade Lymphoma Study Group (GLSG), Groupe D’Etude Des Lymphomes De l’Adulte (GELA), HOVON and CLSGGerman Multicenter Study Group for Adult Acute Lymphoblastic LeukemiaGerman Multicenter Study Group for Adult Acute Lymphoblastic Leukemia, GMALL 07/2003German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia, GMALL 07/2017German Pancreatic Cancer Working Group (AIO-PAK) and NEOLAP investigatorsGerman Rectal Cancer Study Group, CAO/ARO/AIO-04German Testicular Cancer Study GroupGesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH), Studienprotokoll CWS-GuidanceGesellschaft für Pädiatrische Onkologie und Hämatologie, Studienprotokoll COALL 08-09Gifu University, Gifu, Japan, JACCRO GC-07 trialGIMEMA, AIEOP, and EORTC Cooperative Groups, AIDA 0493GIMEMA, AMLSG und SAL, APL0406Glasgow University, Glasgow, SchottlandGMALL Therapieempfehlung Frail ALL 2008GORTEC 2015-01 PembroRadGreek Lung Cancer Cooperative GroupGroupe Coopérateur Multidisciplinaire en Oncologie; GERCORGroupe d'Etude des Lymphomes de l'Adulte (GELA) investigatorsGroupe d'Etude des Lymphomes de l'Adulte (GELA) investigators LNH03-2BGroupe d'Étude du Traitement du PTAIGroupe Tumeurs Digestives of Unicancer and the PRODIGE IntergroupGroup for Research on Adult Acute Lymphoblastic Leukemia, GRAAL 2014/B und TGroup for Research on Adult Acute Lymphoblastic Leukemia, GRAALL 2014/B/T und GRAAPHGroup for Research on Adult Acute Lymphoblastic Leukemia, GRAALL 2014/B und TGroup for Research on Adult Acute Lymphoblastic Leukemia, GRAALL 2014/ TGroup for Research on Adult Acute Lymphoblastic Leukemia, GRAALL 2014/TGroup for Research on Adult Acute Lymphoblastic Leukemia, GRAAPH 2014Guangdong Academy of Medical Sciences and General Hospital, China, ADAURA trialGuangdong Lung Cancer Institute, Guangdong General Hospital and Academy of Medical Sciences, Guangzhou, ChinaGunma Prefectural Cancer Center, Takahayashinishi, Ota, Gunma, JapanGustave Roussy, Cancer Campus, Grand Paris, FIRSTMAPP trialGustave Roussy, University of Paris Sud, Villejuif, France, LATITUDE trialGustave Roussy Cancer Campus and Universitiy Paris-Sud, Orsay, FranceGustave Roussy Cancer Campus Grand Paris, Villejuif, France, EORTC 18071Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif, FranceGustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif, France, Keynote 716Gustave Roussy Institute, Paris-Saclay University, Villejuif, France, TRITON3 trialGustave Roussy Institute, Villejuif, France, Euro-EWING99-R1 TrialGuy's and St. Thomas' National Health Service Foundation Trust, Guy's Hospital, London, COMFORT IIGuys and St Thomas Hospital, London, United KingdomGuy´s and St. Thomas NHS Foundation Trust, London, UKGynecologic Oncology of Indiana, Indianapolis, USA, GOG studyGynecology and Gynecologic Oncology, Charité University Medicine Campus Virchow, Berlin, Germany, NOGGOH. Lee Moffitt Cancer Center and Research Institute, Tampa, FLHaematological Sciences, Newcastle University, Newcastle upon Tyne, UKHaematology Unit, Azienda Ospedaliera Universitaria Senese and University of Siena, Siena, ItalyHamad Medical Corporation, Hematology/Oncology Division, Doha, QatarHamm-Kliniken, Marburg, DeutschlandHanna N, Indiana University, Hoosier Oncology GroupHanna N, Indiana University and Hoosier Oncology GroupHanyang University College of Medicine, Seoul, South KoreaHarvard Medical School, Boston, MA, USA, OPTIMISMM trialHaugesund Hospital, Haugesund, NorwayHead and Neck Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, MilanHead and Neck Oncology, Dana Farber Cancer Institute, arvard Medical School, Boston, MassachusettsHeidelberg University, Mannheim, Germany, RAMONA trialHeidelberg University Hospital, Heidelberg, GermanyHeidelberg University Hospital, Heidelberg, Germany, GMMG-BIRMA trialHelbekkmo N, University of Tromso and Department of Oncology, NorwegenHelen Diller Comprehensive Cancer Center, University of California, San Francisco, CALGB 50202 (Alliance 50202)Helios Klinikum, Hämatologie/Onkologie, Erfurt, Deutschland, Studie OSHO# 19Helios Klinikum Berlin-Buch, GermanyHelios Klinikum Berlin-Buch, Germany, GeparSeptoHematology, Universita Cattolica Sacro Cuore Campobasso, Campobasso, ItalyHematology-Oncology, Baltimore, MarylandHematology-Oncology Practice Eppendorf (HOPE), Hamburg, Germany, AIO IntegaHematology/Oncology Fellowship Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TexasHematology and Oncology, Goethe University, Frankfurt, Frankfurt am Main, GermanyHematology and Stem Cell Transplant Center, Marche Nord Hospital, Pesaro, ItalyHematology and Transplant Center, IRCCS Ospedale Policlinico San Martino, Genova, TELESTO trialHematology Branch and Office of Biostatistics Research, National Heart, Lung, and Blood Institute and Center for Human Immunology, Autoimmunity, and Inflammation, National Institutes of Health, BethesdaHematology Clinic, University Hospital Hotel-Dieu, Nantes, MajesTEC-1 trialHematology Department, Hospital Clinico San Carlos, Madrid, SpanienHematology Division, National Hospital Organization Disaster Medical Center, Tachikawa, TokyoHematology Division, San Gerardo Hospital, Monza, ItalyHematology Division, Stanford University School of Medicine–Stanford Cancer Institute, Stanford, CA Hematology Oncology Associates, Baltimore, MD and Georgetown University, Washington DCHematology Oncology Division, Indiana University School of Medicine, Indianapolis, IndianaHematology Oncology of Indiana, USAHigh Technology Medical Centre, University Clinic Ltd., Tbilisi, Georgia, EMPOWER-Lung 3HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MDHoosier Oncology GroupHoosier Oncology Group, Indianapolis, Indiana, USAHopital Avicenne, Assistance Publique-Hôpitaux de Paris, Université Paris XIII, Bobigny, FranceHopital Avicenne, Universite Paris-Nord, Bobigny, FranceHopital Saint-Louis, Assistance Publique-Hopitaux de Paris, Paris, France, DACOTA trialHopital Saint-Louis, Assistance Publique-Hopitaux de Paris and Universite Paris 7, Paris, FranceHopital Saint-Louis, Hemato-oncologie, Universite de Paris, Paris, FranceHopital Saint-Louis, Paris, FranceHopital Saint Louis, Paris, Frankreich, CORAL StudieHopitaux Universitaires de Geneve, Geneva, SAKK 33/99Horst Schmidt Klinik, Wiesbaden, DeutschlandHospices Civils de Lyon, Université Claude Bernard, FrankreichHospices Civils de Lyon, Université Claude Bernard, Frankreich. PRIMA StudieHospital Clinic Barcelona and IDIBAPS, Barcelona, Spain, LEAP-004 trialHospital e Instituto Biosanitario de Salamanca (IBSAL), Universidad de Salamanca (IBMCC/CSIC), SpainHospital General de Asturias, Oviedo, Spain, E.O.R.T.C. Soft Tissue and Bone Sarcoma GroupHospital of the University of Munich, Munich, Germany, VOLFI Study (AIO KRK0109) Hospital Universitari i Politecnic La Fe, Valencia, AGILE trialHospital Universitario 12 de Octubre, Universidad Complutense and CiberOnc, Madrid, Spain, CheckMate 9LA studyHospital Universitario La Fe, Valencia, SpainHospital Universitario Puerta de Hierro-Majadahonda, Spain, NADIM II trialHospital Universitario Virgen de la Victoria, Malaga, SpainHOVON-65/GMMG-HD4 StudieHOVON / SAKKHOVON 132 AML / SAKK 30/13Humanitas Clinical and Research Center, Rozzano, Milan, ItalyHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New YorkHuntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, UT, USA, TALAPRO-2 trialHuntsman cancer institute, University of Utah, Salt Lake City, Utah, OPTIM trialHématologie clinique et thérapie cellulaire, Hôpital Saint Antoine, APHP, Sorbonne Université, INSERM UMRs 938, Paris, FranceHôpital Saint Louis, Institut Universitaire d´Hématologie, University Paris Diderot, Paris, FranceIFm2009 / Determination trialImperial Cancer Research Fund Clinical Oncology Unit, Churchill Hospital, Oxford, United KingdomImperial College Academic Science National Health Service Trust, London, United KingdomIndiana School of Medicine, IndianapolisIndiana University Cancer Center, Indianapolis, USAIndiana University Medical Center and The Walther Cancer Institute, IndianapolisIndiana University Melvin and Bren Simon Cancer CenterIndiana University Melvin and Bren Simon Cancer Center, IndianapolisInha University School of Medicine, Incheon, South KoreaINSERM U1015, Gustave Roussy, Universite Paris-Saclay, Villejuif, France, VIT-0910 trialInstitut Català d’Oncologia L’Hospitalet, a Spanish Group for Research on Sarcomas StudyInstitut Curie, Paris and Saint Cloud, France, EMERALD TrialInstitut de Cancerologie de Lorraine and APEMAC, Universite de Lorraine, Nancy, France, UNICANCER-PRODIGE 23 trialInstitute for Drug Development, Cancer Therapy and Research Center, San Antonio, USAInstitute for Head and Neck Studies and Education (InHANSE), University of Birmingham, UK, De-ESCALaTE HPV trialInstitute for Medical Sciences, Uppsala University Hospital, Uppsala, Sweden, PROFOUND trialInstitute of Cancer Research and Royal Marsden Hospital, Sutton, COU-AA-301 InvestigatorsInstitute of Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom, PROfound trialInstitute of Clinical Cancer Research, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, GermanyInstitute of Hematology, Ospedale Santa Maria della Misericordia, University of Perugia, Italy, HCL-PG03Institute of Hematology and Medical Oncology, University of Bologna, Bologna, ItalyInstitute of Hematology Seragnoli, Bologna University, Bologna, Italy, Checkmate 436Institute of Hematology – CREO, Ospedale Santa Maria della Misericordia, University of Perugia, ItalyInstitute of Oncology, Bellinzona, SchweizInstitute of Oncology, Ljubljana, SlowenienInstitut Gustave-Roussy, Villejuif, France, LMS-04 trialInstitut Gustave Roussy, Department of Cancer Medicine, Villejuif, France, GETUG 13 trialInstitut Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers, Villejuif, France, FLAURA2 trialInstitut Gustave Roussy, Universite Paris-Sud, Villejuif, France, ARAMIS trialInstitut Gustave Roussy, University of Paris-Saclay, Villejuif, France, PEACE-1Institut Gustave Roussy, University of Paris Sud, Villejuif, France, GEFCAPI 02Institut Gustave Roussy, Ville- juif, Service of Biostatistics, and Lyon- Sud Hospital, Lyon-SudInstitut Gustave Roussy, Villejuif, France, AVOREN trialInstitut Gustave Roussy, Villejuif, France, SOLAR-1 StudyInstitut Gustave Roussy, Villejuif, France, TARGET study groupInstitut Gustave Roussy, Villejuif Cedex, Frankreich; FNCLCC ACCORD 13/0503 StudieInstitut Gustave Roussy Cancer Centre, Villejuif, FranceInstitut Jules Bordet, Brussels, BelgiumInstitut Jules Bordet, Universite Libre de Bruxelles, BelgiumInstitut Jules Bordet, Université Libre de Bruxelles, Belgien; BOLERO-2 StudieInstituto Clinico Humanitas, Rozzzano, ItalyInstitut Universitaire du Cancer, Toulouse-Oncopole, Toulouse, FranceInstitut Universitaire du Cancer de Toulouse-Oncopole and Service d’Epidémiologie, Toulouse, IFM 2009 StudyInstitut Universitaire du Cancer Toulouse Oncopole, Toulouse, France, ICARIA-MMInterdisziplinäres Tumorzentrum Mannheim und die Med. Klinik III, Universitätsklinik Mannheim, DeutschlandIntergroupe Francophone de Cancerologie Thoracique, Institut National du Cancer, FrankreichInternal Medicine III, Ulm University, Ulm, GermanyInternal Medicine I Saarland University Medical School, DSHNHL 2015-1International Breast Cancer Center, Vall d'Hebron Institute of Oncology, Barcelona, Spain, KEYNOTE-355International University of Health and Welfare Mita Hospital, Tokyo, JapanIoannina University Hospital, Ioannina, Greece, Hellenic Cooperative Oncology GroupIoannina University Hospital, Ioannina, Greece, Hellenic cooperative oncology group studyIPASS StudieIRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia, ROSEWOOD trialIRCCS Fondazione Istituto Nazionale TumoriIRCCS San Raffaele Scientific Institute, Milan, Italy, IELSG32 trialIstituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione G Pascale, IRCCS, Napoli, Italy, MITO-7 trialIstituto Nazionale per lo Studio e la Cura dei Tumori, MilanoIstituto Nazionale Tumori, Milan, ItalyIstituto Ortopedico Rizzoli, Bologna, ItalyIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, ItalyJ-L Pujol, Montpellier University Hospital, FrankreichJamaica Hospital Medical Center, Jamaica, USAJapan Clinical Oncology GroupJapan Clinical Oncology Group (JCOG), TOPIC-NETJapan Clinical Oncology Group, Studie 9104Japan Clinical Oncology Group 9702Japanese Gynecologic Oncology Group, JGOG 3016 StudieJD Patel, R H Lurie Comprehensive Cancer Center, Chicago, USA. PointBreak-StudieJewish General Hospital, McGill University, Montreal, Quebec, CanadaJichi Medical University, Tochigi, JapanJohannes-Gutenberg-Universität Mainz, DeutschlandJohn Hopkins School of Medicine, Baltimore, MarylandJohns Hopkins Sidney Kimmel Comprehensive Cancer Center, BalimoreJohns Hopkins University, Baltimore, MDJohns Hopkins University School of Medicine, Baltimore, MarylandJohns Hopkins University School of Medicine, Baltimore, MD, USAJohn Theuer Cancer Center Hackensack, USA MCL-001 EMERGE StudyJP Stevenson, Abramson Cancer Center, Philadelphia, USAJuravinski Cancer Centre, McMaster University, Hamilton, ON, Canada, HELIOSKaiser Franz Josef Hospital, Vienna, Austria, EORTC Study 30986Kansas City Cancer Center, US Oncology Research Inc.Keynote-059KEYNOTE-522 InvestigatorsKeynote 224Kindai University Faculty of Medicine, Osaka, Japan, RELAYKindai University Faculty of Medicine, OsakasayamaKings College Hospital, Denmark Hill, London, UK, GALLIUM trialKitasato University School of Medicine, Sagamihara, JapanKlinik für Innere Medizin, Bremen, DeutschlandKlinik für Innere Medizin, Universität KölnKlinik für Internistische Onkologie, Freiburg, DeutschlandKlinik für Internistische Onkologie und Hämatologie, Krankenhaus Barmherzige Brüder, RegensburgKlinik für Onkologie und Hämatologie, Krankenhaus Nordwest, Frankfurt am Main, DeutschlandKlinik I für Innere Medizin, Universitätsklinikum KölnKlinikum rechts der Isar, Klinik für Innere Medizin III, Technische Universität München, Munich, Germany, DANTE/IKF-s633Klinikum Rechts der Isar, Technische Universität München, München, Germany, RAMIRIS StudyKlinikum Universität MünchenKnight Cancer Institute, Oregon Health and Science University, PortlandKnight Cancer Institute, Oregon Health and Science University, Portland, USAKnight Cancer Institute, Portland, USA, NAVIGATOR trialKorea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of KoreaKrankenhaus Nordwest und German Breast Group, FrankfurtLaboratoire d’Hématologie, Centre Hospitalier Universitaire, Lille, SPIRIT trialLaboratory of Molecular Biology, Clinical Center, Bethesda, MarylandLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, COSMIC-313 trialLaura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, CheckMate 238 CollaboratorsLausanne University Hospital, Lausanne, F. Hoffmann–La Roche, Basel, Switzerland, ALEX TrialLeeds Cancer Research UK Clinical Trials Unit, United Kingdom, FLAIR trialLeeds General Infirmary, Leeds, United Kingdom, TRIUMPHLeeds Institute of Clinical Trials Research, University of Leeds, UK, Phase 2 Muk Five StudyLeeds Teaching Hospitals National Health Service Trust, Leeds, United KingdomLeo W. Jenkins Cancer Center, Brody School of Medicine at East Carolina University, Greenville, GOGLevine Cancer Institute, Atrium Health, Charlotte, GRIFFIN trialLevine Cancer Institute, Atrium Health, Charlotte, NC, USA, FeDeriCa trialLilienbaum R C, Yale Cancer Center, New Haven, USALondon Lung Cancer GroupLouisiana State University Medical Center, New Orleans, LouisianaLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, BostonLoyola University Chicago Stritch School of Medicine, Maywood, USALudwig-Maximilians University of Munich, Campus Grosshadern, Munich, GermanyLudwig Center at Dana-Farber Cancer Institute and Harvard Medical School, Boston, USALudwig Center at Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA, GRID trialLUME-Lung 1 Studien Gruppe, LUME-Lung 1 StudieLung Cancer Group - EORTC 08975Lung Clinic, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany, KEYNOTE-024Lungenfachklinik Immenhausen, Immenhausen, Germany, OAK trialLung Unit, Royal Marsden Hospital, London, UK, PEARLS/KEYNOTE-091Lung Unit, Royal Marsden Hospital, Sutton, EnglandLUX Lung 3 StudieLUX Lung 8 StudieLymphoid Malignancies Branch, National Cancer Institute, BethesdaLymphoma Research Foundation, New York, USA, ACCRU trialM.D. Anderson Cancer Center, HoustonM.D. Anderson Cancer Center, Houston, USA, HER2CLIMB trialM.D. Anderson Cancer Center, Houxton TXM.D. Anderson Cancer Center, University of Texas, Houston, EMBRACA StudieMaebashi Red Cross Hospital, Department of Respiratory Medicine, Asahicho, Maebashi, JapanMakerere College of Health Sciences, Kampala, UgandaManchester and Derriford Hospital,Plymouth, UKManchester Cancer Research Centre, University of Manchester, UKMaria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology, Warsaw PolandMassachusetts General Hospital, BostonMassachusetts General Hospital, Boston, MAMassachusetts General Hospital, Boston, MA, USAMassachusetts General Hospital, Boston, USA, ARROW trialMassachusetts General Hospital, Div. of Hematology -Oncology, USAMassachusetts General Hospital Cancer Center, BostonMassachusetts General Hospital Cancer Center, Boston, USAMassachusetts General Hospital Cancer Center, Boston, USA, CROWN trialMassachusetts General Hospital Cancer Center, Harvard Medical Center, Boston, REACH-2Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, ARASENS trialMateos MMater Misericordiae Ltd/Mater Research Institute and the University of Queensland, Brisbane, Queensland, Australia, SAPPHIREMater Misericordiae Ltd/Mater Research Institute and the University of Queensland, Brisbane, Queensland, Australia, SAPPHIRE trialMATRix / IELSG43 StudieMayo Clinic, Rochester, MinnesotaMayo Clinic, Rochester, MN, Monarch 3 trialMayo Clinic, Rochester, USAMayo Clinic, Rochester, USA, BELLINI trialMayo Clinic, Scottsdale, USAMayo Clinic Cancer Center, Scottsdale, AZ, USA, RELIEFMayo Clinic College of Medicine, Rochester, MN, GOG StudyMayo Clinic Rochester, MN; Roswell Park Cancer Institute, Buffalo, NY, ADOPT trialMayo Clinic Scottsdale, USA, ERIVANCE BCC studyMD Anderson Cancer Center, Houston, TX, USA, BRUIN trialMD Anderson Cancer Center, Houston, USAMD Anderson Cancer Center, University of Texas, Houston, USA, CheckMate 275MD Anderson Cancer Center Spain, Madrid, Spain, ICON7 investigatorsMedical College of Wisconsin, Milwaukee, USAMedical Oncology and Breast Unit, European Institute of Oncology (IRCCS), Milan,Italy, NorCap-CA223 TrialMedical Oncology Department, Ospedale dell’Angelo, Venezia, the GSTTC Italian Study GroupMedical Oncology department, University Hospital, Sfax (Tunisia), GORTEC 2006-02Medical Oncology Unit, Clinical Cancer Centre, AUSL-IRCCS di Reggio Emilia, Italy, RAMESMedical Oncology Unit, Mersin University, Mersin, TurkeyMedical Research Council Clinical Trials Unit, London, United Kingdom, BA06 30894 TrialMedical Research Council Lung Cancer Working PartyMedical School Hannover, Hannover, GermanyMedical University of GdanskMedical University of Lodz, Lodz, PolandMedical University of Silesia, Katowice, Poland, BOSTON trialMedical University of South Carolina, Charleston, USAMedical University of ViennaMedical University of Vienna, ABCSG-12 trialMedical University of Vienna, AustriaMedical University of Vienna, Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Vienna, Austria, ANAHYDRET StudyMedizinische Hochschule Hannover, Hannover, Germany, IMspire150 trialMedizinische Klinik und Poliklinik I, Universitätsklinikum DresdenMedizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg, Germany, L-MIND studyMedizinische Klinik und Poliklinik III, Klinikum Grosshadern, MünchenMelanoma Institute Australia, University of Sydney, AustraliaMelanoma Institute Australia, University of Sydney, AustralienMemorial Hospital of South Bend, South BendMemorial Sloan-Kettering Cancer Center, Kimmel Center, New YorkMemorial Sloan-Kettering Cancer Center, New YorkMemorial Sloan-Kettering Cancer Center, New York, AFFIRM trialMemorial Sloan-Kettering Cancer Center, New York, Gynecologic Oncology GroupMemorial Sloan-Kettering Cancer Center, New York, HOPE 205Memorial Sloan-Kettering Cancer Center, New York, NYMemorial Sloan-Kettering Cancer Center, New York, NY, USAMemorial Sloan-Kettering Cancer Center, New York, SARC 005 trialMemorial Sloan-Kettering Cancer Center, NY, (COMPARZ)Memorial Sloan-Kettering Cancer Center New York, NYMemorial Sloan-Kettering Center, New York, USA, NCI-MATCH trial (EAY131)Memorial Sloan Kettering Cancer CenterMemorial Sloan Kettering Cancer Center, 1275 York Ave., New YorkMemorial Sloan Kettering Cancer Center, A Study of the US Gastric Cancer ConsortiumMemorial Sloan Kettering Cancer Center, KEYNOTE-087 investigatorsMemorial Sloan Kettering Cancer Center, Memorial Hospital, New York, CheckMate 214Memorial Sloan Kettering Cancer Center, New YorkMemorial SloanKettering Cancer Center, New YorkMemorial Sloan Kettering Cancer Center, New York, AETHERA trialMemorial Sloan Kettering Cancer Center, New York, BRIM-3 studyMemorial Sloan Kettering Cancer Center, New York, CLEAR trialMemorial Sloan Kettering Cancer Center, New York, ECHELON-2 study groupMemorial Sloan Kettering Cancer Center, New York, HIMALAYA trialMemorial Sloan Kettering Cancer Center, New York, KEYNOTE-177Memorial Sloan Kettering Cancer Center, New York, KRYSTAL-1 trialMemorial Sloan Kettering Cancer Center, New York, New York, VE-BASKET StudyMemorial Sloan Kettering Cancer Center, New York, NYMemorial Sloan Kettering Cancer Center, New York, NY, Keynote-604Memorial Sloan Kettering Cancer Center, New York, NY, USAMemorial Sloan Kettering Cancer Center, New York, NY, USA, ECHELON-2Memorial Sloan Kettering Cancer Center, New York, OlympiAD TrialMemorial Sloan Kettering Cancer Center, New York, PROSPECT trialMemorial Sloan Kettering Cancer Center, New York, USAMemorial Sloan Kettering Cancer Center, New York, USA, CELESTIAL trialMemorial Sloan Kettering Cancer Center, New York, USA, CENTAURUS trialMemorial Sloan Kettering Cancer Center, New York, USA, DESTINY-Breast01 trialMemorial Sloan Kettering Cancer Center, New York, USA, EV-201 trialMemorial Sloan Kettering Cancer Center, New York, USA; OCEANS StudieMemorial Sloan Kettering Cancer Center, New York, VISION trialMemorial Sloan Kettering CancerCenter, NY, Checkmate-032 StudieMemorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York City, NY, USAMemorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, USAMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, LIBRETTO-001Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, Keynote-811Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, SEAL trialMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA, CheckMate 649Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, DESTINY-Lung01 trialMemorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, DESTINY-PanTumor01 trialMetaxas Memorial Cancer Hospital, Piraeus, GreeceMie University Graduate School of Medicine, Tsu, JapanMILES (The Multicenter Italian Lung Cancer in the Elderly Study)Minnie Pearl Cancer Research NetworkMiriam Hospital and Alpert Medical School of Brown University, Providence, USA, CALGB 40603 (Alliance)M Karamaya, Department of Internal Medicine, Hamamatsu University, JapanMoffitt Cancer Center, Tampa, FL, USA, CheckMate 037Monash University, Australia, ENZAMET TRIALMonash University, Clayton, Victoria, Australia, MAGNOLIA trialMonash University, Melbourne, Australia, QUAZAR AML-001 trialMoores Cancer Center, UC San Diego, San Diego, USA, MyPathway trialMount Sinai Medical Center, New YorkMount Sinai School of Medicine, New York, MonumenTAL-1 trialMount Vernon Cancer Centre, UK, IMCgp100-202 InvestigatorsMRC Clinical Trials Unit, LondonMRC Myelom IX StudieMulticenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. MOSAIC StudieMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA Myeloma Unit, Division of Hematology, University of Torino, IST-CAR-561Médecine Interne, Hôpital Henri-Mondor, Assistance Publique–Hôpitaux de ParisNanjing Medical University, Nanjing, Jiangsu Province, ChinaNantes Medical University, Nantes, FranceNantes University Hospital, Nantes, FranceNational Amyloidosis Centre, University College London (Royal Free Campus), London, UKNational and Kapodistrian University Athens School of Medicine, Athens, Greece, CANDOR trialNational and Kapodistrian University of AthensNational and Kapodistrian University of Athens, Athens, GreeceNational and Kapodistrian University of Athens, School of Medicine, Athens, GreeceNational and Kapodistrian University of Athens, School of Medicine, Athens, Greece, TOURMALINE-MM4 TrialNational Cancer Center Hospital, Tokyo, Japan, CheckMate 648 trialNational Cancer Center Hospital, Tokyo, Japan, FUGA-BT (JCOG1113)National Cancer Center Hospital, Tokyo, Japan, JCOG 9605National Cancer Center Hospital, Tokyo, Japan, KEYNOTE-590National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo, Japan, JCOG9811National Cancer Center Hospital East, Chiba, Japan, TAGSNational Cancer Center Hospital East, Kashiwa, Japan, C-TASK FORCE / Sunlight investigatorsNational Cancer Center Hospital East, Kashiwa, Japan, REGONIVO trial, EPOC1603National Cancer Center Hospital East, Kashiwa-shi-Chiba, Japan, CodeBreaK 101 Subprotocol HNational Cancer Center Hospital East, Kashiwanoha, Kashiwa, Chiba, Japan, DESTINY-Gastric01 trialNational Cancer Institute, BethesdaNational Cancer Institute, Bethesda, USANational Cancer Institute, National Institutes of Health, Bethesda, Maryland, USANational Cancer Institute, National Institutes of Health, Bethesda, MDNational Cancer Institute, National Institutes of Health, Bethesda, MD, USANational Cancer Institute, NIH, Bethesda, MarylandNational Cancer Institute BethesdaNational Cancer Institute of Canada Clinical Trials Group; NCIC CTG PA.3 StudieNational Cancer Institute of Canada Clinical Trials Group and the National Cancer Institute of the United States IntergroupNational Center for Tumor Diseases, University Hospital, Heidelberg, Germany, TryphaenaNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, AustraliaNational Hospital Organization, Kinki-Chuo Chest Medical Center, JapanNational Institutes of HealthNational Institutes of Health, BethesdaNational Kyushu Cancer Center, Fukuoka, JapanNetherlands Cancer Institute, Amsterdam, CheckMate 901 TrialNetherlands Cancer Institute, Amsterdam, Netherlands, CRITICS trialNetherlands Cancer Institute, Amsterdam, Netherlands, TRAIN-2 trialNetherlands Cancer Institute, Amsterdam, the Netherlands, NICHE-1 studyNeurology Clinic and National Center for Tumor Disease, University of Heidelberg and German Cancer Research CenteNeurooncology Working Group of the German Cancer Society, CeTeG/NOA–09New York Medical College, Valhalla, United StatesNew York University Cancer InstituteNew York University Langone Health, Laura and Isaac Perlmutter Cancer Center, New York, KEYNOTE-189 InvestigatorsNew York University Medical Center, New York, New York, USANew York University Medical Center, New York, Radiation Therapy Oncology Group 9501/IntergroupNHL-B1 trial, DSHNHLNHS Blood and Transplant, Oxford, UKNiguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy, Hercales StudieNOGGO-AGONordic Lymphoma GroupNorth American Intergroup E1609Northwestern University, Breast Oncology, Division of Hematology/Oncology, Department of Medicine, Chicago, USANorthwestern University, Chicago, USANorthwestern University, Chicago ILNPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study GroupNRG Oncology-Gynecologic Oncology Group (GOG240)NTT Medical Center Tokyo, Trial JCOG0505Ohio State University, Columbus, Ohio, USAOhio State University Comprehensive Cancer Center, Ohio State University, ColumbusOHSU Knight Cancer Institute, Oregon Health and Science University, PREVAIL trialOncologia Medica, Dipartimento di Scienze Cliniche e Biologiche Universita`di Torino, Orbassano, ItalyOncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ItalyOncologia Medica, San Raffaele Cancer Centre, Milan, Italy, NeoSphere trialOncologia Medica, San Raffaele Cancer Centre, Milan, Italy, NeoSphere trial, sowie National Center for Tumor Diseases, University Hospital, Heidelberg, Germany, TryphaenaOncologia Medica, San Raffaele Cancer Centre, Milan, Italy, NeoSphere trial sowie National Center for Tumor Diseases, University Hospital, Heidelberg, Germany, TryphaenaOncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Duesseldorf, GermanyOncology Center, Klinik Hirslanden, Zürich, SchweizOncology Department, Institut Clinic de Malalties Hemato-Oncologiques, University of BarcelonaOncology Department, Istituto Ortopedico Rizzoli, Bologna-Italy, EURO-B.O.S.S.Oncology Department and Digestive Surgery Department, Tenon Hospital, GERCOR studyOncology Institute, Sheba Medical Center, Tel Aviv University, Israel, POLO trialOncology Institute of Southern Switzerland, Bellinzona, IELSG-19 TrialOncology Institute of Southern Switzerland, Bellinzona, IELSG-19 trialOncology Institute of Southern Switzerland, Division Medical Oncology, Bellinzona, SchweizOncotherapeutics, West Hollywood, USAOnkologie 2022 / 2023Onkologie Ravensburg, Elisabethenstraße 19, 88212, Ravensburg, Germany, VicTORia trialONO-4538-12, ATTRACTION-2Osaka University and Kyowakai Hospital, OsakaOxford Children's Hospital, Oxford University Hospital NHS Trust, OxfordPaseo de San Vicente, Salamanca, Spain, ALCYONE trialPaz-Ares, Servicio de Oncologia Medica, Seville, Spanien, PARAMOUNT-StudiePaz-Ares, Servicio de Oncologia Medica, Seville, Spanien; PARAMOUNT-StudiePeking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaPeking University Cancer Hospital and Institute, Beijing, ChinaPeking University Cancer Hospital and Institute, Beijing, China, RATIONALE-302 trialPeking University Cancer Hospital and Institute, Beijing, People's Republic of ChinaPenn Presbyterian Medical Center, University of Pennsylvania Health System, Philadelphia, PA, USA, KEYNOTE-028Penn State Milton S. Hershey Medical Center Oncology, Hershey, PAPerelman School of Medicine and Abramson Cancer Center, University of Pennsylvania, ELIANA trialPerlmutter Cancer Center, New York University School of Medicine, KEYNOTE-086Perlmutter Cancer Center, NYU Langone Medical Center, New YorkPeter MacCallum Cancer Center, Melbourne, VIC, Australia, CAPTIVATE trialPeter MacCallum Cancer Centre, Melbourne, AustraliaPeter MacCallum Cancer Centre, Melbourne, Australia, TROG 99.03Peter MacCallum Cancer Centre, Melbourne, VIC, AustraliaPeter MacCallum Cancer Centre, Melbourne, VIC, Australia, BGB-3111-302 (ASPEN trial)Peter MacCallum Cancer Centre, Melbourne, Victoria, AustralienPhilipps University Marburg and University Hospital Gießen and Marburg, Campus Marburg, Marburg, Germany, SORMAIN trialPirker R, FLEX Studien TeamP Kosmidis, Second Medical Oncology Department, Hygeia Hospital, Athen, GriechenlandPlanchard DPoliclinico S. Matteo, University of Pavia, ItalyPrimary breast cancer: ESMO Clinical Practice GuidelinesPrince of Wales Hospital, Randwick, Sydney, AustraliaPrincess Alexandra Hospital, Brisbane; Diamantina Institute, University of Queensland, Brisbane, AustraliaPrincess Margaret Cancer Centre, Ontario, CanadaPrincess Margaret Hospital, Toronto, CanadaPrincess of Wales Hospital, Bridgend, British Committee for Standards in HaematologyProspective Clinical Study Committee of Anaplastic Thyroid Carcinoma Research Consortium of Japan, Tokyo, JapanPulmonology Unit, University Hospital Strasbourg, FrankreichQE II Helath Sciences Centre, Halifax, Nova Scotia, CanadaQueen Mary University of London, St. Bartholomew's Hospital, London, JAVELIN Bladder 100Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, CAIRORegina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, ItalyResearch Institute and Tennessee Oncology PLLC, Medical Oncology, Nashville, USA, tnAcity trialRhode Island Hospital, Providence, Rhode IslandRoswell Park Cancer Institute, Buffallo, NY, USARoswell Park Cancer Institute, Buffalo, NY, USARoswellPark Comprehensive Cancer Center, Buffalo, NY, USA, LACEWING trialRoswell Park Memorial Institute, Buffalo, New YorkRotterdam Oncological Thoracic StudygroupRoyal Free Hospital and University College Medical School, UKRoyal Marsden Hospital, Institute of Cancer Research, London, CAPItello-291 trialRoyal Marsden Hospital, LondonRoyal Marsden Hospital, London, UKRoyal Marsden Hospital, London, United KingdomRoyal Marsden Hospital, London, United Kingdom, INTERAACT trialRoyal Marsden Hospital, Surrey and London, UK, MAGIC trialRoyal Marsden Hospital and Institute of Cancer Research, London, PALOMA-3Royal Marsden Hospital London, UK, EORTC Soft Tissue and Bone Sarcoma GroupRoyal Marsden NHS Foundation Trust, London, UKRoyal Marsden NHS Foundation Trust, London, United Kingdom, monarchE trialRoyal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK, TROPICRoyal Women's Hospital, Melbourne, Victoria, AustraliaRutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, USASaint-Antoine Hospital, INSERM, Unité Mixte de Recherche Scientifique 938, Paris, France, GARNET trialSAL - Studienallianz Leukämie Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, ATTLAS trialSamsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, KCSG-BR15-10San Bortolo Hosptial, Vicenza, ItalySandro Pitigliani Medical Oncology Unit, Hospital Prato, ItalienSan Giovanni Antica Sede Hospital, Torino, ItalySan Luigi Gonzaga Hospital, University of Turin, Turin, Italy, ADIUVO trialSarah Cannon Oncology Research ConsortiumSarah Cannon Research Institute, Nashville, ADRIATIC trialSarah Cannon Research Institute, Nashville, TN, SALUTE trialSarah Cannon Research Institute, Nashville, TN, USASarah Cannon Research Institute, Nashville, USASarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN, POSEIDON StudySarah Connor Reearch Inst. Nashville TN USASarcoma Oncology Center, Santa Monica, CA, USASATURN investigators, SATURN StudieScagliotti, Department of Clinical and Biological Sciences, Turin, ItalienScagliotti, Dept. of Clinical and Biological sciences, University of Torino, ItalySchool of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ENDEAVORSchool of Medicine, National and Kapodistrian University of Athens, Athens, Greece, POLLUXSecond Medical Oncology Department, Hygeia Hospital, Athen, GriechenlandSection of Haemato-Oncology, Royal Marsden Hospital/Institute of Cancer Research, Sutton, UKSection of Lymphoma, M.D. Anderson Cancer Center, Houston, TXSeoul National University College of MedicineSeoul National University College of Medicine, Seoul, Republic of Korea, KEYNOTE-585Seoul National University College of Medicine, TOGA StudieSeoul National University College of Medicine, ToGA studySeoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea, TOPAZ-1 trialService de Médecine Interne-Oncologie, Hôpital Saint-Antoine, Paris, FranceService des Maladies du Sang, Centre Hospitalier Regional et Universitaire de Lille, LilleService d Hematologie et Oncologie, Centre Hospitalier de Versailles, ALFA-0701Service d´Hematologie Clinique, Hoptial, Avicenne/Universite Paris, FranceService d’hémato-oncologie Pédiatrique, Centre de référence des histiocytoses, Hopital Trousseau, ParisService Inter-Hospitalier de Cancérologie et de Gastroenteropancréatologie, Hôpital Beaujon, Clichy, FrankreichService of Hematology, Son Espases University Hospital, Palma de Mallorca, SpainServicio de Oncologia Radioterapica, Hospital Clinico Universitario, Malaga, SpainShanghai Chest Hospital, Department of Oncology, Shanghai, People's Republic of China, RATIONALE 304 trialShanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China, PAPILLON trialSHARP investigator´s studySidney Kimmel Comprehensive Cancer Center, Baltimore, MD, CheckMate 358 studySidney Kimmel Comprehensive Cancer Center, Baltimore, USA, CheckMate 017Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, USASidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, USA, KEYNOTE-164Sint Augustinus-University of Antwerp, Antwerp, Belgium, JAVELIN studySocinski MA, University of Pittsburgh Medical Center, Pittsburgh, USASOLTI Breast Cancer Cooperative Group, Barcelona, Spain, NALA TrialSorbonne University, Saint-Antoine Hospital, Paris, France, GERCOR NEONIPIGA studySouthampton University Hospitals Trust, Southampton, United Kingdom, MRC/NCRI LY10 trialSouthern Italy Cooperative Oncology Group and Interr. Assc. for the Study of Lung Carcinoma, ItalienSouthwest Oncology Group, SWOG 9019Southwest Oncology Group studySouth West Wales Cancer Institute, University of Wales, Wales, UK, TEXAS StudieSpanish Breast Cancer Research Group, GEICAM trialSpanish Cancer Group, Groupe Francais de Pneumo-Cancerologie and Assz. Ital. Oncologia Toracica; EURTAC StudieSpanish Head and Neck Cancer Cooperative Group, TTCCSpanish National Cancer Research Centre (CNIO), Madrid, Spain, SWITCH trialSpanish Network on Mastocytosis (REMA), Toledo and Salamanca, SpainSt. Bortolo Hospital, Vicenza, ItalySt. Marianna University School of Medicine Yokohama City Seibu Hospital, Yokohama, Kanagawa, JapanSt. Vincent´s Comprehensive Cancer Center, New YorkStanford Cancer Institute, Stanford, CA, USAStanford Cancer Institute/Stanford University School of Medicine, Stanford, USA, PATHFINDER trialStanford University, School of Medicine, MONARCH 2Stanford University, Stanford, CA, USA, MAVORICStanford University Cancer Center, CA (ECOG E1996)Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto, FOENIX-CCA2 trialStanford University School of Medicine, Stanford Cancer Institute, Stanford, CA, KEYNOTE-671Stanford University School of Medicine and Lucile Packard Childrens Hospital, CA, EURAMOS-1State Key Laboratory of South China, Chinese University of Hong Kong, ARCHER 1050-StudieStevenson Cancer Center, University of Oklahoma, SOLO2/ENGOT-Ov21 investigatorsSt James's University Hospital and University of Leeds, Leeds UKStudy Alliance Leukemia, SAL, AML 2003 StudieStudy Group indolent Lymphomas (StiL)Sungkyunkwan University School of Medicine, Seoul, Korea, The ARTIST trialSungkyunkwan University School of Medicine,Seoul, South Korea, CHRYSALIS trialSunnybrook Odette Cancer Centre, Toronto, CanadaSun Yat-sen University Cancer Center, Guangzhou, ChinaSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South ChinaSun Yatsen University Cancer Center, State KeyLaboratory of Oncology in SouthChinaSylvester Cancer Center, University of Miami Miller School of Medicine, Miami, USASylvester Comprehensive Cancer Center, University of Miami and The University of Texas MD Anderson Cancer CenterSylvester Comprehensive Cancer Center, University of Miami School of Medicine, FloridaSystematic Review Initiative, NHS Blood and Transplant, Oxford, UKTaipei Veterans General Hospital, Taipei, TaiwanTAnDEM studyTata Memorial Centre, Homi Bhabha National Institute, Mumbai, India, GB-SELECTTata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, IndiaTaussig Cancer Institute, Cleveland Clinic, Cleveland, USA, IMmotion151TAX 320 Non-Small-Cell Lung Cancer Study Group, USATaxotere EXperience with Anthracyclines Study; TEXAS StudieTexas Children’s Cancer and Hematology Centers, Baylor College of Medicine, Houston, TXTexas Oncology-Tyler, US Oncology Research, Tyler, USA, LYRA studyTh3resa Studiengruppe, TH3RESA StudieThe AGO Breast and the German Breast Group GAIN-2 StudienprotokollThe AIO colorectal study groupThe ASPIRE Investigators, ASPIRE StudieThe AVEX Study Investigators; AVEX-StudieThe Brain Tumor Center, Duke University, Durham, USAThe British Columbia Cancer AgencyThe Center for Cancer Care and Research, St. Louis, USAThe Central European Cooperative Oncology Group, TURANDOT StudieThe Christie NHS Foundation Trust, Manchester, United KingdomThe Christie NHS Foundation Trust, Wilmslow Rd, Manchester, United KingdomThe Christie NHS Foundation Trust/Institute of Cancer Sciences, University of Manchester, Manchester, UK, ABC-06 trialThe CLARINET Investigators, CLARINET StudieThe CORRECT Study Goup; CORRECT StudieThe Eastern Cooperative Oncology Group, Southwest Oncology Group, Cancer and Leukemia Group, Noth Central Cancer Treatment GroupThe First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR ChinaThe First Affiliated Hospital of Zhejiang University, Hangzhou, ChinaThe First Department of Internal Medicine, Showa University School of Medicine, Tokyo, JapanThe Fourth Trial (RADIANT-4) Study GroupThe Frontline Investigation of Revlimid and Dexamethasone versus Standard Thalidomide (FIRST) Trial Team, First StudieThe German Breast Group, Arbeitsgemeinschaft Gynäkologische Onkologie Breast Group InvestigatorsThe German Chronic Lymphocytic Leukaemia Study Group (GCLLSG)The German Chronic Lymphocytic Leukaemia Study Group (GCLLSG), and international investigatorsThe German CUP Study GroupThe German Rectal Cancer Study Group, CAO/ARO/AIO-94 StudieThe Greek Oncology Cooperative Group for Lung CancerThe Gruppo Oncologico Nord Ovest (GONO)The Gynecologic Oncology GroupThe Gynecologic Oncology Group; GOG-0218 StudieThe ICON7 Investigators, ICON7 StudieThe International Adjuvant Lung Cancer Trial Collaborative GroupThe Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials GroupThe Jikei University School of Medicine, Tokyo, Japan, JGOG3017/GCIG TrialThe Johns Hopkins Oncology Center, Baltimore, MDThe Johns Hopkins University, Baltimore, PROSELICAThe LYM-3002 InvestigatorsThe Medical Research Council Clinical Trials UnitThe Memorial Sloan-Kettering ExperienceThe MM-015 InvestigatorsThe Myocet Study GroupThe National Adjuvant Breast and Bowel Project, Pittsburgh, USAThe National Cancer Institute, Bethesda, USAThe Netherlands Cancer Institute and Leiden University Medical Center, Amsterdam, Netherlands, CheckMate 743 trialThe Nordic Society of Gynecological Oncology (NSGO) and Rigshospitalet, Copenhagen, Denmark, ENGOT-OV24 / AVANOVA1The Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center, Ohio, KEYNOTE-158The Ottawa Hospital Cancer Centre, University of Ottawa, Canada, AURA2The PROMID Study Group, PROMID StudieThe REGAL Study Invetigators, REGAL StudieThe Royal Marsden Hospital, London and Surrey, United KingdomThe Royal Marsden Hospital, London and Surrey, United Kingdom; BOND StudiThe Royal Marsden Hospital, London and Surrey, United Kingdom; BOND StudieThe Royal Marsden Hospital and Institute of Cancer Research, Surrey, United KingdomThe Royal Marsden National Health Service (NHS) Trust, Sutton, United KingdomThe Royal Marsden NHS Foundation Trust, London, United Kingdom, ALTERNATIVE trialThe Royal Marsden NHS Foundation Trust, London and Surrey, UKThe Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of ChinaThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA, ENDEVOL regimenThe Swedish Lung Cancer Study GroupThe TAX 306 Study Groupthe TAX 326 Study GroupThe TAX 326 Study GroupThe Texas Ocology Professional Association, Dallas Texas, USAThe Third Trial (RADIANT-3) Study GroupThe Trabectedin Global Sarcoma Study GroupThe Trophoblastic Tumour Screenig and Treatment CenterThe University of Arkansas for Medical Sciences, Little RockThe University of Melbourne, Melbourne, Australia, The PARAGON trial – ANZGOG 0903The University of Texas, MD Anderson Cancer Center, Houston, Texas, USAThe University of Texas, MD Anderson Cancer Center, Houston, USA, NCI9673The University of Texas Health Science Center at San Antonio, USAThe University of Texas M. D. Anderson Cancer Center, HoustonThe University of Texas M. D. Anderson Cancer Center, Houston, TXThe University of Texas MD Anderson Cancer Center, ARIEL3 StudieThe University of Texas MD Anderson Cancer Center, Houston, ROAR basket studyThe University of Texas MD Anderson Cancer Center, Houston, TexasThe University of Texas MD Anderson Cancer Center, Houston, Texas, USA, ACE-LY-003The University of Texas MD Anderson Cancer Center, Houston, TXThe University of Texas MD Anderson Cancer Center, Houston, TX, BELA trialThe University of Texas MD Anderson Cancer Center, Houston, TX, USA, CheckMate 142 trialThe University of Texas MD Anderson Cancer Center, Houston, USAThe University of Texas MD Anderson Cancer Center, Houston, USA, ARROW trialThe University of Texas MD Anderson Cancer Center, Houston, USA, GOG 281/LOGS trialThe University of Texas MD Anderson Cancer Center, Houston, USA, Natalie TrialThe University of Texas MD Anderson Cancer Center, Texas, USA, innovaTV 201 studyThe University of Washington, USA, DAWN studyThe VISTA Trial InvestigatorsThe West Clinic, Memphis, USAThe Xeloda in Adjuvant Colon Cancer Therapy Trial investigators, X-ACT StudieThoracic Oncology Division, Shizuoka Cancer Center Hospital, Shizuoka, JapanThoracic Oncology Program, Swedish Cancer Institute, Seattle, USA, IMpower130Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, CheckMate 227 TrialThoracic Oncology Unit, IFCT, Respiratory Disease Department, Larrey Hospital, CHU, Toulouse, AcSé trialTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, USA, STORM trialTisch Cancer Institute, Mount Sinai School of Medicine, New YorkTisch Cancer Institute, Mount Sinai School of Medicine, New York, NYTochigi Cancer Center, Utsunomiya, Tochigi, JapanTongji University School of Medicine, Shanghai, People's Republic of China, RATIONALE 304Tor Vergata University, EORTC-GIMEMA AML-19 TrialTranslational Genomics Research Institute, Phoenix, USATranslational Research in Oncology-US Network, Los Angeles, USA ; REVEL StudieTriple-B Study, The Netherlands Cancer Institute, ClinicalTrials.gov Identifier: NCT01898117Trousseau Hospital, Paris, FranceU.S. Oncology, Inc, Houston, TXUC Davis Cancer Center, Sacramento, USAUCLA Medical Center, Santa Monica, CA, MONALEESA-3Ulm University Hospital, Germany, AMLSG 30-18Unicancer-GI/Prodige Group und CCTG, Institute de Cancerologie de Lorraine, NancyUniversidad Complutense and Ciberonc, Madrid, Spain, CASPIAN trialUniversita Degli Studi Della Campania Luigi Vanvitelli, Napoli, Italy, VELO trialUniversita degli Studi di Milano and Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy, DESTINY-CRC01Universitair Ziekenhuis Antwerpen, Edegem, BelgiumUniversitair Ziekenhuis Brussel, Brussels, Belgium, BlaZIB study Universitair Ziekenhuis Gent, Gent, BelgienUniversitaria Pisana and Università di Pisa, Pisa, Italien; TRIBE StudieUniversitat Autonoma de Barcelona, Barcelona, Spain, TAU-TEM studyUniversita Vita-Salute San Raffaele, Milano, ItalyUniversite de Paris, Saint-Louis Hospital, Paris, France, APPOINT-PNH trialUniversite Lille, Centre Hospitalier Universitaire, Lille, France, RELEVANCE trialUniversite Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associees, Lille, France, GALEN trialUniversite Paris-Est Creteil, France, the RAIHA studyUniversite Paris-Saclay, Villejuif, France, KEYNOTE-158Universite Paris-Sud, Universite Paris-Saclay, Villejuif, France, BLC2001 Study GroupUniversite Paris Cite, INSERM U976 HIPI, Paris, FranceUniversite Paris Descartes, Hopitaux Universitaires Paris Centre, AURELIAUniversites Paris, Paris, France, LOC network studyUniversity Central Hospital, Helsinki, FinlandUniversity Childrens Hospital Department of Pediatric Oncology and Hematology, MünsterUniversity Children’s Hospital Department of Pediatric Oncology and Hematology, MünsterUniversity College London Cancer Institute, London, UK, ABC-02University College London Medical School, London, United KingdomUniversity Federico II, Napoli, ItalyUniversity Hospital, Amiens, France, Intergroupe Francophone du Myélome.University Hospital, Amiens, France; Intergroupe Francophone du Myélome.University Hospital, Dresden, GermanyUniversity Hospital, Frankfurt, GermanyUniversity Hospital, Ludwig Maximilian University Munich, GALLIUM trialUniversity hospital, Nantes, FranceUniversity Hospital, Nantes, France, IFM2013-04 trialUniversity Hospital, Nantes, France, IKEMA trialUniversity Hospital, Udine, ItalyUniversity Hospital Berne and University of Berne, Berne, SwitzerlandUniversity Hospital Birmingham, Birmingham, United KingdomUniversity Hospital Cologne, Cologne, Germany, GEOMETRY mono-1 trialUniversity Hospital Cologne, DCLLSG-Studiengruppe, CLL-2-BAGUniversity Hospital Cologne and University Hospital Münster, GermanyUniversity Hospital Essen, Essen, Germany, IMMUNED trialUniversity Hospital Essen, Essen, Germany, NEOAD trialUniversity Hospital Hôtel-Dieu, Nantes, France, CASSIOPEIAUniversity Hospital Hôtel Dieu, Nantes, TOURMALINE-MM1 Study GroupUniversity Hospital Leuven and KU Leuven, Leuven, Belgium, ANCHOR CRC trialUniversity Hospital Mannheim, Heidelberg University, Mannheim, GermanyUniversity Hospital of Salamanca, Salamanca, SpainUniversity Hospital Pavia and University of Pavia, ItalyUniversity Hospitals Charite, Berlin, German Cancer Society 95-06 trialUniversity Hospitals Leuven, Catholic University Leuven, BelgiumUniversity Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium, EORTC trial 90101 CREATEUniversity Hospitals Leuven and KU Leuven, Leuven, Belgium, TASCO1University Hospital Zürich Skin Cancer Center, COLUMBUS trialUniversity Medical Center Freiburg, Freiburg, Germany, REACH2 TrialUniversity Medical Center Freiburg, Freiburg, Germany, REACH3 TrialUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany, GMMG-CONCEPT trialUniversity Medical Centre Mannheim, Mannheim, GermanyUniversity of Alberta and Cross Cancer Institute, Edmonton, Alberta, CanadaUniversity of Athens School of Medicine, Athens, GreeceUniversity of Birmingham, Birmingham, United KingdomUniversity of Birmingham, School of Cancer Sciences, UKUniversity of Bologna, Bologna, ItalyUniversity of Bordeaux, Bordeaux, France, CABONE trialUniversity of British Columbia, CancerdVancouver Center, Vancouver, Canada, MAGNITUDE trialUniversity of California, Irvine, CA, EMPOWER- Cervical 1/GOG-3016/ENGOT-cx9University of California, Los Angeles, USA, KEYNOTE-002University of California, San Diego, Rebecca and John Moores Cancer Center, La Jolla, NRG-GY018 trialUniversity of California, San Diego Moores Cancer Center, AMC-063 trialUniversity of California, San Francisco, San Francisco, HORIZON Pivotal Fracture TrialUniversity of California, San Francisco Benioff Children's Hospital Oakland, Oakland, USAUniversity of California at Irvine and UCI Medical Center, Orange, CA, USAUniversity of California Irvine Medical CenterUniversity of California Los Angeles, Los Angeles, CA, USA, NAPOLI 3University of California Los Angeles, Los Angeles, CA, USA, PALOMA-1/TRIO-18University of California San Francisco Helen Diller Family Comprehensive Cancer Center, SOPHIA TrialUniversity of Chicago Cancer Research CenterUniversity of Chicago Medical Center, Chicago, IllinoisUniversity of Colorado Cancer Center, Anschutz Cancer Pavilion, ALTA-1LUniversity of Florida, Division of Hematology and Oncology, Gainsville, Florida, NSABPUniversity of Freiburg Medical Center, Freiburg, GermanyUniversity of Heidelberg, Heidelberg, GermanyUniversity of Hong Kong, China, CheckMate 040University of Kansas Medical Center, Westwood, KansasUniversity of Leeds, United Kingdom, GO2 trialUniversity of Lille, Centre Hospitalier Universitaire (CHU) LilleUniversity of Liverpool, Liverpool, UK, SADAL trialUniversity of Manchester, Manchester, UK, POUT trialUniversity of Manchester, Manchester, United Kingdom, PROpel trialUniversity of Maryland Cancer CenterUniversity of Miami Miller School of Medicine, Miami, FL, USAUniversity of Michigan, Ann Arbor, MichiganUniversity of Michigan, Ann Arbor, USAUniversity of Michigan Comprehensive Cancer Center, Ann Arbor, USAUniversity of Michigan Rogel Cancer Center, Ann Arbor, USAUniversity of Milan-Bicocca, European Institute of Oncology IRCCS, Italy, KEYNOTE-826 trialUniversity of Milan–Bicocca and European Institute of Oncology IRCCS, MilanUniversity of Mississippi School of Medicine, JacksonUniversity of Munich, Klinikum Muenchen-Grosshadern, AIO KRK-0104 trialUniversity of Newcastle, Newcastle, United Kingdom, IRIS InvestigatorsUniversity of North Carolina at Chapel Hill, Chapel Hill, USA, SUSTAIN trialUniversity of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, USA, CALGB 49907 TrialUniversity of North Carolina School of Medicine, Chapel Hill, A5264/AMC-067 trialUniversity of North Carolina School of Medicine, Chapel Hill, USA, CALGB 9781University of Oulu, Oulu, FinlandUniversity of Paris Sud, Villejuif, France, LATITUDE StudieUniversity of Pennsylvenia, PhiladelphiaUniversity of Pennsylvenia, Philadelphia, Keynote-40University of Pisa, Milan, Italy, EXAMUniversity of Pisa and Azienda Ospedaliera Universitaria Pisana, Pisa, ItalyUniversity of Rochester Cancer Center, New York, Eastern Cooperative Oncology Group StudyUniversity of Siena and Center for Immuno-Oncology, Department of Oncology, University Hospital, Siena, Italy, KEYNOTE-158 studyUniversity of Tennessee, Knoxville, TN, Checkmate 205University of Texas, Anderson Cancer Center, Houston, USAUniversity of Texas, M.D. Anderson Cancer Center, Houston, USA, CodeBreaK100 trialUniversity of Texas, M.D. Anderson Cancer Center, Houston, USA, CodeBreaK 100 trialUniversity of Texas, M.D. Anderson Cancer Center, Houston, USA, MK-6482-004 trialUniversity of Texas, MD Anderson Cancer Center, Houston, INO-VATEUniversity of Texas, MD Anderson Cancer Center, Houston, USAUniversity of Texas, MD Anderson Cancer Center, Houston, USA, SWOG S1406University of Texas M.D. Anderson Cancer CenterUniversity of Texas M.D. Anderson Cancer Center, Department of Leukemia, HoustonUniversity of Texas M.D. Anderson Cancer Center, HoustonUniversity of Texas M.D. Anderson Cancer Center, Houston University of Texas M.D. Anderson Cancer Center, Houston, AEGEAN trialUniversity of Texas M.D. Anderson Cancer Center, Houston, CheckMate 77TUniversity of Texas M.D. Anderson Cancer Center, Houston, CheckMate 204University of Texas M.D. Anderson Cancer Center, Houston, DASISION trialUniversity of Texas M.D. Anderson Cancer Center, Houston, MONALEESA-7University of Texas M.D. Anderson Cancer Center, Houston, SHINE investigatorsUniversity of Texas M. D. Anderson Cancer Center, Houston, TXUniversity of Texas M.D. Anderson Cancer Center, Houston, USAUniversity of Texas MD Anderson Cancer Center, Houston, COG StudieUniversity of Texas MD Anderson Cancer Center, Houston, USAUniversity of Texas MD Anderson Cancer Center, Houston, USA, MyPathway trialUniversity of Texas MD Anderson Cancer Center, USA, FRESCO-2 trialUniversity of Texas Southwestern Medical Center, Dallas, USA, NRG Oncology, GOG0209University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino, Italy, UNITO-EMN10 trialUniversity of Torino, Azienda Ospedaliero Universitaria Citta della Salute e della Scienza, Torino, Italy, EMN09 trialUniversity of Toronto, CanadaUniversity of Toronto Autologous Bone Marrow Transplant Program, Toronto Hospital, CanadaUniversity of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy, ENESTnd InvestigatorsUniversity of Ulsan College of Medicine, Seoul, KoreaUniversity of Ulsan College of Medicine, Seoul, Republic of Korea, RENOBATE trialUniversity of Utah Health Science Center, Salt Lake City, Utah, A Southwest Oncology GroupUniversity of Washington, Seattle, USAUniversity of Washington/Fred Hutchinson Cancer Research Center, Seattle, WAUniversity of Washington Medical Center University of Würzburg, Würzburg, GermanyUniversity Paris-Sud, Orsay, FranceUniversitätsklinikum des Saarlandes, Homburg, SMARTE-R-CHOP-14 Trial, DSHNHLUniversitätsklinikum Hamburg -Eppendorf, Deutschland; OPUS StudieUniversitätsklinikum Münster, NHL-BFM und NOPHO study groupsUniversitätsklinikum Ulm, Ulm, GermanyUniversitätsklinikum Würzburg, Medizinische Klinik I, FIRM-ACT Study GroupUniversitätsmedizin Mannheim, Universität Heidelberg, Mannheim, GermanyUniversité Libre de Bruxelles, Institut Jules Bordet, Brussels, BelgiumUniversité Libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium, MF 4265 Study GroupUniversité Lille, Centre Hospitalier Universitaire, Lille, France, RELEVANCE trialUPMC Univ Paris VI, Hopital Tenon, Paris, FranceUrologic Clinic 2nd, S. Giuseppe Hospital, Milan University, Milan, ItalyUSC Norris Comprehensive Cancer Center, Los Angeles, CA, CheckMate 142 trialUS Oncology Research, Inc., Houston, Texas, USAUS Oncology Research, Texas Oncology, Dallas, USAVall d'Hebron Barcelona Hospital Campus, Barcelona, Spain, BEATcc trialVall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain, IMpower010Vall d'Hebron University Hospital, BarcelonaVall d'Hebron University Hospital, Barcelona, SpainVall d´Hebron University Hospital, Barcelona, Spanien, RAISE studyVall d’Hebron, University Hospital, Barcelona; Hospital Arnau de Vilanova, Lleida, SpainVall d’Hebron University Hospital, BarcelonaVall d’Hebron University Hospital, Barcelona, BEACON TrialVall d’Hebron University Hospital and University Hospital del Mar, BarcelonaVancouver Prostate Centre, Vancouver, Canada, TITANVanderbilt University, Nashville, Eastern Cooperative Oncology Group (ECOG), USAVanderbilt University Medical Center, Nashville, IMpower133VHIO, Barcelona, Spain, TALENT Trial (GETNE1509)Vincenzo Pansadoro Foundatoin, Rome, ItalienWales Cancer Trials Unit, College of Biomedical and Life Sciences, Cardiff University, United Kingdom, Scalop trialWashington University, St. Louis, Missouri, ZEBRA trialWashington University School of Medicine, St Louis, MO, USA, NAPOLI-1Washington University School of Medicine, USAWeill-Cornell Medical College of Cornell University, New York, NY, USAWeill Cornell Medical College, New York, USAWeill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA Weill Cornell Medical College New YorkWeill Cornell Medicine, New York, NY, TROPHY-U-01Weill Cornell Medicine, New York, USAWest Clinic Memphis, Texas, PEAK StudieWestdeutsches Tumorzentrum EssenWest German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, German, CADENZA trialWest German Study Group, Moenchengladbach, Deutschland, WSG-ADAPT-TNWest German Study Group, Mönchengladbach, Germany, The Neoadjuvant WSG-TP-II Randomized Clinical TrialWest Japan Thoracic Oncology Group 9902Westmead Hospital, Westmead, AustraliaWillamette Valley Cancer Institute/US Oncology, Eugene, USA, ELEVATE TNWilmot Cancer Institute, University of Rochester, Rochester, NY, USAWinship Cancer Institute, Emory University School of Medicine, Atlanta, GeorgiaWinship Cancer Institute of Emory University, Atlanta, Georgia, USAWJ Tester, Alber Einstein Cancer Center, Philadelphia, USAW Schuette, Martha-Maria Stadtkrankenhaus Halle-Doelau, DeutschlandW Schütte, Städtisches Krankenhaus Martha-Maria Halle-Dölau, Universität Halle-WittenbergYale Cancer Center, Yale School of Medicine, KEYNOTE-059Yale School of Medicine, New Haven, CT Weill Cornell Medical Center, New YorkYale School of Medicine, Yale Cancer Center, and Smilow Cancer Hospital, New Haven, KEYNOTE-010Yale School of Medicine and Yale Cancer Center, New Haven, CT, USA, Keynote-48Yonsei Cancer Center, Yonsei University College of Medicine, SeoulYonsei Cancer Center, Yonsei University College of Medicine, Seoul, KEYNOTE 158Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, KEYNOTE-859 trialZentralkrankenhaus Gauting, Abteilung Onkologie, DeutschlandZhejiang University, Hangzhou, ChinaProtocols in Revision 2610 protocols foundProtocols under revision.Abemaciclib 150 / Anastrozole 1, Breast Cancer (PID567)Abemaciclib 150 / Anastrozole 1, Breast Cancer, adjuvant (PID1785)Abemaciclib 150 / Fulvestrant 500, Breast Cancer, Cycle 1 (PID1408)Abemaciclib 150 / Fulvestrant 500, Breast Cancer, Cycle 2+ (PID1409)Abemaciclib 150 / Letrozole 2.5, Breast Cancer (PID566)Abemaciclib 150 / Letrozole 2.5, Breast Cancer, Adjuvant (PID1786)Abiraterone 1000 / Dexamethasone 0.5, Prostate Cancer Castration Resistant (PID2311)Abiraterone 1000 / Prednisolone 5 / Goserelin 10.8, Prostate Cancer, First Line (PID1002)Abiraterone 1000 / Prednisolone 5, Prostate Cancer Hormone Sensitive (PID1504)Abiraterone 1000 / Prednisolone 5, Prostate Cancer, First Line (PID919)Abiraterone 1000 / Prednisolone 5, Prostate Cancer, Second Line (PID920)ABVD - Doxorubicin 25 / Bleomycin 10 / Vinblastine 6 / Dacarbazine 375, Hodgkin Lymphoma (PID472)Acalabrutinib 100 / Obinutuzumab (100/900/1000), Chronic Lymphocytic Leukemia, Cycle 2 (PID1655)Acalabrutinib 100 / Obinutuzumab (100/900/1000), Chronic Lymphocytic Leukemia, Cycle 2, Variant 1. (PID2283)Acalabrutinib 100 / Obinutuzumab 1000 / Venetoclax (20/50/100/200/400), Chronic Lymphocytic Leukemia, Cycle 4. (PID2285)Acalabrutinib 100 / Obinutuzumab 1000 / Venetoclax 400, Chronic Lymphocytic Leukemia, cycle 5-7. (PID2286)Acalabrutinib 100 / Obinutuzumab 1000, Chronic Lymphocytic Leukemia, Cycle 3, Variant 1 (PID2284)Acalabrutinib 100 / Obinutuzumab 1000, Chronic Lymphocytic Leukemia, Cycle 3-7 (PID1656)Acalabrutinib 100 / Venetoclax 400, Chronic Lymphocytic Leukemia, Cycle 8+ (PID2287)Acalabrutinib 100, Chronic Lymphocytic Leukemia (PID1653)Acalabrutinib 100, Chronic Lymphocytic Leukemia, second line (PID1657)Acalabrutinib 100, Chronic Lymphocytic Leukemia, Cycle 1 (PID1654)Acalabrutinib 100, Chronic Lymphocytic Leukemia, Cycle 1, Variant 1 (PID2282)Acalabrutinib 100, Marginal Zone Lymphoma (PID2402)ACO II - Doxorubicin 60 / Cyclophosphamide 750 / Vincristine 1.5, Small Cell Lung Carcinoma (PID218)Adagrasib 600 / Cetuximab 250, Colorectal Carcinoma, Cycle 2+ (PID2549)Adagrasib 600 / Cetuximab 400, Colorectal Carcinoma, Cycle 1 (PID2548)Adagrasib 600 / Cetuximab 500, Colorectal Carcinoma, Variant 1, Cycle 2+ (PID2602)Adagrasib 600, Non-Small Cell Lung Cancer (PID2547)Adagrasib 600, Tumor Biomarker Defined (PID2668)ADOC - Cisplatin 50 / Doxorubicin 40 / Vincristine 0.6 / Cyclophosphamide 700, Thymoma (PID369)Afatinib 40, Non-Small Cell Lung Cancer (Squamous) (PID735)Afatinib 40, Non-Small Cell Lung Carcinoma, Adeno- (PID197)AIO (Folinic Acid 500 / Fluorouracil 2000) / Irinotecan 80, Colorectal Carcinoma (PID467)AIO (Folinic Acid 500 / Fluorouracil 2600) / Bevacizumab 5, Colorectal Carcinoma (PID468)AIO (Folinic Acid 500 / Fluorouracil 2600), Colorectal Carcinoma (PID39)AIO - Folinic Acid 500 / Fluorouracil 1500 / Irinotecan 80 / Cetuximab (400/250), Colorectal Carcinoma, Cycle 1 (PID485)AIO - Folinic Acid 500 / Fluorouracil 1500 / Irinotecan 80 / Cetuximab 250, Colorectal Carcinoma, Cycle 2+ (PID486)Alectinib 300, diffuse large B-non-Hodgkin Lymphoma (PID2404)Alectinib 600, Non-Small Cell Lung Cancer (ALK+), First-Line (PID975)Alectinib 600, Non-Small Cell Lung Cancer (ALK+), Second Line (PID888)Alemtuzumab (3/10/30), T-Cell Prolymphocyte Leukemia, Cycle 1 (PID1548)Alemtuzumab 3/10/30, Chronic Lymphocytic Leukemia (PID333)Alemtuzumab 30, Chronic Lymphocytic Leukemia (PID334)Alemtuzumab 30, T-prolymphocytic leukemia, cycle 2+ (PID1549)Alpelisib 300 / Fulvestrant 500, Breast Cancer, Cycle 1 (PID1620)Alpelisib 300 / Fulvestrant 500, Breast Cancer, Cycle 2+ (PID1621)Amivantamab (350/1050/1400), Non-Small Cell Lung Cancer, cycle 1 (PID1912)Amivantamab (350/700/1050), Non-Small Cell Lung Cancer, Cycle 1 (PID1908)Amivantamab 1050, Non-Small Cell Lung Cancer, cycle 2+ (PID1909)Amivantamab 1400, Non-Small Cell Lung Cancer, cycle 2+ (PID1913)Anagrelide 0.5, Essential Thrombocythemia (PID1218)Anakinra 1, Macrophage activation syndrome in Hemophagocytic Lymphohistiocytosis (PID649)Anastrozole 1 / Fulvestrant 500, Breast Cancer (PID1248)Anastrozole 1 / Breast Cancer (PID1233)Anastrozole 1, Endometrial Cancer (PID2199)Anastrozole 1, Breast Carcinoma, adjuvant (PID1581)Anti-thymocyte Globulin (Equine) 15 / Ciclosporin 5, Myelodysplastic Syndrome. (PID1766)Anti-thymocyte globulin (Equine) 40 / Ciclosporin 5 / Eltrombopag 150, Severe Aplastic Anemia (PID1779)Anti-thymocyte Globulin (Equine) 40 / Ciclosporin 5, Severe Aplastic Anemia (PID908)Apalutamide 240, Prostate Cancer hormone sensitive (PID1503)Apalutamide 240, Prostate Cancer Castration Resistant (PID1232)APL2006 V4.1 - A1 - Idarubicin 12 / Cytarabine 200, 1st consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes up to 10000/µl (PID1042)APL2006 V4.1 - A1 - Idarubicin 9 / Cytarabine 1000, 2nd consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes up to 10000/µl (PID1043)APL2006 V4.1 - A1, A2 and A3, Tretinoin 45 / Idarubicin 12 / Cytarabine 200, induction, Acute Promyelocytic Leukemia, up to 70 years, leukocytes up to 10000/µl (PID1035)APL2006 V4.1 - A1, A2, A3, C1, and C2 - Mercaptopurine 90 / Methotrexate 15 / Tretinoin 45, maintenance, Acute Promyelocytic Leukemia, up to 70 years of age (PID1053)APL2006 V4.1 - A2 - Idarubicin 12 / Arsenic Trioxide 0.15, 1st consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes up to 10000/µl (PID1044)APL2006 V4.1 - A2 - Idarubicin 9 / Arsenic Trioxide 0.15, 2nd consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes up to 10000/µl (PID1045)APL2006 V4.1 - A3 - Tretinoin 45 / Idarubicin 12, 1st consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes up to 10000/µl (PID1046)APL2006 V4.1 - A3 - Tretinoin 45 / Idarubicin 12, 2nd consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes up to 10000/µl (PID1047)APL2006 V4.1 - B - Idarubicin 9 / Arsenic Trioxide 0.15, 1st consolidation, Acute Promyelocytic Leukemia, older than 70 years, leukocytes up to 10000/µl (PID1055)APL2006 V4.1 - B - Tretinoin 45 / Arsenic Trioxide 0.15, 2nd consolidation, Acute Promyelocytic Leukemia, older than 70 years of age, leukocytes up to 10000/µl (PID1056)APL2006 V4.1 - B - Tretinoin 45 / Idarubicin 9, induction, Acute Promyelocytic Leukemia, older than 70 years, leukocytes up to 10000/µl (PID1054)APL2006 V4.1 - B and D, Arsenic Trioxide 0.15, maintenance, Acute Promyelocytic Leukemia, older than 70 years, cycle 2-5 (PID1058)APL2006 V4.1 - B and D, Mercaptopurine 90 / Methotrexate 150 / Tretinoin 45, maintenance, Acute Promyelocytic Leukemia, older than 70 years, cycle 1 (PID1057)APL2006 V4.1 - B and D, Mercaptopurine 90 / Methotrexate 150 / Tretinoin 45, maintenance, Acute Promyelocytic Leukemia, older than 70 years, cycle 6-8 (PID1062)APL2006 V4.1 - C1 - Idarubicin 12 / Cytarabine 200, 1st consolidation, Acute Promyelocytic Leukemia, up to 70, leukoc. over 10000/µl (PID1049)APL2006 V4.1 - C1 - Idarubicin 9 / Cytarabine 1000, 2nd consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes over 10000/µl (PID1050)APL2006 V4.1 - C1 and C2, Tretinoin 45 / Idarubicin 12 / Cytarabine 200, induction, Acute Promyelocytic Leukemia, up to 70 years, leukocytes over 10000/µl (PID1048)APL2006 V4.1 - C2 - Idarubicin 12 / Arsenic Trioxide 0.15, 1st consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes over 10000/µl (PID1051)APL2006 V4.1 - C2 - Idarubicin 9 / Arsenic Trioxide 0.15, 2nd consolidation, Acute Promyelocytic Leukemia, up to 70 years, leukocytes over 10000/µl (PID1052)APL2006 V4.1 - D - Idarubicin 9 / Arsenic Trioxide 0.15, 1st consolidation, Acute Promyelocytic Leukemia, over 70 years, leukocytes over 10000/µl (PID1060)APL2006 V4.1 - D - Tretinoin 45 / Arsenic Trioxide 0.15, 2nd consolidation, Acute Promyelocytic Leukemia, over 70 years, leukocytes over 10000/µl (PID1061)APL2006 V4.1 - D - Tretinoin 45 / Idarubicin 9 / Cytarabine 120, induction, Acute Promyelocytic Leukemia, over 70 years, leukocytes over 10000/µl (PID1059)Asciminib 40, Chronic Myeloid Leukemia (PID2144)Atezolimab 1200 / Carboplatin 5 / Etoposide 100, Small Cell Lung Cancer (PID1341)Atezolizumab 1200 / Bevacizumab 15, Hepatocellular Carcinoma (PID1537)Atezolizumab 1200 / Bevacizumab 15, Renal Cell Carcinoma (PID1604)Atezolizumab 1200 / Bevacizumab 15, peritoneal mesothelioma (PID1934)Atezolizumab 1200 / Bevazicumab 15 / Paclitaxel 175 / Carboplatin 5, Non-Small Cell Lung Cancer (PID2525)Atezolizumab 1200 / Bevazicumab 15 / Paclitaxel 175 / Carboplatin 5, Cervical Cancer (PID2657)Atezolizumab 1200 / Bevazicumab 15 / Paclitaxel 175 / Cisplatin 50, Cervical Cancer (PID2658)Atezolizumab 1200 / Bevazicumab 15 / Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer (PID1208)Atezolizumab 1200 / Bevazicumab 15, Maintenance, Non-Small Cell Lung Cancer (PID1209)Atezolizumab 1200 / Bevazicumab 15, Cervical Cancer, maintenance (PID2659)Atezolizumab 1200 / Cabozantinib 40, Renal Cell Carcinoma (PID1957)Atezolizumab 1200 / Carboplatin 6 / Nab-Paclitaxel 100 - Atezolizumab 1200 Maintenance, Non-Small Cell Lung Carcinoma (PID1272)Atezolizumab 1200 / Carboplatin 6 / Nab-Paclitaxel 100, Non-Small Cell Lung Cancer (PID1238)Atezolizumab 1200, Bladder Cancer, first line (PID1034)Atezolizumab 1200, Bladder Cancer, Second Line (PID1026)Atezolizumab 1200, Lung Carcinoma, Small Cell, Maintenance (PID1342)Atezolizumab 1200, Breast Cancer, adjuvant (PID2425)Atezolizumab 1200, Non-Small Cell Lung Cancer, adjuvant (PID2252)Atezolizumab 1200, Non-Small Cell Lung Cancer, First-Line (PID1690)Atezolizumab 1200, Non-Small Cell Lung Cancer, Second Line (PID886)Atezolizumab 1200, Soft Tissue Sarcoma (PID2455)Atezolizumab 1680, Bladder Cancer, First Line (PID1659)Atezolizumab 1680, Bladder Cancer, Second Line (PID1661)Atezolizumab 1680, Non-Small Cell Lung Cancer, Second Line (PID1663)Atezolizumab 840 / Doxorubicin 60 / Cyclophosphamide 600, Breast Cancer, neoadjuvant, cycle 4-5. (PID2424)Atezolizumab 840 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600) - ATEZ1200, Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, Cycle 9-17 (PID2564)Atezolizumab 840 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600), Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, Cycle 1-4,5-8 (PID2563)Atezolizumab 840 / Nab-Paclitaxel 100, Breast Cancer (PID63)Atezolizumab 840 / Nab-Paclitaxel 125, Breast Cancer, neoadjuvant, cycle 1-3. (PID2423)Atezolizumab 840 / Vemurafenib 720 / Cobimetinib 60, Malignant Melanoma, Cycle 2+ (PID2202)Atezolizumab 840, Bladder Cancer, First Line (PID1658)Atezolizumab 840, Bladder Cancer, Second Line (PID1660)Atezolizumab 840, Non-Small Cell Lung Cancer, Second Line (PID1662)Avapritinib 200, Systemic Mastocytosis (PID2071)Avapritinib 300, Gastrointestinal Stroma Tumor (PID1689)Avatrombopag 20, Immune Thrombocytopenia (PID1800)Avelumab 800 / Axitinib 5, Renal Cell Carcinoma (PID1353)Avelumab 800 / Ramucirumab 8 / Paclitaxel 80, Adenocarcinoma Esophagogastric Junction and Stomach (PID2565)Avelumab 800 / Talazoparib 1, Endometrial Cancer (PID2173)Avelumab 800, Gestational Trophoblastic Neoplasia (PID1612)Avelumab 800, Bladder Cancer (PID2179)Avelumab 800, Bladder Cancer, Maintenance (PID679)Avelumab 800, Colorectal Carcinoma (PID2412)Avelumab 800, Breast Cancer (PID66)Avelumab 800, Merkel Cell Carcinoma (PID1076) (PID2355)Axitinib 5, Renal Cell Carcinoma (PID737)Azacitidine 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation (PID2302)Azacitidine 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation, Variant 1. (PID2320)Azacitidine 300, Acute Myeloid Leukemia (PID1807)Azacitidine 75 / Gilteritinib 120, Acute Myeloid Leukemia (PID2430)Azacitidine 75 / Ivosidenib 500, Acute Myeloid Leukemia (PID2368)Azacitidine 75 / Lenalidomide 25, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation (PID827)Azacitidine 75, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation. (PID2327)Azacitidine 75, Acute Myeloid Leukemia, over 65 years of age (PID700)Azacitidine 75, Myelodysplastic Syndrome, High-Risk (PID616)Azacitidine 75, Myelodysplastic Syndrome, Low risk (PID2317)Azathioprine 2, Autoimmune Hemolytic Anemia, warm type (PID2008)BEACOPP Basis, Hodgkin Lymphoma (PID474)BEACOPP dosisescalated, Hodgkin Lymphoma (PID473)BEAM - Carmustine 300 / Etoposide 200 / Cytarabine 200 / Melphalan 140, prior to autologous Stem Cell Transplantation, Autologous (PID280)BeEAM - Bendamustine 100 / Etoposide 200 / Cytarabine 200 / Melphalan 140, prior to autologous Stem Cell Transplantation (PID879)Belantamab Mafodotin 2.5, Multiple Myeloma (PID714)Belzutifan 120, von Hippel-Lindau disease (PID1947)Bendamustine 100, Chronic Lymphocytic Leukemia (PID319)Bendamustine 120, Hodgkin Lymphoma (PID2395)Bendamustine 120, T-cell Lymphoma (PID1923)Bendamustine 120, T-Cell Prolymphocyte Leukemia (PID1561)Bendamustine 60 / Bortezomib 1.3 / Prednisolone 100, Multiple Myeloma (PID615)Bendamustine 70 / Bortezomib 1.3 / Dexamethasone 20, Multiple Myeloma (PID740)Bendamustine 75 / Lenalidomide 10 / Dexamethasone 40, Multiple Myeloma (PID2397)Bendamustine 90 / Bortezomib 1.3 / Prednisolone 60, Multiple Myeloma, Cycle 1 (PID1550)Bendamustine 90 / Bortezomib 1.3 / Prednisolone 60, Multiple Myeloma, Cycle 2-9 (PID1551)Bendamustine 90, diffuse large B-non-Hodgkin Lymphoma, Lymphodepletion (PID1830)BEP - Cisplatin 20 / Etoposide 100 / Bleomycin 30, Testicular Carcinoma, Good Prognosis. (PID771)BEP - Cisplatin 20 / Etoposide 100 / Bleomycin 30, Testicular Carcinoma, Intermediate-High Risk (PID777)BEP - Cisplatin 20 / Etoposide 100 / Bleomycin 30, Testicular Carcinoma, non-Seminoma, adjuvant (PID776)Bevacizumab 10 / Carboplatin 5 / Doxorubicin Pegylated Liposomal 30, Ovarian Ca. (PID2187)Bevacizumab 10 / Interferon Alpha-2a 9 M, Renal Cell Carcinoma (PID788)Bevacizumab 10 / Lomustine 90, Glioblastoma (PID2019)Bevacizumab 10, Glioblastoma (PID549)Bevacizumab 15 / Gemcitabine 1000 / Carboplatin 4, Ovarian ca (PID126)Bevacizumab 15 / Paclitaxel 175 / Carboplatin 5, Ovarian ca (PID1429)Bevacizumab 15 / Paclitaxel 175 / Carboplatin 5, Cervical Cancer (PID2605)Bevacizumab 15 / Paclitaxel 80 / Doxorubicin Liposomal 20 / Carboplatin 1.5, Breast Cancer, tripel-negative (PID754)Bevacizumab 15, Endometrial Cancer (PID896)Bevacizumab 15, Ovarian Carcinoma (PID495)Bevacizumab 15, Ovarian Carcinoma, maintenance. (PID1430)Bevacizumab 15, Soft Tissue Sarcoma (PID1826)Bevacizumab 15, Cervical Cancer, maintenance (PID2611)Bevacizumab 7.5 / Irinotecan 150 / Tegafur 40, Colorectal Carcinoma (PID1404)Bevacizumab 7.5 / Oxaliplatin 130 / Tegafur 40, Colorectal Carcinoma (PID2177)Bevacizumab 7.5, Ovarian Carcinoma (PID501)Bevacizumab 7.5, Radionecrosis (PID2138)Bleomycin 15, Non-Small Cell Lung Cancer (PID2375)Blinatumomab (9/28), Acute Lymphoblastic Leukaemia, Cycle 1 (PID107)Blinatumomab (9/28), ALL/NHL, cycle 1 (PID2117)Blinatumomab 15, Acute Lymphoblastic Leukaemia, MRD positive (PID1140)Blinatumomab 28, Acute Lymphoblastic Leukaemia, maintenance (PID313)Blinatumomab 28, Acute Lymphoblastic Leukaemia, Cycle 2-5 (PID68)Blinatumomab 28, ALL/NHL, cycle 2-4 (PID2118)Bortezomib 1.0 / Doxorubicin 9 / Dexamethasone 40, Multiple Myeloma (PID2428)Bortezomib 1.3 / Cyclophosphamide 300 / Dexamethasone 40, Multiple Myeloma, Cycle 2.4 (PID1964)Bortezomib 1.3 / Daratumumab (8/8/16) / Dexamethasone (20/20), Multiple Myeloma, Cycle 1 (PID1432)Bortezomib 1.3 / Daratumumab (8/8/16) / Lenalidomide 25 / Dexamethasone 20, Induction, Multiple Myeloma, Cycle 1 (PID1718)Bortezomib 1.3 / Daratumumab (8/8/16) / Melphalan 9 / Prednisolone 60, Multiple Myeloma, Cycle 1 (PID1433)Bortezomib 1.3 / Daratumumab (8/8/16) / Thalidomide 100 / Dexamethasone 40, Multiple Myeloma, Cycle 1 (PID1482)Bortezomib 1.3 / Daratumumab 16 / Dexamethasone (20/20) - Daratumumab 16 maintenance, Multiple Myeloma, Cycle 9+ (PID820)Bortezomib 1.3 / Daratumumab 16 / Dexamethasone (20/20), Multiple Myeloma, Cycle 1 (PID817)Bortezomib 1.3 / Daratumumab 16 / Dexamethasone (20/20), Multiple Myeloma, Cycle 2-3 (PID818)Bortezomib 1.3 / Daratumumab 16 / Dexamethasone (20/20), Multiple Myeloma, Cycle 4-8 (PID819)Bortezomib 1.3 / Daratumumab 16 / Lenalidomide 25 / Dexamethasone 20 - Daratumumab 16 / Lenalidomide 10, maintenance, Multiple Myeloma (PID1721)Bortezomib 1.3 / Daratumumab 16 / Lenalidomide 25 / Dexamethasone 20, Induction, Multiple Myeloma, Cycle 2-4 (PID1719)Bortezomib 1.3 / Daratumumab 16 / Lenalidomide 25 / Dexamethasone 20, consolidation, Multiple Myeloma, cycle 5-6 (PID1720)Bortezomib 1.3 / Daratumumab 16 / Melphalan 9 / Prednisolone 60 - Daratumumab 16 maintenance, Multiple Myeloma, Cycle 10+ (PID461)Bortezomib 1.3 / Daratumumab 16 / Melphalan 9 / Prednisolone 60, Multiple Myeloma, cycle 1 (PID588)Bortezomib 1.3 / Daratumumab 16 / Melphalan 9 / Prednisolone 60, Multiple Myeloma, Cycle 2-9 (PID651)Bortezomib 1.3 / Daratumumab 16 / Thalidomide 100 / Dexamethasone (40/20), Multiple Myeloma, Cycle 3-4 (PID1484)Bortezomib 1.3 / Daratumumab 16 / Thalidomide 100 / Dexamethasone 20, Multiple Myeloma, consolidation (PID1485)Bortezomib 1.3 / Daratumumab 16 / Thalidomide 100 / Dexamethasone 40, Multiple Myeloma, Cycle 2 (PID1483)Bortezomib 1.3 / Daratumumab 1800 / Lenalidomide 25 / Dexamethasone 20 - Daratumumab 1800 / Lenalidomide 10, maintenance, Multiple Myeloma (PID1725)Bortezomib 1.3 / Daratumumab 1800 / Dexamethasone (20/20) - Daratumumab 1800 Maintenance, Multiple Myeloma (PID1615)Bortezomib 1.3 / Daratumumab 1800 / Dexamethasone (20/20), Multiple Myeloma, Cycle 1-3 (PID1613)Bortezomib 1.3 / Daratumumab 1800 / Dexamethasone (20/20), Multiple Myeloma, Cycle 4-8 (PID1614)Bortezomib 1.3 / Daratumumab 1800 / Dexamethasone 20 / Thalidomide 100 - Daratumumab 1800 Maintenance, Multiple Myeloma (PID1635)Bortezomib 1.3 / Daratumumab 1800 / Lenalidomide 25 / Dexamethasone 20, consolidation, Multiple Myeloma, cycle 5-6 (PID1724)Bortezomib 1.3 / Daratumumab 1800 / Lenalidomide 25/ Dexamethasone 20, induction, Multiple Myeloma, cycle 1-4 (PID1723)Bortezomib 1.3 / Daratumumab 1800 / Melphalan 9 / Prednisolone 60 - Daratumumab 1800 Maintenance, Multiple Myeloma (PID1619)Bortezomib 1.3 / Daratumumab 1800 / Melphalan 9 / Prednisolone 60, Multiple Myeloma, Cycle 1 (PID1617)Bortezomib 1.3 / Daratumumab 1800 / Melphalan 9 / Prednisolone 60, Multiple Myeloma, Cycle 2-9 (PID1618)Bortezomib 1.3 / Daratumumab 1800 / Thalidomide 100 / Dexamethasone (40/20), Multiple Myeloma, Cycle 3-4 (PID1629)Bortezomib 1.3 / Daratumumab 1800 / Thalidomide 100 / Dexamethasone 20, Multiple Myeloma, consolidation (PID1630)Bortezomib 1.3 / Daratumumab 1800 / Thalidomide 100 / Dexamethasone 40, Multiple Myeloma, Cycle 1-2 (PID1628)Bortezomib 1.3 / Dexamethasone 40, Induction, Multiple Myeloma (PID1164)Bortezomib 1.3 / Isatuximab 10 / Lenalidomide 25 / Dexamethasone 20, multiple myeloma, induction, cycle 1 (PID2660)Bortezomib 1.3 / Isatuximab 10 / Lenalidomide 25 / Dexamethasone 20, multiple myeloma, induction, cycle 2-4 (PID2661)Bortezomib 1.3 / Lenalidomide 15 / Dexamethasone 40, Multiple Myeloma, consolidation (PID1965)Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 10, Consolidation without transplantation, Multiple Myeloma (PID1037)Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 10, Multiple Myeloma, Consolidation after Autologous Stem Cell Transplantation. (PID1040)Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20, Induction, Multiple Myeloma (PID1036)Bortezomib 1.3 / Melphalan 9 / Prednisolone 60, Multiple Myeloma, Cycle 1 (PID1003)Bortezomib 1.3 / Melphalan 9 / Prednisolone 60, Multiple Myeloma, Cycle 1-4 (PID533)Bortezomib 1.3 / Melphalan 9 / Prednisolone 60, Multiple Myeloma, Cycle 2-5 (PID1004)Bortezomib 1.3 / Melphalan 9 / Prednisolone 60, Multiple Myeloma, Cycle 5-9 (PID534)Bortezomib 1.3 / Panobinostat 20 / Dexamethasone 20, Multiple Myeloma, Cycle 1-8 (PID611)Bortezomib 1.3 / Panobinostat 20 / Dexamethasone 20, Multiple Myeloma, Cycle 9-16 (PID612)Bortezomib 1.3 / Doxorubicin Pegylated Liposomal 30 / Dexamethasone 40, Multiple Myeloma, Cycle 1.3 (PID1963)Bortezomib 1,3 / pegylated liposomal Doxorubicin 30, Multiple Myeloma (PID1589)Bortezomib 1.3 / Pomalidomide 4 / Dexamethasone 20 , Multiple Myeloma, Cycle 9+ (PID1592)Bortezomib 1.3 / Pomalidomide 4 / Dexamethasone 20, Multiple Myeloma, Cycle 1-8 (PID1591)Bortezomib 1.3 / Prednisolone 60, maintenance, Multiple Myeloma (PID1005)Bortezomib 1.3 / Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100, Mantle Cell Lymphoma (PID527)Bortezomib 1.3 / Thalidomide 100 / Dexamethasone 40, Multiple Myeloma (PID2427)Bortezomib 1,3 s.c., Mantle Cell Lymphoma (PID277)Bortezomib 1,3, AL Amyloidosis (PID1510)Bortezomib 1,3, Autoimmune Hemolytic Anemia, Cold Agglutinin Disease (PID2023)Bortezomib 1.3, Cutaneous T-cell Lymphoma (PID2459)Bortezomib 1,3, Waldenström's disease, cycle 1 (PID2343)Bortezomib 1,3, TEMPI syndrome (PID2182)Bortezomib 1.5 / Cyclophosphamide 300 / Dexamethasone 40, Multiple Myeloma, cycle 3-4 (PID1853)Bortezomib 1.6 / Rituximab 375 - Bortezomib 1.6 Waldenström's disease, cycle 2+3+5+6 (PID1266)Bortezomib 1.6 / Rituximab 375 / Dexamethasone 40, Waldenström's disease, cycle 2,5 (PID2342)Bortezomib 1.6 / Rituximab 375, Waldenström's disease, cycle 1+4 (PID1235)Bortezomib 1.6, AL Amyloidosis (PID1509)Bortezomib 1.6, Kaposi's Sarcoma (PID2028)Bortezomib 1.6, Waldenström's disease, cycle 3-4 (PID2344)Bosutinib 500, Chronic Myeloid Leukemia (PID946)Brentuximab Vedotin 1.8 / Bendamustine 90, Hodgkin Lymphoma (PID2363)Brentuximab Vedotin 1.8 / Cyclophosphamide 1250 / Doxorubicin 40 / Etoposide 150 / Dacarbazine 250 / Dexamethasone 40, Hodgkin Lymphoma (PID962)Brentuximab Vedotin 1.8 / Dacarbazine 375 - Brentuximab Vedotin 1.8, Hodgkin Lymphoma, Cycle 13-16 (PID2365)Brentuximab Vedotin 1.8 / Dacarbazine 375, Hodgkin Lymphoma, Cycle 1-12 (PID2364)Brentuximab Vedotin 1.8 / Nivolumab 240, Non-Hodgkin Lymphoma, Cycle 1 (PID1516)Brentuximab Vedotin 1.8 / Nivolumab 240, Non-Hodgkin Lymphoma, Cycle 2+ (PID1515)Brentuximab Vedotin 1.8 / Nivolumab 3, Hodgkin Lymphoma (PID90)Brentuximab Vedotin 1.8 / Nivolumab 3, Hodgkin Lymphoma, cycle 1 (PID1903)Brentuximab Vedotin 1.8 / Nivolumab 3, Hodgkin Lymphoma, cycle 2-4 (PID1904)Brentuximab Vedotin 1.8, maintenance, Hodgkin Lymphoma (PID849)Brentuximab Vedotin 1.8, Hodgkin Lymphoma (PID475)Brentuximab Vedotin 1.8, cutaneous T-cell lymphoma (PID1389)Brentuximab Vedotin 1.8, T-cell Lymphoma (PID1925)Brigatinib 180, Non-Small Cell Lung Cancer, First-Line, Cycle 2+ (PID49)Brigatinib 180, Non-Small Cell Lung Cancer, Second Line, Cycle 2+ (PID55)Brigatinib 90/180, Non-Small Cell Lung Cancer, First-Line, Cycle 1 (PID48)Brigatinib 90/180, Non-Small Cell Lung Cancer, Second Line, Cycle 1 (PID54)Burosumab 0.3, Osteomalacia, tumor-induced (PID2057)Buserelin 9.45, Prostate Cancer (PID1523)Busulfan 0.8 / Melphalan 140, Ewing Sarcoma, Autologous Stem Cell Transplantation (PID571)Busulfan 1 / Melphalan 140, Ewing Sarcoma, Autologous Stem Cell Transplantation (PID76)Busulfan 2, Polycythaemia Vera (PID2299)BV-ICE - Brentuximab Vedotin 1.5 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, Hodgkin Lymphoma (PID1902)BV-ICE - Brentuximab Vedotin 1.8 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, T-cell Lymphoma (PID2420)Cabazitaxel 20 / Prednisolone 10, Prostate Cancer, First Line (PID1129)Cabazitaxel 20 / Prednisolone 10, Prostate Cancer, Second Line (PID1134)Cabazitaxel 25 / Carboplatin 4 / Prednisolone 5 Prostate Cancer (PID2310)Cabazitaxel 25 / Prednisolone 10, Prostate Cancer, First Line (PID1104)Cabazitaxel 25 / Prednisolone 10, Prostate Cancer, Second Line (PID645)Cabazitaxel 25, Soft Tissue Sarcoma (PID2172)Cabozantinib 140, Thyroid Cancer (PID825)Cabozantinib 60, Hepatocellular Carcinoma (PID1558)Cabozantinib 60, Adrenocortical Carcinoma (PID2625)Cabozantinib 60, Renal Cell Carcinoma, second-line (PID736)Cabozantinib 60, Osteosarcoma / Ewing Sarcoma (PID1869)Cabozantinib 60, Pheochromocytoma / Paraganglioma (PID2624)CAD - Cyclophosphamide 1000 / Doxorubicin 15 / Dexamethasone 40, stem cell mobilization, Multiple Myeloma (PID530)CAMP - Methylprednisolone (750/375) / Doxorubicin 40 / Cisplatin 20, Thymoma (PID1842)CAP - Cisplatin 50 / Doxorubicin 50 / Cyclophosphamide 500, Thymoma (PID362)CAP - Cisplatin 50 / Doxorubicin 50 / Cyclophosphamide 600, Salivary Gland Tumor (PID1696)Capecitabine 1000 / Bevacizumab 15, Breast Cancer (PID370)Capecitabine 1000 / Bevacizumab 7.5, Colorectal Carcinoma (PID438)Capecitabine 1000 / Cisplatin 60, Gastric Cancer, adjuvant (PID695)Capecitabine 1000 / Cisplatin 80, adenocarcinoma esophagogastric junction and stomach (PID1417)Capecitabine 1000 / Docetaxel 75, Breast Cancer, adjuvant, part A (PID1643)Capecitabine 1000 / Epirubicin 75 / Cyclophosphamide 500, Breast Cancer, adjuvant, part B (PID1644)Capecitabine 1000 / Irinotecan 180, Bile Duct Carcinoma (PID1949)Capecitabine 1000 / Irinotecan 250, adenocarcinoma esophagogastric junction and stomach (PID1418)Capecitabine 1000 / Irinotecan 250, Colorectal Carcinoma (PID1743)Capecitabine 1000 / Margetuximab 15, Breast Cancer (PID1871)Capecitabine 1000 / Oxaliplatin 130, Bile Duct Carcinoma (PID1358)Capecitabine 1000 / Oxaliplatin 130, Carcinoma in an Occult Primary (PID1190)Capecitabine 1000 / Oxaliplatin 130, Colorectal Carcinoma (PID443)Capecitabine 1000 / Oxaliplatin 130, Rectal Cancer, neoadjuvant (PID2054)Capecitabine 1000 / Oxaliplatin 70, colorect. Carcinoma (PID457)Capecitabine 1000 / Paclitaxel 175, Breast Cancer (PID380)Capecitabine 1000, Breast Carcinoma (PID2128)Capecitabine 1250 / Docetaxel 75, Breast Cancer (PID1685)Capecitabine 1250, Bile Duct Carcinoma, adjuvant (PID1183)Capecitabine 1250, Colon Cancer adjuvant (PID463)Capecitabine 1250, Colorectal Carcinoma (PID434)Capecitabine 1250, Breast Cancer, adjuvant (PID1370)Capecitabine 1250, Ovarian Carcinoma (PID2191)Capecitabine 1250, Rectal Cancer, adjuvant, part C (PID2052)Capecitabine 1250, Rectal Cancer, neo-/adjuvant, Part B (PID422)Capecitabine 750 / Temozolomide 200, pancreatic neuroendocrine carcinoma (PID1313)Capecitabine 800 / Radiation, Rectal Cancer, neoadjuvant, part B (PID2050)Capecitabine 825 / Mitomycin 12 / Radiation, Anal Carcinoma (PID481)Capecitabine 825 / Mitomycin 12 / Radiation, Bladder Cancer (PID2505)Capecitabine 825 / Radiation, Gastric Cancer, adjuvant (PID2243)Capecitabine 825 / Radiation, Rectal Cancer, Neo/Adjuvant, Part A (PID421)Capecitabine 825 / Radiation, Rectal Cancer, neoadjuvant (PID2265)Capecitabine 830 / Radiation, Pancreatic Cancer (PID1968)CapIri (Capecitabine 1000 / Irinotecan 200) / Bevacizumab 7.5, Colorectal Carcinoma (PID447)Capivasertib 400 / Fulvestrant 500 / Goserelin 3.6, Breast Cancer, Cycle 1 (PID2609)Capivasertib 400 / Fulvestrant 500 / Goserelin 3.6, Breast Cancer, Cycle 2+ (PID2610)Caplacizumab 10, Thrombotic Thrombocytopenic Purpura, cycle 1 (PID2111)Caplacizumab 10, Thrombotic Thrombocytopenic Purpura, cycle 2+ (PID2112)Capmatinib 400, Non-Small Cell Lung Cancer (PID1793)CAPOX (Capecitabine 1000 / Oxaliplatin 130) / Cetuximab (400/250), Colorectal Carcinoma, Cycle 1 (PID1820)CAPOX (Capecitabine 1000 / Oxaliplatin 130) / Cetuximab 250, Colorectal Carcinoma, Cycle 2+ (PID1821)CAPOX (Capecitabine 1000 / Oxaliplatin 130) / Nivolumab 360, Esophagogastric Carcinoma, Esophagogastric junction and Stomach (PID1906)CAPOX (Capecitabine 1000 / Oxaliplatin 130) / Panitumumab 9, Colorectal Carcinoma (PID692)CAPOX (Capecitabine 1000 / Oxaliplatin 130), Colon Cancer, adjuvant (PID460)CAPOX (Capecitabine 375 / Oxaliplatin 78), Esophagogastric Carcinoma, Esophagus, Esophagogastric junction and Stomach (PID1794)CAPOX (Capecitabine 750 / Oxaliplatin130) / Bevacizumab 7.5, Small bowel Cancer or Ampullary Cancer (PID490)CAPOX (Oxaliplatin 130 / Capecitabine 1000) / Bevacizumab 7.5, Colorectal Carcinoma (PID444)CAPOX (Oxaliplatin 130 / Capecitabine 1000) / TRAS 6, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 2-6 (PID1301)CAPOX (Oxaliplatin 130 / Capecitabine 1000) / Trastuzumab 8, Adenocarcinoma Esophagogastric Junction and Stomach, C1 (PID1258)CAPOX - Capecitabine 1000 / Oxaliplatin 130, Adenocarcinoma Esophagogastric Junction and Stomach, adjuvant, part A+C (PID689)CAPOX - Capecitabine 1000 / Oxaliplatin 130, Gastric Cancer, adjuvant (PID696)CAPOX / Radiation - Capecitabine 825 / Oxaliplatin 40 / Radiation, adenocarcinoma esophagogastric junction and stomach, adjuvant, Part B (PID684)Carboplatin 1.5 / Radiation, Head and Neck Tumors (PID1282)Carboplatin 100 / Radiation, Nasopharyngeal Carcinoma, Part A (PID1781)Carboplatin 150, Breast Cancer (PID2374)Carboplatin 2 / Radiation followed by Carboplatin 4.5 / Etoposide 80, Merkel Cell Carcinoma Part B (PID1111)Carboplatin 2 / Radiation followed by Carboplatin 4.5, Etoposide 80, Merkel Cell Carcinoma Part A (PID109)Carboplatin 2 / Radiation, Squamous Cell Carcinoma of the Skin (PID2178)Carboplatin 2 / Radiation, Cervical Cancer (PID1939)Carboplatin 300 / Etoposide 100, Lung Carcinoma, Small Cell (PID210)Carboplatin 300 / Etoposide 140 / Vincristine 2, Small Cell Lung Carcinoma, Small Cell (PID207)Carboplatin 5 / Cyclophosphamide 600, Breast Cancer (tripel-negative) (PID101)Carboplatin 5 / Etoposide 100, Small Cell Lung Carcinoma, Small Cell (PID209)Carboplatin 5 / Etoposide 100, Merkel Cell Carcinoma (PID1107)Carboplatin 5 / Etoposide 110 / Vincristine 2, Lung Carcinoma, Small Cell (limited disease) (PID1477)Carboplatin 5 / Etoposide 140, Lung Carcinoma, Small Cell (PID204)Carboplatin 5 / Etoposide 80, Lung Carcinoma, Small Cell (PID208)Carboplatin 5 / Etoposide 90 / Vincristine 2, Lung Carcinoma, Small Cell (extensive disease) (PID1476)Carboplatin 5 / Fluorouracil 1000, Nasopharyngeal Carcinoma, Part B (PID1782)Carboplatin 5 / Vinorelbine 25, Non-Small Cell Lung Carcinoma (PID284)Carboplatin 5, Ovarian ca (PID1332)Carboplatin 6 / Etoposide 100 / Radiation, Small Cell Lung Cancer (PID2267)Carboplatin 6 / Etoposide 120, Ovarian Tumor (PID2188)Carboplatin 6, Breast Cancer (PID1940)Carboplatin 7, Testicular Carcinoma, Seminoma, adjuvant (PID775)Carboplatin 7, Ovarian ca (PID1428)Carboplatin 70 / Fluorouracil 600 / Radiation, Oropharyngeal Carcinoma (PID1708)Carfilzomib (20/27) / Bendamustine 70 / Dexamethasone 20, Multiple Myeloma, Cycle 1 (PID2406)Carfilzomib (20/27) / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma Cycle 1 (PID522)Carfilzomib (20/27) / Pomalidomide 4 / Dexamethasone 40, Multiple Myeloma Cycle 1 (PID1586)Carfilzomib (20/36) / Cyclophosphamide 300 / Dexamethasone 40 , Multiple Myeloma, Cycle 1, Variant 1 (PID1458)Carfilzomib (20/36) / Cyclophosphamide 300 / Dexamethasone 40, Multiple Myeloma, Cycle 1 (PID1455)Carfilzomib (20/36) / Cyclophosphamide 500 / Dexamethasone 40, Multiple Myeloma, second line, cycle 1 (PID1460)Carfilzomib (20/56) / Dexamethasone 20, Multiple Myeloma, Cycle 1 (PID733)Carfilzomib (20/70) / Daratumumab (8/8/16) / Dexamethasone (20/20), Multiple Myeloma, Cycle 1 (PID1438)Carfilzomib 20 / Rituximab 375 / Dexamethasone 20, Waldenström, cycle 1 (PID2586)Carfilzomib 27 / Bendamustine 70 / Dexamethasone 20 - Carfilzomib 27 / Dexamethasone 20, Multiple Myeloma, Maintenance, Cycle 9+ (PID2408)Carfilzomib 27 / Bendamustine 70 / Dexamethasone 20, Multiple Myeloma, Cycle 2-8 (PID2407)Carfilzomib 27 / Lenalidomide 25 / Dexamethasone 40 - Lenalidomide 25 / Dexamethasone 40, maintenance, Multiple Myeloma (PID525)Carfilzomib 27 / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma Cycle 13-18 (PID524)Carfilzomib 27 / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma Cycle 2-12 (PID523)Carfilzomib 27 / Pomalidomide 4 / Dexamethasone 20, Multiple Myeloma, Cycle 7+ (PID1588)Carfilzomib 27 / Pomalidomide 4 / Dexamethasone 40, Multiple Myeloma Cycle 2-6 (PID1587)Carfilzomib 36 / Cyclophosphamide 300 / Dexamethasone 40 - Carfilzomib 36 maintenance, Multiple Myeloma (PID1457)Carfilzomib 36 / Cyclophosphamide 300 / Dexamethasone 40, Multiple Myeloma, Cycle 2-9 (PID1456)Carfilzomib 36 / Cyclophosphamide 300 / Dexamethasone 40, Multiple Myeloma, Cycle 2-9, Variant 1 (PID1459)Carfilzomib 36 / Cyclophosphamide 500 / Dexamethasone 40 - Carfilzomib 36 maintenance, Multiple Myeloma, second line, C13-24 (PID1463)Carfilzomib 36 / Cyclophosphamide 500 / Dexamethasone 40 - Carfilzomib 36 maintenance, Multiple Myeloma, second line, cycle 7-12 (PID1462)Carfilzomib 36 / Cyclophosphamide 500 / Dexamethasone 40, Multiple Myeloma, second line, cycle 2-6 (PID1461)Carfilzomib 36 / Rituximab 375 / Dexamethasone 20, Waldenström, cycle 2-6 (PID2587)Carfilzomib 36 / Rituximab 375 / Dexamethasone 20, Waldenström, cycle 7-14 (PID2588)Carfilzomib 56 / Dexamethasone 20, Multiple Myeloma, Cycle 2+ (PID734)Carfilzomib 70 / Cyclophosphamide 300 / Dexamethasone 40 - Carfilzomib 70 Maintenance, Multiple Myeloma (PID1742)Carfilzomib 70 / Cyclophosphamide 300 / Dexamethasone 40, Multiple Myeloma (PID1741)Carfilzomib 70 / Daratumumab 16 / Dexamethasone (20/20), Multiple Myeloma, Cycle 2 (PID1439)Carfilzomib 70 / Daratumumab 16 / Dexamethasone (20/20/40), Multiple Myeloma, Cycle 3-6 (PID1440)Carfilzomib 70 / Daratumumab 16 / Dexamethasone (20/20/40), Multiple Myeloma, Cycle 7+ (PID1441)Carmustine 400 / Thiotepa 5, consolidation before autologous Stem Cell Transplantation, CNS- Non-Hodgkin Lymphoma (PID890)CE (Carboplatin 500 / Etoposide 500), Testicular Carcinoma (PID1574)Cemiplimab 350 / Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2275)Cemiplimab 350 / Paclitaxel 200 / Cisplatin 75, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2274)Cemiplimab 350 / Pemetrexed 500 / Carboplatin 6, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2271)Cemiplimab 350 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2273)Cemiplimab 350 / Pemetrexed 500, Non-Small Cell Lung Cancer, Cycle 5+ (PID2272)Cemiplimab 350, Basal Cell Carcinoma (PID1867)Cemiplimab 350, Non-Small Cell Lung Carcinoma (PID1744)Cemiplimab 350, Non-Small Cell Lung Cancer, Cycle 5+ (PID2276)Cemiplimab 350, Squamous Cell Carcinoma of the Skin (PID1379)Cemiplimab 350, Squamous Cell Carcinoma of the Skin, after organ transplantation (PID2570)Cemiplimab 350, Squamous Cell Carcinoma of the Skin, neoadjuvant (PID2147)Cemiplimab 350, Cervical Cancer (PID1981)Ceritinib 450, Non-Small Cell Lung Cancer, First Line (PID1152)Ceritinib 450, Non-Small Cell Lung Cancer, Second Line (PID811)Cetuximab (400/250) / Capecitabine 800 / Irinotecan 200, Colorectal Carcinoma, Cycle 1 (PID1818)Cetuximab (400/250) / Cisplatin 100, Head and Neck Tumors, Cycle 1 (PID1246)Cetuximab (400/250) / Cisplatin 80 / Vinorelbine 25, Non-Small Cell Lung Cancer, Cycle 1 (PID190)Cetuximab (400/250) / Docetaxel 75 / Cisplatin 100 / Fluorouracil 700, Head and Neck Tumors, Cycle 1 (PID1348)Cetuximab (400/250) / Docetaxel 75 / Cisplatin 75, Head and Neck Tumors, Cycle 1 (PID1275)Cetuximab (400/250) / Irinotecan 350, Colorectal Carcinoma, Cycle 1 (PID425)Cetuximab (400/250) / Paclitaxel 175 / Cisplatin 75, Head and Neck Tumors, Cycle 1 (PID1273)Cetuximab 250 / Capecitabine 800 / Irinotecan 200, Colorectal Carcinoma, Cycle 2+ (PID1819)Cetuximab 250 / Carboplatin 5 / Fluorouracil 1000, Head and Neck Tumors, C2+ (PID337)Cetuximab 250 / Cisplatin 100 / Docetaxel 75 / Fluorouracil 700, Head and Neck Tumors, Cycle 2-3 (PID1349)Cetuximab 250 / Cisplatin 100, Head and Neck Tumors, Cycle 2+ (PID1271)Cetuximab 250 / Cisplatin 80 / Vinorelbine 25 - Cetuximab 250 Maintenance, Non-Small Cell Lung Cancer (PID192)Cetuximab 250 / Cisplatin 80 / Vinorelbine 25, Non-Small Cell Lung Cancer, Cycle 2-6 (PID191)Cetuximab 250 / Docetaxel 75 / Cisplatin 75, Head and Neck Tumors, Cycle 2+ (PID1276)Cetuximab 250 / Irinotecan 350, Colorectal Carcinoma, Cycle 2+ (PID426)Cetuximab 250 / Paclitaxel 175 / Cisplatin 75, Head and Neck Tumors, Cycle 2+ (PID1274)Cetuximab 250 / Paclitaxel 30 / Carboplatin 1 / Radiation, Head and Neck Tumors, Cycle 7-11 (PID1244)Cetuximab 250 / Paclitaxel 40 / Carboplatin 2 / Radiation, Head and Neck Tumors, Cycle 2+ (PID621)Cetuximab 250 / Paclitaxel 80, Head and Neck Tumors, Cycle 2+ (PID708)Cetuximab 250 / Paclitaxel 90 / Carboplatin 2, Head and Neck Tumors, Cycle 2-6 (PID1243)Cetuximab 250 / Radiation, Head and Neck Tumors, Cycle 2+ (PID1195)Cetuximab 250 / Radiation, Squamous Cell Carcinoma of the Skin, Cycle 2+ (PID2164)Cetuximab 250, Colorectal Carcinoma, Cycle 2+ (PID424)Cetuximab 250, Head and Neck Tumors, Cycle 2+ (PID1221)Cetuximab 250, Squamous Cell Carcinoma of the Skin, Cycle 2+ (PID2166)Cetuximab 400 / Carboplatin 5 / Fluorouracil 1000, Head and Neck Tumors, C1 (PID623)Cetuximab 400 / Paclitaxel 40 / Carboplatin 2 / Radiation, Head and Neck Tumors, Cycle 1 (PID622)Cetuximab 400 / Paclitaxel 80, Head and Neck Tumors, Cycle 1 (PID707)Cetuximab 400 / Paclitaxel 90 / Carboplatin 2, Head and Neck Tumors, Cycle 1 (PID1242)Cetuximab 400 / Radiation, Head and Neck Tumors, Cycle 1 (PID1194)Cetuximab 400 / Radiation, Squamous Cell Carcinoma of the Skin, Cycle 1 (PID2163)Cetuximab 400, Colorectal Carcinoma, Cycle 1 (PID423)Cetuximab 400, Head and Neck Tumors, Cycle 1 (PID1220)Cetuximab 400, Squamous Cell Carcinoma of the Skin, Cycle 1 (PID2165)Cetuximab 500 / Docetaxel 50, Head and Neck Tumors (PID1277)Cetuximab 500 / Irinotecan 180 / Vemurafenib 960, Colorectal Carcinoma (PID1746)Cetuximab 500, Head and Neck Tumors (PID1241)Chlorambucil (0.4-0.7), Chronic Lymphocytic Leukemia, cycle 1-4 (PID320)Chlorambucil 0.8, Chronic Lymphocytic Leukemia, cycle 5+ (PID868)Chlorambucil 10, B-Non-Hodgkin Lymphoma (PID2334)Chlorambucil 6, MALT lymphoma, cycle 1 (PID2568)Chlorambucil 6, MALT lymphoma, cycle 2-5 (PID2569)CHOEP 14 - Cyclophosphamide 750 / Doxorubicin 50 / Etoposide 100 / Vincristine 2 / Prednisolone 100, peripheral T-cell lymphoma (PID719)CHOP 14 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, peripheral T-cell lymphoma (PID821)CHOP 21 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, T-cell Lymphoma (PID1799)CHOP 21 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, T-cell Lymphoma, Variant 1 (PID1773)CHOP 21 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 40 followed by IVE/MTX - Ifosfamide 3 / Epirubicin 50 / Etoposide 200 / Methotrexate 1500 x 3, Enteropathy-associated T-cell lymphoma, Part A (PID1650)Cisplatin (50/50) / Doxorubicin 60, Osteosarcoma (PID1362)Cisplatin 100 / Bleomycin 25 / Ifosfamide 2, Testicular Carcinoma (PID2143)Cisplatin 100 / Capecitabine 1000, Nasopharyngeal Carcinoma (PID1784)Cisplatin 100 / Etoposide 100, Lung Carcinoma, Small Cell (PID201)Cisplatin 100 / Etoposide 100, Non-Small Cell Lung Cancer, Adjuvant (PID243)Cisplatin 100 / Fluorouracil 1000 / Radiation, carcinoma esophagus and gastroesophageal junction, neoadjuvant (PID1519)Cisplatin 100 / Fluorouracil 1000 / Radiation, Nasopharyngeal Carcinoma (PID1737)Cisplatin 100 / Fluorouracil 1000, Esophageal Cancer (PID135)Cisplatin 100 / Fluorouracil 1000, Squamous Cell Carcinoma of the Skin (PID2385)Cisplatin 100 / Fluorouracil 800, adenocarcinoma esophagus, esophagogastric junction and stomach (PID136)Cisplatin 100 / Fluorouracil 960, Penile Carcinoma (PID1443)Cisplatin 100 / Gemcitabine 1000, Pleural Mesothelioma (PID373)Cisplatin 100 / Gemcitabine 1250, Carcinoma of Unknown Primary (PID618)Cisplatin 100 / Radiation, Bladder Cancer (PID1668)Cisplatin 100 / Radiation, Head and Neck Tumors (PID1334)Cisplatin 100 / Radiation, Head and Neck Tumors (PID1640)Cisplatin 100 / Radiation, Head and Neck Tumors, adjuvant (PID1291)Cisplatin 100 / Radiation, Nasopharyngeal Carcinoma, Part A (PID1714)Cisplatin 100 / Vinblastine 5 / Radiation, Non-Small Cell Lung Cancer (PID857)Cisplatin 100, Head and Neck Tumors (PID1245)Cisplatin 12 / Fluorouracil 600 / Radiation, Head and Neck Tumors, cycle 1-2 (PID2059)Cisplatin 16 / fluorouracil 600, Head and Neck Tumors, cycle 3 (PID2060)Cisplatin 20 / Etoposide 100, Gestational Trophoblastic Neoplasia, induction (PID1608)Cisplatin 20 / Etoposide 75 / Ifosfamide 1,2, Small Cell Lung Carcinoma (PID233)Cisplatin 20 / Fluorouracil 600, Head and Neck Tumors, cycle 4 (PID2062)Cisplatin 20 / Fluorouracil 800 / Radiation, Head and Neck Tumors (PID2066)Cisplatin 20 / Ifosfamide 1.2 / Vinblastine 0.11, Testicular Carcinoma (PID2039)Cisplatin 20 / Vinorelbine 12.5 / Radiation, Non-Small Cell Lung Cancer (PID669)Cisplatin 25 / Etoposide 100 / Radiation, Small Cell Lung Carcinoma, Small Cell (PID1256)Cisplatin 25 / Etoposide 100, Merkel Cell Carcinoma (PID1108)Cisplatin 25 / Etoposide 100, Neuroendocrine Prostate Cancer (PID1283)Cisplatin 25 / Etoposide 60 / Irinotecan 90, Small Cell Lung Carcinoma (PID741)Cisplatin 25 / Etoposide 80, Lung Carcinoma, Small Cell (PID216)Cisplatin 25 / Gemcitabine 1000, Bile Duct Carcinoma (PID577)Cisplatin 25 / Gemcitabine 600, Pancreatic Cancer (PID476)Cisplatin 30 / Radiation, Head and Neck Tumors, adjuvant (PID1240)Cisplatin 30, Tumor, Various Organs (PID2371)Cisplatin 35 / Gemcitabine 1000, Ovarian Carcinoma (PID2190)Cisplatin 40 / Doxorubicin 60, Thyroid Cancer (PID2140)Cisplatin 40 / Folinic Acid 400 / Fluorouracil 1000, Anal Carcinoma (PID1978)Cisplatin 40 / Radiation, Head and Neck Tumors (PID1637)Cisplatin 40 / Radiation, Squamous Cell Carcinoma of the Skin (PID2162)Cisplatin 40 / Radiation, Salivary Gland Tumor (PID1699)Cisplatin 40 / Radiatio, Vulvar Carcinoma (PID2116)Cisplatin 40 / Radiation, Cervical Cancer Adjuvant (PID540)Cisplatin 50 / Etoposide 100 / Radiation, Non-Small Cell Lung Cancer, Neoadjuvant, Cycle 4 (PID619)Cisplatin 50 / Etoposide 100, Adrenocortical Carcinoma (PID1369)Cisplatin 50 / Etoposide 50 / Radiation, Non-Small Cell Lung Cancer (PID252)Cisplatin 50 / Etoposide 50 / Radiation, Non-Small Cell Lung Cancer, Variant 1 (PID858)Cisplatin 50 / Radiation, Endometrial Cancer adjuvant, Part A (PID922)Cisplatin 60 / Etoposide 120 / Radiation, Small Cell Lung Carcinoma, Small Cell (PID264)Cisplatin 60 / Etoposide 120, Lung Carcinoma, Small Cell (PID217)Cisplatin 60 / Etoposide 150, Non-Small Cell Lung Cancer, Neoadjuvant, Cycle 1-3 (PID620)Cisplatin 60 / Irinotecan 60, gastroenteral and pancreatic neuroendocrine carcinoma (PID2180)Cisplatin 70 / Fluorouracil 700 / Radiation, Esophageal Cancer (PID1569)Cisplatin 75 / Etoposide (100/200), Small Cell Lung Cancer (PID2558)Cisplatin 75 / Etoposide 100 / Radiation, Small Cell Lung Carcinoma, Small Cell (PID1254)Cisplatin 75 / Etoposide 100, Carcinoma of Unknown Primary (PID1186)Cisplatin 75 / Etoposide 100, Small Cell Lung Carcinoma (PID2266)Cisplatin 75 / Fluorouracil 1000 / Radiation, Esophageal Cancer (PID281)Cisplatin 75 / Gemcitabine 1250, Carcinoma in Occult Primary (PID1187)Cisplatin 75 / Gemcitabine 1250, Breast Cancer (PID763)Cisplatin 75 / Tegafur 25 - Tegafur 25, Adenocarcinoma Esophagogastric Junction and Stomach, maintenance. (PID1106)Cisplatin 75 / Tegafur 25, adenocarcinoma esophagogastric junction and stomach (PID202)Cisplatin 80 / Etoposide 100 / Radiation, Small Cell Lung Carcinoma, Small Cell (PID265)Cisplatin 80 / Etoposide 100 / Radiation, Small Cell Lung Cancer, Part A (PID266)Cisplatin 80 / Etoposide 100, gastroenteral and pancreatic neuroendocrine carcinoma (PID2174)Cisplatin 80 / Etoposide 100, Lung Carcinoma, Small Cell (PID214)Cisplatin 80 / Etoposide 120, Lung Carcinoma, Small Cell (PID211)Cisplatin 80 / Etoposide 80, Lung Carcinoma, Small Cell (PID215)Cisplatin 80 / Fluorouracil 1000, Nasopharyngeal Carcinoma, Part B (PID1707)Cisplatin 80 / Gemcitabine 1250 / Bevacizumab 7.5, Non-Small Cell Lung Cancer (PID770)Cladribine 0.1, Langerhans Cell Histiocytosis (PID671)Cladribine 0.12, Hairy Cell Leukemia (PID862)Cladribine 0.14, Hairy Cell Leukemia (PID536)Cladribine 0.14, systemic mastocytosis (PID1680)Cladribine 0.14, Systemic Mastocytosis, Variant 1 (PID2332)Cladribine 0.15 / Rituximab 375, classic Hairy Cell Leukemia and variants (PID864)Cladribine 5 / Cytarabine 2000 / Idarubicin 12 / Filgrastim 300, Acute Myeloid Leukemia, Induction (PID2220)Cladribine 5 / Cytarabine 2000 / Idarubicin 12 / Filgrastim 300, Acute Myeloid Leukemia, consolidation (PID2221)Cladribine 5 / Cytarabine 2000 / Idarubicin 8, Acute Myeloid Leukemia (PID2209)Cladribine 5 / Cytarabine 2000 / Mitoxantrone 10 / Filgrastim 300, Acute Myeloid Leukemia (PID2203)Cladribine 5 / Cytarabine 2000, Acute Myeloid Leukemia (PID2204)Cladribine 5 / Daunorubicin 60 / Cytarabine 200, Acute Myeloid Leukemia (PID2436)Cladribine 5.6 followed by Rituximab 375, Hairy Cell Leukemia, Part A (PID865)Cladribine 5.6 followed by Rituximab 375, Hairy Cell Leukemia, Part B (PID866)CLAEG - Cladribine 0.2 / Etoposide 60 / Cytarabine 1500, T- Acute Lymphoblastic Leukaemia (PID1907)CLAG - Cladribine 5 / Cytarabine 2000 / Filgrastim 300, AML (PID859)Clodronic Acid (1040/520), Breast Cancer, Adjuvant (PID944)Clodronic Acid 1040/520, Bone Metastases (PID945)Clofarabin 10 / Cyclophosphamide 600, B/T-Acute Lymphoblastic Leukemia (PID2269)Clofarabin 40, B/T-Acute Lymphoblastic Leukemia (PID2270)CMF - Cyclophosphamide 100 / Methotrexate 40 / 5-fluorouracil 600, Breast Cancer (PID1153)CMF - Cyclophosphamide 100 / Methotrexate 40 / Fluorouracil 600, Breast Cancer, adjuvant (PID1540)CMF - Cyclophosphamide 600 / Methotrexate 40 / Fluorouracil 600, Breast Ca, adjuvant (PID100)Cobimetinib 60, Langerhans Cell Histiocytosis (PID1996)CODE - Cisplatin 25 / Doxorubicin 40 / Etoposide 80 / Vincristine 1, Thymoma (PID1843)COMP - Cyclophosphamide 750 / Doxorubicin Liposomal 50 / Vincristine 2 / Prednisolone 100, T-cell Lymphoma (PID469)Crizanlizumab 5, Sickle Cell Disease, Cycle 1 (PID1728)Crizanlizumab 5, Sickle Cell Disease, Cycle 2+ (PID1729)Crizotinib 250, diffuse large B-non-Hodgkin Lymphoma (PID2403)Crizotinib 250, Non-Small Cell Lung Cancer (ALK+), First Line (PID807)Crizotinib 250, Non-Small Cell Lung Cancer (ALK+), Second Line (PID198)Crizotinib 250, Non-Small Cell Lung Cancer (METex14+) (PID1984)Crizotinib 250, Non-Small Cell Lung Cancer (ROS1+) (PID806)Crizotinib 250, Soft Tissue Sarcoma (PID2047)CVD - Cyclophosphamide 750 / Vincristine 2 / Dacarbazine 600, Pheochromocytoma / Paraganglioma (PID2480)Cyclophosphamide 1000 / Doxorubicin 45 / Etoposide 50, Small Cell Lung Carcinoma (PID260)Cyclophosphamide 1000 / Doxorubicin 50 / Vincristine2, Small Cell Lung Carcinoma, Small Cell (PID224)Cyclophosphamide 1000 / Etoposide (50/100) / Vincristine 2, Lung Carcinoma, Small Cell (PID225)Cyclophosphamide 150, Ovarian Carcinoma (PID2192)Cyclophosphamide 200 / Prednisolone 60, Pre-phase, Burkitt's lymphoma (PID2214)Cyclophosphamide 2000 / Vincristine 2, Small Cell Lung Carcinoma, Small Cell (PID226)Cyclophosphamide 50 / Methotrexate 2.5, Metastatic Breast Cancer (PID83)Cyclophosphamide 50, Autoimmune Hemolytic Anemia, warm type (PID2016)Cyclophosphamide 500 / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma (PID2264)Cyclophosphamide 500 / Thalidomide 100 / Dexamethasone 40, Multiple Myeloma (PID2532)Cyclophosphamide 500 / Thalidomide 50 / Dexamethasone 20, Multiple Myeloma (PID2533)Cyclophosphamide 600 / Doxorubicin Liposomal 60, Breast Cancer (PID1686)Cyclophosphamide 600 / Doxorubicin Liposomal 75, Breast Cancer (PID386)Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100 / Brentuximab Vedotin 1.8, T-cell Lymphoma (PID1204)Cytarabine 100, Langerhans Cell Histiocytosis (PID1666)Cytarabine 1000, Acute Myeloid Leukemia, consolidation, over 60 years of age (PID601)Cytarabine 1500 / Mitoxantrone 10, Acute Myeloid Leukemia (PID2208)Cytarabine 1500, Acute Myeloid Leukemia, Consolidation (PID2574)Cytarabine 20 / Glasdegib 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome (PID1674)Cytarabine 20, Acute Myeloid Leukemia (PID833)Cytarabine 2000 / Etoposide 5, CNS Lymphoma, cycle 6 (PID1866)Cytarabine 3000 / Midostaurin 50, Acute Myeloid Leukemia, consolidation (PID1080)Cytarabine 3000 / Quizartinib 35.4, Acute Myeloid Leukemia, consolidation (PID2553)Cytarabine 3000, Acute Myeloid Leukemia, consolidation, under 60 years, day 1,3,5 (PID516)Cytarabine 3000, Acute Myeloid Leukemia, consolidation, under 60 years, day 1-3 (PID995)Cytarabine 40 / Dexamethasone 4 / Methotrexate 15, intrathecal, CNS Prophylaxis, Malignant Meningitis (PID602)Cytarabine 50, intrathecal, maintenance, Malignant Meningitis (PID875)Cytarabine 50, intrathecal, induction, Malignant Meningitis (PID873)Cytarabine 50, intrathecal, consolidation, Malignant Meningitis (PID874)Cytarabine 500 / Etoposide 150, Acute Lymphoblastic Leukaemia, Lymphodepletion (PID1832)Cytarabine 500 / Methotrexate 250 / Inotuzumab Ozogamicin 0.3 / Rituximab 375, ALL/NHL, cycle 2,4 (PID2097)DA- EPOCH/BORT - Bortezomib 1.3 / Etoposide 50 / Prednisolone 120 / Vincristine 0.4 / Cyclophosphamide 750 / Doxorubicin 10, Plasmoblastic Lymphoma (PID2037)DA-EPOCH-R - Rituximab 375 / Etoposide 50 / Prednisolone 60 / Vincristine 0.4 / Cyclophosphamide 750 / Doxorubicin 10, B-non-Hodgkin Lymphoma, Cycle 1-2 (PID658)DA-EPOCH-R - Rituximab 375 / Etoposide 72 / Prednisolone 60 / Vincristine 0.4 / Cyclophosphamide 1080 / Doxorubicin 14.4, B-Non-Hodgkin Lymphoma, Cycle 3-6 (PID2056)DA-EPOCH-RR - Rituximab 375 / Etoposide 50 / Prednisolone 60 / Vincristine 0.4 / Cyclophosphamide 750 / Doxorubicin 10, Burkitt lymphoma (PID2222)Dabrafenib 150 / Trametinib 2, Malignant Melanoma (PID717)Dabrafenib 150 / Trametinib 2, Melanoma, adjuvant (PID56)Dabrafenib 150 / Trametinib 2, non-small cell lung cancer (PID578)Dabrafenib 150 / Trametinib 2, Thyroid Cancer (PID1419)Dabrafenib 150 / Trametinib 2, Tumor Biomarker Defined (PID2197)Dacarbazine 1000, Malignant Melanoma (PID726)Dacarbazine 1200, Soft Tissue Sarcoma (PID1211)Dacomitinib 45, Non-Small Cell Lung Cancer (PID1425)Dactinomycin 1,25, Gestational Trophoblastic Neoplasia (PID95)Daratumumab (8/8/16) / Carfilzomib (20/36) / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, Cycle 1 (PID2579)Daratumumab (8/8/16) / Lenalidomide 25 / Dexamethasone (20/20), Multiple Myeloma, Cycle 1 (PID1434)Daratumumab (8/8/16) / Lenalidomide 25 / Dexamethasone (20/20), Multiple Myeloma, Cycle 1, First-line (PID1436)Daratumumab (8/8/16) / Lenalidomide 5 / Dexamethasone 20, AL Amyloidosis, Cycle 1 (PID2444)Daratumumab (8/8/16) / Pomalidomide 4 / Dexamethasone (20/20), Multiple Myeloma, Cycle 1 (PID1435)Daratumumab (8/8/16), AL amyloidosis, cycle 1 (PID1473)Daratumumab (8/8/16), Multiple Myeloma, Smoldering, Cycle 1 (PID1556)Daratumumab (8/8/16), Multiple Myeloma, Cycle 1 (PID1431)Daratumumab 16 / Carfilzomib (20/56) / Lenalidomide 15 / Dexamethasone 40, Multiple Myeloma, Cycle 7 (PID2582)Daratumumab 16 / Carfilzomib 36 / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, Cycle 2 (PID2580)Daratumumab 16 / Carfilzomib 36 / Lenalidomide 25 / Dexamethasone 20, multiple Myeloma, cycle 3-6 (PID2581)Daratumumab 16 / Carfilzomib 56 / Lenalidomide 25 / Dexamethasone 40 - Daratumumab 16 / Lenalidomide 10, multiple Myeloma, maintenance (PID2584)Daratumumab 16 / Carfilzomib 56 / Lenalidomide 25 / Dexamethasone 40, multiple Myeloma, cycle 8-10 (PID2583)Daratumumab 16 / Lenalidomide 25 / Dexamethasone (20/20), Multiple Myeloma, Cycle 1 (PID813)Daratumumab 16 / Lenalidomide 25 / Dexamethasone (20/20), Multiple Myeloma, Cycle 1, First-line (PID1333)Daratumumab 16 / Lenalidomide 25 / Dexamethasone (20/20), Multiple Myeloma, Cycle 2 (PID814)Daratumumab 16 / Lenalidomide 25 / Dexamethasone (20/20), Multiple Myeloma, cycle 2, first-line (PID1437)Daratumumab 16 / Lenalidomide 25 / Dexamethasone (20/20/40), Multiple Myeloma, Cycle 3-6 (PID815)Daratumumab 16 / Lenalidomide 25 / Dexamethasone (20/20/40), Multiple Myeloma, Cycle 3-6, First-line (PID1337)Daratumumab 16 / Lenalidomide 25 / Dexamethasone (20/20/40), Multiple Myeloma, Cycle 7+ (PID816)Daratumumab 16 / Lenalidomide 25 / Dexamethasone (20/20/40), Multiple Myeloma, Cycle 7+, First-line (PID1338)Daratumumab 16 / Lenalidomide 5 / Dexamethasone 20, AL Amyloidosis, cycle 2 (PID2445)Daratumumab 16 / Lenalidomide 5 / Dexamethasone 20, AL Amyloidosis, cycle 3-6 (PID2446)Daratumumab 16 / Lenalidomide 5 / Dexamethasone 20, AL Amyloidosis, Cycle 7+ (PID2447)Daratumumab 16 / Pomalidomide 4 / Dexamethasone (20/20), Multiple Myeloma, Cycle 1 (PID1222)Daratumumab 16 / Pomalidomide 4 / Dexamethasone (20/20), Multiple Myeloma, Cycle 2 (PID1223)Daratumumab 16 / Pomalidomide 4 / Dexamethasone (20/20/40), Multiple Myeloma, Cycle 7+ (PID1225)Daratumumab 16 / Pomalidomide 4 / Dexamethasone 40, Multiple Myeloma, Cycle 3-6 (PID1224)Daratumumab 16, AL amyloidosis, cycle 2 (PID1478)Daratumumab 16, AL Amyloidosis, cycle 3-6 (PID1479)Daratumumab 16, AL amyloidosis, cycle 7+ (PID1480)Daratumumab 16, maintenance after Bortezomib 1.3 / Daratumumab 16 / Dexamethasone 20 / Thalidomide 100, Multiple Myeloma (PID1486)Daratumumab 16, Multiple Myeloma Cycle 3-6 (PID745)Daratumumab 16, Multiple Myeloma, Smoldering, cycle 2-3 (PID2123)Daratumumab 16, Multiple Myeloma, Smoldering, cycle 4-7 (PID2124)Daratumumab 16, Multiple Myeloma, Smoldering, cycle 8-20 (PID2125)Daratumumab 16, Multiple Myeloma, Cycle 1 (PID744)Daratumumab 16, Multiple Myeloma, Cycle 2 (PID746)Daratumumab 16, Multiple Myeloma, Cycle 7+ (PID747)Daratumumab 1800 / Bortezomib 1.0 / Dexamethasone 20 - Daratumumab 1800 maintenance, AL-Amyloidosis, cycle 7+. (PID2458)Daratumumab 1800 / Bortezomib 1.0 / Dexamethasone 20, AL-Amyloidosis, cycle 1-2. (PID2456)Daratumumab 1800 / Bortezomib 1.0 / Dexamethasone 20, AL-Amyloidosis, cycle 3-6. (PID2457)Daratumumab 1800 / Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 40 - Daratumumab 1800 / Lenalidomide 10, multiple myeloma, maintenance, cycle 7+ (PID2519)Daratumumab 1800 / Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 40, multiple myeloma, induction, cycle 1-2 (PID2516)Daratumumab 1800 / Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 40, multiple Myeloma, induction, cycle 3-4 (PID2517)Daratumumab 1800 / Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma, consolidation, cycle 5-6 (PID2518)Daratumumab 1800 / Bortezomib 1.5 / Cyclophosphamide 300 / Dexamethasone (20/20) - Daratumumab 1800 / Dexamethasone 12 Maintenance, Multiple Myeloma (PID1944)Daratumumab 1800 / Bortezomib 1.5 / Cyclophosphamide 300 / Dexamethasone (20/20), Multiple Myeloma, Cycle 1-2 (PID1941)Daratumumab 1800 / Bortezomib 1.5 / Cyclophosphamide 300 / Dexamethasone (20/20), Multiple Myeloma, Cycle 3-6 (PID1942)Daratumumab 1800 / Bortezomib 1.5 / Cyclophosphamide 300 / Dexamethasone (20/20), Multiple Myeloma, Cycle 7-8 (PID1943)Daratumumab 1800 / Carfilzomib (20/56) / Dexamethasone (20/20), Multiple Myeloma, Cycle 1. (PID2152)Daratumumab 1800 / Carfilzomib 56 / Dexamethasone (20/20), Multiple Myeloma, Cycle 2. (PID2330)Daratumumab 1800 / Carfilzomib 56 / Dexamethasone (20/20/40), Multiple Myeloma, Cycle 3-6 (PID2153)Daratumumab 1800 / Carfilzomib 56 / Dexamethasone (20/20/40), Multiple Myeloma, Cycle 7+ (PID2154)Daratumumab 1800 / Lenalidomide 25 / Dexamethasone (20/20), Multiple Myeloma, Cycle 1-2, First-line (PID1625)Daratumumab 1800 / Lenalidomide 25 / Dexamethasone (20/20/40), Multiple Myeloma, Cycle 3-6, First-line (PID1626)Daratumumab 1800 / Lenalidomide 25 / Dexamethasone (20/20/40), Multiple Myeloma, Cycle 7+, First-line (PID1627)Daratumumab 1800 / Lenalidomide 5 / Dexamethasone 20, AL Amyloidosis, cycle 1-2 (PID2452)Daratumumab 1800 / Lenalidomide 5 / Dexamethasone 20, AL Amyloidosis, cycle 3-6 (PID2453)Daratumumab 1800 / Lenalidomide 5 / Dexamethasone 20, AL Amyloidosis, Cycle 7+ (PID2454)Daratumumab 1800 / Pomalidomide 4 / Dexamethasone (20/20), Multiple Myeloma, cycle 1-2 (PID1993)Daratumumab 1800 / Pomalidomide 4 / Dexamethasone (20/20/40), Multiple Myeloma, cycle 3-6 (PID1994)Daratumumab 1800 / Pomalidomide 4 / Dexamethasone (20/20/40), Multiple Myeloma, cycle 7+ (PID1995)Daratumumab 1800, maintenance after Dexamethasone (20/20/40) / Cyclophosphamide 300 / Daratumumab 1800 / Bortezomib 1.3 - Daratumumab 1800 maintenance, AL amyloidosis, cycle 7+ (PID1633)Daratumumab 1800, Multiple Myeloma, Cycle 1-2 (PID1622)Daratumumab 1800, Multiple Myeloma, Cycle 3-6 (PID1623)Daratumumab 1800, Multiple Myeloma, Cycle 7+ (PID1624)Daratumumab 1800, TEMPI syndrome, cycle 1-2 (PID2167)Daratumumab 1800, TEMPI syndrome, cycle 3-6 (PID2168)Daratumumab 1800, TEMPI syndrome, cycle 7+ (PID2169)Darbepoetin alfa 150, Myelodysplastic Syndrome (PID783)Darbepoetin alfa 300 / Filgrastim 300, Myelodysplastic Syndrome (PID838)Darbepoetin alfa 300, Myelodysplastic Syndrome (PID836)Darbepoetin alfa 500 / Ferric Carboxymaltose 1000, Iron Deficiency/Anemia in Cancer (PID907)Darbepoetin alfa 500, Anemia, Chemotherapy Induced (PID910)Darbepoetin alfa 500, Myelodysplastic Syndrome (PID837)Darolutamide 600, Prostate Cancer Castration Resistant (PID1642)Dasatinib 100, Chronic Myeloid Leukemia (PID940)Dasatinib 70, Chondrosarcoma (PID2507)Daunorubicin 60 / Cytarabine 100 / Quizartinib 35.4, Acute Myeloid Leukemia, Induction (PID2551)Daunorubicin 60 / Cytarabine 100, Acute Myeloid Leukemia, Induction (PID293)Daunorubicin 60 / Cytarabine 200 / Midostaurin 50, Acute Myeloid Leukemia, Induction (PID1079)Daunorubicin 60 / Cytarabine 200, Acute Myeloid Leukemia, induction (PID1825)Daunorubicin Liposomal - Cytarabine liposomal 144, Acute Myeloid Leukemia, Induction, Cycle 1 (PID1414)Daunorubicin Liposomal - Cytarabine liposomal 144, Acute Myeloid Leukemia, Induction, Cycle 2 (PID1426)Daunorubicin Liposomal - Cytarabine liposomal 94, Acute Myeloid Leukemia, consolidation (PID1427)DCEP - dexamethasone 40 / cyclophosphamide 400 / etoposide 40 / cisplatin 10, multiple myeloma (PID1472)DDGP (Cisplatin 20 / Gemcitabine 800 / PEG-Asparaginase 2500 / Dexamethasone (7.5/15)), extranodal NK/T-cell Lymphoma (PID2349)Decitabine 15, Acute Myeloid Leukemia, cycle 1-4 (PID2321)Decitabine 15, Myelodysplastic Syndrome (PID727)Decitabine 20, Acute Myeloid Leukemia (PID834)Decitabine 20, Acute Myeloid Leukemia, First-Line (PID582)Decitabine 20, Acute Myeloid Leukemia, cycle 5+ (PID2322)Decitabine 20, Myelodysplastic Syndrome (PID904)Decitabine 20, Myelodysplastic Syndrome, Low risk (PID2318)Decitabine-Cedazuridine 135, Myelodysplastic Syndrome (PID2514)Deferasirox 14, Beta Thalassemia (PID1837)Deferasirox 14, Myelodysplastic Syndrome (PID1840)Deferiprone 25, Beta Thalassemia (PID1841)Deferoxamine 25, Beta Thalassemia (PID1838)Deferoxamine 25, Myelodysplastic Syndrome (PID2301)Degarelix 240, Prostate Cancer, Cycle 1 (PID1524)Degarelix 80, Prostate Cancer, Cycle 2+ (PID1525)Denosumab 120, Bone Metastases (PID541)Denosumab 120, multiple myleoma (PID1163)Denosumab 120, Giant Cell Tumor of the Bone, Cycle 1 (PID925)Denosumab 120, Giant Cell Tumor of the Bone, Cycle 2+ (PID927)Denosumab 60, Breast Cancer, adjuvant (PID884)Denosumab 60, Osteoporosis (PID1383)Dexamethasone (20/20) / Cyclophosphamide 300 / Daratumumab 1800 / Bortezomib 1.3, AL amyloidosis, cycle 1-2 (PID1631)Dexamethasone (20/20/40) / Cyclophosphamide 300 / Daratumumab 1800 / Bortezomib 1.3, AL Amyloidosis, cycle 3-6 (PID1632)Dexamethasone 20 / Bendamustine 100, AL-Amyloidosis (PID1513)Dexamethasone 20 / Bortezomib 1.3, AL Amyloidosis (PID1511)Dexamethasone 20 / Cyclophosphamide 350 / Bortezomib 1.0, AL amyloidosis (PID1514)Dexamethasone 20 / Melphalan 0.15 / Lenalidomide 10, AL Amyloidosis (PID1512)Dexamethasone 20 / Melphalan 0.22, AL-Amyloidosis (PID1506)Dexamethasone 20 / Melphalan 16, AL Amyloidosis (PID1508)Dexamethasone 20 / Rituximab 375 / Cyclophosphamide 100, Waldenström's disease (PID52)Dexamethasone 40 / Melphalan 0.22 / Bortezomib 1.3, AL amyloidosis, cycle 1-2 (PID1638)Dexamethasone 40 / Melphalan 0.22 / Bortezomib 1.3, AL amyloidosis, cycle 3-8 (PID1639)Dexamethasone 40, Immune Thrombocytopenia (PID956)Dexrazoxane 1000 / 500, anthracycline extravasation (PID59)DHAC - Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, Non-Hodgkin Lymphoma / Hodgkin Lymphoma. (PID2346)DHAP - Dexamethasone 40 / Cisplatin 100 / Cytarabine 2000, Hodgkin Lymphoma (PID1156)DHAP - Dexamethasone 40 / Cisplatin 100 / Cytarabine 2000, T-cell lymphoma, under 70 years of age (PID71)Docetaxel 100, Breast Cancer (PID752)Docetaxel 15 / Radiatio, Head and Neck Tumors (PID2259)Docetaxel 20 / Cisplatin 25 / Radiation, carcinoma esophagus and gastroesophageal junction, neoadjuvant, part B (PID1403)Docetaxel 30 / Prednisolone 5, Prostate Cancer (PID1391)Docetaxel 35 weekly, Non-Small Cell Lung Cancer (PID166)Docetaxel 35, Breast Cancer (PID753)Docetaxel 36 weekly, Non-Small Cell Lung Cancer (PID168)Docetaxel 40 / Fluorouracil 2000 / Cisplatin 40, adenocarcinoma esophagogastric junction and stomach (PID2171)Docetaxel 40 / Tegafur 60, Gastric Cancer, adjuvant, cycle 1 (PID872)Docetaxel 40 / Tegafur 60, Gastric Cancer, adjuvant, cycle 2-7 (PID1394)Docetaxel 40 / Tegafur 60, Gastric Cancer, adjuvant, cycle 8+ (PID1395)Docetaxel 50 / Oxaliplatin 100 / Tegafur 40, Adenocarcinoma Esophagogastric Junction and Stomach, neoadjuvant (PID2038)Docetaxel 50 / Prednisolone 10, Prostate Cancer (PID941)Docetaxel 60 / Cisplatin 60 / Fluorouracil 600, Nasopharyngeal Carcinoma (PID1373)Docetaxel 60 / Oxaliplatin 100 / Capecitabine 500, adenocarcinoma esophagogastric junction and stomach (PID1230)Docetaxel 60, Gastric Cancer (PID129)Docetaxel 65 / Carboplatin 6, Head and Neck Tumors (PID1278)Docetaxel 75 / Carboplatin 5, Carcinoma with Occult Primary unknown (PID1188)Docetaxel 75 / Carboplatin 5, Ovarian ca (PID1421)Docetaxel 75 / Carboplatin 6 / Trastuzumab (4/2), Breast Cancer,adjuvant, cycle 1 (PID411)Docetaxel 75 / Carboplatin 6 / Trastuzumab 2, Breast Cancer, adjuvant, cycle 2+ (PID412)Docetaxel 75 / Carboplatin 6 / Trastuzumab 6, Breast Cancer, neoadjuvant, cycle 2+. (PID654)Docetaxel 75 / Carboplatin 6 / Trastuzumab 8, Breast Cancer, neoadjuvant, cycle 1. (PID655)Docetaxel 75 / Carboplatin 6, Breast Cancer (PID1664)Docetaxel 75 / Carboplatin 6, Non-Small Cell Lung Carcinoma, Non-Small Cell (PID154)Docetaxel 75 / Cisplatin 75 / Fluorouracil 750 - Cisplatin 40 / Radiation, Nasopharyngeal Carcinoma, Part A (PID1099)Docetaxel 75 / Cisplatin 75 / Fluorouracil 750 - Cisplatin 40 / Radiation, Nasopharyngeal Carcinoma, Part B (PID1101)Docetaxel 75 / Cisplatin 75 / Fluorouracil 750, adenocarcinoma esophagogastric junction and stomach (PID128)Docetaxel 75 / Cisplatin 75 / Fluorouracil 750, Head and Neck Tumors (PID1102)Docetaxel 75 / Cisplatin 75, carcinoma esophagus and gastroesophageal junction, neoadjuvant, part A (PID1402)Docetaxel 75 / Cisplatin 75, Non-Small Cell Lung Carcinoma (PID144)Docetaxel 75 / Cyclophosphamide 600, Breast Cancer, adjuvant (PID393)Docetaxel 75 / Gemcitabine 1000, Breast Cancer (PID372)Docetaxel 75 / Nintedanib 200, Non-Small Cell (Adeno) Lung Carcinoma (PID433)Docetaxel 75 / Prednisolone 5 / Abiraterone 1000 / Goserelin 10.8 -Abiraterone 1000 / Goserelin 10.8, Prostate Cancer hormone sensitive, Part C (PID2307)Docetaxel 75 / Prednisolone 5 / Abiraterone 1000 / Goserelin 10.8, Prostate Cancer hormone sensitive, Part A (PID2305)Docetaxel 75 / Prednisolone 5 / Abiraterone 1000 / Goserelin 10.8, Prostate Cancer hormone sensitive, Part B (PID2306)Docetaxel 75 / Prednisolone 5 / Darolutamide 600 / Goserelin 10.8 - Darolutamide 600 / Goserelin 10.8, Prostate Cancer hormone sensitive, part C (PID2081)Docetaxel 75 / Prednisolone 5 / Darolutamide 600 / Goserelin 10.8, Prostate Cancer Hormone Sensitive, part A (PID2040)Docetaxel 75 / Prednisolone 5 / Darolutamide 600 / Goserelin 10.8, Prostate Cancer hormone sensitive, part B (PID2041)Docetaxel 75 / Prednisolone 5 / Goserelin 10.8 - Goserelin 10.8, Prostate Cancer hormone sensitive, part C (PID2082)Docetaxel 75 / Prednisolone 5 / Goserelin 10.8, Prostate Cancer hormone sensitive, Part A (PID641)Docetaxel 75 / Prednisolone 5 / Goserelin 10.8, Prostate Cancer hormone sensitive, Part B (PID664)Docetaxel 75 / Prednisolone 5, Prostate Cancer (PID921)Docetaxel 75, adenocarcinoma esophagus, esophagogastric junction, and stomach (PID134)Docetaxel 75, Non-Small Cell Lung Carcinoma (PID162)Docetaxel 85 / Gemcitabine 1000, Non-Small Cell Lung Carcinoma, Non-Small Cell (PID156)Dostarlimab 1000, Endometrial Cancer, Cycle 5+ (PID1798)Dostarlimab 1000, Tumor Biomarker Defined, Cycle 5+ (PID2633)Dostarlimab 500 / Paclitaxel 175 / Carboplatin 5 - Dostarlimab 1000, Endometrial Cancer, Cycle 7+ (PID2314)Dostarlimab 500 / Paclitaxel 175 / Carboplatin 5, Endometrial Cancer, Cycle 1-6 (PID2313)Dostarlimab 500, Endometrial Cancer, Cycle 1-4 (PID1797)Dostarlimab 500, Rectal Cancer (PID2238)Dostarlimab 500, Tumor Biomarker Defined, Cycle 1-4 (PID2632)Doxorubicin / Cyclophosphamide dose-dense x 4 followed by Paclitaxel 175 x 4, Breast Ca, adjuvant, Part B (PID403)Doxorubicin 20 / Ifosfamide 2.5 / Dacarbazine 225 / Radiation, Soft Tissue Sarcoma, perioperative (PID2359)Doxorubicin 20, Breast Carcinoma (PID2131)Doxorubicin 25 / Ifosfamide 2.5, Soft Tissue Sarcoma (PID506)Doxorubicin 25 / Ifosfamide 3, Soft Tissue Sarcoma neoadjuvant (PID2545)Doxorubicin 25 / Vinblastine 6 / Dacarbazine 375 / Brentuximab Vedotin 1,2 / Radiation, Hodgkin Lymphoma (PID1951)Doxorubicin 25 / Vinblastine 6 / Dacarbazine 375 / Brentuximab Vedotin 1,2, Hodgkin Lymphoma (PID587)Doxorubicin 25 / Vinblastine 6 / Dacarbazine 375, Hodgkin Lymphoma (PID257)Doxorubicin 25 / Vinblastine 6 / Dacarbazine 375, Hodgkin Lymphoma, Part B (PID1962)Doxorubicin 40 / Etoposide 100 / Cisplatin 40 / Mitotane 1.5, Adrenocortical Carcinoma, cycle 1 (PID2021)Doxorubicin 40 / Etoposide 100 / Cisplatin 40 / Mitotan 1.5, Adrenocortical Carcinoma, Cycle 2+ (PID1257)Doxorubicin 40 / Lurbinectedin 2, Small Cell Lung Cancer (PID2628)Doxorubicin 45 / Cisplatin 50, Endometrial Cancer, Adjuvant (PID893)Doxorubicin 50 / Cyclophosphamide 500 / Docetaxel 75, Breast Cancer, Adjuvant (PID398)Doxorubicin 50 / Cyclophosphamide 500 / Docetaxel 75, Breast Cancer, neoadjuvant (PID593)Doxorubicin 50 / Docetaxel 75, Breast Cancer (PID378)Doxorubicin 50 / Gemcitabine 1500, Renal Cell Carcinoma (PID1979)Doxorubicin 60 / Cisplatin 50 - Cisplatin 50, Endometrial Cancer, Cycle 8 (PID895)Doxorubicin 60 / Cisplatin 50, Endometrial Cancer, Cycle 1-7 (PID894)Doxorubicin 60 / Cyclophosphamide 600 dose-dense x 4 followed by Paclitaxel 175 x 4, Breast Ca, adjuvant, Part A (PID402)Doxorubicin 60 / Cyclophosphamide 600 dose-dense x 4 followed by Pertuzumab 1200 / Trastuzumab 600 / Paclitaxel 80 x 4, Breast Ca, adjuvant, Part B Cycle 1 (PID1753)Doxorubicin 60 / Cyclophosphamide 600 dose-dense x 4 followed by Pertuzumab 600 / Trastuzumab 600 / Paclitaxel 80 x 4, Breast Ca, adjuvant, Part B Cycle 2-4 (PID1754)Doxorubicin 60 / Cyclophosphamide 600 x 4 followed by Docetaxel 100 x 4, Breast Ca, adjuvant, Part A (PID599)Doxorubicin 60 / Cyclophosphamide 600 x 4 followed by Docetaxel 100 x 4, Breast Ca, adjuvant, Part B (PID395)Doxorubicin 60 / Cyclophosphamide 600 x 4 followed by Paclitaxel 175 x 4, Breast Ca, adjuvant, Part B (PID396)Doxorubicin 60 / Cyclophosphamide 600 x 4 followed by Paclitaxel 80 / Trastuzumab 2 x 12, Breast Ca, adjuvant, Part B Cycle 2+ (PID492)Doxorubicin 60 / Cyclophosphamide 600 x 4 followed by Paclitaxel 80 / Trastuzumab 4 x 12, Breast Ca, adjuvant, Part B Cycle 1 (PID491)Doxorubicin 60 / Cyclophosphamide 600 x 4 followed by Paclitaxel 80 x 12, Breast Ca, adjuvant, Part B (PID397)Doxorubicin 60 / Cyclophosphamide 600 x 4 followed by Paclitaxel, Breast Ca, adjuvant, Part A (PID394)Doxorubicin 60 / Cyclophosphamide 600 x 4 followed by Pertuzumab 1200 / Trastuzumab 600 / Docetaxel 100 x 4, Breast Ca, adjuvant, Part B Cycle 1 (PID1751)Doxorubicin 60 / Cyclophosphamide 600 x 4 followed by Pertuzumab 600 / Trastuzumab 600 / Docetaxel 100 x 4, Breast Ca, adjuvant, Part B Cycle 2-4 (PID1752)Doxorubicin 60 / Cyclophosphamide 600, Breast Cancer (PID381)Doxorubicin 60 / Cyclophosphamide 600, Breast Cancer, adjuvant (PID478)Doxorubicin 60 / Dacarbazine 750, Soft Tissue Sarcoma (PID1215)Doxorubicin 60 / Trabectedin 1.1, Soft Tissue Sarcoma (PID2210)Doxorubicin 60 x 4 / Paclitaxel 175 x 4 / Cyclophosphamide 600 x 4, Breast Cancer, adjuvant, Part A (PID1141)Doxorubicin 60 x 4 / Paclitaxel 175 x 4 / Cyclophosphamide 600 x 4, Breast Cancer, adjuvant, Part C (PID1143)Doxorubicin 60, Thyroid Cancer (PID2137)Doxorubicin 60, Soft Tissue Sarcoma, adjuvant, Part B (PID1946)Doxorubicin 75 / Ifosfamide 2.5, Soft Tissue Sarcoma neo/adjuvant (PID575)Doxorubicin 75, Soft Tissue Sarcoma (PID507)Doxorubicin Liposomal 25 / Etoposide 100 / Prednisolone 20 - Etoposide 100 / Prednisolone 0.4, Hemophagocytic Lymphohistiocytosis, Part A (PID947)Doxorubicin Liposomal 25 / Etoposide 100 / Prednisolone 20 - Etoposide 100 / Prednisolone 0.4, Hemophagocytic Lymphohistiocytosis, Part B (PID1039)Doxorubicin60 x 4 / Paclitaxel 175 x 4 / Cyclophosphamide 600 x 4, Breast Cancer, adjuvant, Part B (PID1142)DTPACE (Dexamethasone 40 / Thalidomide 400 / Cisplatin 10 / Doxorubicin 10 / Cyclophosphamide 400 / Etoposide 40), Multiple Myeloma (PID1471)DTPACE/BORT - Bortezomib 1.0 / Dexamethasone 40 / Thalidomide 200 / Cisplatin 10 / Doxorubicin 10 / Cyclophosphamide 400 / Etoposide 40), Multiple Myeloma (PID1966)Durvalumab 10, Bladder Cancer (PID471)Durvalumab 10, Non-Small Cell Lung Carcinoma (PID470)Durvalumab 1500 / Carboplatin 5 / Etoposide 100 - Durvalumab 1500 Maintenance, Small Cell Lung Carcinoma (PID1594)Durvalumab 1500 / Carboplatin 5 / Etoposide 100, Small Cell Lung Carcinoma (PID1593)Durvalumab 1500 / Cisplatin 25 / Gemcitabine 1000 - Durvalumab 1500, Bile Duct Carcinoma, maintenance (PID2146)Durvalumab 1500 / Cisplatin 25 / Gemcitabine 1000, Bile Duct Carcinoma (PID2145)Durvalumab 1500 / Cisplatin 80 / Etoposide 100, Small Cell Lung Carcinoma (PID1734)Durvalumab 1500 / Gemcitabine 1250 / Carboplatin 5, Non-Small Cell Lung Cancer, neoadjuvant, Cycle 1-4 (PID2495)Durvalumab 1500 / Gemcitabine 1250 / Cisplatin 75, Non-Small Cell Lung Cancer, neoadjuvant, Cycle 1-4 (PID2493)Durvalumab 1500 / Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer, neoadjuvant, cycle 1-4 (PID2496)Durvalumab 1500 / Pemetrexed 500 / Carboplatin 5, Non-Small Cell Lung Cancer, neoadjuvant, cycle 1-4 (PID2494)Durvalumab 1500 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, neoadjuvant, cycle 1-4 (PID2492)Durvalumab 1500 / Pemetrexed 500, Non-Small Cell Lung Cancer, Cycle 5,7+ (PID2297)Durvalumab 1500, Hepatocellular Carcinoma (PID2510)Durvalumab 1500, Small Cell Lung Cancer (PID2651)Durvalumab 1500, Non-Small Cell Lung Cancer (PID1715)Durvalumab 1500, Non-Small Cell Lung Cancer, adjuvant, cycle 5-17 (PID2497)Durvalumab 1500, Non-Small Cell Lung Cancer, Cycle 5,7+ (PID2291)Duvalumab 1500, carcinoma esophagus and gastroesophageal junction, adjuvant (PID2228)Eculizumab 600, Paroxysmal Nocturnal Hemoglobinuria, Induction (PID791)Eculizumab 900, Paroxysmal Nocturnal Hemoglobinuria, maintenance (PID792)Ferric carboxymaltose 1000, Iron Deficiency/Anemia (PID905)Ferric Carboxymaltose 750, Iron Deficiency/Anemia (PID2561)Iron(III)-derisomaltose 1000, Iron Deficiency/Anemia (PID2449)Ferric Derisomaltose 1000, Iron Deficiency/Anemia in Cancer (PID892)Elacestrant 345, Breast Cancer (PID2515)Elo-KRd - Elotuzumab 10 / Carfilzomib (20/56)/ Lenalidomide 25 / Dexamethasone (20/20/40), Multiple Myeloma, Cycle 1 (PID2398)Elo-KRd - Elotuzumab 10 / Carfilzomib 70 / Lenalidomide 25 / Dexamethasone (20/20/40), Multiple Myeloma, Cycle 2 (PID2399)Elo-KRd - Elotuzumab 10 / Carfilzomib 70 / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, Cycle 9-12 (PID2401)Elo-KRd - Elotuzumab 10 / Carfilzomib 70 / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma, Cycle 3-8 (PID2400)Elo-Rd - Elotuzumab 10 / Lenalidomide 25 / Dexamethasone (28/40), Multiple Myeloma Cycle 3+ (PID702)Elo-Rd - Elotuzumab 10 / Lenalidomide 25 / Dexamethasone 28, Multiple Myeloma Cycle 1-2 (PID701)Elotuzumab 10 / Pomalidomide 4 / Dexamethasone 28, Multiple Myeloma Cycle 1+2 (PID1227)Elotuzumab 20 / Pomalidomide 4 / Dexamethasone 28, Multiple Myeloma Cycle 3+ (PID1229)Elranatamab (12/32/76), multiple myeloma, cycle 1 (PID2537)Elranatamab 76, multiple myeloma, cycle 2-6 (PID2538)Elranatamab 76, multiple myeloma, cycle 7+ (PID2539)Eltrombopag 100, Thrombocytopenia, Chemotherapy Induced (PID960)Eltrombopag 50, Immune Thrombocytopenia (PID954)Eltrombopag 50, Myelodysplastic Syndrome (PID2513)EMA/CO (Etoposide 100 / Dactinomycin 0.5 / Methotrexate 1000 / Vincristine 1.0 / Cyclophosphamide 600), Gestational Trophoblastic Neoplasia with Brain Metastases (PID1610)EMA/CO (Etoposide 100 / Dactinomycin 0.5 / Methotrexate 300 / Vincristine 1.0 / Cyclophosphamide 600), Gestational Trophoblastic Neoplasia (PID1607)Emapalumab 1, Hemophagocytic Lymphohistiocytosis (PID848)Encorafenib 300 / Binimetinib 45 / Cetuximab (400/250), Colorectal Carcinoma, Cycle 1 (PID2464)Encorafenib 300 / Binimetinib 45 / Cetuximab 250, Colorectal Carcinoma, Cycle 2+ (PID1407)Encorafenib 300 / Binimetinib 45 / Cetuximab 250, Colorectal Carcinoma, Cycle 2-7 (PID2465)Encorafenib 300 / Binimetinib 45 / Cetuximab 400, Colorectal Carcinoma, Cycle 1 (PID1406)Encorafenib 300 / Binimetinib 45 / Cetuximab 500, Colorectal Carcinoma, Cycle 8+ (PID2466)Encorafenib 300 / Cetuximab 250, Colorectal Carcinoma, Cycle 2+ (PID1606)Encorafenib 300 / Cetuximab 400, Colorectal Carcinoma, Cycle 1 (PID1605)Encorafenib 450 / Binimetinib 45, Malignant Melanoma (PID1361)Encorafenib 450 / Binimetinib 45, Multiple Myeloma (PID2653)Enfortumab Vedotin 1.25 / Pembrolizumab 200, Bladder Cancer (PID2366)Enfortumab Vedotin 1.25, Bladder Cancer (PID1733)Entrectinib 600, Non-Small Cell Lung Cancer (PID1745)Entrectinib 600, Tumor Biomarker Defined (PID758)Enzalutamide 160 / Goserelin 10.8, Prostate Cancer Hormone Sensitive, First Line (PID1360)Enzalutamide 160, Prostate Cancer Castration Resistant (PID1557)Enzalutamide 160, Prostate Cancer castration-resistant, first-line (PID918)Enzalutamide 160, Prostate Cancer castration-resistant, second-line (PID917)EP - Cisplatin 20 / Etoposide 100, Testicular Carcinoma (PID772)EP/EMA - Etoposide 150 / Cisplatin 75 / Etoposide 100 / Methotrexate 300 / Dactinomycin 0.5, Gestational Trophoblastic Neoplasia. (PID1611)Epcoritamab (0.16/0.8/48), diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID2486)Epcoritamab 48, diffuse large B-non-Hodgkin Lymphoma, cycle 10+ (PID2489)Epcoritamab 48, diffuse large B-non-Hodgkin Lymphoma, Cycle 2-3 (PID2487)Epcoritamab 48, diffuse large B-non-Hodgkin Lymphoma, cycle 4-9 (PID2488)Epirubicin 110, Pleural Mesothelioma (PID2567)Epirubicin 150 x 3 / Paclitaxel 225 x 3 / Cyclophosphamide 2500 x 3, dose-dense, Breast Cancer, adjuvant Part A (PID399)Epirubicin 150 x 3 / Paclitaxel 225 x 3 / Cyclophosphamide 2500 x 3, dose-dense, Breast Cancer, adjuvant Part B (PID400)Epirubicin 150 x 3 / Paclitaxel 225 x 3 / Cyclophosphamide 2500 x 3, dose-dense, Breast Cancer, adjuvant Part C (PID401)Epirubicin 50 / Cisplatin 60 / Capecitabine 1000, adenocarcinoma esophagogastric junction and stomach (PID1776)Epirubicin 50 / Cisplatin 60 / Fluorouracil 200, Adenocarcinoma Esophagogastric Junction and Stomach, neoadjuvant/adjuvant. (PID1228)Epirubicin 50 / Cyclophosphamide 1000 / Vincristine 2, Small Cell Lung Cancer (PID259)Epirubicin 50 / Oxaliplatin 130 / Capecitabine 625, adenocarcinoma esophagogastric junction and stomach (PID1775)Epirubicin 60 / Ifosfamide 3, Soft Tissue Sarcoma neoadjuvant (PID976)Epirubicin 75 / Cyclophosphamide 600, Breast Cancer (PID382)Epirubicin 75 / Docetaxel 75, Breast Cancer (PID379)Epirubicin 90 / Cyclophosphamide 600 x 4 followed by Docetaxel 100, Breast Ca, neoadjuvant, part A (PID404)Epirubicin 90 / Cyclophosphamide 600 x4 followed by Doce 100, Breast Ca, neoadjuvant, part B (PID405)Epirubicin 90 / Cyclophosphamide 600, Breast Cancer, adjuvant (PID579)Epirubicin 90 x 4 / Paclitaxel 175 x 4 / Cyclophosphamide 600 x 4, dose-dense, Breast Cancer, adjuvant, Part A (PID86)Epirubicin 90 x 4 / Paclitaxel 175 x 4 / Cyclophosphamide 600 x 4, dose-dense, Breast Cancer, adjuvant, Part B (PID87)Epirubicin 90 x 4 / Paclitaxel 175 x 4 / Cyclophosphamide 600 x 4, dose-dense, Breast Cancer, adjuvant, Part C (PID88)Epirubicin 90, Breast Carcinoma (PID2130)Epoetin Alfa 40000 / Ferric Carboxymaltose 1000, Iron Deficiency/Anemia in Cancer (PID906)Epoetin Alfa 40000 / Filgrastim 120, Myelodysplastic Syndrome (PID728)Epoetin Alfa 40000, Anemia, Chemotherapy Induced (PID911)Epoetin Alfa 40000, Myelodysplastic Syndrome (PID841)Epoetin Theta 20000 / Ferric Carboxymaltose 1000, Iron Deficiency/Anemia in Cancer (PID912)Epoetin Theta 20000, Anemia, Chemotherapy Induced (PID909)Erdafitinib 8, urinary Bladder Cancer (PID2001)Eribulin 1.23, Lipo- and Leiomyosarcoma (PID826)Eribulin 1.23, Breast Cancer (PID387)Erlotinib 150 / Bevacizumab 15, Non-Small Cell (Adeno) Lung Carcinoma (PID742)Erlotinib 150 Maintenance, Non-Small Cell Lung Cancer (PID212)Erlotinib 150, Non-Small Cell Lung Cancer (second- and third-line) (PID195)Erlotinib 150, Non-Small Cell Lung Cancer, First Line (PID206)ESHAOx - Etoposide 40 / Oxaliplatin 130 / Cytarabine 2000 / Methylprednisolone 500, Hodgkin Lymphoma (PID2347)ESHAP - Etoposide 40 / Cisplatin 25 / Cytarabine 2000 / Methylprednisolone 375, Non-Hodgkin Lymphoma. (PID2348)Etoposide (50/100) / Paclitaxel 200 / Carboplatin 5, Merkel Cell Carcinoma (PID117)Etoposide 100 / Cisplatin 40 / Mitotan 1.5, Adrenocortical Carcinoma (PID2479)Etoposide 100 / Dexamethasone 10, Hemophagocytic Lymphohistiocytosis (PID1652)Etoposide 100, Merkel Cell Carcinoma (PID116)Etoposide 110 / Paclitaxel 175 / Carboplatin 5, Lung Carcinoma, Small Cell (limited disease) (PID263)Etoposide 120 / Ifosfamide 5, Small Cell Lung Carcinoma, Small Cell (PID227)Etoposide 25, Thymoma (PID2323)Etoposide 50, Testicular Carcinoma (PID1577)Etoposide 50, Kaposi's Sarcoma (PID2032)Etoposide 50, Small Cell Lung Carcinoma (PID244)Etoposide 50, Merkel Cell Carcinoma (PID115)Etoposide 90 / Paclitaxel 175 / Carboplatin 5, Lung Carcinoma, Small Cell (extensive disease) (PID200)Everolimus 10 / Exemestane 25, Breast Cancer (PID371)Everolimus 10 / Fulvestrant 500, Breast Cancer, cycle 1 (PID1875)Everolimus 10 / Fulvestrant 500, Breast Cancer, cycle 2+ (PID1876)Everolimus 10 / Letrozole 2.5, Endometrial Cancer (PID897)Everolimus 10, Renal Cell Carcinoma, second-line (PID731)Everolimus 10, Pancreatic Neuroendocrine Tumor (PID560)Everolimus 10, Pulmonary and Gastroenteric Neuroendocrine Tumors (PID650)Everolimus 10, Thymoma (PID1847)Exemestane 25, Breast Cancer, adjuvant (PID1582)FC - Cyclophosphamide 1000 / Fludarabine 20, Mantle Cell Lymphoma (PID283)Fedratinib 400, Primary Myelofibrosis (PID1740)Filgrastim 5, Neutropenia (PID1554)FLAGAMSA (Fludarabine 30 / Cytarabine 2000 / Amsacrine 100), Acute Myeloid Leukemia (PID1710)FLAGIDA - Fludarabine 30 / Cytarabine 2000 / Idarubicin 8, Acute Myeloid Leukemia (PID762) (PID748)FLAGIDA/Venetoclax - Fludarabine 30 / Cytarabine 1500 / Idarubicin 8 / Venetoclax 400, Acute Myeloid Leukemia, Induction (PID2522)FLAGIDA/Venetoclax - Fludarabine 30 / Cytarabine 1500 / Idarubicin 8 / Venetoclax 400, Acute Myeloid Leukemia, Consolidation (PID2524)FLO - Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600, adenocarcinoma esophagogastric junction and stomach (PID142)FLOT - Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600, adenocarcinoma esophagogastric junction and stomach (PID67)FLOT - Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600, adenocarcinoma esophagogastric junction and stomach, perioperative (PID336)Fludarabine 25 / Cyclophosphamide 200 / Mitoxantrone 8, T-Cell Prolymphocyte Leukemia (PID1560)Fludarabine 25 / Cyclophosphamide 250, diffuse large B-non-Hodgkin Lymphoma, Lymphodepletion (PID1829)Fludarabine 30 / Cyclophosphamide 300, B-non-Hodgkin Lymphoma, Lymphodepletion (PID2471)Fludarabine 30 / Cyclophosphamide 500, Acute Lymphoblastic Leukaemia, Lymphodepletion (PID1831)Fluorouracil 1000 / Cisplatin 100, Anal Carcinoma (PID482)Fluorouracil 1000 / Mitomycin 10 / Radiation, Anal Carcinoma (PID480)Fluorouracil 1000 / Radiation, Rectal Cancer, neoadjuvant/adjuvant (PID464)Fluorouracil 2600 / Sodium Folinate 500, Colorectal Carcinoma (PID51)Fluorouracil 400 / Folinic Acid 20 / Radiation, Adenocarcinoma Esophagogastric Junction and Stomach, adjuvant, Part B (PID698)Fluorouracil 400 / Streptozocin 500, Neuroendocrine Tumor (PID1399)Fluorouracil 400 / Streptozocin 500, Neuroendocrine Tumor (PID643)Fluorouracil 425 / Folinic Acid 20, Adenocarcinoma Esophagogastric Junction and Stomach, adjuvant, part A+C. (PID697)Fluorouracil 500 / Epirubicin 100 / Cyclophosphamide 500 x 3 followed by Docetaxel 100 x 3, Breast Cancer, adjuvant, Part A (PID388)Fluorouracil 500 / Epirubicin 100 / Cyclophosphamide 500 x 3 followed by Docetaxel 100 x 3, Breast Cancer, adjuvant, Part B (PID389)Fluorouracil 500 / Epirubicin 90 / Cyclophosphamide 600 / Trastuzumab 6 / Pertuzumab 420, Breast Cancer, neoadjuvant, cycle 2-3 (PID1468)Fluorouracil 500 / Epirubicin 90 / Cyclophosphamide 600 / Trastuzumab 8 / Pertuzumab 840, Breast Cancer, neoadjuvant, cycle 1 (PID1467)Fluorouracil 500 / Epirubicin 90 / Cyclophosphamide 600, Breast Cancer, neoadjuvant, cycle 1-3 (PID1357)Fluorouracil 500 / Mitomycin 12 / Radiation, Bladder Cancer (PID949)Fluorouracil 500, Rectal Cancer, adjuvant (PID465)Fluorouracil 600 / Epirubicin 90 / Cyclophosphamide 600 / Trastuzumab 6, Breast Cancer, Adjuvant (PID759)Fluorouracil 600 / Mitomycin 10 / Radiation, Head and Neck Tumors (PID2058)FOLFIRI (Irinotecan 180 / Folinic Acid 400 / Fluorouracil 2400) / Aflibercept 4, Colorectal Carcinoma (PID439)FOLFIRI (Irinotecan 180 / Folinic Acid 400 / Fluorouracil 2400) / Bevacizumab 5, Colorectal Carcinoma (PID448)FOLFIRI (Irinotecan 180 / Folinic Acid 400 / Fluorouracil 2400) / Panitumumab 6, Colorectal Carcinoma (PID440)FOLFIRI - Irinotecan 180 / Folinic Acid 400 / Fluorouracil 2400, gastroenteric and pancreatic neuroendocrine Cancer (PID2631)FOLFIRI - Irinotecan 180 / Folinic Acid 400 / Fluorouracil 2400, Colorectal Carcinoma (PID449)FOLFIRI - Irinotecan 80 / Folinic Acid 500 / Fluorouracil 2000, adenocarcinoma esophagogastric junction and stomach (PID143)FOLFIRI/CETU - Cetuximab (400/250) / Irinotecan 180 / Folinic Acid 400 / Fluorouracil 2400, Colorectal Carcinoma, Cycle 1 (PID441)FOLFIRI/CETU - Cetuximab 250 / Irinotecan 180 / Folinic Acid 400 / Fluorouracil 2400, Colorectal Carcinoma, Cycle 2+ (PID442)FOLFIRI/RAMU - Ramucirumab 8 / Irinotecan 180 / Folinic Acid 400 / Fluorouracil 2400, adenocarcinoma esophagogastric junction and stomach (PID1599)Folfiri/Ramucirumab - Ramucirumab 8 / Irinotecan 180/ Folinic Acid 400 / Fluorouracil 2400, Colorectal Carcinoma (PID686)FOLFIRINOX - Oxaliplatin 85 / Folinic Acid 400 / Irinotecan 180 / Fluorouracil 2400, Pancreatic Cancer (PID47)FOLFIRINOX - Oxaliplatin 85 / Folinic Acid 400 / Irinotecan 180 / Fluorouracil 2400, Pancreatic Cancer, Neoadjuvant (PID789)FOLFIRINOX - Oxaliplatin 85 / Folinic Acid 400 / Irinotecan 180 / Fluorouracil 2400, Rectal Cancer, neoadjuvant, part A (PID2049)FOLFOX (Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 1600) / Radiation, Esophageal Cancer (PID694)FOLFOX-4 - Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 600, Bile Duct Carcinoma (PID1948)FOLFOX-4 (Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 600) / Bevacizumab 5, Colorectal Carcinoma (PID445)FOLFOX-4 (Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 600) / Panitumumab 6, Colorectal Carcinoma (PID450)FOLFOX-4 - Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 600, Colon Cancer, adjuvant (PID462)FOLFOX-4 - Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 600, Colorectal Carcinoma (PID60)FOLFOX-4 - Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 600, Rectal Cancer, neoadjuvant (PID2055)FOLFOX-4/CETU - Cetuximab (400/250) / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 600, Colorectal Carcinoma, Cycle 1 (PID451)FOLFOX-4/CETU - Cetuximab 250 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 600, Colorectal Carcinoma, Cycle 2+ (PID452)FOLFOX-6 - Cetuximab (400/250) / Oxaliplatin 100 / Folinic Acid 400 / Fluorouracil 2400, Colorectal Carcinoma, Cycle 1 (PID1114)FOLFOX-6 - Cetuximab 250 / Oxaliplatin 100 / Folinic Acid 400 / Fluorouracil 2400, Colorectal Carcinoma, Cycle 2+ (PID1178)FOLFOX-6 - Oxaliplatin 100 / Folinic Acid 400 / Fluorouracil 2400, Colorectal Carcinoma (PID110)FOLFOXIRI (Irinotecan 150, Oxaliplatin 85, Folinic Acid 200, Fluorouracil 3000)/Panitumumab 6, colorect. Ca (PID1413)FOLFOXIRI (Irinotecan 165 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 3200) / Bevacizumab 5, Colorectal Carcinoma (PID453)FOLFOXIRI - Irinotecan 165 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 3200, Colorectal Carcinoma (PID455)FOLFOXIRI/BEVA5 - Bevacizumab 5 / Folinic Acid 200 / Fluorouracil 3200, Colorectal Carcinoma, Maintenance (PID454)FOLFOXIRI/CETU - Oxaliplatin 85 / Irinotecan 180 / Folinic Acid 200 / Fluorouracil 2400 / Cetuximab (400/250), Colorectal Carcinoma, Cycle 1 (PID687)FOLFOXIRI/CETU - Oxaliplatin 85 / Irinotecan 180 / Folinic Acid 200 / Fluorouracil 2400 / Cetuximab 250, Colorectal Carcinoma, Cycle 2+ (PID688)Folinic Acid 350 / Fluorouracil 2800, Colorectal Carcinoma (PID2175)Fostamatinib 100, Immune Thrombocytopenia (PID1063)Fruquintinib 5, Colorectal Carcinoma (PID2560)FUFOX - Oxaliplatin 50 / Folinic Acid 500 / Fluorouracil 2000, Colorectal Carcinoma (PID456)FUFOX/CETU - Oxaliplatin 50 / Folinic Acid 500 / Fluorouracil 2000 / Cetuximab (400/250), Colorectal Carcinoma, Cycle 1 (PID483)FUFOX/CETU - Oxaliplatin 50 / Folinic Acid 500 / Fluorouracil 2000 / Cetuximab 250, Colorectal Carcinoma, Cycle 2 (PID484)Fulvestrant 500, Breast Cancer (PID552)Futibatinib 20, Bile Duct Carcinoma (PID2576)GDP - Gemcitabine 1000 / Dexamethasone 40 / Cisplatin 25, T-cell Lymphoma (PID2435)Gefitinib 250, non-small cell lung carcinoma (PID196)Gefitinib 250, Non-Small Cell Lung Cancer, Adjuvant (PID1162)Gemcitabine 100 / Radiation, Bladder Cancer (PID2213)Gemcitabine 1000 / Capecitabine 650, Breast Cancer (PID1684)Gemcitabine 1000 / Capecitabine 650, Thymoma (PID1844)Gemcitabine 1000 / Capecitabine 830, Pancreatic Cancer (PID1980)Gemcitabine 1000 / Capecitabine 830, Pancreatic Cancer Adjuvant (PID766)Gemcitabine 1000 / Carboplatin 4 / Trastuzumab 6, Breast Cancer, Cycle 2+ (PID414)Gemcitabine 1000 / Carboplatin 4 / Trastuzumab 8, Breast Cancer, Cycle 1 (PID413)Gemcitabine 1000 / Carboplatin 4, Breast Cancer (PID383)Gemcitabine 1000 / Carboplatin 4, Ovarian ca (PID493)Gemcitabine 1000 / Carboplatin 5, Bladder Cancer (PID1502)Gemcitabine 1000 / Carboplatin 5, Bladder Cancer, adjuvant (PID1491)Gemcitabine 1000 / Carboplatin 5, Non-Small Cell Lung Cancer (PID132)Gemcitabine 1000 / Cisplatin 100 / Methylprednisolone 1000, T-cell Lymphoma (PID2354)Gemcitabine 1000 / Cisplatin 100, Non-Small Cell Lung Carcinoma, Non-Small Cell (PID146)Gemcitabine 1000 / Cisplatin 30, Breast Cancer (PID1683)Gemcitabine 1000 / Cisplatin 35, Bladder Cancer, Neoadjuvant (PID2246)Gemcitabine 1000 / Cisplatin 35, Bladder Cancer, Neoadjuvant (PID1499)Gemcitabine 1000 / Cisplatin 50, Pancreatic Cancer (PID939)Gemcitabine 1000 / Cisplatin 70, Bladder Cancer (PID544)Gemcitabine 1000 / Cisplatin 70, Bladder Cancer Adjuvant (PID1490)Gemcitabine 1000 / Cisplatin 70, Bladder Cancer, Neoadjuvant (PID562)Gemcitabine 1000 / Cisplatin 80, Nasopharyngeal Carcinoma (PID1325)Gemcitabine 1000 / Docetaxel 75, Carcinoma of Unknown Primary (PID617)Gemcitabine 1000 / Erlotinib 100, Pancreatic Cancer, Part A (PID512)Gemcitabine 1000 / Erlotinib100, Pancreatic Cancer Part B (PID513)Gemcitabine 1000 / Margetuximab 15, Breast Cancer (PID1873)Gemcitabine 1000 / Paclitaxel 100, Testicular Carcinoma (PID1572)Gemcitabine 1000 / Paclitaxel 175, Bladder Cancer, Second Line (PID1300)Gemcitabine 1000 / Tegafur 50, Bile Duct Carcinoma (PID1481)Gemcitabine 1000 / Treosulfan 3500, malignant Uveal Melanoma (PID1160)Gemcitabine 1000 / Vinorelbine 25, Breast Cancer (PID1682)Gemcitabine 1000 / Vinorelbine 25, Pleural Mesothelioma (PID2566)Gemcitabine 1000, Kaposi's Sarcoma (PID2033)Gemcitabine 1000, cutaneous T-cell lymphoma (PID1388)Gemcitabine 1000, Non-Small Cell Lung Cancer (PID172)Gemcitabine 1000, Ovarian Carcinoma (PID504)Gemcitabine 1000, Ovarian ca, variant 1 (PID505)Gemcitabine 1000, Pancreatic Cancer, Adjuvant (PID292)Gemcitabine 1000, Pancreatic Cancer, Part A (PID285)Gemcitabine 1000, Pancreatic Cancer, Part B (PID286)Gemcitabine 1100 / Docetaxel 100, Non-Small Cell Lung Cancer (PID526)Gemcitabine 1150, Non-Small Cell Lung Cancer (PID173)Gemcitabine 1200 / Carboplatin 5, Non-Small Cell Lung Cancer (PID160)Gemcitabine 1200 / Cisplatin 80, Non-Small Cell Lung Carcinoma, Non-Small Cell (PID151)Gemcitabine 1200, Non-Small Cell Lung Cancer (PID174)Gemcitabine 1200, T-cell Lymphoma (PID1924)Gemcitabine 1250 / Carboplatin 5, Non-Small Cell Lung Carcinoma (PID155)Gemcitabine 1250 / Cisplatin 80, Non-Small Cell Lung Carcinoma, Non-Small Cell (PID159)Gemcitabine 1250 / Cisplatin 80, Pleural Mesothelioma (PID374)Gemcitabine 1250, Non-Small Cell Lung Cancer (PID171)Gemcitabine 1800 / Dacarbazine 500, Soft Tissue Sarcoma (PID1181)Gemcitabine 50 / Cisplatin 40 / Radiation, vulvar carcinoma (PID2603)Gemcitabine 600 / Radiation, Pancreatic Cancer, Neoadjuvant (PID1161)Gemcitabine 800 / Capecitabine 750 / Mitotan 1.5, Adrenocortical Carcinoma (PID1024)Gemcitabine 800, Breast Cancer (PID2133)Gemcitabine 900 / Docetaxel 100, Soft Tissue Sarcoma (PID570)Gemcitabine 900 / Docetaxel 100, Soft Tissue Sarcoma neo/adjuvant (PID576)Gemcitabine 900 / Docetaxel 75 / Bevacizumab 15, Soft Tissue Sarcoma (PID573)Gemcitabine 900 / Docetaxel 75, Osteosarcoma (PID1935)Gemcitabine 900 / Docetaxel 75, Soft Tissue Sarcoma, adjuvant, part A (PID1945)GemOx - Gemcitabine 1000 / Oxaliplatin 100, Bile Duct Carcinoma (PID685)GemOx - Gemcitabine 1000 / Oxaliplatin 100, Hodgkin Lymphoma (PID2382)GemOx - Gemcitabine 1000 / Oxaliplatin 100, T-cell Lymphoma (PID2350)GemOx - Gemcitabine 1000 / Oxaliplatin 130, Testicular Carcinoma (PID1571)GemOx - Gemcitabine 1000 / Oxaliplatin 130, Ovarian Carcinoma (PID2195)Gemtuzumab Ozogamicin (6/3), Acute Myeloid Leukemia, Induction (PID2590)Gemtuzumab Ozogamicin / Daunorubicin 35 / Cytarabine 1000, Acute Myeloid Leukemia, Induction, Cycle 2 (PID1)Gemtuzumab Ozogamicin 2, Acute Myeloid Leukemia, consolidation (PID2591)Gemtuzumab Ozogamicin 3 / Cytarabine 1000 / Daunorubicin 60, Acute Myeloid Leukemia, consolidation, cycle 1 (PID4)Gemtuzumab Ozogamicin 3 / Cytarabine 1000 / Daunorubicin 60, Acute Myeloid Leukemia, consolidation, cycle 2 (PID5)Gemtuzumab Ozogamicin 3 / Daunorubicin 60 / Cytarabine 200, Acute Myeloid Leukemia, Induction, Leukocyte count from 30,000/µl, Cycle 1 (PID3)Gemtuzumab Ozogamicin 3 / Daunorubicin 60 / Cytarabine 200, Acute Myeloid Leukemia, Induction, Leukocyte count up to 30,000/µl, Cycle 1 (PID2)Gilteritinib 120, Acute Myeloid Leukemia (PID1505)Gilteritinib 120, Acute Myeloid Leukemia after allogeneic stem cell transplantation (PID2589)GIP - Gemcitabine 1000 / Ifosfamide 1.2 / Cisplatin 20, Testicular Carcinoma (PID778)Glofitamab 30, diffuse large B-non-Hodgkin Lymphoma, cycle 2-12 (PID2394)GMALL - ALL - Frail patients, maintenance (week 14) (PID105)GMALL - ALL - Frail patients, maintenance option Cyclophosphamide (week 18,26,34,42,50) (PID85)GMALL - ALL - Frail patients, maintenance option Vincristine (week 18,26,34,42,50) (PID84)GMALL - ALL - Frail patients, induction (PID103)GMALL - ALL - Frail patients, reinduction, week 10 (PID104)GMALL - ALL - Frail patients, Pre-phase, all risk groups (PID102)GMALL - ALL - Frail, Induction + Maintenance, Ph/BCR-ABL+ (PID106)GMALL 08/2013 - ALL maintenance (week 40-51 and month 21-30), 56 - 75 years (PID720)GMALL 08/2013 - ALL maintenance (week 40-51 and month 21-30), 56 - 75 years, Ph/BCR-ABL+ (PID2139)GMALL 08/2013 - ALL maintenance (week 52 to month 20), 56 - 75 years (PID721)GMALL 08/2013 - ALL maintenance (week 52 to month 20), 56 - 75 years, Ph/BCR-ABL+ (PID662)GMALL 08/2013 - ALL maintenance, 18 - 55 years old (PID638)GMALL 08/2013 - ALL/LBL consolidation III and V (weeks 24, 32), 18 - 55 years (PID634)GMALL 08/2013 - ALL/LBL Consolidation IV (Week 30), 56 - 75 years (PID1097)GMALL 08/2013 - ALL/LBL Induction (Day 6), 18 - 55 years, Ph/BCR-ABL+ (PID964)GMALL 08/2013 - ALL/LBL Induction (Day 6), 56 - 75 years, Ph/BCR-ABL+ (PID1103)GMALL 08/2013 - ALL/LBL Induction I (Day 6), 18 - 55 years, all risk groups (PID592)GMALL 08/2013 - ALL/LBL Induction I (Day 6), 56 - 75 years (PID1087)GMALL 08/2013 - ALL/LBL Induction II (Day 20), 56 - 75 years (PID1088)GMALL 08/2013 - ALL/LBL Induction II (Day 23), 18 - 55 years, all risk groups (PID594)GMALL 08/2013 - ALL/LBL consolidation I (day 60), 18 - 55 years, all risk groups (PID595)GMALL 08/2013 - ALL/LBL consolidation I (day 60), 18 - 55 years, Ph/BCR-ABL+ (PID966)GMALL 08/2013 - ALL/LBL consolidation I (week 8), 56 - 75 years, Ph/BCR-ABL+ (PID639)GMALL 08/2013 - ALL/LBL Consolidation I (Week 9), 56 - 75 years (PID1086)GMALL 08/2013 - ALL/LBL Consolidation II (Week 14), 18 - 55 years (PID1098)GMALL 08/2013 - ALL/LBL consolidation II (week 14), 56 - 75 years, Ph/BCR-ABL+ (PID640)GMALL 08/2013 - ALL/LBL Consolidation II (Week 15), 56 - 75 years (PID1091)GMALL 08/2013 - ALL/LBL consolidation II in treatment failure/MRD persistence of T-ALL/T-LBL, 18 - 55 years (PID965)GMALL 08/2013 - ALL/LBL consolidation III and V (weeks 23, 33), 56 - 75 years, Ph/BCR-ABL+ (PID635)GMALL 08/2013 - ALL/LBL consolidation III and V (week 24,34), 56 - 75 yrs (PID1090)GMALL 08/2013 - ALL/LBL consolidation IV (week 29), 56 - 75 years, Ph/BCR-ABL+ (PID637)GMALL 08/2013 - ALL/LBL consolidation IV and VI (weeks 27, 35), 18 - 55 yrs (PID632)GMALL 08/2013 - ALL/LBL Reinduction (Week 18), 56 - 75 years, Ph/BCR-ABL+ (PID709)GMALL 08/2013 - ALL/LBL Reinduction (Week 19), 18 - 55 years (PID636)GMALL 08/2013 - ALL/LBL Reinduction (Week 19), 56 - 75 years (PID1096)GMALL 08/2013 - ALL/LBL Pre-phase, 18 - 55 yrs (PID591)GMALL 08/2013 - ALL/LBL Pre-phase, 56 - 75 yrs (PID1085)GMALL 08/2013 - B-ALL/NHL 2002 Regimen, 18 - 55, Part A (PID344)GMALL 08/2013 - B-ALL/NHL 2002 Regimen, 18 - 55, Part B (PID346)GMALL 08/2013 - B-ALL/NHL 2002 Regimen, 18 - 55, Part C (PID347)GMALL 08/2013 - B-ALL/NHL 2002 regimen, all ages, Pre-phase (PID345)GMALL 08/2013 - B-ALL/NHL 2002 regimen, older than 55, part A, NHL only (PID704)GMALL 08/2013 - B-ALL/NHL 2002 regimen, older than 55, part B, NHL only (PID705)GMALL 08/2013 - B-ALL/NHL 2002 regimen, older than 55, Part C, B-ALL only (PID357)GMALL 08/2013 - B-ALL/NHL 2002 regimen, older than 55,Part A, B-ALL only (PID355)GMALL 08/2013 - B-ALL/NHL 2002 regimen, older than 55,Part B, B-ALL only (PID356)GMALL 08/2013 - B-ALL/NHL 2002 regimen, Rituximab consolidation (PID784)GOP - Gemcitabine 800 / Paclitaxel 80 / Oxaliplatin 130, Testicular Carcinoma (PID779)Goserelin 10.8, Prostate Cancer (PID1520)HIPEC - Cisplatin 100, Ovarian ca (PID108)HIPEC - Mitomycin 15 / Cisplatin 75, Peritoneal Carcinomatosis, Secondary (PID121)HIPEC - Mitomycin 35, Peritoneal Carcinomatosis, Secondary (PID123)High dose Cyclophosphamide 2000 for stem cell mobilization, Multiple Myeloma (PID535)High-dose Cytarabine 3000 / Mitoxantrone 10, Acute Myeloid Leukemia, induction less than 60 years of age (PID596)High-dose Cytarabine 3000 / Mitoxantrone 10, sequential, Acute Myeloid Leukemia, induction, less than 60 years of age (PID603)HOVON 132 AML / SAKK 30/13 - B - Idarubicin 12 / Cytarabine 200 / Lenalidomide 20, induction, Acute Myeloid Leukemia, cycle 1 (PID1065)HOVON Daunorubicin 60 / Cytarabine 1000, induction, Acute Myeloid Leukemia, cycle 2 (PID1067)HOVON Idarubicin 12 / Cytarabine 200, induction, Acute Myeloid Leukemia, cycle 1 (PID1064)HOVON Mitoxantrone 10 / Etoposide 100, consolidation, Acute Myeloid Leukemia (PID1069)Hydroxyurea 1000, Chronic Myelomonocytic Leukemia (PID2300)Hydroxyurea 15, Polycythaemia Vera (PID9)Hydroxyurea 15, Sickle Cell Disease (PID1747)Hydroxyurea 15, Systemic Mastocytosis (PID1804)Hydroxyurea 20, Essential Thrombocythemia (PID8)Hydroxyurea 500, Langerhans Cell Histiocytosis (PID1998)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 5 (PID2087)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Ddoxorubicin 50 / Dexamethasone 40) / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 7 (PID2089)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Rituximab 375 / Imatinib 400, ALL/NHL, Ph/BCR-ABL+, intensification, month 7,19 (PID2113)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Rituximab 375 / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 3 (PID2086)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Rituximab 375 / Imatinib 800, ALL/NHL, Ph/BCR-ABL+, cycle 1 (PID2084)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Rituximab 375, ALL/NHL, cycle 1,3 (PID2061)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40), ALL/NHL, cycle 5,7 (PID2063)IbandronAcid 50, Bone Metastases (PID948)IbandronAcid 6, Bone Metastases (PID937)Ibrutinib 420 / Obinutuzumab 1000, Chronic Lymphocytic Leukemia, first-line, cycle 2-6 (PID1340)Ibrutinib 420 / Obinutuzumab(100/900/1000), Chronic Lymphocytic Leukemia, first-line, cycle 1 (PID1339)Ibrutinib 420 / Rituximab (50,325), Chronic Lymphocytic Leukemia, cycle 2, first-line (PID1326)Ibrutinib 420 / Rituximab 375 / Bendamustine 70, Chronic Lymphocytic Leukemia, cycle 1 (PID119)Ibrutinib 420 / Rituximab 375 / Fludarabine 25 / Cyclophosphamide 250, Chronic Lymphocytic Leukemia, first-line, cycle 1 (PID1546)Ibrutinib 420 / Rituximab 375, Waldenström's disease (PID1255)Ibrutinib 420 / Rituximab 375, Waldenström's disease, maintenance (PID1265)Ibrutinib 420 / Rituximab 500 / Bendamustine 70, Chronic Lymphocytic Leukemia, cycle 2+ (PID1179)Ibrutinib 420 / Rituximab 500, Chronic Lymphocytic Leukemia, cycle 3-7, first-line (PID1327)Ibrutinib 420 / Rituximab 500/ Fludarabine 25 / Cyclophosphamide 250, Chronic Lymphocytic Leukemiaa, first-line, cycle 2-6 (PID1547)Ibrutinib 420 / Venetoclax (20/50/100/200), Chronic Lymphocytic Leukemia, first-line, cycle 3, variant 1 (PID2600)Ibrutinib 420 / Venetoclax (20/50/100/200), Chronic Lymphocytic Leukemia, first-line, cycle 4 (PID1236)Ibrutinib 420 / Venetoclax 400, Chronic Lymphocytic Leukemia, first-line, cycle 4+, variant 1 (PID2601)Ibrutinib 420 / Venetoclax 400, Chronic Lymphocytic Leukemia, first-line, cycle 5-15. (PID1268)Ibrutinib 420 / Venetoclax 400, Chronic Lymphocytic Leukemia, Cycle 7-12 (PID2280)Ibrutinib 420, Chronic Lymphocytic Leukemia, first-line (PID790)Ibrutinib 420, Chronic Lymphocytic Leukemia, first-line, cycle 1-2, variant 1 (PID2599)Ibrutinib 420, Chronic Lymphocytic Leukemia, first-line, cycle 1-3. (PID1267)Ibrutinib 420, Chronic Lymphocytic Leukemia, second line (PID332)Ibrutinib 420, Chronic Lymphocytic Leukemia, cycle 1 and maintenance, first-line (PID1328)Ibrutinib 420, Chronic Lymphocytic Leukemia, Cycle 13-36 (PID2281)Ibrutinib 420, CLL, maintenance (PID82)Ibrutinib 420, Waldenström's disease (PID585)Ibrutinib 560 / Rituximab 375 / Bendamustine 90, Mantle Cell Lymphoma (PID2103)Ibrutinib 560 / Rituximab 375, Mantle Cell Lymphoma, Maintenance (PID2104)Ibrutinib 560 / Venetoclax (50/100/200/400), Mantle Cell Lymphoma, cycle 2. (PID2185)Ibrutinib 560 / Venetoclax 400, Mantle Cell Lymphoma, Cycle 3+ (PID2186)Ibrutinib 560, follicular lymphoma °I-IIIa (PID2335)Ibrutinib 560, Mantle Cell Lymphoma (PID274)Ibrutinib 560, Mantle Cell Lymphoma, Cycle 1 (PID2184)ICE - Ifosfamide 1.33 / Carboplatin 5 / Etoposide 100, Hodgkin Lymphoma. (PID2380)Idarubicin 12 / Cytarabine 100 / Quizartinib 35.4, Acute Myeloid Leukemia, Induction (PID2552)Idarubicin 12 / Cytarabine 1000, Acute Myeloid Leukemia, Induction, Cycle 2, salvage therapy (PID1247)Idelalisib 150 / Rituximab 375, Chronic Lymphocytic Leukemia, cycle 1 (PID276)Idelalisib 150 / Rituximab 500, Chronic Lymphocytic Leukemia, cycle 2-5 (PID330)Idelalisib 150 / Rituximab 500, Chronic Lymphocytic Leukemia, cycle 6-8 (PID331)Idelalisib 150, indolent B-non-Hodgkin Lymphoma (PID308)IE - Ifosfamide 1800 / Etoposide 100, Ewing Sarcoma (PID2068)Ifosfamide 1.5 / Cisplatin 20, Uterine Carcinosarcoma, adjuvant (PID1584)Ifosfamide 2 / Gemcitabine 800 / Vinorelbine 20 / Prednisolone 100, Hodgkin Lymphoma (PID70)Ifosfamide 2, Non-Small Cell Lung Carcinoma (PID1495)Ifosfamide 3 / Cisplatin (50/50), Osteosarcoma (PID1363)Ifosfamide 3 / Doxorubicin 60, Osteosarcoma (PID1364)Ifosfamide 3, Soft Tissue Sarcoma (PID509)Ifosfamide 5 / Carboplatin 300 / Etoposide (120/240) / Vincristine 1, Small Cell Lung Carcinoma (PID258)Ifosfamide 7, Soft Tissue Sarcoma, neoadjuvant (PID2546)Imatinib 300, Soft Tissue Sarcoma (PID2044)Imatinib 400 / Binimetinib 30, Gastrointestinal Stromal Tumor, cycle 1 (PID2009)Imatinib 400 / Binimetinib 30, Gastrointestinal Stromal Tumor, cycle 2+ (PID2010)Imatinib 400 / peginterferon alpha-2a 90, Chronic Myeloid Leukemia, Chronic Phase (PID952)Imatinib 400, Chronic Myeloid Leukemia (PID934)Imatinib 400, Gastrointestinal Stroma Tumor (PID796)Imatinib 400, Gastrointestinal Stroma Tumor, adjuvant (PID569)Imatinib 400, Myeloid/Lymphoid Neoplasia with Eosinophilia and TK Fusion. (PID2100)Imatinib 400, Systemic Mastocytosis (PID1806)Imatinib 400, Soft Tissue Sarcoma (PID2048)Inotuzumab Ozogamicin 0.8, Acute Lymphoblastic Leukaemia, Cycle 1 (PID161)Inotuzumab Ozogamicin 0.8, Acute Lymphoblastic Leukaemia, Cycle 2-6 (PID145)Interferon Alpha-2a 3 million, Chronic Myeloid Leukemia (PID951)Interferon Alpha-2a 3Mio / Temozolomide 150, cycle 2 (PID2473)Interferon Alpha-2a 3Mio / Temozolomide 200, Glioblastoma, Cycle 3-12 (PID2474)Intravenous Immunoglobulin-G 1, Immune Thrombocytopenia (PID955)Intravenous immunoglobulin-G 250, secondary antibody deficiency, hematologic neoplasms, stem cell transplantation (PID832)Ipilimumab 10, Malignant Melanoma, Adjuvant, Part A (PID887)Ipilimumab 10, Malignant Melanoma, Adjuvant, Part B (PID889)Ipilimumab 3, Malignant Melanoma (PID718)Ipilimumab 3, Malignant Melanoma, adjuvant, Cycle 1-4 (PID583)Ipilimumab 3, Malignant Melanoma, adjuvant, Cycle 5-8 (PID584)Iptacopan 200, Paroxysmal Nocturnal Hemoglobinuria (PID2669)Irinotecan 100 / Gemcitabine 1000, Carcinoma of Unknown Primary (PID515)Irinotecan 125, Colorectal Carcinoma (PID437)Irinotecan 150, Gastric Cancer (PID1489)Irinotecan 20 / Temozolomide 100, Ewing Sarcoma (PID1199)Irinotecan 240, Bile Duct Carcinoma (PID1954)Irinotecan 350, adenocarcinoma esophagogastric junction and stomach (PID139)Irinotecan 350, Colorectal Carcinoma (PID436)Irinotecan 50 / Carboplatin 5, Lung Carcinoma, Small Cell (PID241)Irinotecan 60 / Cisplatin 60, Lung Carcinoma, Small Cell (PID230)Irinotecan 60 / Cisplatin 60, Small Cell Lung Cancer, Part B (PID267)Irinotecan 60 / Cisplatin 60, Ovarian Carcinoma (PID2194)Irinotecan 65 / Cisplatin 30, Lung Carcinoma, Small Cell (PID229)Irinotecan 80 / Sodium Folinate 500 / Fluorouracil 2000, Colorectal Carcinoma (PID1157)Isatuximab 10 / Carfilzomib (20/56) / Dexamethasone 20, Multiple Myeloma, Cycle 1 (PID1808)Isatuximab 10 / Carfilzomib (20/56) / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma, Induction, Cycle 1 (PID2206)Isatuximab 10 / Carfilzomib 45 / Lenalidomide 15 / Dexamethasone 40, Multiple Myeloma, consolidation, cycle 7 (PID2261)Isatuximab 10 / Carfilzomib 56 / Dexamethasone 20, Multiple Myeloma, Cycle 2+ (PID1809)Isatuximab 10 / Carfilzomib 56 / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma, Induction, Cycle 2-6 (PID2207)Isatuximab 10 / Carfilzomib 56 / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma, consolidation, cycle 8-10 (PID2262)Isatuximab 10 / Carfilzomib 70 / Lenalidomide 15, Multiple Myeloma, maintenance, cycle 1-26 (PID2263)Isatuximab 10 / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, maintenance, cycle 18+ (PID2663)Isatuximab 10 / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, maintenance, cycle 5-17 (PID2662)Isatuximab 10 / Pomalidomide 4 / Dexamethasone 40, Multiple Myeloma, Cycle 1 (PID1716)Isatuximab 10 / Pomalidomide 4 / Dexamethasone 40, Multiple Myeloma, Cycle 2+ (PID1717)IVE/MTX - Epirubicin 50 / Etoposide 200 / Ifosfamide 3 / Methotrexate 1500, Enteropathy-associated T-cell Lymphoma, Part B (PID1651)Ivosidenib 500, acute myeloid leukaemia (PID2369)Ivosidenib 500, chondrosarcoma (PID2506)Ivosidenib 500, Bile Duct Carcinoma (PID2367)Ixazomib 3, Multiple Myeloma, Maintenance (PID2189)Ixazomib 4 / Bendamustine 75 / Dexamethasone 40, Multiple Myeloma, Cycle 1-9 (PID2409)Ixazomib 4 / Cyclophosphamide 300 / Dexamethasone 40, Multiple Myeloma, Cycle 1-9 (PID2411)Ixazomib 4 / Dexamethasone 20, AL-Amyloidosis (PID2534)Ixazomib 4 / Dexamethasone 20, Waldenström's disease, cycle 1-2 (PID2025)Ixazomib 4 / Lenalidomide 15 / Dexamethasone 40, AL-Amyloidosis (PID2477)Ixazomib 4 / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma (PID835)Ixazomib 4 / Pomalidomide 4 / Dexamethasone 40, Multiple Myeloma (PID1378)Ixazomib 4 / Rituximab 1400 / Dexamethasone 20, Waldenström's disease, cycle 4-8 (PID2027)Ixazomib 4 / Rituximab 375 / Dexamethasone 20, Waldenström's disease, cycle 3 (PID2026)Ixazomib 4, Multiple Myeloma, maintenance, cycle 10+ (PID2410)Lanreotide 120, Neuroendocrine Tumor (PID542)Lapatinib 1250 / Capecitabine 1000, Breast Cancer (PID367)Lapatinib 1500 / Fulvestrant (500/250), Breast Cancer, Cycle 1 (PID1770)Lapatinib 1500 / Fulvestrant 250, Breast Cancer, Cycle 2+ (PID1771)Lapatinib 1500 / Letrozole 2.5, Breast Cancer (PID1772)Larotrectinib 100, Tumor Biomarker Defined (PID1314)Lenalidomide 10, Multiple Myeloma, maintenance (PID2181)Lenalidomide 10, Multiple Myeloma, Maintenance after Autologous Stem Cell Transplantation, Autologous (PID891)Lenalidomide 10, Myelodysplastic Syndrome 5q- (PID118)Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma (PID521)Lenalidomide 25, diffuse large B-Non-Hodgkin Lymphoma, maintenance (PID2504)Lenalidomide 25, Kaposi's Sarcoma (PID2029)Lenalidomide 25, Mantle Cell Lymphoma (PID279)Lenalidomide 25, Multiple Myeloma, Smoldering (PID1544)Lenalidomide 25, T-cell Lymphoma (PID2462)Lenvatinib 12 / Pembrolizumab 200, Bile Duct Carcinoma (PID2481)Lenvatinib 12, Hepatocellular Carcinoma (PID79)Lenvatinib 18 / Everolimus 5, Renal Cell Carcinoma, second line (PID850)Lenvatinib 20 / Pembrolizumab 200, Endometrial Cancer (PID590)Lenvatinib 20 / Pembrolizumab 200, Melanoma (PID2254)Lenvatinib 20 / Pembrolizumab 200, Renal Cell Carcinoma (PID1927)Lenvatinib 20 / Pembrolizumab 200, Tumor, Various Organs (PID1518)Lenvatinib 24 / Pembrolizumab 200, Thyroid Cancer (PID2161)Lenvatinib 24, Adenoid Cystic Carcinoma (PID670)Lenvatinib 24, Gastroenteric and Pancreatic Neuroendocrine Tumors (PID2018)Lenvatinib 24, Thyroid Cancer (PID824)Letrozole 2.5, Breast Cancer, adjuvant (PID1580)Letrozole 2.5, Ovarian Carcinoma (PID2200)Leuprorelin 11.25, Prostate Cancer (PID1521)Leuprorelin 3.75 / Abiraterone 1000 / Prednisolone 5, Salivary Gland Tumor (PID1956)Leuprorelin 3.75 / Bicalutamide 80, Salivary Gland Tumor (PID1700)Lipegfilgrastim 6, Neutropenia (PID1539)Lomustine 100 / Temozolomide 100 / Radiation, Glioblastoma (PID488)Lomustine 110 / Vincristine 2 / Procarbazine 60 / Radiation, Glioma (PID1694)Lomustine 110 / Vincristine 2 / Procarbazine 60, Glioma (PID1347)Lomustine 110, Glioblastoma (PID550)Lomustine 75 / Vincristine 1.5 / Cisplatin 70, Medulloblastoma, maintenance. (PID915)Loncastuximab Tesirin 150, diffuse large B-non-Hodgkin Lymphoma, cycle 1-2 (PID2229)Loncastuximab Tesirin 75, diffuse large B-non-Hodgkin Lymphoma, cycle 3+ (PID2230)Lorlatinib 100, Non-Small Cell Lung Cancer (PID1344)Lorlatinib 100, Non-Small Cell Lung Cancer, First Line (PID1673)Lurbinectedin 3,2, small cell lung cancer (PID1839)Lurbinectedin 3.2, Small Cell Lung Cancer, Maintenance (PID2629)Luspatercept 1.0, Beta Thalassemia (PID1535)Luspatercept 1.0, Myelodysplastic Syndrome (PID1603)MAMAC - Cytarabine 2000 / Amsacrine 100, Acute Myeloid Leukemia (PID642)MAP - Cisplatin 60 / Doxorubicin 37.5 / Methotrexate 12, Osteosarcoma (PID1346)MCL Younger Trial, R-CHOP - Rituximab 375 / Cyclophosphamide 750 / Doxorbicin 50 / Vincristine 2 / Prednisolone 100, Mantle Cell Lymphoma Cycle 1, 3, 5 (PID291)MCL Younger Trial, R-DHAP - Rituximab 375 / Cisplatin 100 / Cytarabine 2000 / Dexamethasone 40, Mantle Cell Lymphoma Cycle 2, 4, 6 (PID325)MEC - Mitoxantrone 8 / Etoposide 100 / Cytarabine 1000, Acute Myeloid Leukemia (PID861)Megestrol 160, Endometrial Cancer (PID2198)Melphalan 0.18 / Prednisolone 2 / Lenalidomide 10 - Lenalidomide 10 maintenance, Multiple Myeloma, Part B (PID520)Melphalan 0.18 / Prednisolone 2 / Lenalidomide 10, induction, Multiple Myeloma, part A (PID518)Melphalan 140 / Treosulfan 12, Ewing Sarcoma, Autologous Stem Cell Transplantation (PID1396)Melphalan 2, Acute Myeloid Leukemia, over 65 years of age (PID1735)Mepolizumab 300, hypereosinophilic syndrome (PID2092)Methotrexate 100 / Peg-asparaginase 2000 / Imatinib 400, ALL/NHL, Ph/BCR-ABL+, intensification, month 6,18 (PID2110)Methotrexate 100 / Peg-asparaginase 2000, ALL/NHL, intensification, month 6,18 (PID2074)Methotrexate 1000 / Cytarabine 100, Langerhans Cell Histiocytosis (PID1999)Methotrexate 1000 / Cytarabine 3000 / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 6 (PID2088)Methotrexate 1000 / Cytarabine 3000 / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 8 (PID2090)Methotrexate 1000 / Cytarabine 3000, ALL/NHL, cycle 6,8 (PID2065)Methotrexate 12 / Cytarabine 100, Malignant Meningitis, CNS Prophylaxis (PID2575)Methotrexate 12, Malignant Meningitis, induction (PID608)Methotrexate 12, Malignant Meningitis, consolidation (PID871)Methotrexate 12, CNS therapy, Burkitt's Lymphoma (PID2231)Methotrexate 12.5, Gestational Trophoblastic Neoplasia (PID1616)Methotrexate 15 / Cytarabine 30, Burkitt's Lymphoma (PID2240)Methotrexate 15, Malignant Meningitis, CNS Prophylaxis (PID876)Methotrexate 30 / Vinblastine 3 / Doxorubicin 30 / Cisplatin 70, dose-dense, Bladder Cancer (PID545)Methotrexate 30 / Vinblastine 3 / Doxorubicin 30 / Cisplatin 70, Urinary Bladder Carcinoma, neoadjuvant (PID663)Methotrexate 30 / Vinblastine 3 / Doxorubicin 30 / Cisplatin 70, Urinary Bladder Carcinoma, neoadjuvant (PID1991)Methotrexate 30 / Vinblastine 4 / Cisplatin 100, Urinary Bladder Carcinoma, neoadjuvant (PID1992)Methotrexate 30 / Vinblastine 6, Soft Tissue Sarcoma (PID2042)Methotrexate 40, Head and Neck Tumors (PID1281)Methotrexate 50 / Vinorelbine 20, Soft Tissue Sarcoma (PID2043)Methotrexate 50, i.m., Gestational Trophoblastic Neoplasia (PID564)Methotrexate 500/3000, Malignant Meningitis (PID1000)Methotrexate 500/3000, CNS Prophylaxis, Malignant Meningitis (PID1001)Methotrexate 8000 / Rituximab 375 / Temozolomide 150, CNS Lymphoma, cycle 1 (PID1859)Methotrexate 8000 / Rituximab 375 / Temozolomide 150, CNS Lymphoma, cycle 2 (PID1860)Methotrexate 8000 / Temozolomide 150, CNS Lymphoma, cycle 3 (PID1861)Methotrexate 8000 / Temozolomide 150, CNS Lymphoma, cycle 4 (PID1864)Methotrexate 8000 / Temozolomide 150, CNS Lymphoma, cycle 5 (PID1865)Methotrexate 8000, Osteosarcoma (PID1365)Methylprednisolone 1000, CNS Lymphoma, maintenance. (PID2439)mFOLFIRINOX - Oxaliplatin 85 / Folinic Acid 400 / Irinotecan 150 / Fluorouracil 2400, Pancreatic Cancer, Adjuvant (PID1176)mFOLFOX-6 (Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400) / Nivolumab 240, Cancer Esophagus, Esophagogastric junction and Stomach (PID1905)mFOLFOX-6 - Nivolumab 240 / Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400 - Nivolumab 240, Cancer Esophagus, Esophagogastric junction and Stomach, maintenance (PID1910)mFOLFOX-6 - Nivolumab 240 / Trastuzumab 4 / Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400, Cancer Esophagus, Esophagogastric junction and Stomach, Cycle 2+ (PID2422)mFOLFOX-6 - Nivolumab 240 / Trastuzumab 6 / Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400, Cancer Esophagus, Esophagogastric junction and Stomach, Cycle 1 (PID2421)mFOLFOX-6 - Panitumumab 6 / Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400 - Panitumumab 6 / Folinic Acid 400 / Fluorouracil 2400, Colorectal Carcinoma, maintenance (PID1988)mFOLFOX-7 - Aflibercept 4 / Folinic Acid 400 / Fluorouracil 3000, Colorectal Carcinoma, maintenance (PID1917)mFOLFOX-7 - Aflibercept 4 / Oxaliplatin 100 / Folinic Acid 400 / Fluorouracil 3000, Colorectal Carcinoma (PID1916)Midostaurin 100, Aggressive Systemic Mastocytosis (PID1082)Midostaurin 50, Acute Myeloid Leukemia, maintenance (PID1081)MINE (Ifosfamide 1.33 / Mitoxantrone 8 / Etoposide 65), B-non-Hodgkin Lymphoma. (PID2389)mini-BEAM - Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 30, Hodgkin Lymphoma (PID2381)Mini-hyperCVD (Cyclophosphamide 150 / Vincristine 2 / Dexamethasone 20) / Inotuzumab Ozogamicin (0.6/0.3) / Rituximab 375, ALL/NHL, cycle 1 (PID2098)Mini-hyperCVD (Cyclophosphamide 150 / Vincristine 2 / Dexamethasone 20) / Inotuzumab Ozogamicin 0.3 / Rituximab 375, ALL/NHL, cycle 3 (PID2099)Mirvetuximab soravtansine 6, Ovarian Carcinoma (PID2606)Mito-FLAG - Fludarabine 15 / Cytarabine 1000 / Mitoxantrone 7, Acute Myeloid Leukemia (PID2521)Mitomycin 2, Non-Small Cell Lung Cancer (PID2373)Mitomycin 8 / Vinorelbine 25, Non-Small Cell Lung Cancer (PID757)Mitotan 1.5, Adrenocortical Carcinoma, adjuvant (PID2463)Mitoxantrone 12 / Prednisolone 5, Prostate Cancer castration resistant (PID2309)Mitoxantrone 12, Breast Cancer (PID1424)Mitoxantrone 20, Tumor, Various Organs (PID2370)Modified CAPIRI (Capecitabine 800 / Irinotecan 200) / Bevacizumab 7.5, Colorectal Carcinoma (PID446)modified Docetaxel 40 / Cisplatin 40 / Fluorouracil 1200, Anal Carcinoma (PID628)Modified FOLFOX-6 (Oxaliplain 85 / Folinic Acid 350 / Fluorouracil 2400) / Bevacizumab 5, Colorectal Carcinoma (PID26)modified FOLFOX-6 - Aflibercept 4 / Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400, carcinoma esophagus, esophagogastric junction and stomach (PID1915)modified FOLFOX-6 - Oxaliplatin 68 / Folinic Acid 350 / Fluorouracil 1920, Colorectal Carcinoma (PID1084)modified FOLFOX-6 - Oxaliplatin 85 / Folinic Acid 350 / Fluorouracil 2400, Bile Duct Carcinoma (PID1950)modified FOLFOX-6 - Oxaliplatin 85 / Folinic Acid 350 / Fluorouracil 2400, Colon Cancer, perioperative (PID2257)modified FOLFOX-6 - Oxaliplatin 85 / Folinic Acid 350 / Fluorouracil 2400, Colorectal Carcinoma (PID840)modified FOLFOX-6 - Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400 / Cetuximab (400/250), Colorectal Carcinoma, Cycle 1 (PID1112)modified FOLFOX-6 - Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400, colon carcinoma adjuvant (PID644)Modified FOLFOX-6 - Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400, Rectal Cancer, adjuvant, part C (PID2051)modified FOLFOX-6 - Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400, Rectal Cancer, neoadjuvant / adjuvant (PID2379)modified FOLFOX-6 - Panitumumab 6 / Oxaliplain 85 / Folinic Acid 400 / Fluorouracil 2400, Colorectal Carcinoma (PID96)modified FOLFOX-6/CETU - Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400 / Cetuximab 250, Colorectal Carcinoma, Cycle 2+ (PID1113)Modified FOLFOX-6/PNTM - Panitumumab 6 / Oxaliplain 85 / Folinic acid 400 / Fluorouracil 2400, Colorectal Carcinoma, induction (PID1989)modified FOLFOXIRI/CETU - Oxaliplatin 85 / Folinotecan 130 / Folinic Acid 200 / Fluorouracil 2400 / Cetuximab 500 - Bevacizumab 5 maintenance, Colorectal Carcinoma (PID1543)modified FOLFOXIRI/CETU - Oxaliplatin 85 / Irinotecan 130 / Folinic Acid 200 / Fluorouracil 2400 / Cetuximab 500 - Cetuximab 500 maintenance, Colorectal Carcinoma (PID1542)modified FOLFOXIRI/CETU - Oxaliplatin 85 / Irinotecan 130 / Folinic Acid 200 / Fluorouracil 2400 / Cetuximab 500, Colorectal Carcinoma, Cycle 1 (PID1553)modified FOLFOXIRI/CETU - Oxaliplatin 85 / Irinotecan 130 / Folinic Acid 200 / Fluorouracil 2400 / Cetuximab 500, Colorectal Carcinoma, Cycle 2-8 (PID1541)Mogamulizumab 1, cutaneous T-cell lymphoma, cycle 1 (PID1397)Mogamulizumab 1, cutaneous T-cell lymphoma, cycle 2-12 (PID1398)Momelotinib 200, Primary Myelofibrosis (PID2573)Mosunetuzumab (1/2/60), B-Non-Hodgkin Lymphoma, cycle 1 (PID2105)Mosunetuzumab 30, B-Non-Hodgkin Lymphoma, cycle 3+ (PID2107)Mosunetuzumab 60, B-Non-Hodgkin lymphoma, cycle 2 (PID2106)Moxetumomab Pasudotox 0.04, Hairy Cell Leukemia (PID1713)Mycophenolate Mofetil (500/1000), Autoimmune Hemolytic Anemia, warm type (PID2014)Nab-Paclitaxel 100 / Bevacizumab 10, Ovarian ca (PID900)Nab-Paclitaxel 100 / Carboplatin 2 / Bevacizumab 10, Breast Ca (tripel-negative) (PID466)Nab-Paclitaxel 100 / Carboplatin 6, Non-Small Cell Lung Cancer (PID213)Nab-Paclitaxel 100 / Cyclophosphamide 600 / Trastuzumab 6, Breast Cancer, adjuvant Cycle 2+ (PID410)Nab-Paclitaxel 100 / Cyclophosphamide 600 / Trastuzumab 8, Breast Cancer, adjuvant, cycle 1 (PID409)Nab-Paclitaxel 100 / Cyclophosphamide 600, Breast Cancer, adjuvant (PID58)Nab-Paclitaxel 125 / Carboplatin 2, Breast Cancer (PID61)Nab-Paclitaxel 125 / Carboplatin 2, Breast Cancer, neoadjuvant (PID1371)Nab-Paclitaxel 125 / Gemcitabine 1000, Pancreatic Cancer, adj. (PID810)Nab-Paclitaxel 125 / Gemcitabine 1000, Pancreatic Cancer, neoadjuvant (PID782)Nab-Paclitaxel 125 / Gemcitabine 1000, pancreatic cancer (PID287)Nab-Paclitaxel 125 / Trastuzumab (4/2), weekly, Breast Cancer Cycle 1 (PID427)Nab-Paclitaxel 125 / Trastuzumab 2, weekly, Breast Cancer Cycus 2+ (PID428)Nab-Paclitaxel 125 weekly, Breast Cancer (PID415)Nab-Paclitaxel 125, Breast Cancer, neoadj. (PID1354)Nab-Paclitaxel 125, Breast Cancer, Variant 1 (PID2512)Nab-Paclitaxel 150 weekly, Breast Cancer (PID114)Nab-Paclitaxel 260, Bladder Cancer (PID1528)Nab-Paclitaxel 260, Breast Cancer (PID98)NALIRIFOX - Pegylated Liposomal Irinotecan 50 / Oxaliplatin 60 / Folinic Acid 400 / Fluorouracil 2400, Pancreatic Cancer (PID2475)Sodium Thiosulfate 20, Hearing Loss, Cisplatin Induced (PID1401)Nelarabine 1500, T-ALL/T-LBL (PID1922)Nelarabine 650 / Etoposide 100 / Cyclophosphamide 440, T-ALL/T-LBL (PID1926)Nelarabine 650 / Peg-asparaginase 1500, T-ALL, maintenance, month 6, 7 (PID2083)Neratinib 240 / Capecitabine 750, Breast Cancer (PID1870)Neratinib 240, Breast Cancer (PID1415)Nilotinib 300, Chronic Myeloid Leukemia, Chronic Phase (PID938)Niraparib 200 / Abiraterone 1000 / Prednisolone 10, Prostate Cancer castration-resistant (PID2557)Niraparib 300 / Bevacizumab 15, Ovarian ca, maintenance (PID487)Niraparib 300, ovarian carcinoma, maintenance (PID477)Nivolumab - Relatlimab 320, Non-Small Cell Lung Cancer (PID2612)Nivolumab - Relatlimab 640, Malignant Melanoma (PID2329)Nivolumab 1 / Ipilimumab 3 - Nivolumab 240, Adenocarcinoma Esophagogastric Junction and Stomach, maintenance (PID1493)Nivolumab 1 / Ipilimumab 3 - Nivolumab 240, Hepatocellular Carcinoma, Maintenance (PID1789)Nivolumab 1 / Ipilimumab 3 - Nivolumab 240, Malignant Melanoma with Brain Metastases, maintenance (PID1206)Nivolumab 1 / Ipilimumab 3 - Nivolumab 240, Malignant Melanoma, adjuvant, Cycle 5-24 (PID1895)Nivolumab 1 / Ipilimumab 3 - Nivolumab 240, Melanoma, Malignant, maintenance (PID713)Nivolumab 1 / Ipilimumab 3, adenocarcinoma esophagogastric junction and stomach (PID1492)Nivolumab 1 / Ipilimumab 3, Hepatocellular Carcinoma (PID1788)Nivolumab 1 / Ipilimumab 3, Malignant Melanoma (PID711)Nivolumab 1 / Ipilimumab 3, Malignant Melanoma with Brain Metastases (PID1205)Nivolumab 1 / Ipilimumab 3, Melanoma, Malignant, Adjuvant, cycle 1-4 (PID1894)Nivolumab 240 / Cabozantinib 40, Renal Cell Carcinoma (PID1730)Nivolumab 240 / Cisplatin 80 / Fluorouracil 800 - Nivolumab 240, Esophageal Cancer, maintenance (PID1986)Nivolumab 240 / Cisplatin 80 / Fluorouracil 800, Esophageal Cancer (PID1985)Nivolumab 240 / Doxorubicin 25 / Vinblastine 6 / Dacarbazine 375, Hodgkin Lymphoma (PID1970)Nivolumab 240 / Doxorubicin 25 / Vinblastine 6 / Dacarbazine 375, Hodgkin Lymphoma, Part B (PID1375)Nivolumab 240 / Ipilimumab 1 - Nivolumab 480, Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 3-11 (PID2245)Nivolumab 240 / Ipilimumab 1, Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 1-2 (PID2244)Nivolumab 240 / Ipilimumab 1, Kaposi Sarcoma (PID2160)Nivolumab 240 / Ipilimumab 1, Merkel Cell Carcinoma (PID2414)Nivolumab 240 / Ipilimumab 1, Esophageal Cancer, Cycle 4+ (PID2151)Nivolumab 240 / Regorafenib 80, Adenocarcinoma Esophagogastric junction, Gastric and Colorectal Carcinoma (PID580)Nivolumab 240, adenocarcinoma esophagogastric junction and stomach (PID1381)Nivolumab 240, Anal Carcinoma (PID1749)Nivolumab 240, Bile Duct Carcinoma, Cycle 1-8 (PID2482)Nivolumab 240, Bladder Cancer (PID1007)Nivolumab 240, Bladder Cancer, Adjuvant (PID1801)Nivolumab 240, Hodgkin Lymphoma (PID844)Nivolumab 240, Hodgkin Lymphoma, part A (PID1374)Nivolumab 240, Carcinoma of Unknown Primary (PID1967)Nivolumab 240, carcinoma esophagus and gastroesophageal junction, adjuvant, cycle 1-8 (PID1764)Nivolumab 240, Colorectal Carcinoma (PID1234)Nivolumab 240, Head and Neck Tumors (PID856)Nivolumab 240, Malignant Melanoma, Adjuvant (PID1033)Nivolumab 240, Malignant Melanoma, First Line (PID712)Nivolumab 240, Melanoma, second line (PID629)Nivolumab 240, Merkel Cell Carcinoma, neoadjuvant (PID2413)Nivolumab 240, Non-Small Cell Lung Cancer, Second Line (PID598)Nivolumab 240, Renal Cell Carcinoma, second-line (PID729)Nivolumab 240, Renal Cell Carcinoma, cycle 1-6 (PID2156)Nivolumab 240, Esophageal Cancer (PID572)Nivolumab 240, Esophageal Cancer, Cycle 1-3 (PID2150)Nivolumab 3 / Ipilimumab 1 - Nivolumab 240, Renal Cell Carcinoma, maintenance (PID1139)Nivolumab 3 / Ipilimumab 1 - Nivolumab 480, Melanoma, Malignant, Maintenance (PID648)Nivolumab 3 / Ipilimumab 1 - Nivolumab 480, Renal Cell Carcinoma, maintenance (PID2260)Nivolumab 3 / Ipilimumab 1 / Cabozantinib 40 - Nivolumab 480 / Cabozantinib 40 Maintenance, Renal Cell Carcinoma, Cycle 5+ (PID2353)Nivolumab 3 / Ipilimumab 1 / Cabozantinib 40, Renal Cell Carcinoma, Cycle 1-4 (PID2352)Nivolumab 3 / Ipilimumab 1, Colorectal Carcinoma, first-line (PID2011)Nivolumab 3 / Ipilimumab 1, Colorectal Carcinoma, neoadjuvant (PID2328)Nivolumab 3 / Ipilimumab 1, Colorectal Carcinoma, Second Line (PID1386)Nivolumab 3 / Ipilimumab 1, Malignant Melanoma (PID647)Nivolumab 3 / Ipilimumab 1, Non-Small Cell Lung Cancer (PID1231)Nivolumab 3 / Ipilimumab 1, Renal Cell Carcinoma (PID1138)Nivolumab 3 / Ipilimumab 1, Renal Cell Carcinoma, salvage (PID2159)Nivolumab 3 / Ipilimumab 1, Esophageal Cancer (PID1987)Nivolumab 3 / Ipilimumab 1, Pleural Mesothelioma (PID1203)Nivolumab 360 / Capecitabine 1000 / Oxaliplatin 130 - Nivolumab 360 maintenance, Carcinoma Esophagus, Esophagogastric Junction and Stomach (PID1911)Nivolumab 360 / Carboplatin 5 / Paclitaxel 175, Non-Small Cell Lung Cancer, neoadjuvant, cycle 1-4 (PID2642)Nivolumab 360 / Carboplatin 5 / Pemetrexed 500, Non-Small Cell Lung Cancer, neoadjuvant, Cycle 1-4 (PID2643)Nivolumab 360 / Cisplatin 75 / Doxetaxel 75, Non-Small Cell Lung Cancer, neoadjuvant, Cycle 1-4 (PID2645)Nivolumab 360 / Gemcitabine 1000 / Cisplatin 70 - Nivolumab 480 Maintenance, Bladder Cancer (PID2491)Nivolumab 360 / Gemcitabine 1000 / Cisplatin 70, Bladder Cancer (PID2490)Nivolumab 360 / Gemcitabine 1250 / Cisplatin 75, Non-Small Cell Lung Cancer, neoadjuvant (PID2091)Nivolumab 360 / Ipilimumab 1 / Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer (PID1670)Nivolumab 360 / Ipilimumab 1 / Pemetrexed 500 / Carboplatin 6, Non-Small Cell Lung Cancer (PID1669)Nivolumab 360 / Ipilimumab 1 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer (PID1676)Nivolumab 360 / Ipilimumab 1, Non-Small Cell Lung Cancer, Maintenance (PID1671)Nivolumab 360 / Ipilimumab 1, Pleural Mesothelioma, first-line (PID1919)Nivolumab 360 / Paclitaxel 200 / Carboplatin 5, Non-Small Cell Lung Cancer, Neoadjuvant, Cycles 1-3 (PID2387)Nivolumab 360 / paclitaxel 200 / carboplatin 6 / bevacizumab 15 - Nivolumab 360 / bevacizumab 15, non-small cell lung cancer, maintenance (PID2126)Nivolumab 360 / Paclitaxel 200 / Carboplatin 6 / Bevacizumab 15, Non-Small Cell Lung Cancer (PID1929)Nivolumab 360 / Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer, neoadjuvant (PID2096)Nivolumab 360 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, neoadjuvant (PID2095)Nivolumab 360 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, neoadjuvant, Cycle 1-4 (PID2644)Nivolumab 360, Renal Cell Carcinoma, Cycle 7-10 (PID2157)Nivolumab 480 / Regorafenib 80, Hepatocellular Carcinoma (PID2572)Nivolumab 480, Bile Duct Carcinoma, Cycle 9+ (PID2483)Nivolumab 480, carcinoma esophagus and gastroesophageal junction, adjuvant, cycle 9-16 (PID1765)Nivolumab 480, Malignant Melanoma, Adjuvant (PID1411)Nivolumab 480, Malignant Melanoma, First Line (PID1136)Nivolumab 480, Malignant Melanoma, Second Line (PID1137)Nivolumab 480, Non-Small Cell Lung Cancer, adjuvant, Cycle 4-9 (PID2388)Nivolumab 480, Non-Small Cell Lung Cancer, adjuvant, Cycle 5-18 (PID2646)Nivolumab 480, Renal Cell Carcinoma, Second Line (PID1135)Nivolumab 480, Renal Cell Carcinoma, cycle 11+ (PID2158)NLG MCL-2 regimen - Cyclophosphamide 1200 / Doxorubicin 75 / Vincristine 2 / Prednisolone 100, Mantle Cell Lymphoma, cycle 1, younger than 60 years (PID289)NLG MCL-2 regimen - Cytarabine 3000 / Rituximab 375, Mantle Cell Lymphoma, cycle 2 and 4, younger than 60 years (PID290)NLG MCL-2 regimen - Cytarabine 3000 / Rituximab 375, Mantle Cell Lymphoma, cycle 6, younger than 60 years (PID269)NLG MCL-2 regimen - Rituximab 375 / Cyclophosphamide 1200 / Doxorubicin 75 / Vincristine 2 / Prednisolone 100, Mantle Cell Lymphoma, cycles 3 and 5, younger than 60 years (PID268)Obinutuzumab (100/900/1000) / Chlorambucil 0.5, CLL Cycle 1 (PID323)Obinutuzumab (100/900/1000) / Ibrutinib 420 / Venetoclax 20, Chronic Lymphocytic Leukemia, Cycle 1 (PID2277)Obinutuzumab (100/900/1000) / Venetoclax 20, Chronic Lymphocytic Leukemia, cycle 1, first-line (PID1259)Obinutuzumab (100/900/1000) / Zanubrutinib 160, Chronic Lymphocytic Leukemia, Cycle 1 (PID2637)Obinutuzumab 1000 - CHOP - Obinutuzumab 1000, follicular lymphoma °I-IIIa, maintenance (PID1173)Obinutuzumab 1000 - CHOP - Obinutuzumab 1000, follicular lymphoma °I-IIIa, cycle 7-8 (PID1174)Obinutuzumab 1000 / Bendamustine 90 - Obinutuzumab 1000 Maintenance, follicular lymphoma °I-IIIa (PID725)Obinutuzumab 1000 / Bendamustine 90 - Obinutuzumab 1000 maintenance, follicular lymphoma °I-IIIa, first-line (PID1647)Obinutuzumab 1000 / Bendamustine 90, follicular lymphoma °I-IIIa, cycle 1 (PID710)Obinutuzumab 1000 / Bendamustine 90, follicular lymphoma °I-IIIa, cycle 1, first-line (PID1645)Obinutuzumab 1000 / Bendamustine 90, follicular lymphoma °I-IIIa, cycle 2-6 (PID724)Obinutuzumab 1000 / Bendamustine 90, follicular lymphoma °I-IIIa, cycle 2-6, first-line (PID1646)Obinutuzumab 1000 / Chlorambucil 0.5, CLL Cycle 2-6 (PID335)Obinutuzumab 1000 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, follicular lymphoma grade I-IIIa, cycle 1 (PID1171)Obinutuzumab 1000 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, follicular lymphoma grade I-IIIa, cycle 2-6 (PID1172)Obinutuzumab 1000 / Cyclophosphamide 750 / Vincristine 2 / Prednisolone 100, follicular lymphoma grade I-IIIa, cycle 1. (PID2416)Obinutuzumab 1000 / Cyclophosphamide 750 / Vincristine 2 / Prednisolone 100, follicular lymphoma grade I-IIIa, cycle 2-6. (PID2417)Obinutuzumab 1000 / glofitamab (2.5/10), diffuse large B-non-Hodgkin Lymphoma, cycle 1 (PID2393)Obinutuzumab 1000 / Ibrutinib 420 / Venetoclax (50/100/200/400), Chronic Lymphocytic Leukemia, Cycle 2 (PID2278)Obinutuzumab 1000 / Ibrutinib 420 / Venetoclax 400, Chronic Lymphocytic Leukemia, Cycle 3-6 (PID2279)Obinutuzumab 1000 / Lenalidomide 20 - Obinutuzumab 1000 / Lenalidomide 10 maintenance, follicular Lymphoma °I-IIIa, cycle 7-12 (PID2338)Obinutuzumab 1000 / Lenalidomide 20 - Obinutuzumab 1000 maintenance, follicular Lymphoma °I-IIIa, cycle 13-18 (PID2339)Obinutuzumab 1000 / Lenalidomide 20, follicular Lymphoma °I-IIIa, cycle 1 (PID2336)Obinutuzumab 1000 / Lenalidomide 20, follicular Lymphoma °I-IIIa, cycle 2-6 (PID2337)Obinutuzumab 1000 / Venetoclax (20/50/100/200), CLL, Induction Cycle 2 (PID613)Obinutuzumab 1000 / Venetoclax (50/100/200/400), Chronic Lymphocytic Leukemia, cycle 2, first line (PID1316)Obinutuzumab 1000 / Venetoclax 400 - Obinutuzumab (100/900/1000), CLL, Induction Cycle 1 (PID609)Obinutuzumab 1000 / Venetoclax 400 - Venetoclax 400, Chronic Lymphocytic Leukemia, maintenance, first-line (PID1318)Obinutuzumab 1000 / Venetoclax 400, Chronic Lymphocytic Leukemia, cycle 3-6, first line (PID1317)Obinutuzumab 1000 / Venetoclax 400, CLL, maintenance (PID633)Obinutuzumab 1000 / Venetoclax 400, CLL, Induction, Cycle 3-6 (PID624)Obinutuzumab 1000 / Zanubrutinib 160 / Venetoclax (20/50/100/200), Chronic Lymphocytic Leukemia, Cycle 3 (PID2639)Obinutuzumab 1000 / Zanubrutinib 160 / Venetoclax 400, Chronic Lymphocytic Leukemia, Cycle 4-8 (PID2640)Obinutuzumab 1000 / Zanubrutinib 160, Chronic Lymphocytic Leukemia, Cycle 2 (PID2638)Obinutuzumab 1000 / zanubrutinib 160, follicular Lymphoma °I-IIIa, cycle 1 (PID2593)Obinutuzumab 1000 / zanubrutinib 160, follicular Lymphoma °I-IIIa, cycle 2-6 (PID2594)Obinutuzumab 1000 / zanubrutinib 160, follicular Lymphoma °I-IIIa, cycle 7+ (PID2595)Obinutuzumab 1000, B-non-Hodgkin Lymphoma, maintenance (PID2341)Obinutuzumab 1000, B-Non-Hodgkin Lymphoma, Induction (PID2340)Obinutuzumab 1000, follicular lymphoma °I-IIIa, maintenance (PID2419)Obinutuzumab 1000, follicular Lymphoma °I-IIIa, cycle 7-8 (PID2418)Octreotide 0.5, Thymoma (PID1845)Octreotide LAR 30, gastroenteric and pancreatic Neuroendocrine Tumor (PID543)Octreotide LAR 30, Merkel Cell Carcinoma (PID2415)OFAR - Oxaliplatin 25 / Fludarabine 30 / Cytarabine 1000 / Rituximab 375, Chronic Lymphocytic Leukemia, Richter Syndrome, cycle 1 (PID828)OFAR - Oxaliplatin 25 / Fludarabine 30 / Cytarabine 1000 / Rituximab 375, Chronic Lymphocytic Leukemia, Richter Syndrome, cycle 2+ (PID829)Ofatumumab (300/1000) / Bendamustine 90, Chronic Lymphocytic Leukemia, cycle 1 (PID431)Ofatumumab (300/1000) / Chlorambucil 10, Chronic Lymphocytic Leukemia, cycle 1 (PID407)Ofatumumab (300/1000), follicular lymphoma grade I-IIIa (PID314)Ofatumumab 1000 / Bendamustine 90, Chronic Lymphocytic Leukemia, cycle 2+ (PID432)Ofatumumab 1000 / Chlorambucil 10, Chronic Lymphocytic Leukemia, cycle 2+ (PID408)Ofatumumab 1000 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, follicular lymphoma grade I-IIIa cycle 2-6 (PID149)Ofatumumab 300 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, follicular lymphoma grade I-IIIa cycle 1 (PID133)OFF - Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2000, Pancreatic Cancer (PID517)Olaparib 300 / Abiraterone 1000 / Prednisolone 5, Prostate Cancer castration resistant (PID2326)Olaparib 300 / Bevacizumab 15, Ovarian ca, maintenance (PID1351)Olaparib 300, Breast Cancer (PID1105)Olaparib 300, Breast Cancer, adjuvant (PID2134)Olaparib 300, Ovarian ca, maintenance (PID531)Olaparib 300, Pancreatic Cancer, Maintenance (PID1475)Olaparib 300, Prostate Cancer Castration Resistant (PID1559)Olaratumab 15 / Doxorubicin 75 - Olaratumab 15 maintenance, Soft Tissue Sarcoma (PID847)Olaratumab 15 / Doxorubicin 75, Soft Tissue Sarcoma, Cycle 1 (PID845)Olaratumab 15 / Doxorubicin 75, Soft Tissue Sarcoma, Cycle 2-4 (PID846)Olaratumab 15 / Doxorubicin 75, Soft Tissue Sarcoma, Cycle 5-8 (PID851)Osimertinib 80 / Pemetrexed 500 / Carboplatin 5, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2543)Osimertinib 80 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2540)Osimertinib 80 / Pemetrexed 500, Non-Small Cell Lung Cancer, Cycle 5+ (PID2541)Osimertinib 80, Non-Small Cell Lung Cancer, Adjuvant (PID1672)Osimertinib 80, Non-Small Cell Lung Cancer, First Line (PID1100)Osimertinib 80, Non-Small Cell Lung Cancer, Second Line (PID812)Oxaliplatin 100 / Folinic Acid 400 / Fluorouracil 2400, Rectal Cancer, adjuvant, B (PID64)Oxaliplatin 100 / Sodium Folinate 400 / Fluorouracil 2400, Colorectal Carcinoma (PID1175)Oxaliplatin 130, Testicular Carcinoma (PID1576)Oxaliplatin 50 / Fluorouracil 250 / Radiation, Rectal Cancer, neoadjuvant, Part A (PID65)Oxaliplatin 60, Testicular Carcinoma (PID1585)Oxaliplatin 65 / Sodium Folinate 300 / Fluorouracil 2600, Gastric Cancer (PID2528)Oxaliplatin 70 / Radiation, Nasopharyngeal Carcinoma (PID1783)Oxaliplatin 80 / Irinotecan 160, Carcinoma in Unknown Primary (PID1189)Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 600, Ovarian Carcinoma. (PID2196)Paclitaxel 100 / Carboplatin 2, Breast Cancer (PID1961)Paclitaxel 100 / Carboplatin 2, Non-Small Cell Lung Cancer (PID205)Paclitaxel 100 / Carboplatin 4, Carcinoma Esophagus and Gastroesophageal Junction, Induction (PID2312)Paclitaxel 100 / Carboplatin 6, Non-Small Cell Lung Cancer (PID148)Paclitaxel 100, Kaposi Sarcoma (PID1202)Paclitaxel 120 / Cisplatin 50 / Fluorouracil 1000, Penile Carcinoma (PID1442)Paclitaxel 135 / Cisplatin 20 / Radiation, Esophageal Cancer, adjuvant (PID2242)Paclitaxel 135 / Cisplatin 30 / Radiation, Cervical Carcinoma (PID1990)Paclitaxel 135 / Ifosfamide 1.6, Uterine Carcinosarcoma (PID1110)Paclitaxel 175 / Carboplatin 5 / Bevacizumab 5, Melanoma (PID2017)Paclitaxel 175 / Carboplatin 5 / Bevacizumab 7.5, Ovarian Carcinoma (PID500)Paclitaxel 175 / Carboplatin 5 followed by Radiation, Cervical Cancer adjuvant (PID97)Paclitaxel 175 / Carboplatin 5, Endometrial Cancer (PID124)Paclitaxel 175 / Carboplatin 5, Endometrial Cancer adjuvant, Part B (PID923)Paclitaxel 175 / Carboplatin 5, Carcinoma of Unknown Primary (PID514)Paclitaxel 175 / Carboplatin 5, Uterine Carcinosarcoma, adjuvant (PID1600)Paclitaxel 175 / Carboplatin 5, Ovarian ca (PID497)Paclitaxel 175 / Carboplatin 5, Cervical Cancer (PID1937)Paclitaxel 175 / Carboplatin 6 / Bevacizumab 15, Ovarian Carcinoma cycle 1 (PID498)Paclitaxel 175 / Carboplatin 6 / Bevacizumab 15, Ovarian Carcinoma cycle 2+ (PID499)Paclitaxel 175 / Carboplatin 6, Endometrial Cancer (PID1703)Paclitaxel 175 / Carboplatin 6, Endometrial Cancer adjuvant (PID1579)Paclitaxel 175 / Carboplatin 7.5, Ovarian ca, adjuvant (PID1335)Paclitaxel 175 / Cisplatin 20 / Etoposide 100 / Bleomycin 30 / Oxaliplatin 130, Testicular Carcinoma (PID2142)Paclitaxel 175 / Cisplatin 50 / Bevacizumab 15, Cervical Cancer (PID600)Paclitaxel 175 / Cisplatin 50, Non-Small Cell Lung Cancer, Induction, Neoadjuvant, Part A (PID852)Paclitaxel 175 / Cisplatin 80 / Etoposide 80, Small Cell Lung Cancer (PID232)Paclitaxel 175 / Cisplatin 80, Non-Small Cell Lung Cancer (PID157)Paclitaxel 175 / Gemcitabine 1250, Breast Cancer (PID377)Paclitaxel 175 / Gemcitabine 1250, Non-Small Cell Lung Cancer (PID158)Paclitaxel 175 / Topotecan 0.75 / Bevacizumab 15, Cervical Cancer (PID769)Paclitaxel 175, Endometrial Cancer (PID732)Paclitaxel 175, Breast Carcinoma (PID2132)Paclitaxel 175, Breast Cancer (tripel-negative) adjuvant (PID479)Paclitaxel 175, Penile Carcinoma (PID1648)Paclitaxel 200 / Bevacizumab 15, Soft Tissue Sarcoma (PID1828)Paclitaxel 200 / Carboplatin 6 / Bevacizumab 15 - Bevacizumab 15 Maintenance , Non-Small Cell Lung Cancer, (Adeno) Part A (PID130)Paclitaxel 200 / Carboplatin 6 / Bevacizumab 15 - Bevacizumab 15 Maintenance, Non-Small Cell (Adeno) Lung Carcinoma, Non-Small Cell (Adeno) Part B (PID167)Paclitaxel 200 / Carboplatin 6 consolidation after Paclitaxel 45 / Carboplatin 2 / Radiation, Non-Small Cell Lung Cancer Part B (PID254)Paclitaxel 200 / Carboplatin 6 consolidation after Paclitaxel 50 / Carboplatin 2 / Radiation, Non-Small Cell Lung Cancer Part B (PID256)Paclitaxel 200 / Carboplatin 6, Carcinoma in Occult Primary (PID1192)Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer (PID170)Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer, adjuvant (PID246)Paclitaxel 200 / Carboplatin 6, Thyroid Cancer (PID2136)Paclitaxel 200 / Carboplatin 6, Thymic Carcinoma (PID1185)Paclitaxel 200 / Gemcitabine 1000, Non-Small Cell Lung Cancer (PID169)Paclitaxel 200, Non-Small Cell Lung Cancer (PID193)Paclitaxel 200, Salivary Gland Tumor (PID2239)Paclitaxel 225 / Carboplatin 6, Non-Small Cell Lung Cancer (PID92)Paclitaxel 225 / Carboplatin 6, Thymoma (PID363)Paclitaxel 225, Testicular Carcinoma (PID1573)Paclitaxel 40 / Carboplatin 1 / Radiation, Head and Neck Tumors (PID2386)Paclitaxel 45 / Carboplatin 1.5 / Radiation, Head and Neck Tumors (PID1295)Paclitaxel 45 / Carboplatin 2 / Radiation, Non-Small Cell Lung Cancer, Part A (PID253)Paclitaxel 50 / Carboplatin 2 / Radiation, Cancer Esophagus and Gastroesophageal Junction (PID2241)Paclitaxel 50 / Carboplatin 2 / Radiation, carcinoma esophagus and gastroesophageal junction, neoadjuvant (PID131)Paclitaxel 50 / Carboplatin 2 / Radiation, Non-Small Cell Lung Cancer, Part A (PID255)Paclitaxel 60 / Carboplatin 2, Ovarian Carcinoma (PID2429)Paclitaxel 80 / Bevacizumab 10, Ovarian ca (PID1366)Paclitaxel 80 / Carboplatin 2, Carcinoma of Unknown Primary (PID568)Paclitaxel 80 / Carboplatin 2, Small Cell Lung Carcinoma (PID242)Paclitaxel 80 / Carboplatin 5, Anal Carcinoma (PID1352)Paclitaxel 80 / Carboplatin 6, Breast Cancer (PID1552)Paclitaxel 80 / Carboplatin 6, Ovarian ca (PID91)Paclitaxel 80 / Gemcitabine 1000 / Cisplatin 70, Bladder Cancer (PID1359)Paclitaxel 80 / Trastuzumab 2, Breast Cancer, adjuvant, cycle 2-12 (PID933)Paclitaxel 80 / Trastuzumab 4, Breast Cancer adjuvant, Cycle 1 (PID932)Paclitaxel 80, Bladder Cancer (PID1527)Paclitaxel 80, Small Cell Lung Carcinoma (PID245)Paclitaxel 80, Head and Neck Tumors (PID1216)Paclitaxel 80, Gastric Cancer (PID1488)Paclitaxel 80, Breast Carcinoma (PID2127)Paclitaxel 80, Breast Cancer, adjuvant (PID581)Paclitaxel 80, Esophageal Cancer (PID693)Paclitaxel 80, Ovarian Carcinoma (PID508)Paclitaxel 80, Thyroid Cancer (PID2135)Paclitaxel 80, Soft Tissue Sarcoma (PID1207)Paclitaxel 90 / Bevacizumab 10, Breast Cancer (PID120)Paclitaxel 90 / Bevacizumab 15, Soft Tissue Sarcoma (PID1827)Paclitaxel 90, Non-Small Cell Lung Cancer (PID194)PAED B-NHL 2013, AAZ1_24, B-non-Hodgkin Lymphoma (PID1323)PAED B-NHL 2013, AAZ2_24, B-non-Hodgkin Lymphoma (PID1886)PAED B-NHL 2013, AA_24, B-Non-Hodgkin Lymphoma (PID1877)PAED B-NHL 2013, AA_8Z1, B-non-Hodgkin Lymphoma (PID1878)PAED B-NHL 2013, A_4, B-Non-Hodgkin Lymphoma (PID1863)PAED B-NHL 2013, BBZ1_24, B-non-Hodgkin Lymphoma (PID1897)PAED B-NHL 2013, BBZ2_24, B-Non-Hodgkin Lymphoma (PID1898)PAED B-NHL 2013, BB_24, B-Non-Hodgkin Lymphoma (PID1889)PAED B-NHL 2013, b_4, B-non-Hodgkin Lymphoma (PID1887)PAED B-NHL 2013, B_4, B-Non-Hodgkin Lymphoma (PID1888)PAED B-NHL 2013, CC, B-Non-Hodgkin Lymphoma (PID1899)PAED B-NHL 2013, Prephase P(IT), B-Non-Hodgkin Lymphoma (PID1322)PAED B-NHL 2013, Prephase P, B-Non-Hodgkin Lymphoma (PID1261)PAED B-NHL 2013, Rituximab 375, B-non-Hodgkin Lymphoma (PID1884)PAED B-NHL 2013, Rituximab 375, B-non-Hodgkin Lymphoma (PID1885)PAED B-NHL 2013, Rituximab Window RZ, B-Non-Hodgkin Lymphoma (PID1862)PAED B-NHL 2013, Rituximab Window, B-non-Hodgkin Lymphoma (PID1321)PAED Carboplatin 500 / Fluorouracil 1000, Nasopharyngeal Carcinoma, Part A (PID681)PAED Cisplatin 100 / Folinic Acid 25 / Fluorouracil 1000, Nasopharyngeal Carcinoma, Part A (PID723)PAED Cisplatin 20 / Radiation, Nasopharyngeal Carcinoma, Part B (PID682)PAED Cisplatin 80, Hepatoblastoma, perioperative (PID1405)PAED Clofarabin 25, Langerhans Cell Histiocytosis (PID80)PAED COALL 08-09, maintenance, B-ALL/T-ALL, LR-reduced, and HR-reduced (PID24)PAED COALL 08-09, Maintenance, B-ALL/T-ALL, LR-Standard and LR-Intensified and HR-Standard and HR- Intensified (PID25)PAED COALL 08-09, maintenance, B-ALL/T-ALL, MTX intrathecal (without CNS irradiation) (PID33)PAED COALL 08-09, induction, all patients (PID11)PAED COALL 08-09, Intensive phase, B-ALL, HR-Intensified C1a-C4-C4-C3-C3-C1a-C5 (PID19)PAED COALL 08-09, intensive phase, B-ALL, HR-Intensified C1b-C4-C3-C3-C1a-C5 (PID20)PAED COALL 08-09, intensive phase, B-ALL, LR intensified and HR reduced, and HR standard C1a-C4-C4-C3-C3-C1a (PID15)PAED COALL 08-09, intensive phase, B-ALL, LR intensified and HR standard C1b-C4-C4-C3-C3-C1a (PID14)PAED COALL 08-09, intensive phase, B-ALL, LR standard C1b-C2-C3-C2 (PID13)PAED COALL 08-09, Intensive Phase, B-ALL, LR Standard and LR Reduced C1a-C2-C3-C2. (PID12)PAED COALL 08-09, intensive phase, T-ALL, HR-Intensified C4-C1a-C4-C3-C3-C1a-C5 (PID18)PAED COALL 08-09, intensive phase, T-ALL, HR-Intensified C4-C1b-C4-C3-C1a-C5 (PID1412)PAED COALL 08-09, intensive phase, T-ALL, HR standard C4-C1b-C4-C3-C1a (PID17)PAED COALL 08-09, intensive phase, T-ALL, HR standard and HR reduced C4-C1a-C4-C3-C3-C1a (PID16)PAED COALL 08-09, Reinduction, B-ALL, LR-Standard R2(ADR)-R3 (PID30)PAED COALL 08-09, Reinduction, B-ALL, LR-Standard R2(DNR)-R3 (PID22)PAED COALL 08-09, Reinduction, B-ALL/T-ALL, HR Intensified R2 before CNS (PID32)PAED COALL 08-09, Reinduction, B-ALL/T-ALL, LR-Intensified and HR-Standard and HR-Intensified R2(ADR)-R2-R3-R3 (PID31)PAED COALL 08-09, Reinduction, B-ALL/T-ALL, LR-Intensified and HR-Standard and HR-Intensified R2(DNR)-R2-R3-R3 (PID23)PAED COALL 08-09, Reinduction, B-ALL/T-ALL, LR-Reduced and HR-Reduced R1 (PID21)PAED COALL 08-09, Pre-phase, all patients (PID10)PAED COALL 08-09, CNS, B-ALL/T-ALL, initial CNS involvement (PID29)PAED COALL 08-09, CNS, B-ALL/T-ALL, LR and HR (B-ALL leukoc. up to 200000/µl, T-ALL leukoc. up to 100000/µl) (PID28)PAED CWS-Guidance, ACCTTIVE - Vincristine 1.5 / Doxorubicin 20 / Cyclophosphamide 1200, Soft Tissue Sarcoma (PID1311)PAED CWS-Guidance, CEVAIE, CEV - Carboplatin 500 / Epirubicin 150 / Vincristine 1.5, Vincristine intensification, Soft Tissue Sarcoma (PID1296)PAED CWS-Guidance, CEVAIE, CEV - Carboplatin 500 / Epirubicin 150 / Vincristine 1.5, Soft Tissue Sarcoma (PID1297)PAED CWS-Guidance, CEVAIE, I³VA- Ifosfamide 3 / Vincristine 1.5 / Dactinomycin 1.5, Vincristine intensification, Soft Tissue Sarcoma (PID1293)PAED CWS-Guidance, CEVAIE, I³VA- Ifosfamide 3 / Vincristine 1.5 / Dactinomycin 1.5, Soft Tissue Sarcoma (PID1294)PAED CWS-Guidance, CEVAIE, I³VE - Ifosfamide 3 / Vincristine 1.5 / Etoposide 150, Soft Tissue Sarcoma (PID1298)PAED CWS-Guidance, CWS-91-REZ, Block A - Carboplatin 150 / Etoposide 150, Soft Tissue Sarcoma (PID1305)PAED CWS-Guidance, CWS-91-REZ, Block B- Ifosfamide 2 / Etoposide 150, Soft Tissue Sarcoma (PID1306)PAED CWS-Guidance, CWS-91-REZ, Block C - Carboplatin 150 / Ifosfamide 2, Soft Tissue Sarcoma (PID1307)PAED CWS-Guidance, I²VA - Ifosfamide 3 / Vincristine 1.5 / Dactinomycin 1.5, VNCR intensification, Soft Tissue Sarcoma (PID1287)PAED CWS-Guidance, I²VA - Ifosfamide 3 / Vincristine 1.5 / Dactinomycin 1.5, Soft Tissue Sarcoma (PID1288)PAED CWS-Guidance, I²VAd - Ifosfamide 3 / Vincristine 1.5 / Doxorubicin 20, Vincristine intensification, Soft Tissue Sarcoma (PID1290)PAED CWS-Guidance, I²VAd - Ifosfamide 3 / Vincristine 1.5 / Doxorubicin 20, Soft Tissue Sarcoma (PID1292)PAED CWS guidance, Methotrexate 20 / Vinblastine 3, fibromatosis, aggressive (PID1315)PAED CWS-Guidance, O-TE - Trofosfamide 75 / Etoposide 25, Soft Tissue Sarcoma, maintenance (PID1304)PAED CWS-Guidance, O-TI - Trofosfamide 75 / Idarubicin 5, Soft Tissue Sarcoma, Maintenance (PID1303)PAED CWS-Guidance, Paclitaxel 200, Angiosarcoma (PID1320)PAED CWS-Guidance, TECC Block A / ACCTTIVE - Topotecan 1 / Carboplatin 150, Soft Tissue Sarcoma (PID1308)PAED CWS-Guidance, TECC Block B - Topotecan 1 / Cyclophosphamide 250, Soft Tissue Sarcoma (PID1309)PAED CWS-Guidance, TECC Block C / ACCTTIVE - Carboplatin 150 / Etoposide 150, Soft Tissue Sarcoma (PID1310)PAED CWS-Guidance, VA - Vincristine 1.5 / Dactinomycin 1.5, Rhabdomyosarcoma (PID1237)PAED CWS-Guidance, VA2 - Vincristine 1.5 / Dactinomycin 1.5, Rhabdomyosarcoma (PID1289)PAED CWS-Guidance, VAC - Vincristine 1.5 / Dactinomycin 1.5 / Cyclophosphamide 20, fibromatosis, aggressive (PID1312)PAED Cytarabine 500 / Cladribine 9, Langerhans Cell Histiocytosis (PID916)PAED Etoposide 150 / Dexamethasone (5 / 2.5 / 1.25), Hemophagocytic Lymphohistiocytosis, cycle 2 (PID666)PAED Etoposide 150 / Dexamethasone 10, Hemophagocytic Lymphohistiocytosis, Cycle 1 (PID665)PAED Etoposide 150 / Dexamethasone 10, Hemophagocytic Lymphohistiocytosis, Cycle 3+ (PID667)PAED EuroNet-PHL-C2, COPDAC-28, Hodgkin Lymphoma (PID1279)PAED EuroNet-PHL-C2, DECOPDAC-21, Hodgkin Lymphoma (PID1239)PAED EuroNet-PHL-C2, OEPA, Hodgkin Lymphoma (PID1280)PAED Interferon beta 1A 0.1m, Nasopharyngeal Carcinoma, Part C (PID738)PAED Methotrexate 12, Hemophagocytic Lymphohistiocytosis (PID672)PAED SIOP CNS GCT II - Etoposide 100 / Carboplatin 600, Germ Cell Tumor, Intracranial, Cycle 1 and 3 (PID1555)PAED SIOP CNS GCT II - Ifosfamide 1.8 / Etoposide 100, Germ Cell Tumor, Intracranial, Cycle 2 and 4 (PID1382)PAED Vemurafenib 10, Langerhans Cell Histiocytosis (PID1667)PAED Vinblastine 6 / Prednisolone 40, Langerhans Cell Histiocytosis, maintenance (PID78)PAED Vinblastine 6 / Prednisolone 40, Langerhans Cell Histiocytosis, induction (PID81)Palbociclib 125 / Exemestane 25 / Leuprorelin 3.75, Breast Cancer (PID1532)Palbociclib 125 / Fulvestrant 500, Breast Cancer, Cycle 1 (PID607)Palbociclib 125 / Fulvestrant 500, Breast Cancer, Cycle 2+ (PID822)Palbociclib 125 / Letrozole 2.5, Breast Cancer (PID823)Panitumumab 6 / Folinic Acid 200 / Fluorouracil 2400, Colorectal Carcinoma (PID1416)Panitumumab 6 / Sotorasib 960, Colorectal Carcinoma (PID2205)Panitumumab 6, Colorectal Carcinoma (PID435)Panitumumab 6, Squamous Cell Carcinoma of the Skin (PID2384)Pazopanib 800, Chondrosarcoma (PID2511)Pazopanib 800, renal cell carcinoma (PID94)Pazopanib 800, Ovarian Carcinoma (PID2193)Pazopanib 800, von Hippel-Lindau disease (PID1958)Pazopanib 800, Soft Tissue Sarcoma (PID511)Pazopanib 800, Soft Tissue Sarcoma, first-line (PID1665)PE - Cisplatin 60 / Etoposide 120, Thymoma (PID368)Pegcetacoplan 1080, Paroxysmal Nocturnal Hemoglobinuria (PID1928)Pegfilgrastim 6, Neutropenia (PID1538)Peginterferon alpha-2a 90, Essential Thrombocythemia (PID1217)Peginterferon alpha-2a 90, Systemic Mastocytosis (PID1805)Doxorubicin Pegylated Liposomal 20, Kaposi Sarcoma (PID1201)Pegylated liposomal Doxorubicin 30 / Carboplatin 5, Ovarian Ca (PID494)Pegylated Liposomal Doxorubicin 30 / Trabectedin 1,1, Ovarian Carcinoma (PID496)Pegylated liposomal Doxorubicin 40 / Bevacizumab 10, Ovarian ca (PID1367)Pegylated Doxorubicin Liposomal 40, cutaneous T-cell lymphoma (PID1387)Pegylated Liposomal Doxorubicin 40, Breast Cancer (PID914)Pegylated Liposomal Doxorubicin 40, Ovarian ca (PID913)pegylated liposomal Doxorubicin 5 / Pomalidomide 3 / Dexamethasone 40, Multiple Myeloma (PID1590)Pegylated Liposomal Doxorubicin 50, Ovarian Carcinoma (PID502)Doxorubicin Pegylated Liposomal 50, Soft Tissue Sarcoma (PID1200)Pegylated Liposomal Irinotecan 70 / Folinic Acid 400 / Fluorouracil 2400, Pancreatic Cancer (PID793)PEI - Cisplatin 20 / Etoposide 100 / Ifosfamide 1.2, testicular carcinoma (PID1284)PEI - Cisplatin 20 / Etoposide 75 / Ifosfamide 1.2, Testicular Carcinoma (PID773)Pembrolizumab / Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer (PID36)Pembrolizumab 200 / Axitinib 5, Renal Cell Carcinoma (PID1219)Pembrolizumab 200 / Axitinib 5, Soft Tissue Sarcoma (PID2460)Pembrolizumab 200 / Bevacizumab 15 / Cyclophosphamide 50, Ovarian ca (PID1109)Pembrolizumab 200 / Bevacizumab 15, Cervical Cancer, Cycle 7+ (PID2251)Pembrolizumab 200 / Carboplatin 2 / Gemcitabine 1000, Breast Cancer (PID1933)Pembrolizumab 200 / Carboplatin 5 / Etoposide 100, Lung Carcinoma, Small Cell (PID630)Pembrolizumab 200 / Carboplatin 5 / Fluorouracil 1000, Head and Neck Tumors, first-line (PID1446)Pembrolizumab 200 / Cisplatin 100 / Fluorouracil 1000, Head and Neck Tumors (PID1447)Pembrolizumab 200 / Cisplatin 25 / Gemcitabine 1000, Bile Duct Carcinoma (PID2550)Pembrolizumab 200 / Cisplatin 40 / Radiation, Cervical Cancer, Cycle 1-2 (PID2654)Pembrolizumab 200 / Cisplatin 75 / Etoposide 100, Small Cell Lung Carcinoma, Small Cell (PID610)Pembrolizumab 200 / Cisplatin 75 / Gemcitabine 1000, Non-Small Cell Lung Cancer, Neoadjuvant, Cycle 1-4 (PID2376)Pembrolizumab 200 / Cisplatin 80 / Capecitabine 1000 - Pembrolizumab 200, Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 7-17. (PID2237)Pembrolizumab 200 / Cisplatin 80 / Capecitabine 1000, Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 1-6. (PID2236)Pembrolizumab 200 / Cisplatin 80 / Fluorouracil 800 - Pembrolizumab 200 / Fluorouracil 800 maintenance, adenocarcinoma esophagogastric junction and stomach (PID1507)Pembrolizumab 200 / Cisplatin 80 / Fluorouracil 800 - Pembrolizumab 200 / Fluorouracil 800 maintenance, esophageal and gastroesophageal junction carcinoma (PID1823)Pembrolizumab 200 / Cisplatin 80 / Fluorouracil 800, adenocarcinoma esophagogastric junction and stomach (PID1451)Pembrolizumab 200 / Cisplatin 80 / Fluorouracil 800, Carcinoma Esophagus and Gastroesophageal Junction (PID1822)Pembrolizumab 200 / Doxorubicin 60 / Cyclophosphamide 600, Breast Ca, neoadjuvant, cycle 5-8 (PID1466)Pembrolizumab 200 / Doxorubicin liposomal 15 / Gemcitabine 1000 / Vinorelbine 20, Hodgkin lymphoma (PID2024)Pembrolizumab 200 / Epirubicin 90 / Cyclophosphamide 600, Breast Ca, neoadjuvant, cycle 5-8 (PID1465)Pembrolizumab 200 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600) - PEMB200, Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 7-17 (PID2235)Pembrolizumab 200 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600), Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 1,4 (PID2232)Pembrolizumab 200 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600), Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 2,5 (PID2233)Pembrolizumab 200 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600), Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 3,6 (PID2234)Pembrolizumab 200 / Nab-Paclitaxel 100 / Carboplatin 6, Non-Small Cell Lung Cancer (PID35)Pembrolizumab 200 / Nab-Paclitaxel 100, Breast Cancer (PID1930)Pembrolizumab 200 / Nab-Paclitaxel 125, Bladder Cancer (PID1767)Pembrolizumab 200 / Oxaliplatin 130 / Capecitabine 1000, Adenocarcinoma Esophagogastric Junction and Stomach (PID2577)Pembrolizumab 200 / Paclitaxel 175 / Carboplatin 5 - Pembrolizumab 400, Endometrial Cancer, Cycle 7-20 (PID2316)Pembrolizumab 200 / Paclitaxel 175 / Carboplatin 5 / Bevacizumab 15, Cervical Cancer, Cycle 1-6 (PID1890)Pembrolizumab 200 / Paclitaxel 175 / Carboplatin 5, Endometrial Cancer, Cycle 1-6 (PID2315)Pembrolizumab 200 / Paclitaxel 175 / Carboplatin 5, Cervical Cancer, Cycle 1-6 (PID1892)Pembrolizumab 200 / Paclitaxel 175 / Cisplatin 50 / Bevacizumab 15, Cervical Cancer, Cycle 1-6 (PID1891)Pembrolizumab 200 / Paclitaxel 175 / Cisplatin 50, Cervical Cancer, cycle 1-6 (PID1900)Pembrolizumab 200 / Paclitaxel 80 / Carboplatin 5, Breast Cancer, neoadjuvant, cycle 1-4 (PID1464)Pembrolizumab 200 / Paclitaxel 90, Breast Cancer (PID1932)Pembrolizumab 200 / Pemetrexed 500 / Carboplatin 5, Non-Small Cell Lung Cancer (PID842)Pembrolizumab 200 / Pemetrexed 500 / Carboplatin 5, Pleural Mesothelioma (PID2598)Pembrolizumab 200 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer (PID1177)Pembrolizumab 200 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, Neoadjuvant, Cycles 1-4 (PID2377)Pembrolizumab 200 / Pemetrexed 500 / Cisplatin 75, Pleural Mesothelioma (PID2597)Pembrolizumab 200 / Pemetrexed 500, Non-Small Cell Lung Cancer, Maintenance (PID1170)Pembrolizumab 200 / Radiation, Head and Neck Tumors (PID2258)Pembrolizumab 200 / Sacituzumab Govitecan 10, Bladder Cancer (PID2562)Pembrolizumab 200 / Trastuzumab 6 / Cisplatin 80 / Fluorouracil 800, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 2+ (PID2102)Pembrolizumab 200 / Trastuzumab 6 / Oxaliplatin 130 / Capecitabine 1000, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 2+ (PID2094)Pembrolizumab 200 / Trastuzumab 8 / Cisplatin 80 / Fluorouracil 800, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 1 (PID2101)Pembrolizumab 200 / Trastuzumab 8 / Oxaliplatin 130 / Capecitabine 1000, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 1 (PID2093)Pembrolizumab 200, adenocarcinoma esophagogastric junction and stomach (PID1299)Pembrolizumab 200, Anal Carcinoma (PID1750)Pembrolizumab 200, Cancer of the Small Intestine (PID2356)Pembrolizumab 200, Endometrial Cancer (PID1960)Pembrolizumab 200, Gestational Trophoblastic Neoplasia (PID1536)Pembrolizumab 200, Bladder Cancer, First Line (PID1158)Pembrolizumab 200, Bladder Cancer, Second Line (PID99)Pembrolizumab 200, Hepatocellular Carcinoma (PID1376)Pembrolizumab 200, Hodgkin Lymphoma (PID1264)Pembrolizumab 200, Hodgkin Lymphoma, A (PID1969)Pembrolizumab 200, Kaposi Sarcoma (PID2592)Pembrolizumab 200, Carcinoma of Unknown Primary (PID2426)Pembrolizumab 200, Lung Carcinoma, Small Cell, Maintenance (PID631)Pembrolizumab 200, Small Cell Lung Carcinoma, Second Line (PID1345)Pembrolizumab 200, Colorectal Carcinoma (PID1517)Pembrolizumab 200, Colorectal Carcinoma, First Line (PID1675)Pembrolizumab 200, Head and Neck Tumors, first-line (PID1445)Pembrolizumab 200, Head and Neck Tumors, Second Line (PID239)Pembrolizumab 200, Breast Ca, adjuvant, cycle 9-17 (PID1868)Pembrolizumab 200, Breast Cancer, Maintenance (PID1931)Pembrolizumab 200, Breast Cancer, First-Line (PID1324)Pembrolizumab 200, Breast Cancer, Second Line (PID1329)Pembrolizumab 200, Melanoma (PID597)Pembrolizumab 200, Melanoma, adjuvant (PID1154)Pembrolizumab 200, Melanoma, neoadjuvant/adjuvant (PID2303)Pembrolizumab 200, Merkel Cell Carcinoma, first-line (PID1285)Pembrolizumab 200, Merkel Cell Carcinoma, second-line (PID1078)Pembrolizumab 200, Adrenocortical Carcinoma (PID2484)Pembrolizumab 200, non-small cell lung cancer, adjuvant (PID2170)Pembrolizumab 200, Non-Small Cell Lung Cancer, adjuvant, Cycle 5-18 (PID2378)Pembrolizumab 200, Non-Small Cell Lung Cancer, Maintenance (PID1083)Pembrolizumab 200, Non-Small Cell Lung Cancer, First-Line (PID809)Pembrolizumab 200, Non-Small Cell Lung Cancer, Second Line (PID808)Pembrolizumab 200, Renal Cell Carcinoma, adjuvant (PID1834)Pembrolizumab 200, Pancreatic Cancer (PID2476)Pembrolizumab 200, Squamous Cell Carcinoma of the Skin (PID1691)Pembrolizumab 200, Pleural Mesothelioma (PID1636)Pembrolizumab 200, Pleural Mesothelioma, maintenance (PID2613)Pembrolizumab 200, Thymoma (PID2324)Pembrolizumab 200, Tumor Biomarker Defined (PID1704)Pembrolizumab 200, Soft Tissue Sarcoma (PID2461)Pembrolizumab 200, Cervical Cancer (PID1331)Pembrolizumab 200, Cervical Cancer, Cycle 3-5 (PID2655)Pembrolizumab 200, Cervical Cancer, Cycle 7+ (PID1893)Pembrolizumab 400, Bladder Cancer, First Line (PID1262)Pembrolizumab 400, Bladder Cancer, Second Line (PID1263)Pembrolizumab 400, Hodgkin Lymphoma (PID1269)Pembrolizumab 400, Head and Neck Tumors (PID1270)Pembrolizumab 400, Melanoma (PID1250)Pembrolizumab 400, Melanoma, adjuvant (PID1251)Pembrolizumab 400, Non-Small Cell Lung Cancer, First Line (PID1252)Pembrolizumab 400, Non-Small Cell Lung Cancer, Second Line (PID1253)Pembrolizumab 400, Tumor Biomarker Defined (PID1286)Pembrolizumab 400, Cervical Cancer, Cycle 6-21 (PID2656)Pembrolizumab, B-NHL, Primary Mediastinal (PID1545)Pemetrexed 50 / Dexamethasone 5, intrathecal, Malignant Meningitis, cycle 1 (PID2529)Pemetrexed 50 / Dexamethasone 5, intrathecal, Malignant Meningitis, cycle 2 (PID2530)Pemetrexed 50 / Dexamethasone 5, intrathecal, Malignant Meningitis, cycle 3+ (PID2531)Pemetrexed 500 / Amivantamab 1750, Non-Small Cell Lung Cancer, Cycle 5+ (PID2501)Pemetrexed 500 / Carboplatin 5 / Amivantamab (350/1050/1400), Non-Small Cell Lung Cancer, Cycle 1 (PID2498)Pemetrexed 500 / Carboplatin 5 / Amivantamab 1400, Non-Small Cell Lung Cancer, Cycle 2 (PID2499)Pemetrexed 500 / Carboplatin 5 / Amivantamab 1750, Non-Small Cell Lung Cancer, Cycle 3-4 (PID2500)Pemetrexed 500 / Carboplatin 5 / Radiation - Pemetrexed 500 Consolidation, Non-Small Cell Lung Cancer, (Adeno) Part A (PID250)Pemetrexed 500 / Carboplatin 5 / Radiation - Pemetrexed 500 Consolidation, Non-Small Cell Lung Cancer (Adeno) Part B (PID251)Pemetrexed 500 / Carboplatin 5, non-small cell lung carcinoma (Adeno-) (PID178)Pemetrexed 500 / Carboplatin 5, Pleural Mesothelioma (PID391)Pemetrexed 500 / Carboplatin 6 - Pemetrexed 500 Maintenance, Non-Small Cell (Adeno) Lung Cancer, Part A (PID181)Pemetrexed 500 / Carboplatin 6 - Pemetrexed 500 Maintenance, Non-Small Cell (Adeno) Lung Cancer, Part B (PID182)Pemetrexed 500 / Carboplatin 6 / Bevacizumab 15 - Bevacizumab 15 Maintenance, Non-Small Cell Lung Carcinoma, Non-Small Cell (Adeno) Part A (Stevenson) (PID188)Pemetrexed 500 / Carboplatin 6 / Bevacizumab 15 - Bevacizumab 15 Maintenance, Non-Small Cell Lung Carcinoma, Non-Small Cell (Adeno) Part B (Stevenson) (PID189)Pemetrexed 500 / Carboplatin 6 / Bevacizumab 15 - Pemetrexed 500 / Bevacizumab 15 maintenance, non-small cell lung carcinoma (Adeno-) part A (PID183)Pemetrexed 500 / Carboplatin 6 / Bevacizumab 15 - Pemetrexed 500 / Bevacizumab 15 maintenance, non-small cell lung cancer (Adeno) Part B (PID184)Pemetrexed 500 / Carboplatin 6, Non-Small Cell Lung Cancer (PID177)Pemetrexed 500 / Cisplatin 75 / Bevacizumab 15, Pleural Mesothelioma (PID830)Pemetrexed 500 / Cisplatin 75 / Bevacizumab 7.5 - Bevacizumab 7.5 Maintenance, Non-Small Cell (Adeno) Lung Carcinoma, Non-Small Cell (Adeno) Part B (PID187)Pemetrexed 500 / Cisplatin 75 / Bevacizumab 7.5 - Pemetrexed 500 / Bevacizumab 7.5 Maintenance, Non-Small Cell Lung Carcinoma, Non-Small Cell (Adeno) Part B (PID186)Pemetrexed 500 / Cisplatin 75 / Bevacizumab 7.5, Non-Small Cell Lung Cancer, Part A (PID185)Pemetrexed 500 / Cisplatin 75 / Radiation - Pemetrexed 500 Consolidation, Non-Small Cell (Adeno) Lung Carcinoma, Non-Small Cell (Adeno) Part B (PID249)Pemetrexed 500 / Cisplatin 75 / Radiation, Non-Small Cell Lung Cancer, Part A (PID247)Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer (PID27)Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, Part A (PID179)Pemetrexed 500 / Cisplatin 75, Pleural Mesothelioma (PID390)Pemetrexed 500, Bladder Cancer (PID1526)Pemetrexed 500, Non-Small Cell Lung Cancer, Non-Small Cell (Adeno), First-Line (PID176)Pemetrexed 500, Non-Small Cell Lung Cancer, Non-Small Cell (Adeno), Second Line (PID175)Pemetrexed 500, Non-Small Cell Lung Cancer, Part B, Maintenance (PID180)Pemetrexed 500, Pleural Mesothelioma (PID392)Pemetrexed 500, Thymoma (PID1846)Pemigatinib 13.5, Bile Duct Carcinoma (PID1787)Pemigatinib 13.5, Myeloid/Lymphoid Neoplasia with Eosinophilia and TK Fusion (PID2114)Pentostatin 4 / Alemtuzumab (3/10/30), T-Cell Prolymphocyte Leukemia, Cycle 1 (PID1566)Pentostatin 4 / Alemtuzumab 30, T-Cell Prolymphocyte Leukemia, Cycle 2-4 (PID1567)Pentostatin 4 / Alemtuzumab 30, T-Cell Prolymphocyte Leukemia, Cycle 5-8 (PID1568)Pentostatin 4 / Rituximab 375, Hairy Cell Leukemia (PID839)Pentostatin 4, Hairy Cell Leukemia (PID537)Pentostatin 4, T-Cell Prolymphocyte Leukemia, Cycle 1-4 (PID1562)Pentostatin 4, T-Cell Prolymphocyte Leukemia, Cycle 5-8 (PID1563)Pertuzumab 1200 / Trastuzumab 600 / Nab-Paclitaxel 125, Breast Cancer, Cycle 1 (PID1756)Pertuzumab 1200 / Trastuzumab 600 / Paclitaxel 80, Breast Cancer, Cycle 1 (PID1758)Pertuzumab 420 / Trastuzumab 6 / Anastrozole 1, Breast Cancer, Cycle 2+ (PID1500)Pertuzumab 420 / Trastuzumab 6 / Docetaxel 75 / Carboplatin 6, Breast Cancer, neoadjuvant, cycle 2-6 (PID1470)Pertuzumab 420 / Trastuzumab 6 / Docetaxel 75, Breast Cancer, adjuvant, cycle 2-4 (PID1166)Pertuzumab 420 / Trastuzumab 6 / Docetaxel 75, Breast Cancer, neoadjuvant, cycle 2-4, 4-6, or 5-6 (PID750)Pertuzumab 420 / Trastuzumab 6 / Docetaxel 75, Breast Cancer, Cycle 2+ (PID364)Pertuzumab 420 / Trastuzumab 6 / Docetaxel 75, Non-Small Cell Lung Cancer, Cycle 2+ (PID1976)Pertuzumab 420 / Trastuzumab 6 / Epirubicin 90 / Cyclophosphamide 600, Breast Cancer, neoadj, cycle 2-5 (PID1410)Pertuzumab 420 / Trastuzumab 6 / Letrozole 2.5, Breast Cancer, adjuvant, Cycle 2-9 (PID2442)Pertuzumab 420 / Trastuzumab 6 / Letrozole 2.5, Breast Cancer, Neoadjuvant, Cycle 2-4 (PID2434)Pertuzumab 420 / Trastuzumab 6 / Letrozole 2.5, Breast Cancer, Cycle 2+ (PID1497)Pertuzumab 420 / Trastuzumab 6 / Nab-Paclitaxel 125, Breast Cancer, neoadj. cycle 2-4 (PID1356)Pertuzumab 420 / Trastuzumab 6 / Paclitaxel 80 / Carboplatin 6, Breast Carcinoma, neoadjuvant, cycle 2-9 (PID2122)Pertuzumab 420 / Trastuzumab 6 / Paclitaxel 80, Breast Cancer, adj. cycle 2-4 (PID1168)Pertuzumab 420 / Trastuzumab 6 / Paclitaxel 80, Breast Cancer, neoadjuvant, cycle 2-4 (PID2432)Pertuzumab 420 / Trastuzumab 6 / Tamoxifen 20, Breast Cancer, adjuvant, cycle 2-9 (PID2443)Pertuzumab 420 / Trastuzumab 6 / Tamoxifen 20, Breast Cancer, Neoadjuvant, Cycle 2-4 (PID2441)Pertuzumab 420 / Trastuzumab 6, Breast Cancer, adjuvant (PID1350)Pertuzumab 420 / Trastuzumab 6, Breast Cancer, Adjuvant, Cycle 5-18 (PID680)Pertuzumab 420 / Trastuzumab 6, Salivary Gland Tumor, Cycle 2+ (PID1702)Pertuzumab 420 / Trastuzumab 6, Tumor Biomarker Defined, Cycle 2+ (PID1534)Pertuzumab 420, Breast Cancer, Cycle 2+ (PID2608)Pertuzumab 600 / Trastuzumab 600 / Nab-Paclitaxel 125, Breast Cancer, Cycle 2+ (PID1757)Pertuzumab 600 / Trastuzumab 600 / Paclitaxel 80, Breast Cancer, Cycle 2+ (PID1759)Pertuzumab 600 / Trastuzumab 600, Breast Ca, adjuvant, 5-18 (PID1755)Pertuzumab 600 / Trastuzumab 600, Breast Cancer (PID1760)Pertuzumab 840 / Trastuzumab 8 / Docetaxel 75, Breast Cancer, Cycle 1 (PID361)Pertuzumab 840 / Trastuzumab 8 / Anastrozole 1, Breast Cancer, Cycle 1 (PID1498)Pertuzumab 840 / Trastuzumab 8 / Docetaxel 75 / Carboplatin 6, Breast Cancer, neoadjuvant, cycle 1 (PID1469)Pertuzumab 840 / Trastuzumab 8 / Docetaxel 75, Breast Cancer, adjuvant, cycle 1 (PID1165)Pertuzumab 840 / Trastuzumab 8 / Docetaxel 75, Breast Cancer, neoadjuvant, cycle 1 or cycle 4 (PID589)Pertuzumab 840 / Trastuzumab 8 / Docetaxel 75, Non-Small Cell Lung Cancer, Cycle 1 (PID1975)Pertuzumab 840 / Trastuzumab 8 / Letrozole 2.5, Breast Cancer, Adjuvant, Cycle 1 (PID2451)Pertuzumab 840 / Trastuzumab 8 / Letrozole 2.5, Breast Cancer, Neoadjuvant, Cycle 1 (PID2433)Pertuzumab 840 / Trastuzumab 8 / Letrozole 2.5, Breast Cancer, Cycle 1 (PID1496)Pertuzumab 840 / Trastuzumab 8 / Nab-Paclitaxel 125, Breast Cancer, neoadj. cycle 1 (PID1355)Pertuzumab 840 / Trastuzumab 8 / Paclitaxel 80, Breast Cancer, adj. cycle 1 (PID1167)Pertuzumab 840 / Trastuzumab 8 / Paclitaxel 80, Breast Cancer, neoadjuvant, cycle 1 (PID2431)Pertuzumab 840 / Trastuzumab 8 / Tamoxifen 20, Breast Cancer, adjuvant, cycle 1 (PID2450)Pertuzumab 840 / Trastuzumab 8 / Tamoxifen 20, Breast Cancer, neoadjuvant, cycle 1 (PID2440)Pertuzumab 840 / Trastuzumab 8, Salivary Gland Tumor, Cycle 1 (PID1701)Pertuzumab 840 / Trastuzumab 8, Tumor Biomarker Defined, Cycle 1 (PID1533)Pertuzumab 840, Breast Cancer, Cycle 1 (PID2607)Pertuzumab 840/ Trastuzumab 8/ Paclitaxel 80/ Carboplatin 6, Breast Carcinoma, neoadjuvant, cycle 1 (PID2121)Pirtobrutinib 200, Mantle Cell Lymphoma (PID2509)Pixantron 50, diffuse large B-non-Hodgkin Lymphoma (PID360)Pola-R-CHP - Polatuzumab Vedotin 1.8 / Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 1-6 (PID1920)Pola-R-CHP - Rituximab 375, Diffuse Large B-Non-Hodgkin Lymphoma, cycle 7-8. (PID1921)Pomalidomide 4 / Cyclophosphamide 400 / Dexamethasone 40, Multiple Myeloma (PID57)Pomalidomide 4 / Cyclophosphamide 400 / Dexamethasone 40, Multiple Myeloma, Variant 1 (PID53)Pomalidomide 4 / Cyclophosphamide 500 / Dexamethasone 40, Multiple Myeloma (PID1226)Pomalidomide 4 / Dexamethasone 40, Multiple Myeloma (PID122)Pomalidomide 4, Kaposi's Sarcoma (PID2030)POMP (Mercaptopurine 50 / Methotrexate 10), ALL/NHL, maintenance, month 13-36, variant 1 (PID2120)POMP (Mercaptopurine 50 / Vincristine 2 / Methotrexate 10 / Prednisolone 50), ALL/NHL, maintenance, month 1-12, variant 1 (PID2119)POMP (Mercaptopurine 50 / Vincristine 2 / Methotrexate 20 / Prednisolone 200), ALL/NHL, maintenance, month 1-5,8-17,20-30 (PID2072)Ponatinib 45, Chronic Myeloid Leukemia (PID950)Pralsetinib 400, Non-Small Cell Lung Cancer (PID1936)Pralsetinib 400, Thyroid Cancer (PID2141)Prednisolone (1.5/0.75/0.5) / Rituximab 375, Autoimmune Hemolytic Anemia, warm type (PID2007)Prednisolone (1.5/0.75/0.5), Autoimmune Hemolytic Anemia, warm type (PID2006)Prednisolone 1 / Rituximab 1000, Autoimmune Hemolytic Anemia, warm type (PID2015)Prednisolone 40 / Vinblastine 6 / Doxorubicin 50 / Gemcitabine 1000, Hodgkin Lymphoma (PID1075)Prednisolone 5 / Ciclosporin (2.5/1.5), Autoimmune Hemolytic Anemia, warm type (PID2013)Prednisolone 60 / Dasatinib 140 - Blinatumomab 28 / Dasatinib 140, Acute Lymphoblastic Leukaemia, Part A (PID1678)Prednisolone 60 / Dasatinib 140 - Blinatumomab 28 / Dasatinib 140, Acute Lymphoblastic Leukaemia, Part B (PID1679)Tumor Lysis Syndrome Prophylaxis for High Risk Tumor Lysis Syndrome (PID312)Prophylaxis of tumor lysis syndrome in intermediate risk tumor lysis syndrome (PID311)Quizartinib (26.5/53), Acute Myeloid Leukemia, maintenance, cycle 1 (PID2554)Quizartinib 53, Acute Myeloid Leukemia, maintenance, cycle 2+ (PID2555)R- Benda - Rituximab 375 / Bendamustine 120, diffuse large B-non-Hodgkin Lymphoma (PID338)R- Benda - Rituximab 375 / Bendamustine 120, Hodgkin Lymphoma (PID2405)R- Benda - Rituximab 375 / Bendamustine 90, diffuse large B-non-Hodgkin Lymphoma (PID1159)R- ICE - Rituximab 375 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID348)R- ICE - Rituximab 375 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, diffuse large B-non-Hodgkin Lymphoma, cycle 2+3 (PID349)R-ABVD - Rituximab 375 / Doxorubicin 25 / Bleomycin 10 / Vinblastine 6 / Dacarbazine 375, Hodgkin Lymphoma (PID2396)R-ACVBP - Cytarabine 100 consolidation, diffuse large B-non-Hodgkin Lymphoma Part D (PID343)R-ACVBP - high-dose Methotrexate 3000, diffuse large B-non-Hodgkin Lymphoma, consolidation, part B (PID341)R-ACVBP - Rituximab 375 / Doxorubicin 75 / Cyclophosphamide 1200 / Vindesin 2 / Bleomycin 10 / Prednisolone 60, induction, diffuse large B-non-Hodgkin Lymphoma Part A (PID340)R-ACVBP - Rituximab 375 / Ifosfamide 1.5 / Etoposide 300 consolidation, diffuse large B-non-Hodgkin Lymphoma Part C (PID342)R-ASHAP - Rituximab 375 / Doxorubicin 10 / Cisplatin 25 / Cytarabine 2000 / Methylprednisolone 375, diffuse large B-non-Hodgkin Lymphoma (PID359)R-BAC - Rituximab 375 / Bendamustine 70 / Cytarabine 800, mantle cell lymphoma, cycle 2+ (PID691)R-BAC - Rituximab 375 / Bendamustine 70 / Cytararbine 800, mantle cell lymphoma, cycle 1 (PID690)R-BOP - Rituximab 375 / Bendamustine 60 / Vincristine 2 / Prednisolone 100, indolent B non-Hodgkin Lymphoma and Mantle Cell Lymphoma (PID297)R-CEPP - Rituximab 375 / Cyclophosphamide 600 / Etoposide 70 / Procarbazine 60 / Prednisolone 60, diffuse large B-Non-Hodgkin Lymphoma (PID2508)R-CHOEP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Etoposide 100 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID722)R-CHOP - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone, 100 Waldenström's disease (PID676)R-CHOP - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, Mantle Cell Lymphoma (PID275)R-CHOP - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, follicular lymphoma grade I-IIIa (PID294)R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 1-6 (PID112)R-CHOP 14 - Rituximab 375, diffuse large B-non-Hodgkin Lymphoma, cycle 7-8 (PID1448)R-CHOP 21 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100 / Methotrexate 12, Testicular Lymphoma, Cycle 1 (PID901)R-CHOP 21 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100 / Methotrexate 12, Testicular Lymphoma, Cycle 2 (PID902)R-CHOP 21 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, Testicular Lymphoma, Cycle 3-6 (PID903)R-CHOP 21 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 40, diffuse large B-non-Hodgkin Lymphoma (PID113)R-COEP - Rituximab 375 / Cyclophosphamide 750 / Etoposide (50/100) / Vincristine 2 / Prednisolone 45, diffuse large B-non-Hodgkin Lymphoma (PID1777)R-COMP 21 - Rituximab 375 / Cyclophosphamide 750 / Vincristine 2 / lip. doxorubicin 50 / Prednisolone 100, diffuse large B-cell lymphoma (PID125)R-COP - Rituximab 375 / Cyclophosphamide 400 / Vincristine 2 / Prednisolone 100, indolent B non-Hodgkin Lymphoma and Mantle Cell Lymphoma (PID298)R-CPOP 21 - Rituximab 375 / Cyclophosphamide 750 / Pixantron 88 / Vincristine 2 / Prednisolone 40, diffuse large B-non-Hodgkin Lymphoma (PID931)R-CVP - Rituximab 375 / Cyclophosphamide 1000 / Vincristine 2 / Prednisolone 50 / Radiation, follicular lymphoma grade I-IIIa (PID1575)R-CVP - Rituximab 375 / Cyclophosphamide 750 / Vincristine 2 / Prednisolone 40, follicular lymphoma grade I-IIIa (PID296)R-DexaBEAM - Rituximab 375 / Dexamethasone 8 / Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 20, B-Non-Hodgkin Lymphoma (PID1006)R-DHAC - Rituximab 375 / Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, B-Non-Hodgkin's Lymphoma/Hodgkin's Lymphoma (PID2345)R-DHAP - Rituximab 375 / Cisplatin 100 / Cytarabine 2000 / Dexamethasone 40, diffuse large B-non-Hodgkin Lymphoma (PID350)R-ESHAP - Rituximab 375 / Etoposide 40 / Cisplatin 25 / Cytarabine 2000 / Methylprednisolone 250, diffuse large B-non-Hodgkin Lymphoma (PID358)R-FC - Rituximab 375 / Fludarabine 25 / Cyclophosphamide 250, Waldenström's disease (PID674)R-FC - Rituximab 375 / Fludarabine 30 / Cyclophosphamide 250, Mantle Cell Lymphoma (PID326)R-GCVP - Rituximab 375 / Gemcitabine 750 / Cyclophosphamide 750 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID1774)R-GDC - Rituximab 375 / Gemcitabine 1000 / Dexamethasone 40 / Carboplatin 5, diffuse large B-non-Hodgkin Lymphoma (PID1681)R-GDP - Rituximab 375 / Gemcitabine 1000 / Dexamethasone 40 / Cisplatin 75, diffuse large B-non-Hodgkin Lymphoma (PID605)R-HAD - Rituximab 375 / Cytarabine 2000 / Dexamethasone 40 / Bortezomib 1.5, mantle cell lymphoma (PID1564)R-HAD - Rituximab 375 / Cytarabine 2000 / Dexamethasone 40, mantle cell lymphoma (PID1565)R-ICE - Rituximab 375 / Etoposide 100 / Carboplatin 5 / Ifosfamide 1.67, Hodgkin Lymphoma (PID2383)R-ICE - Rituximab 375 / Etoposide 100 / Carboplatin 5 / Ifosfamide 3, Burkitt's Lymphoma, Cycle 1-2. (PID2223)R-ICE - Rituximab 375 / Etoposide 100 / Carboplatin 5 / Ifosfamide 3, Burkitt's Lymphoma, Cycle 3. (PID2224)R-IVAC - Cytarabine 2000 / Rituximab 375 / Etoposide 60 / Ifosfamide 1.5, Burkitt's lymphoma (PID2212)R-MCP - Rituximab 375 / Mitoxantrone 8 / Chlorambucil 3 / Prednisolone 25, follicular lymphoma grade I-IIIa (PID299)R-miniCHOP - Rituximab 1400 / Cyclophosphamide 400 / Doxorubicin 25 / Vincristine 1 / Prednisolone 40, diffuse large B-Non-Hodgkin Lymphoma, cycle 2-6, variant 1 (PID2536)R-miniCHOP - Rituximab 375 / Cyclophosphamide 375 / Doxorubicin 25 / Vincristine 0.7 / Prednisolone 60, Waldenström's disease (PID673)R-miniCHOP - Rituximab 375 / Cyclophosphamide 400 / Doxorubicin 25 / Vincristine 1 / Prednisolone 40, diffuse large B-non-Hodgkin Lymphoma (PID339)R-miniCHOP - Rituximab 375 / Cyclophosphamide 400 / Doxorubicin 25 / Vincristine 1 / Prednisolone 40, diffuse large B-Non-Hodgkin Lymphoma, cycle 1, variant 1 (PID2535)R-modified CODOX-M - Rituximab 375 / Cyclophosphamide (800/200) / Vincristine 2 / Doxorubicin 40 / Methotrexate 3000, Burkitt lymphoma (PID2211)Ramucirumab 10 / Docetaxel 75, Non-Small Cell Lung Cancer (PID223)Ramucirumab 10 / Erlotinib 150, Non-Small Cell Lung Cancer (PID1487)Ramucirumab 10 / Gemcitabine 1000, Pleural Mesothelioma (PID2155)Ramucirumab 8 / Paclitaxel 80, adenocarcinoma esophagogastric junction and stomach (PID327)Ramucirumab 8, adenocarcinoma esophagogastric junction and stomach (PID328)Ramucirumab 8, Hepatocellular Carcinoma (PID1400)Ravulizumab 2700, Paroxysmal Nocturnal Hemoglobinuria, Induction (PID1449)Ravulizumab 3300, Paroxysmal Nocturnal Hemoglobinuria, maintenance (PID1450)Regorafenib 160, Gastrointestinal Stroma Tumor (PID795)Regorafenib 160, Colorectal Carcinoma (PID459)Regorafenib 160, hepatocellular carcinoma (PID248)Regorafenib 160, Osteosarcoma (PID1578)Recombinant Human Hyaluronidase (800/1600/2400) / Subcutaneous Immunoglobulin-G (10/20/30), Primary Antibody Deficiency, Cycle 1 (PID1726)Recombinant Human Hyaluronidase (800/1600/2400) / Subcutaneous Immunoglobulin-G (10/20/30), secondary antibody deficiency, hematologic neoplasms, stem cell transplantation, cycle 1 (PID1722)Recombinant Human Hyaluronidase 2400 / Subcutaneous Immunoglobulin-G 30, Primary Antibody Deficiency, Cycle 2+ (PID1731)Recombinant Human Hyaluronidase 2400 / Subcutaneous Immunoglobulin-G 30, secondary antibody deficiency, hematologic neoplasms, stem cell transplantation, cycle 2+ (PID1727)Relugolix (360/120), Prostate Cancer, Cycle 1 (PID2250)Relugolix 120, Prostate Cancer, Cycle 2+ (PID2247)Ribociclib 400 / Anastrozole 1 / Goserelin 3,6, Breast Cancer, adjuvant (PID2585)Ribociclib 400 / Letrozole 2.5 / Goserelin 3.6, Breast Cancer, adjuvant (PID2578)Ribociclib 600 / Fulvestrant 500, Breast Cancer (PID73)Ribociclib 600 / Letrozole 2.5 / Goserelin 3.6, Breast Cancer (PID1372)Ribociclib 600 / Letrozole 2.5, Breast Cancer (PID127)Ripretinib 150, Gastrointestinal Stroma Tumor (PID1955)RITU375/FLUD25, follicular lymphoma and indolent B-NHL (PID304)Rituximab 1400, single dose subcutaneous (PID310)Rituximab 25, Malignant Meningitis (PID2571)Rituximab 250 / 90 Yttrium-Ibritumomab Tiuxetan consolidation, follicular lymphoma grade I-IIIa (PID305)Rituximab 250 / 90 Yttrium-Ibritumomab Tiuxetan, follicular lymphoma grade I-IIIa (PID303)Rituximab 250 / 90 Yttrium-Ibritumomab Tiuxetan, follicular lymphoma grade I-IIIa, second-line (PID306)Rituximab 375 / Bendamustine 120 / Carboplatin 5 / Etoposide 100, B-Non-Hodgkin Lymphoma. (PID2390)Rituximab 375 / Bendamustine 70, Chronic Lymphocytic Leukemia, second line, cycle 1 (PID574)Rituximab 375 / Bendamustine 90, Autoimmune Hemolytic Anemia / Cold Agglutinin Disease (PID1089)Rituximab 375 / Bendamustine 90, Chronic Lymphocytic Leukemia, first-line, cycle 1 (PID315)Rituximab 375 / Bendamustine 90, Hairy Cell Leukemia (PID1712)Rituximab 375 / Bendamustine 90, indolent B-non-Hodgkin Lymphoma and Mantle Cell Lymphoma, first-line (PID271)Rituximab 375 / Bendamustine 90, indolent B-non-Hodgkin Lymphoma and Mantle Cell Lymphoma, second line (PID270)Rituximab 375 / Bortezomib 1.3, Mantle Cell Lymphoma and Follicular Lymphoma (PID278)Rituximab 375 / Carboplatin 300 / Ifosfamide 1.5 / Etoposide 100 / Dexamethasone 40, CNS- Non-Hodgkin Lymphoma, consolidation (PID831)Rituximab 375 / Carmustine 400 / Thiotepa 5, CNS- Non-Hodgkin Lymphoma, conditioning, cycle 5 (PID1883)Rituximab 375 / Chlorambucil 10, Chronic Lymphocytic Leukemia, cycle 1 (PID321)Rituximab 375 / Chlorambucil 6, MALT Lymphoma, cycle 1 (PID1971)Rituximab 375 / Chlorambucil 6, MALT Lymphoma, cycle 2-5 (PID1974)Rituximab 375 / Chlorambucil 6, follicular lymphoma °I-IIIa, cycle 1 (PID1835)Rituximab 375 / Chlorambucil 6, Follicular Lymphoma °I-IIIa, cycle 2-5 (PID1836)Rituximab 375 / Cytarabine 3000 / Thiotepa 40, CNS- Non-Hodgkin Lymphoma, induction, cycle 3 (PID1881)Rituximab 375 / Cytarabine 3000 / Thiotepa 40, CNS- Non-Hodgkin Lymphoma, Induction, Cycle 4 (PID1882)Rituximab 375 / Cytarabine 3000, CNS- lymphoma, cycle 4-6 (PID1901)Rituximab 375 / Doxorubicin Liposomal 20, Multicentric Castleman disease (PID1959)Rituximab 375 / Fludarabine 25 / Cyclophosphamide 200 / Mitoxantrone 8, follicular lymphoma and Mantle Cell Lymphoma (PID272)Rituximab 375 / Fludarabine 25 / Cyclophosphamide 250, Chronic Lymphocytic Leukemia, first-line, cycle 1 (PID317)Rituximab 375 / Fludarabine 25, Autoimmune Hemolytic Anemia, Cold Agglutinin Disease (PID2022)Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, B-non-Hodgkin Lymphoma (PID354)Rituximab 375 / Lenalidomide 10, follicular lymphoma grade I-IIIa, cycle 7-12 (PID1531)Rituximab 375 / lenalidomide 20 - Lenalidomide 20 maintenance, indolent B non-Hodgkin Lymphoma induction (PID329)Rituximab 375 / Lenalidomide 20, follicular lymphoma grade I-IIIa, cycle 1 (PID1529)Rituximab 375 / Lenalidomide 20, follicular lymphoma grade I-IIIa, cycle 2-6 (PID1530)Rituximab 375 / Lenalidomide 20, indolent B non-Hodgkin Lymphoma, induction (PID309)Rituximab 375 / Lenalidomide 20, Mantle Cell Lymphoma Cycle 1 (PID282)Rituximab 375 / Lenalidomide 20, Mantle Cell Lymphoma Cycle 2+ (PID324)Rituximab 375 / Methotrexate 1000 / Cytarabine 3000 / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 2,4 (PID2085)Rituximab 375 / Methotrexate 1000 / Cytarabine 3000, ALL/NHL, cycle 2,4 (PID2064)Rituximab 375 / Methotrexate 3000 / Procarbazine 60 - Procarbazine 100, maintenance, CNS- Lymphoma (PID1031)Rituximab 375 / Methotrexate 3000 / Procarbazine 60, CNS lymphoma, cycle 1 (PID1191)Rituximab 375 / Methotrexate 3000 / Procarbazine 60, CNS- lymphoma, cycle 2-3 (PID1030)Rituximab 375 / Methotrexate 3500 / Procarbazine 100 / Vincristine 2, CNS Lymphoma, cycle 1-3 (PID1896)Rituximab 375 / Methotrexate 500/3000 / Cytarabine 2000 / Thiotepa 30, CNS- Non-Hodgkin Lymphoma, induction (PID703)Rituximab 375 / Methotrexate 8000, CNS- Non-Hodgkin Lymphoma, induction, cycle 1 (PID1879)Rituximab 375 / Methotrexate 8000, CNS- Non-Hodgkin Lymphoma, induction, cycle 2 (PID1880)Rituximab 375 / Doxorubicin Liposomal 30 / Cyclophosphamide 750 / Vincristine 2 / Prednisolone 40, diffuse large B-Non-Hodgkin Lymphoma, cycle 1 (PID2502)Rituximab 375 / Doxorubicin Liposomal 30 / Cyclophosphamide 750 / Vincristine 2 / Prednisolone 40, diffuse large B-Non-Hodgkin Lymphoma, cycle 2-6 (PID2503)Rituximab 375 / Polatuzumab Vedotin 1.8 / Bendamustine 90, diffuse large B-non-Hodgkin Lymphoma, cycle 2-6 (PID1423)Rituximab 375 / Polatuzumab Vedotin 1.8 / Bendamustine 90, diffuse large B-non-Hodgkin Lymphoma, cycle 1 (PID1422)Rituximab 375 / Radiation, follicular lymphoma (PID2333)Rituximab 375 / Vemurafenib 960 - Rituximab 375, Hairy Cell Leukemia, Part A (PID1802)Rituximab 375 / Vemurafenib 960 - Rituximab 375, Hairy Cell Leukemia, Part B (PID1803)Rituximab 375 / Venetoclax (20/50/100/200/400), Chronic Lymphocytic Leukemia, cycle 1 (PID1148)Rituximab 375 / Venetoclax 400, Chronic Lymphocytic Leukemia, cycle 2 (PID1149)Rituximab 375 maintenance after first-line, grade I-IIIa follicular lymphoma (PID295)Rituximab 375 maintenance after Rituximab induction, follicular lymphoma grade I-IIIa part B (PID301)Rituximab 375 maintenance after second-line, grade I-IIIa follicular lymphoma (PID302)Rituximab 375 Maintenance, Mantle Cell Lymphoma (PID288)Rituximab 375 induction, follicular lymphoma grade I-IIIa part A (PID300)Rituximab 375, Autoimmune Hemolytic Anemia, Cold Agglutinin Disease (PID2005)Rituximab 375, Burkitt's lymphoma (PID2218)Rituximab 375, Hairy Cell Leukemia (PID538)Rituximab 375, Hodgkin Lymphoma, maintenance, cycle 5-8 (PID2361)Rituximab 375, Hodgkin Lymphoma, Cycle 1-4 (PID2360)Rituximab 375, Immune Thrombocytopenia (PID957)Rituximab 375, cutaneous B-cell lymphoma (PID1390)Rituximab 375, MALT Lymphoma (PID353)Rituximab 375, Multicentric Castleman disease (PID1952)Rituximab 375, Waldenström's disease (PID677)Rituximab 500 / Bendamustine 70, Chronic Lymphocytic Leukemia, second-line, cycle 2-6 (PID683)Rituximab 500 / bendamustine 90, Chronic Lymphocytic Leukemia, first-line, cycle 2-6 (PID316)Rituximab 500 / Chlorambucil 10, Chronic Lymphocytic Leukemia, cycle 2-6 (PID322)Rituximab 500 / Fludarabine 25 / Cyclophosphamide 250, Chronic Lymphocytic Leukemia, first-line, cycle 2-6 (PID318)Rituximab 500 / Venetoclax 400 - Venetoclax 400, Chronic Lymphocytic Leukemia, maintenance (PID1151)Rituximab 500 / Venetoclax 400, Chronic Lymphocytic Leukemia, cycle 3-7 (PID1150)Rituximab 750 / Temozolomide 150, CNS Lymphoma, Induction (PID2437)Romiplostim 1, Immune Thrombocytopenia (PID953)Romiplostim 2, Thrombocytopenia, Chemotherapy Induced (PID961)Ropeginterferon Alfa-2b, Polycythaemia Vera (PID1249)Rucaparib 600, Ovarian ca, maintenance (PID1501)Rucaparib 600, Prostate Cancer Castration Resistant (PID2308)Ruxolitinib 10, Graft-versus-Host Disease, acute (PID2108)Ruxolitinib 10, Graft-versus-Host Disease, chronic (PID2109)Ruxolitinib 10, Polycythaemia Vera (PID899)Ruxolitinib 15 / Dexamethasone (10/5/2.5/1.25), Hemophagocytic Lymphohistiocytosis (PID2596)Ruxolitinib 15, Chronic Myeloid Leukemia, atypical (PID1649)Ruxolitinib 15, Chronic Neutrophil Leukemia (PID804)Ruxolitinib 15, Hemophagocytic Lymphohistiocytosis (PID1041)Ruxolitinib 15, Myeloid/Lymphoid Neoplasia with Eosinophilia and TK Fusion (PID2115)Ruxolitinib 15, Primary Myelofibrosis (PID898)Ruxolitinib 20, Chronic Myelomonocytic Leukemia (PID2319)Ruxolitinib 20, T-Cell Lymphoma / T-Cell Prolymphocyte Leukemia (PID2478)Ruxolitinib 25, Essential Thrombocythemia (PID924)Sacituzumab Govitecan 10, Bladder Cancer (PID2000)Sacituzumab Govitecan 10, Breast Cancer (PID1780)Sacituzumab Govitecan 10, Non-Small Cell Lung Cancer (PID2664)Selinexor 100 / Bortezomib 1.3 / Dexamethasone 20, Multiple Myeloma (PID1795)Selinexor 60, diffuse large B-non-Hodgkin Lymphoma (PID1796)Selinexor 60, Soft Tissue Sarcoma (PID2053)Selinexor 80 / Dexamethasone 20, Multiple Myeloma (PID1792)Selpercatinib 160, Tumor Biomarker Defined (PID1732)Selumetinib 25, neurofibromatosis (PID2226)Siltuximab 11, Multicentric Castleman disease (PID352)SMARTE- R-CHOP 14 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 2,4,6 (PID929)SMARTE- R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID926)SMARTE- R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 3.5 (PID930)SMARTE- R-CHOP 14 - Rituximab 375, diffuse large B-non-Hodgkin Lymphoma, cycle 7+ (PID75)SMILE (Methotrexate 2000 / Ifosfamide 1.5 / Dexamethasone 40 / Etoposide 100 / Asparaginase 6000), extranodal NK/T-cell Lymphoma (PID2351)Sorafenib 400 / Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400, Hepatocellular Carcinoma (PID675)Sorafenib 400, Adenoid Cystic Carcinoma (PID2362)Sorafenib 400, Aggressive Fibromatosis (PID699)Sorafenib 400, hepatocellular carcinoma (PID749)Sorafenib 400, Renal Cell Carcinoma (PID743)Sorafenib 400, Thyroid Cancer (PID751)Sorafenib 400/600, Acute Myeloid Leukemia, maintenance, cycle 1 (PID1020)Sorafenib 800, Acute Myeloid Leukemia, maintenance, cycle 2+ (PID1038)Sotorasib 960, Non-Small Cell Lung Cancer (PID1914)Sotorasib 960, Pancreatic Cancer (PID2304)Stem Cell Infusion (PID614)Streptozocin 1 / Mitotane 1.5, Adrenocortical Carcinoma, cycle 1 (PID2012)Streptozocin 2 / Mitotane 1.5, Adrenocortical Carcinoma, cycle 2+ (PID2020)Study - CELESTIMO - Lenalidomide 20, Follicular Lymphoma grade I-IIIa, cycle 2,4,6,8,10,12 (PID2079)Study - CELESTIMO - Mosunetuzumab (1/2/30), Follicular Lymphoma grade I-IIIa, cycle 1 (PID2075)Study - CELESTIMO - Mosunetuzumab 30/ Lenalidomide 20, Follicular Lymphoma grade I-IIIa, cycle 2-12 (PID2076)Study - CELESTIMO - Rituximab 375 / Lenalidomide 20, Follicular Lymphoma grade I-IIIa, cycle 1 (PID2077)Study - CELESTIMO - Rituximab 375 / Lenalidomide 20, Follicular Lymphoma grade I-IIIa, cycle 3,5,7,9,11 (PID2078)Study - CLL13 - GVe - Obinutuzumab (100/900/1000) / Venetoclax 20, Chronic Lymphocytic Leukemia, Cycle 1 (PID1144)Study - CLL13 - GVe - Obinutuzumab 1000 / Venetoclax (50/100/200/400), CLL, Cycle 2 (PID1145)Study - CLL13 - GVe - Obinutuzumab 1000 / Venetoclax 400, CLL, Cycle 3-6 (PID1146)Study - CLL13 - GVe/RVe - Venetoclax 400, CLL, cycle 7-12, maintenance (PID1147)Study - CLL13 - RVe - Rituximab 375 / Venetoclax 20, Chronic Lymphocytic Leukemia, cycle 1 (PID1196)Study - CLL13 - RVe - Rituximab 500 / Venetoclax (50/100/200/400), Chronic Lymphocytic Leukemia, cycle 2 (PID1197)Study - CLL13 - RVe - Rituximab 500 / Venetoclax 400, Chronic Lymphocytic Leukemia, Cycle 3-6 (PID1198)Study - CLL17 - Obinutuzumab (100/900/1000) / Venetoclax 20, Chronic Lymphocytic Leukemia, cycle 1 (PID1854)Study - CLL17 - Obinutuzumab 1000 / Venetoclax (50/100/200/400), Chronic Lymphocytic Leukemia, cycle 2 (PID1855)Study - CLL17 - Obinutuzumab 1000 / Venetoclax 400, Chronic Lymphocytic Leukemia, cycle 3-6 (PID1856)Study - CLL17 - Venetoclax 400, Chronic Lymphocytic Leukemia, cycle 7-12 (PID1857)Study - DaunoDouble - Daunorubicin 45 / Cytarabine 100, AML Induction II, under 60 years of age (PID626)Study - DaunoDouble - Daunorubicin 60 / Cytarabine 100, AML Induction I+II, under 60 years of age (PID627)Study - DaunoDouble - Daunorubicin 90 / Cytarabine 100, AML Induction I, under 60 years of age (PID625)STUDY - GAIN 2 - dtEC-dtD, Epirubicin 38-120 / Cyclophosphamide 450-1200, Breast Cancer, Part A (PID558)STUDY - GAIN-2 - dtEC-dtD, Docetaxel (60-100), Breast Cancer, Part B (PID559)STUDY - GAIN-2 - EnPC, Cyclophosphamide 2000, Breast Cancer, Part C (PID557)STUDY - GAIN-2 - EnPC, Epirubicin 150, Breast Cancer, Part A (PID554)STUDY - GAIN-2 - EnPC, Nab-Paclitaxel 330, Breast Cancer, Part B (PID556)STUDY - GAIN-2 - Pertuzumab 420 / Trastuzumab 6, Breast Cancer, neoadjuvant, cycle 2-4 (PID768)STUDY - GAIN-2 - Pertuzumab 840 / Trastuzumab 8, Breast Cancer, neoadjuvant, cycle 1 (PID767)STUDY - GAIN-2 - Trastuzumab 6, Breast Cancer (PID786)STUDY - GAIN-2 - Trastuzumab 600, Breast Cancer (PID555)STUDY - GAIN-2 - Trastuzumab 8, Breast Cancer (PID785)Study - GMMG-HD 6 - Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20 / Elotuzumab 10, Multiple Myeloma, Induction, Cycle 1-2 (PID798)Study - GMMG-HD 6 - Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20 / Elotuzumab 10, Multiple Myeloma, Induction, Cycle 3-4 (PID799)Study - GMMG-HD 6 - Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20 / Elotuzumab 10, Multiple Myeloma, consolidation (PID802)Study - GMMG-HD 6 - Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, Induction, Cycle 1-2 (PID797)Study - GMMG-HD 6 - Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, Induction, Cycle 3-4 (PID800)Study - GMMG-HD 6 - Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, consolidation (PID801)Study - GMMG-HD 6 - Lenalidomide 10 / Dexamethasone 12 / Elotuzumab 10, Multiple Myeloma, Maintenance Cycle 1-6 (PID1092)Study - GMMG-HD 6 - Lenalidomide 10 / Dexamethasone 12, Multiple Myeloma, Maintenance Cycle 1-6 (PID1094)Study - GMMG-HD 6 - Lenalidomide 10 / Dexamethasone 12, Multiple Myeloma, Maintenance Cycle 7+ (PID1095)Study - GMMG-HD 6 - Lenalidomide 15 / Dexamethasone 12 / Elotuzumab 10, Multiple Myeloma, Maintenance Cycle 7+ (PID1093)Study - GMMG-HD 7 - Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, Induction, IA (PID40)Study - GMMG-HD 7 - Lenalidomide 10 / Dexamethasone 20 / Isatuximab 10, Multiple Myeloma, Maintenance, IIB, Cycle 1 (PID45)Study - GMMG-HD 7 - Lenalidomide 10 / Dexamethasone 20, Multiple Myeloma, Maintenance, IIA, Cycle 1 (PID43)Study - GMMG-HD 7 - Lenalidomide 10 / Isatuximab 10, Multiple Myeloma, Maintenance, IIB, Cycle 2-3 (PID46)Study - GMMG-HD 7 - Lenalidomide 10, Multiple Myeloma, Maintenance, IIA, Cycle 2-3 (PID44)Study - GMMG-HD 7 - Lenalidomide 15 / Isatuximab 10, Multiple Myeloma, Maintenance, IIB, Cycle 4+ (PID38)Study - GMMG-HD 7 - Lenalidomide 15, Multiple Myeloma, Maintenance, IIA, Cycle 4+ (PID37)Study - HOVON 132 AML / SAKK 30/13 - B - Daunorubicin 60 / Cytarabine 1000 / Lenalidomide 20, Induction, Acute Myeloid Leukemia, Cycle 2 (PID1066)Study - HOVON 132 AML / SAKK 30/13 - Lenalidomide 10, maintenance, Acute Myeloid Leukemia (PID1068)Study - Level - Gemcitabine 1000 / Oxaliplatin 100, Aggressive Non-Hodgkin Lymphoma (PID972)Study - Level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, Cycle 1 (PID968)Study - level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, cycle 2+ (PID970)Study - Level - Nivolumab 240 / Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, Cycle 1 (PID967)Study - level - Nivolumab 240 / Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, cycle 2+ (PID969)Study - Level - Nivolumab 240, diffuse large B-Non-Hodgkin Lymphoma, consolidation (PID971)Study - Level - Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID973)Study - Level - Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 2+ (PID974)Study - OPTIMAL - Arm F-A, R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID1124)Study - OPTIMAL - Arm F-B, R-CHLIP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine Liposomal 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID1123)Study - OPTIMAL - Arm LF-A, R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID1121)Study - OPTIMAL - Arm LF-B, R-CHLIP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine Liposomal 1.67 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID1122)Study - OPTIMAL - Arm LF-C optimised, CHOP 14 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 6 (PID1131)Study - OPTIMAL - Arm LF-C optimised, R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID1126)Study - OPTIMAL - Arm LF-C optimised, R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 2-5 (PID1127)Study - OPTIMAL - Arm LF-D optimised, CHLIP 14 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine liposomal 1.67 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 6 (PID1130)Study - OPTIMAL - Arm LF-D optimised, R-CHLIP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine Liposomal 1.67 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID1125)Study - OPTIMAL - Arm LF-D optimised, R-CHLIP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine Liposomal 1.67 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 2-5 (PID1128)Study - OPTIMAL - Rituximab 375 / high dose Methotrexate 3000, diffuse large B-non-Hodgkin Lymphoma, CNS Prophylaxis (PID1133)Study - OPTIMAL - Pre-phase, Diffuse Large B-Non-Hodgkin Lymphoma (PID1120)Avoid study - R-CHOP 21 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID706)GRAALL study - B- ALL maintenance, month 2,4,6-12, 18 - 59 years (PID985)GRAALL study - B-/T- ALL consolidation block S1, S4, S7 (day 1-14), 18 - 59 years (PID980)GRAALL study - B-/T-ALL maintenance, month 1,3,5, 18 - 59 years (PID983)GRAALL study - B-/T-ALL maintenance, month 13-24, 18 - 59 years (PID984)GRAALL Study - B-/T-ALL Induction, 18 - 44 Years (PID978)GRAALL study - B-/T-ALL induction, 45- 59 years (PID1027)GRAALL study - B-/T-ALL consolidation block S2, S5, S8 (day 15-28), 18 - 44 years (PID981)GRAALL study - B-/T-ALL consolidation block S2, S5, S8 (day 15-28), 45 - 59 years (PID1028)GRAALL study - B-/T-ALL consolidation block S3, S6, S9 (day 29-35), 18 - 59 years (PID982)Study GRAALL - B-/T-ALL salvage, 18-59 (PID979)GRAALL Study - B-/T-ALL Late Intensification, 18 - 44 years for patients without salvage therapy (PID986)GRAALL Study - B-/T-ALL Late Intensification, 18 - 59 for Patients with salvage (PID988)GRAALL Study - B-/T-ALL Late Intensification, 45 - 59 years for patients without salvage therapy (PID1032)GRAALL study - B-/T-ALL stand-by block, 18-59 (PID987)Study GRAALL - B-/T-ALL and GRAAPH - B-ALL Pre-phase (PID992)Study GRAALL - B-/T-ALL Waiting Block 1 and 3, 18-59 (PID1071)GRAALL Study - B-/T-ALL Waiting Block 2 and 4, 18-59 (PID1074)Study GRAALL - B-/T-ALL, CNS Treatment (PID1029)GRAALL study - T- ALL consolidation block T5, T8 (day 22-35), 18 - 59 years (PID990)GRAALL study - T-ALL maintenance, month 2,4,6, 18 - 59 years (PID994)GRAALL study - T-ALL maintenance, month 7-12, 18 - 59 years (PID993)GRAALL study - T-ALL consolidation block T4, T7 (day 1-21), 18 - 59 years (PID989)GRAALL study - T-ALL consolidation block T6, T9 (day 36-49), 18 - 59 years (PID991)GRAAPH study - B-ALL, interphase, Ph/BCR-ABL+ (PID1072)GRAAPH Study - B-ALL, Cycle 1, Ph/BCR-ABL+ (PID996)GRAAPH study - B-ALL, cycle 2 and 4, arm A, Ph/BCR-ABL+, 18-44 years (PID998)GRAAPH study - B-ALL, cycle 2 and 4, arm A, Ph/BCR-ABL+, 45-59 years (PID1073)GRAAPH Study - B-ALL, Cycle 2 and 4, Arm B, Ph/BCR-ABL+ (PID999)GRAAPH Study - B-ALL, Cycle 3, Ph/BCR-ABL+ (PID997)Study-AMLSG - Cytarabine 1000, Acute Myeloid Leukemia, consolidation, over 60 years of age (PID1814)Study-AMLSG - Cytarabine 1500, Acute Myeloid Leukemia, consolidation, under 60 years of age (PID1813)Study-AMLSG - Daunorubicin 50 / Cytarabine 1000, Acute Myeloid Leukemia, Induction II, under 60 years of age (PID1810)Study-AMLSG - Daunorubicin 50 / Cytarabine 500, Acute Myeloid Leukemia, Induction II, over 60 years of age (PID1812)Study-AMLSG - Daunorubicin 60 / Cytarabine 200, Acute Myeloid Leukemia, Induction I (PID1811)Study-AMLSG - Daunorubicin Liposomal - Cytarabine liposomal 144, Acute Myeloid Leukemia, Induction I (PID1815)Study-AMLSG - Daunorubicin Liposomal - Cytarabine liposomal 144, Acute Myeloid Leukemia, Induction II (PID1816)Study-AMLSG - Daunorubicin Liposomal - Cytarabine liposomal 94, Acute Myeloid Leukemia, consolidation (PID1817)Study-OPTIMAL - Rituximab 375, DLBCL (PID1132)Sunitinib 37.5, pancreatic Neuroendocrine Tumor (PID561)Sunitinib 37.5, Pheochromocytoma / Paraganglioma (PID2485)Sunitinib 37.5, Soft Tissue Sarcoma (PID2046)Sunitinib 50, Gastrointestinal Stroma Tumor (PID794)Sunitinib 50, Renal Cell Carcinoma (PID730)Sunitinib 50, Renal Cell Carcinoma, adjuvant (PID803)Sunitinib 50, Thymic Carcinoma (PID2325)Sutimlimab 6.5, Autoimmune Hemolytic Anemia, Cold Agglutinin Disease, Cycle 1. (PID2248)Sutimlimab 6.5, Autoimmune Hemolytic Anemia, Cold Agglutinin Disease, Cycle 2+. (PID2249)TAD - Tioguanin 100 / Cytarabine 100 / Daunorubicin 60, AML induction, under 60 years of age (PID519)Tafasitamab 12 / Lenalidomide 25 - Tafasitamab 12, maintenance, diffuse large B-non-Hodgkin Lymphoma, cycle 13+ (PID1851)Tafasitamab 12 / Lenalidomide 25, diffuse large B-non-Hodgkin Lymphoma, cycle 1 (PID1848)Tafasitamab 12 / Lenalidomide 25, diffuse large B-non-Hodgkin Lymphoma, cycle 2-3 (PID1849)Tafasitamab 12 / Lenalidomide 25, diffuse large B-non-Hodgkin Lymphoma, cycle 4-12 (PID1850)Tagraxofusp 12, Blastic plasmocytoid dendritic cell neoplasia (PID1824)Talazoparib 0.5 / Enzalutamide 160, Prostate Cancer castration-resistant (PID2556)Talazoparib 1, Breast Cancer (PID1420)Talimogen Laherparepvec 1, malignant Melanoma, cycle 1 (PID1182)Talimogen Laherparepvec 100, Malignant Melanoma, Cycle 2+ (PID1184)Talquetamab (0.01/0.06/0.4), Multiple Myeloma, cycle 1 (PID2469)Talquetamab (0.01/0.06/0.4/0.8), Multiple Myeloma, cycle 1 (PID2467)Talquetamab 0.4, Multiple Myeloma, Cycle 2+ (PID2470)Talquetamab 0.8, Multiple Myeloma, Cycle 2+ (PID2468)Tamoxifen 20, Breast Cancer, adjuvant (PID1583)Tebentafusp (20/30/68), Uveal Melanoma, Cycle 1 (PID883)Tebentafusp 68, Uveal Melanoma, cycle 2+ (PID2080)Teclistamab (0.06/0.3/1.5), Multiple Myeloma, Cycle 1 (PID2391)Teclistamab 1.5, Multiple Myeloma, Cycle 2+ (PID2392)Tegafur 60, Colon Cancer, adjuvant (PID2176)Tegafur 60, Gastric Cancer, Adjuvant (PID606)Temozolomide 150 / Bevacizumab 5, Soft Tissue Sarcoma (PID2045)Temozolomide 150 after Radio-Chemo, Glioblastoma cycle 1 (PID547)Temozolomide 150, Glioma, cycle 2 (PID1453)Temozolomide 150, CNS Lymphoma, consolidation (PID2438)Temozolomide 200 after Radio-Chemo, Glioblastoma cycle 2-6 (PID548)Temozolomide 200, Glioma, Cycle 3-13 (PID1454)Temozolomide 75 / Radiation, Glioblastoma (PID546)Temozolomide 75 / Radiation, Glioblastoma, Cycle 1 (PID2472)Temozolomide 75 / Radiation, Glioma, Cycle 1 (PID1452)Temsirolimus 175 / 75, Mantle Cell Lymphoma, cycle 1 (PID273)Temsirolimus 175 / 75, Mantle Cell Lymphoma, Cycle 2+ (PID307)Temsirolimus 25, Renal Cell Carcinoma (PID787)Tepotinib 450, Non-Small Cell Lung Cancer (PID1983)Thiotepa 10, Malignant Meningitis (PID867)Thiotepa 15 / Hydrocortisone 30, Tumor, Various Organs (PID2372)TI-CE - Paclitaxel 200 / Ifosfamide 2, Testicular Carcinoma, part A (PID780)Tioguanin 30 / Procarbazine 50 / Lomustine 110 / Vincristine 1.5, Glioma (PID604)TIP (Paclitaxel 175 / Ifosfamide 1.2 / Cisplatin 25), Penile Carcinoma, neoadjuvant / adjuvant. (PID1444)TIP - Paclitaxel 250 / Ifosfamide 1.5 / Cisplatin 25, Testicular Carcinoma (PID774)Tislelizumab 200 / Capecitabine 1000, Esophageal Cancer, maintenance (PID2619)Tislelizumab 200 / Cisplatin 80 / Capecitabine 1000, Esophageal Cancer (PID2618)Tislelizumab 200 / Cisplatin 80 / Fluorouracil 800, Esophageal Cancer (PID2615)Tislelizumab 200 / Cisplatin 80 / Paclitaxel 175, Esophageal Cancer (PID2622)Tislelizumab 200 / Fluorouracil 800, Esophageal Cancer, maintenance (PID2616)Tislelizumab 200 / Nab-Paclitaxel 100 / Carboplatin 5, Non-Small Cell Lung Cancer (PID2648)Tislelizumab 200 / Oxaliplatin 130 / Capecitabine 1000, Esophageal Cancer (PID2621)Tislelizumab 200 / Oxaliplatin 130 / Fluorouracil 800, Esophageal Cancer (PID2620)Tislelizumab 200 / Paclitaxel 175 / Carboplatin 5, Non-Small Cell Lung Cancer (PID2647)Tislelizumab 200 / Paclitaxel 175, Esophageal Cancer, maintenance (PID2623)Tislelizumab 200 / Pemetrexed 500 / Carboplatin 5, Non-Small Cell Lung Cancer (PID2635)Tislelizumab 200 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer (PID2634)Tislelizumab 200 / Pemetrexed 500, Non-Small Cell Lung Cancer, Maintenance (PID2636)Tislelizumab 200, Non-Small Cell Lung Cancer (PID2650)Tislelizumab 200, Non-Small Cell Lung Cancer, Maintenance (PID2649)Tislelizumab 200, Esophageal Cancer (PID2559)Tislelizumab 200, Esophageal Cancer, maintenance (PID2617)Tisotumab Vedotin 2, Cervical Carcinoma (PID2002)Tivozanib 1.34, Renal Cell Carcinoma (PID489)Tocilizumab 8, Cytokine release Syndrome (PID1833)Tocilizumab 8, Multicentric Castleman disease (PID1953)Topotecan 0.4, Malignant Meningitis (PID2520)Topotecan 0.75 / Carboplatin 5, Lung Carcinoma, Small Cell (PID238)Topotecan 0.75 / Cisplatin 50, Cervical Cancer (PID1938)Topotecan 0.75 / Cyclophosphamide 250, Ewing Sarcoma (PID1180)Topotecan 0.8, Endometrial Cancer (PID141)Topotecan 1 / Cisplatin 75, Small Cell Lung Carcinoma (PID235)Topotecan 1.25 / Bevacizumab 15, Ovarian ca (PID1368)Topotecan 1.25 / Carboplatin 5, Lung Carcinoma, Small Cell (PID237)Topotecan 1.5 / Cisplatin 75, Lung Carcinoma, Small Cell (PID236)Topotecan 1.5, small cell lung cancer (PID203)Topotecan 1.5, Ovarian Carcinoma (PID503)Topotecan 1.7 / Cisplatin 60, Lung Carcinoma, Small Cell (PID228)Topotecan 2, Small Cell Lung Carcinoma (Schiller variant) (PID234)Topotecan 2,3, Small Cell Lung Cancer (PID231)Topotecan 4, Small Cell Lung Carcinoma (PID240)Topotecan 4, Ovarian ca (PID860)TP-TE (Paclitaxel 135 / Cisplatin 60 - Paclitaxel 135 / Etoposide 150), Gestational Trophoblastic Neoplasia (PID1609)TPG - Paclitaxel 80 / Gemcitabine 800 / Cisplatin 50, Testicular Carcinoma (PID1570)Trabectedin 1.1, Soft Tissue Sarcoma, maintenance (PID2219)Trabectedin 1.3, Soft Tissue Sarcoma, neoadjuvant (PID2544)Trabectedin 1.5, Soft Tissue Sarcoma (PID510)Trametinib 2, ovarian cancer (PID2670)Trastuzumab (4/2) / Anastrozole 1, Breast Cancer, Cycle 1 (PID755)Trastuzumab 150, Malignant Meningitis (PID2523)Trastuzumab 2 / Anastrozole 1, Breast Cancer, Cycle 2+ (PID756)Trastuzumab 2 / Lapatinib 1000, Colorectal Carcinoma, Cycle 2+ (PID1155)Trastuzumab 4 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600) - Trastuzumab 6, Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 9-17 (PID2036)Trastuzumab 4 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600), Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, Cycle 2-4,6-8 (PID2035)Trastuzumab 4 / Lapatinib 1000, Colorectal Carcinoma, Cycle 1 (PID72)Trastuzumab 6 / Abemaciclib 150 / Fulvestrant 500, Breast Cancer, Cycle 2+ (PID1602)Trastuzumab 6 / Capecitabine 1000, adenocarcinoma esophagogastric junction and stomach, cycle 7+ (PID1302)Trastuzumab 6 / Cisplatin 80 / Capecitabine 1000, adenocarcinoma esophagogastric junction and stomach, cycle 2+ (PID220)Trastuzumab 6 / Cisplatin 80 / Fluorouracil 800, adenocarcinoma esophagogastric junction and stomach, cycle 2+ (PID140)Trastuzumab 6 / Docetaxel 100, Breast Cancer, Cycle 2+ (PID417)Trastuzumab 6 / Docetaxel 70 - Trastuzumab 6 Maintenance, Salivary Gland Tumor (PID1711)Trastuzumab 6 / Docetaxel 70, Salivary Gland Tumor, Cycle 2+ (PID1698)Trastuzumab 6 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2600), Adenocarcinoma Esophagogastric Junction and Stomach, perioperative, cycle 1.5 (PID2034)Trastuzumab 6 / Lapatinib 1000 / Letrozole 2.5, Breast Cancer, Cycle 2+ (PID1769)Trastuzumab 6 / Letrozole 2.5, Breast Cancer, Cycle 2+ (PID765)Trastuzumab 6 / Paclitaxel 175 / Carboplatin 5, Endometrial Cancer, Cycle 2-6 (PID2216)Trastuzumab 6 / Vinorelbine 30, Breast Cancer, Cycle 2+ (PID419)Trastuzumab 6, Endometrial Cancer, Cycle 7+ (PID2217)Trastuzumab 6, maintenance, adenocarcinoma esophagogastric junction and stomach (PID222)Trastuzumab 6, Breast Cancer, adjuvant, cycle 2+ (PID1688)Trastuzumab 6, Breast Cancer, adjuvant, cycle 2+ (PID1474)Trastuzumab 6, Breast Cancer, Cycle 2+ (PID385)Trastuzumab 6, Metastatic Breast Cancer, Cycle 2+ (PID760)Trastuzumab 600, Breast Cancer (PID1330)Trastuzumab 8 / Abemaciclib 150 / Fulvestrant 500, Breast Cancer, Cycle 1 (PID1601)Trastuzumab 8 / Cisplatin 80 / Capecitabine 1000, adenocarcinoma esophagogastric junction and stomach, cycle 1 (PID221)Trastuzumab 8 / Cisplatin 80 / Fluorouracil 800, adenocarcinoma esophagogastric junction and stomach, cycle 1 (PID219)Trastuzumab 8 / Docetaxel 100, Breast Cancer, Cycle 1 (PID416)Trastuzumab 8 / Docetaxel 70, Salivary Gland Tumor, Cycle 1 (PID1697)Trastuzumab 8 / Lapatinib 1000 / Letrozole 2.5, Breast Cancer, Cycle 1 (PID1768)Trastuzumab 8 / Letrozole 2.5, Breast Cancer, Cycle 1 (PID764)Trastuzumab 8 / Paclitaxel 175 / Carboplatin 5, Endometrial Cancer, Cycle 1 (PID2215)Trastuzumab 8 / Vinorelbine 30, Breast Cancer, Cycle 1 (PID418)Trastuzumab 8, Breast Cancer, adjuvant, cycle 1 (PID1687)Trastuzumab 8, Breast Cancer, Cycle 1 (PID384)Trastuzumab 8, metastatic Breast Cancer, Cycle 1 (PID761)Trastuzumab 80, Malignant Meningitis, Cycle 1 (PID2526)Trastuzumab 80, Malignant Meningitis, Cycle 2 (PID2527)Trastuzumab 80, Malignant Meningitis, Cycle 3+ (PID2542)Trastuzumab Deruxtecan 5,4, Adenocarcinoma Esophagogastric Junction and Stomach (PID1736)Trastuzumab Deruxtecan 5.4, Breast Cancer (PID1634)Trastuzumab Deruxtecan 5.4, Non-Small Cell Lung Cancer (PID1977)Trastuzumab Deruxtecan 5,4, Tumor Biomarker Defined (PID2652)Trastuzumab Deruxtecan 6.4, adenocarcinoma esophagogastric junction and stomach (PID2253)Trastuzumab Deruxtecan 6.4, Colorectal Carcinoma (PID2357)Trastuzumab Emtansine 3.6, Breast Cancer, adjuvant (PID1343)Trastuzumab Emtansine 3.6, Breast Cancer, Third Line (PID366)Trastuzumab Emtansine 3.6, Breast Cancer, Second Line (PID365)Trastuzumab Emtansine 3.6, Non-Small Cell Lung Cancer (PID1982)Trastuzumab Emtansine 3.6, Tumor Biomarker Defined (PID1677)Trastuzumab Emtansine 3.6, Breast Cancer, Neoadjuvant (PID111)Tremelimumab 300 / Durvalumab 1500 - Durvalumab 1500, Hepatocellular Carcinoma, Cycle 2+ (PID2289)Tremelimumab 300 / Durvalumab 1500, Hepatocellular Carcinoma, Cycle 1 (PID2288)Tremelimumab 75 / Durvalumab 1500 / Gemcitabine 1250 / Carboplatin 6, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2293)Tremelimumab 75 / Durvalumab 1500 / Gemcitabine 1250 / Cisplatin 75, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2294)Tremelimumab 75 / Durvalumab 1500 / Nab-Paclitaxel 100 / Carboplatin 6, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2290)Tremelimumab 75 / Durvalumab 1500 / Pemetrexed 500 / Carboplatin 6, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2295)Tremelimumab 75 / Durvalumab 1500 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, Cycles 1-4 (PID2296)Tremelimumab 75 / Durvalumab 1500 / Pemetrexed 500, Non-Small Cell Lung Cancer, Cycle 6 (PID2298)Tremelimumab 75 / Durvalumab 1500, Non-Small Cell Lung Cancer, Cycle 6 (PID2292)Treosulfan 7, Ovarian ca (PID863)Tretinoin 22.5 / Idarubicin 12, Acute Promyelocytic Leukemia, induction, high risk (PID1118)Tretinoin 45 / Arsenic Trioxide 0.15, Induction, Acute Promyelocytic Leukemia (PID652)Tretinoin 45 / Arsenic Trioxide 0.15, consolidation, Acute Promyelocytic Leukemia, cycle 1-3 (PID653)Tretinoin 45 / Arsenic Trioxide 0.15, consolidation, Acute Promyelocytic Leukemia, cycle 4 (PID656)Tretinoin 45 / Idarubicin 12 / Cytarabine 150, Acute Promyelocytic Leukemia, 3rd consolidation, high risk (PID1117)Tretinoin 45 / Idarubicin 5 / Cytarabine 1000, Acute Promyelocytic Leukemia, 1st consolidation, high risk (PID1115)Tretinoin 45 / Mercaptopurine 50 / Methotrexate 15 , Acute Promyelocytic Leukemia, maintenance, high risk (PID1119)Tretinoin 45 / Mitoxantrone 10, Acute Promyelocytic Leukemia, 2nd consolidation, high risk (PID1116)Trifluridine 35 / Bevacizumab 5, Colorectal Carcinoma (PID1641)Trifluridine 35 / Bevacizumab 5, Colorectal Carcinoma, second line (PID1210)Trifluridine 35 / Panitumumab 6, Colorectal Carcinoma (PID2358)Trifluridine 35, adenocarcinoma esophagogastric junction and stomach (PID62)Trifluridine 35, Colorectal Carcinoma (PID843)Triptorelin 11,25, Prostate Cancer (PID1522)Trofosfamide 150, Breast Cancer (PID430)Trofosfamide 50, Breast Cancer (PID429)Tucatinib 300 / Capecitabine 1000 / Trastuzumab 6, Breast Cancer, Cycle 2+ (PID1762)Tucatinib 300 / Capecitabine 1000 / Trastuzumab 600, Breast Cancer (PID1763)Tucatinib 300 / Capecitabine 1000 / Trastuzumab 8, Breast Cancer, Cycle 1 (PID1761)Tucatinib 300 / Trastuzumab 6, Colorectal Carcinoma, Cycle 2+ (PID2627)Tucatinib 300 / Trastuzumab 8, Colorectal Carcinoma, Cycle 1 (PID2626)VAIA III Block 1 - Vincristine 1.5 / Ifosfamide 3 / Doxorubicin 40, Soft Tissue Sarcoma (PID657)VAIA III Block 2 - Vincristine 1.5 / Dactinomycin 1.5 / Ifosfamide 3, Soft Tissue Sarcoma (PID659)VAIA III Block 3,4,6 - Vincristine 1.5 / Ifosfamide 3 / Doxorubicin 40, Soft Tissue Sarcoma (PID660)VAIA III Block 5,7,8,9 - Vincristine 1.5 / Dactinomycin 1.5 / Ifosfamide 3, Soft Tissue Sarcoma (PID661)Vandetanib 300, Thyroid Cancer (PID1380)VC - Vincristine 2 / Cyclophosphamide 1200, Ewing Sarcoma (PID2069)VDC - Vincristine 2 / Doxorubicin 37.5 / Cyclophosphamide 1200, Ewing Sarcoma (PID2067)Vemurafenib (960/720) / Cobimetinib 60, Malignant Melanoma, Cycle 1 (PID2201)Vemurafenib 960 / Cobimetinib 60, Malignant Melanoma (PID716)Vemurafenib 960, Hairy Cell Leukemia (PID539)Vemurafenib 960, Langerhans Cell Histiocytosis (PID1997)Vemurafenib 960, Malignant Melanoma (PID715)Vemurafenib 960, Non-Small Cell Lung Cancer (PID1494)Venetoclax (100/200/300/400/600) / Cytarabine 20, Acute Myeloid Leukemia, 60 years of age and older, Cycle 1 (PID1260)Venetoclax (100/200/400) / Azacitidine 75, Acute Myeloid Leukemia, Cycle 1 (PID1595)Venetoclax (100/200/400) / Decitabine 20, Acute Myeloid Leukemia, Cycle 1 (PID1597)Venetoclax (100/200/400) / Gilteritinib 120, Acute Myeloid Leukemia, Cycle 1 (PID2148)Venetoclax (400/800), Waldenström's disease, cycle 1 (PID2003)Venetoclax 20/50/100/200, Chronic Lymphocytic Leukemia, cycle 1 (PID854)Venetoclax 400 / Gilteritinib 120, Acute Myeloid Leukemia, Cycle 2+ (PID2149)Venetoclax 400 / Azacitidine 75, Acute Myeloid Leukemia, Cycle 2+ (PID1596)Venetoclax 400 / Decitabine 20, Acute Myeloid Leukemia, Cycle 2+ (PID1598)Venetoclax 400, Chronic Lymphocytic Leukemia, Cycle 2+ (PID855)Venetoclax 600 / Cytarabine 20, Acute Myeloid Leukemia, 60 years and older, cycle 2+ (PID1319)Venetoclax 800 / Bortezomib 1.3 / Dexamethasone 20, Multiple Myeloma, Cycle 1-8 (PID1790)Venetoclax 800 / Bortezomib 1.3 / Dexamethasone 20, Multiple Myeloma, Cycle 9+ (PID1791)Venetoclax 800 / Dexamethasone 40, Multiple Myeloma (PID2448)Venetoclax 800, Waldenström's disease, cycle 2+ (PID2004)Vinblastine 6 / Prednisolone (20/10), Langerhans Cell Histiocytosis, maintenance (PID959)Vinblastine 6 / Prednisolone (20/10), Langerhans Cell Histiocytosis, induction (PID963)Vinblastine 6, Hodgkin Lymphoma (PID2331)Vincristine 1 / Prednisolone 100, Pre-phase, diffuse large B-non-Hodgkin Lymphoma (PID69)Vincristine 1 / Prednisolone 60, diffuse large B-non-Hodgkin Lymphoma (PID1778)Vincristine 1.5 / Dactinomycin 0.75 / Cyclophosphamide 1500, Ewing Sarcoma (PID50)Vincristine 1.5 / Dactinomycin 0.75 / Ifosfamide 3, Ewing Sarcoma (PID74)Vincristine 1.5 / Ifosfamide 3 / Doxorubicin 20 / Etoposide 150, Ewing Sarcoma (PID77)Vincristine 1.5, Immune Thrombocytopenia (PID958)Vincristine 2 / Prednisolone 200 / Imatinib 400, ALL/NHL, maintenance, Ph/BCR-ABL+ (PID2073)Vindesin 3 / Methotrexate 1500 / Etoposide 250 / Cytarabine 2000 / Dexamethasone 10, Acute Lymphoblastic Leukaemia (PID2268)Vinflunin 320, Bladder Cancer (PID563)Vinorelbine 12.5 / Carboplatin 1 / Radiation, Non-Small Cell Lung Cancer (PID668)Vinorelbine 15 / Cisplatin 40 / Radiation, Non-Small Cell Lung Cancer, Part C (PID1169)Vinorelbine 15 / Cisplatin 80 / Radiation, Non-Small Cell Lung Cancer, B (PID262)Vinorelbine 20 / Cisplatin 50 / Radiation, Non-Small Cell Lung Cancer, Neoadjuvant, Part B (PID853)Vinorelbine 20 / Cisplatin 40 / Radiation, Non-Small Cell Lung Cancer (PID1193)Vinorelbine 20 / Cisplatin 80 / Radiation, Non-Small Cell Lung Cancer (PID646)Vinorelbine 25 / Capecitabine 1000 - Capecitabine 1000 Maintenance, Breast Cancer (PID1693)Vinorelbine 25 / Capecitabine 1000, Breast Cancer (PID1692)Vinorelbine 25 / Cisplatin 100, Non-Small Cell Lung Cancer (PID147)Vinorelbine 25 / Cisplatin 25 / Radiation, Esophageal Cancer, neoadjuvant (PID1384)Vinorelbine 25 / Cisplatin 50, Non-Small Cell Lung Cancer, Adjuvant (PID199)Vinorelbine 25 / Cisplatin 75 / Radiation, Esophageal Cancer, neoadjuvant (PID1385)Vinorelbine 25 / Cisplatin 80, Non-Small Cell Lung Cancer, A (PID261)Vinorelbine 25 / Cisplatin 80, Non-Small Cell Lung Carcinoma, Adjuvant (PID34)Vinorelbine 25 / Cisplatin 80, Esophageal Cancer (PID137)Vinorelbine 25 / Cisplatin 80, Salivary Gland Tumor (PID1695)Vinorelbine 25 / Gemcitabine 1000, Non-Small Cell Lung Carcinoma (PID152)Vinorelbine 25, Breast Carcinoma (PID2129)Vinorelbine 25, Esophageal Cancer (PID138)Vinorelbine 30 / Cisplatin 100, Non-Small Cell Lung Carcinoma (PID150)Vinorelbine 30 / Cisplatin 100, Non-Small Cell Lung Cancer, Adjuvant (PID93)Vinorelbine 30 / Cisplatin 80, Non-Small Cell Lung Carcinoma (PID153)Vinorelbine 30 / Fluorouracil 750, Breast Cancer (PID678)Vinorelbine 30 / Gemcitabine 1200, Non-Small Cell Lung Carcinoma (PID164)Vinorelbine 30 / Margetuximab 15, Breast Cancer (PID1874)Vinorelbine 30, Kaposi's Sarcoma (PID2031)Vinorelbine 30, Breast Cancer (PID739)Vinorelbine 30, Non-Small Cell Lung Cancer (first-line) (PID165)Vinorelbine 30, Non-Small Cell Lung Cancer (second-line) (PID163)Vinorelbine 30, Pleural Mesothelioma (PID375)Vinorelbine 30, Pleural Mesothelioma, Variant 1 (PID376)Vinorelbine 40 / Cyclophosphamide 50 / Capecitabine 500, Breast Cancer (PID1377)Vinorelbine 60 / Capecitabine 1000, Breast Cancer, Cycle 1 (PID942)Vinorelbine 70, Breast Cancer (PID420)Vinorelbine 80 / Capecitabine 1000, Breast Cancer, Cycle 2+ (PID943)VIP - Cisplatin 20 / Ifosfamide 1.2 / Etoposide 75, Thymoma (PID805)Vismodegib 150, Basal Cell Carcinoma (PID1858)VIT (Temozolomide 125 / Vincristine 2 / Irinotecan 50), Soft Tissue Sarcoma, Cycle 1 (PID2255)VIT (Temozolomide 150 / Vincristine 2 / Irinotecan 50), Soft Tissue Sarcoma, Cycle 2-12 (PID2256)Vitamin B12 1000 Maintenance, Vitamin B12 Deficiency/Anemia (PID6)Vitamin B12 1000, Vitamin B12 Deficiency/Anemia (PID7)Voxelotor 1500, Sickle Cell Disease (PID1748)Zanubrutinib 160 / Venetoclax 400, Chronic Lymphocytic Leukemia, Cycle 9+ (PID2641)Zanubrutinib 160, Chronic Lymphocytic Leukemia (PID2225)Zanubrutinib 160, marginal zone lymphoma (PID2227)Zanubrutinib 160, Waldenström's disease (PID1918)Zoledronate 4, Ewing Sarcoma (PID2070)Zoledronate 4, Bone Metastases (PID936)Zoledronate 4, Multiple Myeloma (PID351)Zoledronate 4, Osteoporosis (PID1392)Zoledronate 5, Osteoporosis (PID1393)Zoledronic Acid 4, Breast Cancer, adjuvant (PID928)Zoledronic Acid 4, Breast Cancer, adjuvant (PID935)
